

# Intensive versus Moderate Lipid Lowering with Statins

New England Journal of Medicine

350, 1495-1504

DOI: [10.1056/nejmoa040583](https://doi.org/10.1056/nejmoa040583)

Citation Report

#	ARTICLE	IF	CITATIONS
2	Chick-Embryo Deaths Traced to Tincture of Iodine. <i>Journal of Infectious Diseases</i> , 1973, 127, 581-581.	1.9	0
3	Selective release of newly synthesised and newly captured GABA from synaptosomes by potassium depolarisation. <i>Nature</i> , 1975, 258, 254-256.	13.7	41
4	Oversight Hearings Promote NSF Insight. <i>BioScience</i> , 1979, 29, 433-434.	2.2	0
5	Sperm tail axoneme alterations in the Wobbler mouse. <i>Reproduction</i> , 1980, 58, 267-270.	1.1	38
7	Management of Neurological Disorders. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1996, 61, 658-658.	0.9	0
8	Prevention and Health Services Delivery. <i>Stroke</i> , 2003, 34, 367-369.	1.0	6
9	Prevention of cardiovascular disease: an evidence-based clinical aid 2004. <i>Medical Journal of Australia</i> , 2004, 181, 1-14.	0.8	4
10	Prevention of cardiovascular disease: an evidence-based clinical aid 2004. <i>Medical Journal of Australia</i> , 2004, 181, S1-S14.	0.8	10
11	The Impact of Recent Clinical Trials on National Cholesterol Education Program Adult Treatment Panel III Guidelines. <i>AMA Journal of Ethics</i> , 2004, 6, 550.	0.4	0
12	Dyslipidemia Management in Women and Men: Exploring Potential Gender Differences. , 2004, , 234-240.		0
13	Statins and Endothelial Dysfunction. <i>Seminars in Vascular Medicine</i> , 2004, 4, 333-346.	2.1	14
14	Lipid Lowering Therapy in Atherosclerosis. <i>Seminars in Vascular Medicine</i> , 2004, 4, 357-366.	2.1	27
15	Statins in Atherothrombosis. <i>Seminars in Vascular Medicine</i> , 2004, 4, 407-415.	2.1	6
16	New Strategies in the Treatment of Dyslipidemia: Do We Know How?. <i>Seminars in Vascular Medicine</i> , 2004, 4, 305-310.	2.1	0
17	Intensive lipid-lowering therapy in coronary artery disease: implications of the REVERSAL and PROVE-IT trials. <i>Expert Opinion on Investigational Drugs</i> , 2004, 13, 707-713.	1.9	1
18	Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2004, 351, 714-717.	13.9	18
19	Statins Effect on Smooth Muscle Cell Proliferation. <i>Seminars in Vascular Medicine</i> , 2004, 4, 347-356.	2.1	25
20	Have recent statin trial findings affected the National Cholesterol Education Program guidelines?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2004, 1, 76-77.	3.3	0

#	ARTICLE	IF	CITATIONS
21	Atorvastatin versus pravastatin: intensive versus moderate lipid lowering. Expert Opinion on Pharmacotherapy, 2004, 5, 2025-2028.	0.9	1
22	Aggressive Lowering of Low-Density Lipoprotein Cholesterol: Do the Studies Apply to the Elderly?. The American Journal of Geriatric Cardiology, 2004, 13, 217-218.	0.7	0
23	What Did PROVE-IT Prove?. Diabetes Technology and Therapeutics, 2004, 6, 864-867.	2.4	1
26	Atherosclerosis Imaging and the Future of Lipid Management. Circulation, 2004, 110, 3509-3511.	1.6	20
27	Review: Ezetimibe â€™ clinical and pharmacological profile. British Journal of Diabetes and Vascular Disease, 2004, 4, 163-171.	0.6	2
28	High-Dose Statins in Acute Coronary Syndromes. JAMA - Journal of the American Medical Association, 2004, 292, 1365.	3.8	99
29	Dyslipidemia and the Metabolic Syndrome. Diabetes Care, 2004, 27, 3009-3016.	4.3	25
30	Aggressive Lipid-Lowering Therapy and Regression of Coronary Atheromaâ€™Reply. JAMA - Journal of the American Medical Association, 2004, 292, 38.	3.8	1
31	Antiplatelet Therapy in Nonâ€™ST-Segment Elevation Acute Coronary Syndromes. JAMA - Journal of the American Medical Association, 2004, 292, 1875.	3.8	35
32	Coronary artery disease in the elderly patient. Reviews in Clinical Gerontology, 2004, 14, 105-118.	0.5	0
33	Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation, 2004, 110, 227-239.	1.6	5,602
34	Prior Statin Therapy Is Associated With a Decreased Rate of Severe Sepsis. Circulation, 2004, 110, 880-885.	1.6	366
35	Early Intensive vs a Delayed Conservative Simvastatin Strategy in Patients With Acute Coronary Syndromes. JAMA - Journal of the American Medical Association, 2004, 292, 1307.	3.8	1,166
36	Stopping Statins. Circulation, 2004, 110, 2280-2282.	1.6	14
38	Statins Are Associated With a Reduced Incidence of Perioperative Mortality After Coronary Artery Bypass Graft Surgery. Circulation, 2004, 110, II-45-II-49.	1.6	178
39	High-Dose Atorvastatin Reduces Total Plasma Levels of Oxidized Phospholipids and Immune Complexes Present on Apolipoprotein B-100 in Patients With Acute Coronary Syndromes in the MIRACL Trial. Circulation, 2004, 110, 1406-1412.	1.6	209
40	Effect of Antihypertensive Agents on Cardiovascular Events in Patients With Coronary Disease and Normal Blood Pressure. JAMA - Journal of the American Medical Association, 2004, 292, 2217.	3.8	1,016
41	High dose atorvastatin was superior to standard dose pravastatin in reducing death or major CV events in acute coronary syndrome. Evidence-Based Medicine, 2004, 9, 144-144.	0.6	0

#	ARTICLE	IF	CITATIONS
43	Aggressive Lipid-Lowering Therapy and Regression of Coronary Atheroma. JAMA - Journal of the American Medical Association, 2004, 292, 38.	3.8	1
44	Statin use after renal transplantation: a systematic quality review of trial-based evidence. Nephrology Dialysis Transplantation, 2004, 19, 2378-2386.	0.4	42
45	Intensive treatment with statins and the progression of cardiovascular diseases: the beginning of a new era?. Nephrology Dialysis Transplantation, 2004, 19, 2696-2699.	0.4	4
46	Management of dyslipidaemia. Heart, 2004, 90, 949-955.	1.2	24
48	Practising what is preached: the MINAP study. Heart, 2004, 90, 969-971.	1.2	1
49	Multiple antiplatelet effects of clopidogrel are not modulated by statin type in patients undergoing percutaneous coronary intervention. Platelets, 2004, 15, 465-474.	1.1	31
51	Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid â€” a position paper developed by the European Consensus Panel on HDL-C*. Current Medical Research and Opinion, 2004, 20, 1253-1268.	0.9	248
52	Statins: can the new generation make an impression?. Expert Opinion on Emerging Drugs, 2004, 9, 269-279.	1.0	26
53	Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, e149-61.	1.1	189
54	Update on Statins: 2003. Circulation, 2004, 110, 886-892.	1.6	196
55	Believe-it then PROVE-IT. International Journal of Clinical Practice, 2004, 58, 325-326.	0.8	1
56	Statins - threatening the evidence base of effectiveness and safety. International Journal of Clinical Practice, 2004, 58, 539-540.	0.8	2
57	Statins: potent vascular anti-inflammatory agents. International Journal of Clinical Practice, 2004, 58, 41-48.	0.8	24
58	A review of the efficacy of rosuvastatin in patients with type 2 diabetes. International Journal of Clinical Practice, 2004, 58, 30-40.	0.8	14
59	Publication of clinical trials: accountability and accessibility. Journal of Internal Medicine, 2004, 256, 271-283.	2.7	22
60	Clinical Update on the Use of Niacin for the Treatment of Dyslipidemia. Journal of the American Academy of Nurse Practitioners, 2004, 16, 526-534.	1.4	4
62	The metabolic syndrome: Diagnosis and treatment. Clinical Cornerstone, 2004, 6, S5-S13.	1.0	14
63	Pharmacologic Treatment of Type 2 Diabetic Dyslipidemia. Pharmacotherapy, 2004, 24, 1692-1713.	1.2	33

#	ARTICLE	IF	CITATIONS
64	Statins and Liver Toxicity: A Meta-Analysis. <i>Pharmacotherapy</i> , 2004, 24, 584-591.	1.2	179
65	Design and baseline characteristics of the Incremental Decrease in End Points through Aggressive Lipid Lowering study. <i>American Journal of Cardiology</i> , 2004, 94, 720-724.	0.7	50
66	Pharmacology update: statin therapy lowers mortality in elders with severe heart failure. <i>Geriatric Nursing</i> , 2004, 25, 250.	0.9	0
68	Lipids and the Elderly. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2004, 5, 359-364.	2.6	8
69	Optimizing lipid lowering in patients at risk. <i>Clinical Cardiology</i> , 2004, 27, 22-26.	0.7	2
72	Pathological Changes in Acute Coronary Syndromes: The Role of Statin Therapy in the Modulation of Inflammation, Endothelial Function and Coagulation. <i>Journal of Thrombosis and Thrombolysis</i> , 2004, 18, 89-101.	1.0	41
73	Biosynthesis of isoprenoids via the non-mevalonate pathway. <i>Cellular and Molecular Life Sciences</i> , 2004, 61, 1401-26.	2.4	539
75	Low-density lipoprotein reduction in high-risk patients: How low do you go?. <i>Current Atherosclerosis Reports</i> , 2004, 6, 348-352.	2.0	15
76	ASCOT-LLA and the primary prevention of coronary artery disease in hypertensive patients. <i>Current Atherosclerosis Reports</i> , 2004, 6, 353-358.	2.0	1
77	ALLHAT-LLT: Questions, questions, and more questions (and some answers). <i>Current Atherosclerosis Reports</i> , 2004, 6, 375-380.	2.0	3
78	Evidence-based treatment of lipids in the elderly. <i>Current Atherosclerosis Reports</i> , 2004, 6, 388-397.	2.0	8
80	Treatment of lipids and type 2 diabetes. <i>Current Cardiology Reports</i> , 2004, 6, 443-450.	1.3	4
81	The evaluation and management of dyslipidemia and impaired glucose metabolism during acute coronary syndromes. <i>Current Cardiology Reports</i> , 2004, 6, 300-307.	1.3	2
82	Mechanistic and epidemiologic considerations in the evaluation of adverse birth outcomes following gestational exposure to statins. <i>American Journal of Medical Genetics Part A</i> , 2004, 131A, 287-298.	2.4	171
83	Adenosine sestamibi SPECT post-infarction evaluation (INSPIRE) trial: A randomized, prospective multicenter trial evaluating the role of adenosine Tc-99m sestamibi SPECT for assessing risk and therapeutic outcomes in survivors of acute myocardial infarction*1. <i>Journal of Nuclear Cardiology</i> , 2004, 11, 458-469.	1.4	43
84	A new era in atherosclerosis drug discovery. <i>Expert Review of Cardiovascular Therapy</i> , 2004, 2, 633-636.	0.6	4
85	Clopidogrel and vascular disease prevention. <i>Current Medical Research and Opinion</i> , 2004, 20, 1835-1838.	0.9	6
86	Relationship between LDL-C and non-HDL-C levels and clinical outcome in the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. <i>Current Medical Research and Opinion</i> , 2004, 20, 1385-1392.	0.9	15

#	ARTICLE	IF	CITATIONS
87	Current lipid management and low cholesterol goal attainment in common daily practice in Spain. <i>Pharmacoeconomics</i> , 2004, 22, 1-12.	1.7	52
88	Cost of care for patients treated with lipid-lowering drugs. <i>Pharmacoeconomics</i> , 2004, 22, 25-35.	1.7	24
89	Cost-effectiveness of ezetimibe coadministration in statin-treated patients not at cholesterol goal. <i>Pharmacoeconomics</i> , 2004, 22, 49-61.	1.7	26
90	Ezetimibe/Simvastatin. <i>American Journal of Cardiovascular Drugs</i> , 2004, 4, 405-422.	1.0	19
91	Intensive Statin Therapy â€” A Sea Change in Cardiovascular Prevention. <i>New England Journal of Medicine</i> , 2004, 350, 1562-1564.	13.9	175
92	Crystallographic Structures of Two Bisphosphonate:1-Deoxyxylulose-5-Phosphate Reductoisomerase Complexes. <i>Journal of the American Chemical Society</i> , 2004, 126, 10824-10825.	6.6	68
93	Rosuvastatin safety: lessons from the FDA review and post-approval surveillance. <i>Expert Opinion on Drug Safety</i> , 2004, 3, 547-557.	1.0	71
94	Secondary Prevention Strategies in Ischemic Stroke: Identification and Optimal Management of Modifiable Risk Factors. <i>Mayo Clinic Proceedings</i> , 2004, 79, 1330-1340.	1.4	34
95	GuÃ­as para el tratamiento de las dislipemias en el adulto: Adult Treatment Panel III (ATP-III). <i>Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion</i> , 2004, 51, 254-265.	0.8	10
97	Medical Treatment of Peripheral Arterial Disease: A Comprehensive Review. <i>Journal of Vascular and Interventional Radiology</i> , 2004, 15, 1197-1207.	0.2	86
99	Effect of the Early Administration of Pravastatin on C-Reactive Protein and Interleukin-6 Levels in the Acute Phase of Myocardial Infarction With ST Segment Elevation. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2004, 57, 916-923.	0.4	0
100	HMG-coA reductase inhibitors: lipid-lowering and beyond. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2004, 1, 189-194.	0.5	4
101	Intensive lipid lowering with atorvastatin reduces progression of coronary atherosclerosis, as measured by intravascular ultrasound. <i>Evidence-Based Healthcare and Public Health</i> , 2004, 8, 298-301.	0.2	0
102	Optimal low-density lipoprotein is 50 to 70 mg/dl. <i>Journal of the American College of Cardiology</i> , 2004, 43, 2142-2146.	1.2	444
103	Vascular disease, hypertension, and prevention. <i>Journal of the American College of Cardiology</i> , 2004, 44, S19-S22.	1.2	0
104	Myocardial ischemia and infarction. <i>Journal of the American College of Cardiology</i> , 2004, 44, S10-S12.	1.2	8
105	The year in atherothrombosis. <i>Journal of the American College of Cardiology</i> , 2004, 44, 2099-2110.	1.2	68
106	Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics. <i>Journal of the American College of Cardiology</i> , 2004, 44, 1772-1779.	1.2	130

#	ARTICLE	IF	CITATIONS
107	Pharmacologic strategies for the prevention of atherosclerotic plaque progression. Expert Review of Cardiovascular Therapy, 2004, 2, 855-866.	0.6	0
108	Assessing compliance of cardiologists with the national cholesterol education program (NCEP) III guidelines in an ambulatory care setting. Lipids in Health and Disease, 2004, 3, 9.	1.2	12
109	Plant sterols: factors affecting their efficacy and safety as functional food ingredients. Lipids in Health and Disease, 2004, 3, 5.	1.2	233
110	Extended-release niacin/lovastatin: the first combination product for dyslipidemia. Expert Review of Cardiovascular Therapy, 2004, 2, 485-501.	0.6	22
111	Recent advances in the secondary prevention of coronary heart disease. Expert Review of Cardiovascular Therapy, 2004, 2, 877-889.	0.6	6
112	Syndromes coronaires aigus sans surdÃ©calage du segment ST. Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique, 2004, 2004, 18-21.	0.0	0
113	Rosuvastatin in the management of hyperlipidemia. Clinical Therapeutics, 2004, 26, 1368-1387.	1.1	64
114	A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia. Clinical Therapeutics, 2004, 26, 1758-1773.	1.1	171
115	Commentary. Evidence-based Cardiovascular Medicine, 2004, 8, 337-338.	0.0	0
116	Effect of pravastatin compared with placebo initiated within 24 hours of onset of acute myocardial infarction or unstable angina: The Pravastatin in Acute Coronary Treatment (PACT) trial. American Heart Journal, 2004, 148, 91.	1.2	78
117	Elective coronary revascularization, an iatrogenic form of acute coronary syndrome: How can clinicians reduce the risks?. American Heart Journal, 2004, 148, 371-377.	1.2	7
118	Statins as the cornerstone of drug therapy for dyslipidemia: monotherapy and combination therapy options. American Heart Journal, 2004, 148, S9-S13.	1.2	24
119	Effect of aggressive versus moderate lipid-lowering therapy on myocardial ischemia: The rationale, design, and baseline characteristics of the Study Assessing Goals in the Elderly (SAGE). American Heart Journal, 2004, 148, 1053-1059.	1.2	12
121	Statins and age-related macular degeneration. American Journal of Ophthalmology, 2004, 138, 688.	1.7	4
123	PROVE IT and REVERSAL. Preventive Cardiology, 2004, 7, 138-141.	1.1	0
124	Should the National Cholesterol Education Program Guidelines Be Changed for Persons at High Risk for Cardiovascular Events?. Preventive Cardiology, 2004, 7, 71-72.	1.1	1
125	Prescription of statins to dyslipidemic patients affected by liver diseases: a subtle balance between risks and benefits. Nutrition, Metabolism and Cardiovascular Diseases, 2004, 14, 215-224.	1.1	39
126	Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Journal of the American College of Cardiology, 2004, 44, 720-732.	1.2	1,207

#	ARTICLE	IF	CITATIONS
127	Drotrecogin Alfa (Activated) for the Treatment of Severe Sepsis and Septic Shock. American Journal of the Medical Sciences, 2004, 328, 205-214.	0.4	11
128	National Survey of Pharmacists About Coronary Heart Disease, Hypercholesterolemia, Nonprescription Statin Therapy, and Pharmacists's™ Services. Journal of the American Pharmacists Association: JAPhA, 2004, 44, 562-568.	0.7	12
129	Evidence-based Medical Perspectives: The Evolving Role of PSA for Early Detection, Monitoring of Treatment Response, and as a Surrogate End Point of Efficacy for Interventions in Men with Different Clinical Risk States for the Prevention and Progression of Prostate Cancer. American Journal of Therapeutics, 2004, 11, 501-506.	0.5	52
131	Inflammation and cardiovascular diseases: lessons that can be learned for the patient with cardiogenic shock in the intensive care unit. Current Opinion in Critical Care, 2004, 10, 347-353.	1.6	10
132	Risk Stratification and the Management of Non-“ST-Segment Elevation Acute Coronary Syndromes. Critical Pathways in Cardiology, 2004, 3, 83-86.	0.2	2
133	Statin policy and target populations: evidence-based or evidence-biased?. Current Opinion in Lipidology, 2004, 15, 381-386.	1.2	2
134	Combination therapy in the management of complex dyslipidemias. Current Opinion in Lipidology, 2004, 15, 423-431.	1.2	25
135	Post myocardial infarction care by the GP. South African Family Practice: Official Journal of the South African Academy of Family Practice/Primary Care, 2004, 46, 15-18.	0.2	1
136	Management of the acute coronary syndrome patient. European Heart Journal Supplements, 2004, 6, C49-C57.	0.0	0
137	Natural History of Sonographically Detected Simple Unilocular Adnexal Cysts in Asymptomatic Postmenopausal Women. Obstetrical and Gynecological Survey, 2004, 59, 511-513.	0.2	0
138	Intensive statin therapy in acute coronary syndromes: clinical benefits and vascular biology. Current Opinion in Lipidology, 2004, 15, 637-643.	1.2	47
139	Cancer Risk After Hospital Discharge Diagnosis of Benign Ovarian Cysts and Endometriosis. Obstetrical and Gynecological Survey, 2004, 59, 510-511.	0.2	1
140	Progress in Prevention. Journal of Cardiovascular Nursing, 2004, 19, 287-289.	0.6	0
141	Efficacy of Preemptive Analgesia for Wound Pain After Laparoscopic Operations in Infertile Women: A Randomized, Double-Blind, and Placebo-Controlled Study. Obstetrical and Gynecological Survey, 2004, 59, 508-509.	0.2	0
142	The Effects of Strontium Ranelate on the Risk of Vertebral Fracture in Women With Postmenopausal Osteoporosis. Obstetrical and Gynecological Survey, 2004, 59, 526-527.	0.2	9
143	Limitations of Screening Tests for the Detection of Chlamydia trachomatis in Asymptomatic Adolescent and Young Adult Women. Obstetrical and Gynecological Survey, 2004, 59, 513-515.	0.2	2
144	A Phase III Trial of Surgery With or Without Adjunctive External Pelvic Radiation Therapy in Intermediate-Risk Endometrial Adenocarcinoma: A Gynecologic Oncology Group Study. Obstetrical and Gynecological Survey, 2004, 59, 516-518.	0.2	3
145	Germline Stem Cells and Follicular Renewal in the Postnatal Mammalian Ovary. Obstetrical and Gynecological Survey, 2004, 59, 518-520.	0.2	5



#	ARTICLE	IF	CITATIONS
146	Embryo Development After Heterotopic Transplantation of Cryopreserved Ovarian Tissue. <i>Obstetrical and Gynecological Survey</i> , 2004, 59, 520-522.	0.2	5
147	Comparison of Intensive and Moderate Lipid Lowering With Statins After Acute Coronary Symptoms. <i>Obstetrical and Gynecological Survey</i> , 2004, 59, 522-524.	0.2	34
148	Metabolic, Inflammatory, and Hemostatic Effects of a Low-Dose Continuous Combined HRT in Women With Type 2 Diabetes: Potentially Safer With Respect to Vascular Risk. <i>Obstetrical and Gynecological Survey</i> , 2004, 59, 524-525.	0.2	2
149	Early, aggressive lipid management in the treatment of acute coronary syndromes. <i>Therapy: Open Access in Clinical Medicine</i> , 2004, 1, 213-216.	0.2	0
150	Practice Patterns in Treating High-Risk Patients with Hyperlipidemia at a Northeast Tennessee University Clinic. <i>Journal of Investigative Medicine</i> , 2005, 53, 31-36.	0.7	1
151	Importance and Management of Dyslipidemia in the Metabolic Syndrome. <i>American Journal of the Medical Sciences</i> , 2005, 330, 295-302.	0.4	29
152	Addressing the Global Cardiovascular Risk of Hypertension, Dyslipidemia, Diabetes Mellitus, and the Metabolic Syndrome in the Southeastern United States, Part II: Treatment Recommendations for Management of the Global Cardiovascular Risk of Hypertension, Dyslipidemia, Diabetes Mellitus, and the Metabolic Syndrome. <i>American Journal of the Medical Sciences</i> , 2005, 329, 292-305.	0.4	69
153	Are Statins Being Underdosed in Clinical Practice?. <i>Critical Pathways in Cardiology</i> , 2005, 4, 169-173.	0.2	8
154	Management of Stable Angina and Acute Coronary Syndromes. <i>American Journal of Pharmaceutical Education</i> , 2005, 69, 99.	0.7	1
155	Colesevelam HCl and Ezetimibe Combination Therapy Provides Effective Lipid-Lowering in Difficult-to-Treat Patients with Hypercholesterolemia. <i>American Journal of Therapeutics</i> , 2005, 12, 306-310.	0.5	52
156	HDL-raising strategies in the treatment of coronary artery disease: perspectives from the Armed Forces Regression Study. <i>Current Opinion in Lipidology</i> , 2005, 16, 652-657.	1.2	5
157	Effectiveness of using rosuvastatin in difficult-to-control dyslipidemia patients: an audit in secondary care. <i>Therapy: Open Access in Clinical Medicine</i> , 2005, 2, 895-900.	0.2	0
160	Outcome measures for clinical research in sepsis: A report of the 2nd Cambridge Colloquium of the International Sepsis Forum. <i>Critical Care Medicine</i> , 2005, 33, 1708-1716.	0.4	131
161	Optimal goals for statin use in patients with coronary artery disease. <i>Current Opinion in Cardiology</i> , 2005, 20, 525-529.	0.8	2
162	Treating to Low-Density Lipoprotein Goal. <i>Critical Pathways in Cardiology</i> , 2005, 4, 174-176.	0.2	0
163	The pleiotropic effects of statins. <i>Current Opinion in Cardiology</i> , 2005, 20, 541-546.	0.8	138
164	Statins and Cardiovascular Risks. <i>International Anesthesiology Clinics</i> , 2005, 43, 55-68.	0.3	4
165	Drugs in development: targeting high-density lipoprotein metabolism and reverse cholesterol transport. <i>Current Opinion in Cardiology</i> , 2005, 20, 301-306.	0.8	28

#	ARTICLE	IF	CITATIONS
166	How to Join a Clinical Trial. <i>Critical Pathways in Cardiology</i> , 2005, 4, 26-29.	0.2	0
167	Time to Benefit. <i>Critical Pathways in Cardiology</i> , 2005, 4, 43-45.	0.2	8
168	Cost-Effectiveness Analysis. <i>Medical Care</i> , 2005, 43, II-49.	1.1	13
169	Clinical implications for statin pleiotropy. <i>Current Opinion in Lipidology</i> , 2005, 16, 624-629.	1.2	123
170	Beyond guidelines: achieving the optimum in LDL cholesterol control. <i>Current Opinion in Lipidology</i> , 2005, 16, 635-639.	1.2	1
171	Update on acute coronary syndromes and ST-elevation myocardial infarction. <i>Current Opinion in Internal Medicine</i> , 2005, 4, 614-618.	1.5	1
172	Surrogate markers for atherosclerotic disease. <i>Current Opinion in Lipidology</i> , 2005, 16, 434-441.	1.2	47
174	Lowering LDL Cholesterol: Where Is the End of the Journey?. <i>Cardiology</i> , 2005, 5, 39-50.	0.3	1
175	Creating a New Structure for Research on Health Care Effectiveness. <i>Journal of Investigative Medicine</i> , 2005, 53, 67-72.	0.7	18
177	Use of A Treatment Algorithm to Achieve NCEP ATP III Goals With Atorvastatin. <i>Journal of Cardiovascular Pharmacology</i> , 2005, 46, 594-599.	0.8	17
178	Prediabetes & Atherosclerosis: What???s the Connection?. <i>Nurse Practitioner</i> , 2005, 30, 24-35.	0.2	4
179	Torcetrapib/atorvastatin combination therapy. <i>Expert Review of Cardiovascular Therapy</i> , 2005, 3, 789-820.	0.6	27
181	Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage. <i>Pharmacogenetics and Genomics</i> , 2005, 15, 415-421.	0.7	117
182	New Guidelines in Statin Therapy. <i>Plastic Surgical Nursing</i> , 2005, 25, 109-110.	0.3	0
184	Cardiovascular Drug Therapy in Women. <i>Journal of Cardiovascular Nursing</i> , 2005, 20, 410-419.	0.6	0
185	Prevention. <i>Journal of Cardiovascular Nursing</i> , 2005, 20, 433-441.	0.6	4
186	Combination Pharmacotherapy for Cardiovascular Disease. <i>Annals of Internal Medicine</i> , 2005, 143, 593.	2.0	53
187	Sustained Upregulation of Inflammatory Chemokine and Its Receptor in Aneurysmal and Occlusive Atherosclerotic Disease Results From Tissue Analysis With cDNA Macroarray and Real-Time Reverse Transcriptional Polymerase Chain Reaction Methods. <i>Circulation Journal</i> , 2005, 69, 1490-1495.	0.7	22

#	ARTICLE	IF	CITATIONS
188	Part 5: Acute coronary syndromes. Resuscitation, 2005, 67, 249-269.	1.3	36
189	High-dose statins and skeletal muscle metabolism in humans: A randomized, controlled trial. Clinical Pharmacology and Therapeutics, 2005, 78, 60-68.	2.3	272
193	The role of shear stress in the destabilization of vulnerable plaques and related therapeutic implications. Nature Clinical Practice Cardiovascular Medicine, 2005, 2, 456-464.	3.3	247
194	Is aggressive lipid-lowering effective and safe in the older adult?. Clinical Cardiology, 2005, 28, 404-407.	0.7	4
195	The benefits of statin therapy-what questions remain?. Clinical Cardiology, 2005, 28, 499-503.	0.7	11
196	Novel determinants of plaque instability. Journal of Thrombosis and Haemostasis, 2005, 3, 1962-1975.	1.9	37
197	A novel nitric oxide-releasing statin derivative exerts an antiplatelet/antithrombotic activity and inhibits tissue factor expression1. Journal of Thrombosis and Haemostasis, 2005, 3, 2554-2562.	1.9	51
198	Ambulatory hypercholesterolemia management in patients with atherosclerosis. Journal of General Internal Medicine, 2005, 20, 123-130.	1.3	33
199	Management of dyslipidemia in women in the post-hormone therapy era. Journal of General Internal Medicine, 2005, 20, 297-305.	1.3	10
200	Cost-Effectiveness of Rosuvastatin Compared with Other Statins from a Managed Care Perspective. Value in Health, 2005, 8, 618-628.	0.1	21
201	Insulin resistance, diabetes and cardiovascular risk: approaches to treatment. Diabetes, Obesity and Metabolism, 2005, 7, 642-653.	2.2	50
202	Lipids and cardiovascular risk reduction - new targets, new challenges. International Journal of Clinical Practice, 2005, 59, 617-618.	0.8	2
203	Efficacy and safety of ezetimibe co-administered with ongoing atorvastatin therapy in achieving low-density lipoprotein goal in patients with hypercholesterolemia and coronary heart disease. International Journal of Clinical Practice, 2005, 59, 619-627.	0.8	41
204	Simultaneous treatment of hypertension and dyslipidaemia may help to reduce overall cardiovascular risk: focus on amlodipine/atorvastatin single-pill therapy. International Journal of Clinical Practice, 2005, 59, 839-846.	0.8	15
205	Achievement of English National Service Framework lipid-lowering goals: pooled data from recent comparative treatment trials of statins at starting doses. International Journal of Clinical Practice, 2005, 59, 1171-1177.	0.8	8
206	Lipid-altering efficacy of switching from atorvastatin 10â€ƒmg/day to ezetimibe/simvastatin 10/20â€ƒmg/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease. International Journal of Clinical Practice, 2005, 59, 1377-1386.	0.8	38
207	Ezetimibe/simvastatin (INEGYâ„¢) in the treatment of hyperlipidaemia. International Journal of Clinical Practice, 2005, 59, 1464-1471.	0.8	14
209	Guidelines for the treatment and management of new-onset diabetes after transplantation1.. Clinical Transplantation, 2005, 19, 291-298.	0.8	228

#	ARTICLE	IF	CITATIONS
210	Cautionary tales in the clinical interpretation of therapeutic trial reports. <i>Internal Medicine Journal</i> , 2005, 35, 611-621.	0.5	10
211	The pharmaco-economics of peri-operative statin therapy. <i>Anaesthesia</i> , 2005, 60, 1059-1063.	1.8	26
212	Statin therapy: a potentially useful peri-operative intervention in patients with cardiovascular disease. <i>Anaesthesia</i> , 2005, 60, 1106-1114.	1.8	55
213	Statin use after acute myocardial infarction: a nationwide study in Denmark. <i>British Journal of Clinical Pharmacology</i> , 2005, 60, 150-158.	1.1	33
214	Not all statins interfere with clopidogrel during antiplatelet therapy. <i>European Journal of Clinical Investigation</i> , 2005, 35, 476-481.	1.7	40
215	HDL as a target in the treatment of atherosclerotic cardiovascular disease. <i>Nature Reviews Drug Discovery</i> , 2005, 4, 193-205.	21.5	418
216	Pitavastatin. <i>International Journal of Clinical Practice</i> , 2005, 59, 239-252.	0.8	148
217	Percutaneous coronary interventions for coronary artery disease: the long and short of optimizing medical therapy. <i>International Journal of Clinical Practice</i> , 2005, 59, 1070-1081.	0.8	2
218	PROVE IT then believe it. <i>International Journal of Clinical Practice</i> , 2005, 59, 124-124.	0.8	2
219	Early Initiation of Statin Therapy in Acute Coronary Syndromes: A Review of the Evidence. <i>Journal of Interventional Cardiology</i> , 2005, 18, 55-63.	0.5	7
220	The Nurse Practitioner's Role in Helping Patients Achieve Lipid Goals with Statin Therapy. <i>Journal of the American Academy of Nurse Practitioners</i> , 2005, 17, 256-262.	1.4	12
221	Serum Lipids and Anthropometric Factors Related to the Prevalence of Intermittent Claudication. <i>European Journal of Vascular and Endovascular Surgery</i> , 2005, 30, 582-587.	0.8	5
222	Cardiovascular disease in lupus patients: Should all patients be treated with statins and aspirin?. <i>Best Practice and Research in Clinical Rheumatology</i> , 2005, 19, 823-838.	1.4	56
223	Simvastatin reverses the downregulation of dopamine D1 and D2 receptor expression in the prefrontal cortex of 6-hydroxydopamine-induced Parkinsonian rats. <i>Brain Research</i> , 2005, 1045, 229-233.	1.1	48
224	Comparison of flow-mediated dilatation of the brachial artery in coronary patients with low-density lipoprotein cholesterol levels <80 mg/dl versus patients with levels 80 to 100 mg/dl. <i>American Journal of Cardiology</i> , 2005, 95, 93-95.	0.7	16
225	Long-term safety and efficacy of high-dose atorvastatin treatment in patients with familial hypercholesterolemia. <i>American Journal of Cardiology</i> , 2005, 95, 264-266.	0.7	63
226	A "poly-portfolio" for secondary prevention: A strategy to reduce subsequent events by up to 97% over five years. <i>American Journal of Cardiology</i> , 2005, 95, 373-378.	0.7	44
227	Lipid management in patients with unstable angina pectoris and non-ST-segment elevation acute myocardial infarction (from CRUSADE). <i>American Journal of Cardiology</i> , 2005, 95, 483-485.	0.7	17

#	ARTICLE	IF	CITATIONS
228	Effect of early initiation of statins on survival in patients with acute myocardial infarction (the USC) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.7	27
229	Do Statins Increase the Risk of Idiopathic Polyneuropathy?. American Journal of Cardiology, 2005, 95, 1097-1099.	0.7	26
230	Rationale for New American Diabetes Association Guidelines: Are National Cholesterol Education Program Goals Adequate for the Patient with Diabetes Mellitus?. American Journal of Cardiology, 2005, 96, 33-36.	0.7	17
231	Recent National Cholesterol Education Program Adult Treatment Panel III Update: Adjustments and Options. American Journal of Cardiology, 2005, 96, 53-59.	0.7	208
232	Pharmacologic Options for Aggressive Low-Density Lipoprotein Cholesterol Lowering: Benefits Versus Risks. American Journal of Cardiology, 2005, 96, 60-66.	0.7	66
233	Effects of Statins on 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibition Beyond Low-Density Lipoprotein Cholesterol. American Journal of Cardiology, 2005, 96, 24-33.	0.7	243
234	Review of Primary and Secondary Prevention Trials with Lovastatin, Pravastatin, and Simvastatin. American Journal of Cardiology, 2005, 96, 34-38.	0.7	38
235	Diet, Lifestyle, and Nonstatin Trials: Review of Time to Benefit. American Journal of Cardiology, 2005, 96, 3-10.	0.7	34
237	Assessment of Patients at Intermediate Cardiac Risk. American Journal of Cardiology, 2005, 96, 2-10.	0.7	19
238	Different Time Course for Prevention of Coronary and Stroke Events by Atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trialâ€“Lipid-Lowering Arm (ASCOT-LLA). American Journal of Cardiology, 2005, 96, 39-44.	0.7	54
239	The Case for Intensive Statin Therapy After Acute Coronary Syndromes. American Journal of Cardiology, 2005, 96, 45-53.	0.7	26
240	Early Time to Benefit with Intensive Statin Treatment: Could It Be the Pleiotropic Effects?. American Journal of Cardiology, 2005, 96, 54-60.	0.7	70
241	Safety of High-Dose Atorvastatin Therapy. American Journal of Cardiology, 2005, 96, 69-75.	0.7	67
242	Effect of Intensive Lipid Lowering on Progression of Coronary Atherosclerosis: Evidence for an Early Benefit from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Trial. American Journal of Cardiology, 2005, 96, 61-68.	0.7	103
243	Effect of Statin Use in Patients With Acute Coronary Syndromes and a Serum Low-Density Lipoprotein â‰ƒ80 mg/dl. American Journal of Cardiology, 2005, 96, 1491-1493.	0.7	23
244	Reducing Residual Risk for Patients on Statin Therapy: The Potential Role of Combination Therapy. American Journal of Cardiology, 2005, 96, 3-13.	0.7	68
245	Rationale for Targeting Multiple Lipid Pathways for Optimal Cardiovascular Risk Reduction. American Journal of Cardiology, 2005, 96, 14-19.	0.7	15
246	Nonâ€“High-Density Lipoprotein Cholesterol: The Forgotten Therapeutic Target. American Journal of Cardiology, 2005, 96, 59-64.	0.7	27

#	ARTICLE	IF	CITATIONS
248	Temas de actualidad en cardiología preventiva: el síndrome metabólico. Revista Española De Cardiología Suplementos, 2005, 5, 13A-23A.	0.2	1
249	Long-term Cardiac Outcomes in Renal Transplant Recipients Receiving Fluvastatin: The ALERT Extension Study. American Journal of Transplantation, 2005, 5, 2929-2936.	2.6	299
250	Pharmacological basis of different targets for the treatment of atherosclerosis. Journal of Cellular and Molecular Medicine, 2005, 9, 818-839.	1.6	23
251	The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial [ISRCTN48489393]. BMC Medicine, 2005, 3, 6.	2.3	99
252	Effect of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors on High-Sensitivity C-Reactive Protein Levels. Pharmacotherapy, 2005, 25, 1365-1377.	1.2	9
253	Rosuvastatin for the Treatment of Hypercholesterolemia. Pharmacotherapy, 2005, 25, 990-1000.	1.2	23
254	Cardiovascular Morbidity Associated with Nonadherence to Statin Therapy. Pharmacotherapy, 2005, 25, 1035-1043.	1.2	98
255	Cost-Efficacy Analysis of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Based on Results of the STELLAR Trial: Clinical Implications for Therapeutic Selection. Pharmacotherapy, 2005, 25, 270-278.	1.2	12
256	Achieving Cholesterol Target in a Managed Care Organization (ACTION) Trial. Pharmacotherapy, 2005, 25, 360-371.	1.2	30
257	Considerations in the Treatment of Dyslipidemia Associated With Chronic Kidney Failure and Renal Transplantation. Preventive Cardiology, 2005, 8, 244-249.	1.1	10
258	Long-term effects of LDL apheresis in patients with severe hypercholesterolemia. Journal of Clinical Apheresis, 2005, 20, 252-255.	0.7	49
259	IVUS max. Catheterization and Cardiovascular Interventions, 2005, 66, 519-520.	0.7	1
260	Rhabdomyolysis in a patient receiving atorvastatin and fluconazole. European Journal of Clinical Pharmacology, 2005, 60, 905-907.	0.8	45
263	Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia, 2005, 48, 2482-2485.	2.9	55
264	Comparison of apolipoprotein B and plasma lipids as targets for lipid lowering treatment. Clinical Biochemistry, 2005, 38, 509-513.	0.8	6
266	Possible assessment of coronary plaque morphology before and after treatment with statin by multislice spiral computed tomographic coronary angiography—a case report. International Journal of Angiology, 2005, 14, 225-227.	0.2	2
267	Women and cardiovascular disease—Prevention of heart disease. International Journal of Angiology, 2005, 14, 218-224.	0.2	2
269	Using atorvastatin with the guidelines to prevent recurrent cardiovascular disease. Current Treatment Options in Cardiovascular Medicine, 2005, 7, 287-292.	0.4	2

#	ARTICLE	IF	CITATIONS
271	New insights in the treatment of dyslipidemia: A focus on cardiovascular event reduction and the antiatherosclerotic effects of atorvastatin. <i>Current Atherosclerosis Reports</i> , 2005, 7, 335-343.	2.0	6
273	Results of new statin trials: Should the low-density lipoprotein cholesterol treatment guidelines be revised?. <i>Current Atherosclerosis Reports</i> , 2005, 7, 11-16.	2.0	2
274	Utility of statin therapy using high-sensitivity C-reactive protein as an indicator of coronary heart disease risk. <i>Current Atherosclerosis Reports</i> , 2005, 7, 22-28.	2.0	7
275	How aggressive should lipid lowering be among patients with acute coronary syndromes?. <i>Current Cardiology Reports</i> , 2005, 7, 283-287.	1.3	0
276	New benefits of statin treatment. <i>Current Diabetes Reports</i> , 2005, 5, 165-166.	1.7	0
277	Treatment of multiple-risk patients: Using combination therapy to treat beyond LDL lowering. <i>Current Hypertension Reports</i> , 2005, 7, 265-270.	1.5	1
278	Metabolic syndrome and endothelial dysfunction. <i>Current Hypertension Reports</i> , 2005, 7, 88-95.	1.5	79
279	Atherosclerosis imaging and circulating blood biomarkers: insights into subclinical atherosclerotic plaque burden and disease activity. <i>International Journal of Cardiovascular Imaging</i> , 2005, 21, 443-445.	0.7	0
280	Non-invasive Imaging of a Coronary Bypass Stenosis using CT Angiography in a Patient with Negative Stress Testing. <i>International Journal of Cardiovascular Imaging</i> , 2005, 21, 549-554.	0.7	0
281	Strategies for Modifying High-Density Lipoprotein Cholesterol: A Role for Nicotinic Acid. <i>Cardiovascular Drugs and Therapy</i> , 2005, 19, 415-422.	1.3	21
282	Fluvastatin in the therapy of acute coronary syndrome: Rationale and design of a multicenter, randomized, double-blind, placebo-controlled trial (The FACS Trial)[ISRCTN81331696]. <i>Current Controlled Trials in Cardiovascular Medicine</i> , 2005, 6, 4.	1.5	17
283	Statins research unfinished saga: desirability versus feasibility. <i>Cardiovascular Diabetology</i> , 2005, 4, 8.	2.7	9
284	The "Statinth" wonder of the world: a panacea for all illnesses or a bubble about to burst. <i>Journal of Negative Results in BioMedicine</i> , 2005, 4, 3.	1.4	8
285	Prevention of coronary artery disease in cancer patients. <i>Pediatric Blood and Cancer</i> , 2005, 44, 620-624.	0.8	16
286	Statin therapy should be considered routinely for people with diabetes mellitus. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 2005, 22, 233-236.	0.2	0
288	Treating non-ST-segment elevation ACS. <i>Postgraduate Medicine</i> , 2005, 118, 23-32.	0.9	0
289	Total First-Year Costs of Acute Coronary Syndrome in a Managed Care Setting. <i>Journal of Managed Care Pharmacy</i> , 2005, 11, 300-306.	2.2	70
290	Similar Medication Compliance and Control of Dyslipidemia With Simvastatin or Atorvastatin in a Staff-Model HMO Medical Clinic. <i>Journal of Managed Care Pharmacy</i> , 2005, 11, 499-504.	2.2	8

#	ARTICLE	IF	CITATIONS
291	Clinical and Economic Outcomes of Conversion of Simvastatin to Lovastatin in a Group-Model Health Maintenance Organization. <i>Journal of Managed Care Pharmacy</i> , 2005, 11, 681-686.	2.2	19
292	Implement Community Based Standards of Care. <i>Journal of Managed Care Pharmacy</i> , 2005, 11, S11-S16.	2.2	2
293	Potential Adverse Effects of Statins on Muscle. <i>Physical Therapy</i> , 2005, 85, 459-465.	1.1	57
294	Rationale and Design of the OACIS-LIPID Study That Evaluates Early Use of Pravastatin in Acute Myocardial Infarction. <i>Cardiology</i> , 2005, 5, 193-196.	0.3	3
295	Efficacy and safety of rosuvastatin in treatment of dyslipidemia. <i>American Journal of Health-System Pharmacy</i> , 2005, 62, 1033-1047.	0.5	72
297	Lipid-modifying drugs. <i>Medical Journal of Australia</i> , 2005, 182, 286-289.	0.8	13
298	STATINES IN PREVENTION AND TREATMENT OF ATHEROSCLEROSIS CONNECTED DISEASES: EFFICIENCY AND SAFETY. <i>Rational Pharmacotherapy in Cardiology</i> , 2005, 1, 48-53.	0.3	1
299	The management of hyperlipidaemia. <i>Practice Nursing</i> , 2005, 16, 382-387.	0.1	0
300	Angina. , 2005, , 127-174.		0
301	Real-World Effectiveness of Lipid-Lowering Therapy in Male and Female Outpatients with Coronary Heart Disease: Relation to Pre-Treatment Low-Density Lipoprotein-Cholesterol, Pre-Treatment Coronary Heart Disease Risk, and other Factors. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> . 2005. 12. 37-45.	3.1	18
302	Role of nicotinic acid in raising high-density lipoprotein cholesterol (HDL-C) to reduce cardiovascular risk: an Asian/Pacific consensus. <i>British Journal of Diabetes and Vascular Disease</i> , 2005, 5, S1-S15.	0.6	0
303	The Era of Statins " Is There Still a Place for Other Classes of Lipid-Lowering Drugs?. <i>Cardiology</i> , 2005, 5, 34-38.	0.3	1
305	Update in Endocrinology. <i>Annals of Internal Medicine</i> , 2005, 143, 673.	2.0	5
306	Pravastatin reduces thrombogenicity by mechanisms beyond plasma cholesterol lowering. <i>Thrombosis and Haemostasis</i> , 2005, 94, 1035-1041.	1.8	45
307	Value for Money in Disease Management of Acute Coronary Syndrome - The Price of Aspirin to Reduce the Costs of ACS. <i>Journal of Managed Care Pharmacy</i> , 2005, 11, 355-357.	2.2	1
308	The Status of Lipid Management in 1,836 Patients with Coronary Artery Disease: A multicenter survey to evaluate the percentage of Japanese coronary artery disease patients achieving the target low-density lipoprotein cholesterol level specified by the Japan Atherosclerosis Society. <i>Journal of Atherosclerosis and Thrombosis</i> . 2005. 12. 338-342.	0.9	15
309	Lipid-Lowering Therapy in Patients with Peripheral Arterial Disease. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2005, 10, 145-147.	1.0	13
311	Increasing High-Density Lipoprotein Cholesterol in Dyslipidemia by Cholesteryl Ester Transfer Protein Inhibition. <i>Circulation</i> , 2005, 111, 1847-1854.	1.6	84



#	ARTICLE	IF	CITATIONS
312	Mechanisms of Statin-Induced Myopathy. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, 2441-2444.	1.1	26
313	Commentary. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2005, 60, 598-598.	1.7	0
314	Clinical Significance of Statin Pleiotropic Effects. <i>Circulation</i> , 2005, 111, 2280-2281.	1.6	67
315	Commentary: Geoffrey Rose's thinking about coronary artery disease. <i>International Journal of Epidemiology</i> , 2005, 34, 246-247.	0.9	1
316	Effect of statins on the mortality of patients with ischaemic heart disease: population based cohort study with nested case-control analysis. <i>Heart</i> , 2005, 92, 752-758.	1.2	35
317	The Predictive Value of Lipid Markers in Vascular Disease. <i>Current Pharmaceutical Design</i> , 2005, 11, 2209-2224.	0.9	8
319	Low-Density Lipoprotein Cholesterol in Patients with Stable Coronary Heart Disease " Is It Time to Shift Our Goals?. <i>New England Journal of Medicine</i> , 2005, 352, 1483-1484.	13.9	46
320	Endothelial Function in the Forearm Circulation of Patients with the Metabolic Syndrome " Effect of Different Lipid-Lowering Regimens. <i>Cardiology</i> , 2005, 104, 176-180.	0.6	37
322	Optimizing Percutaneous Coronary Intervention Outcomes. <i>Circulation</i> , 2005, 111, 125-126.	1.6	5
323	The inhibitory potency of clopidogrel on ADP-induced platelet activation is not attenuated when it is co-administered with atorvastatin (20%mg/day) for 5 weeks in patients with acute coronary syndromes. <i>Platelets</i> , 2005, 16, 287-292.	1.1	17
324	Cardiovascular Disease Risk of Type 2 Diabetes Mellitus and Metabolic Syndrome: Focus on Aggressive Management of Dyslipidemia. <i>Current Diabetes Reviews</i> , 2005, 1, 127-135.	0.6	8
325	Reporting Clinical Trial Results To Inform Providers, Payers, And Consumers. <i>Health Affairs</i> , 2005, 24, 1571-1581.	2.5	81
326	Antibiotic Treatment of Chlamydia pneumoniae after Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2005, 352, 1646-1654.	13.9	278
327	Pharmacological modulation of plaque instability. <i>Lupus</i> , 2005, 14, 769-772.	0.8	14
328	Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey Replication. <i>Archives of General Psychiatry</i> , 2005, 62, 593.	13.8	15,111
329	Aim Low. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2005, 60, 599-600.	1.7	0
332	The effect of intensive lipid lowering on coronary atheroma and clinical outcome. <i>Heart</i> , 2005, 93, 149-151.	1.2	4
333	Short-term Risk of Death After Treatment With Nesiritide for Decompensated Heart Failure. <i>JAMA - Journal of the American Medical Association</i> , 2005, 293, 1900-5.	3.8	617

#	ARTICLE	IF	CITATIONS
334	Efficacy and Safety of Pravastatin in Children and Adolescents with Heterozygous Familial Hypercholesterolemia: A Prospective Clinical Follow-Up Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 1942-1952.	1.8	39
335	Lipid Management with Statins in Type 2 Diabetes Mellitus. <i>Annals of Pharmacotherapy</i> , 2005, 39, 1714-1719.	0.9	5
336	Impact on cardiovascular events of increasing high density lipoprotein cholesterol with and without lipid lowering drugs. <i>Heart</i> , 2005, 92, 746-751.	1.2	10
337	Aggressive Versus Moderate Lipid-Lowering Therapy in Hypercholesterolemic Postmenopausal Women. <i>Circulation</i> , 2005, 112, 563-571.	1.6	256
338	HMG-CoA Reductase Inhibitors Inhibit Endothelial Exocytosis and Decrease Myocardial Infarct Size. <i>Circulation Research</i> , 2005, 96, 1185-1192.	2.0	75
340	Circulating transcriptome reveals markers of atherosclerosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 3423-3428.	3.3	88
341	The declining prevalence of ST elevation myocardial infarction in patients presenting with acute coronary syndromes. <i>Heart</i> , 2005, 91, 1121-1123.	1.2	15
342	Intensive Lipid-Lowering Therapy in Patients with Coronary Heart Disease. <i>Annals of Pharmacotherapy</i> , 2005, 39, 329-334.	0.9	1
343	Impact of Short-Term Administration of High-Density Lipoproteins and Atorvastatin on Atherosclerosis in Rabbits. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, 2416-2421.	1.1	146
344	Pharmacogenetics: the outlook for genetic testing in statin therapy. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2005, 2, 2-3.	3.3	3
346	Does intensified cholesterol lowering provide greater protection from cardiovascular events among patients with stable coronary artery disease?. <i>Cmaj</i> , 2005, 172, 1294-1295.	0.9	0
347	A Simplified Approach to the Management of Non-ST-Segment Elevation Acute Coronary Syndromes. <i>JAMA - Journal of the American Medical Association</i> , 2005, 293, 349.	3.8	54
348	Update of antibiotic trials for secondary prevention of coronary heart disease. <i>Future Cardiology</i> , 2005, 1, 225-234.	0.5	1
349	Cathepsins: novel drug targets for cardiovascular diseases?. <i>Future Cardiology</i> , 2005, 1, 563-565.	0.5	1
350	High prevalence of low HDL-cholesterol in a pan-European survey of 8545 dyslipidaemic patients. <i>Current Medical Research and Opinion</i> , 2005, 21, 1927-1934.	0.9	85
351	Rosuvastatin: achieving cholesterol targets. <i>Future Cardiology</i> , 2005, 1, 289-297.	0.5	0
352	Anticipating the evolution of clinical cholesterol guidelines: implications of recent statin intervention trials. <i>Future Cardiology</i> , 2005, 1, 461-471.	0.5	0
353	Intensive Lipid Lowering with Atorvastatin in Coronary Disease. <i>New England Journal of Medicine</i> , 2005, 353, 93-96.	13.9	26

#	ARTICLE	IF	CITATIONS
354	Acute Coronary Syndromes without ST-Segment Elevation – What Is the Role of Early Intervention?. New England Journal of Medicine, 2005, 353, 1159-1161.	13.9	10
355	Are the benefits of statins a class effect?. Cmaj, 2005, 172, 1195-1196.	0.9	2
356	Effectiveness of statins for secondary prevention in elderly patients after acute myocardial infarction: an evaluation of class effect. Cmaj, 2005, 172, 1187-1194.	0.9	49
357	Management of patients with type 2 diabetes after acute coronary syndromes. Diabetes and Vascular Disease Research, 2005, 2, 144-154.	0.9	7
359	Progenitor cell therapy of ischemic heart disease: the new frontier. Future Cardiology, 2005, 1, 87-98.	0.5	1
360	Relation of Characteristics of Metabolic Syndrome to Short-Term Prognosis and Effects of Intensive Statin Therapy After Acute Coronary Syndrome: An analysis of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial. Diabetes Care, 2005, 28, 2508-2513.	4.3	67
361	Medical Management of Myocardial Ischemia. The American Journal of Geriatric Cardiology, 2005, 14, 205-209.	0.7	1
363	Evaluating Cardiovascular Pathophysiology and Anatomy in Atherosclerosis. The American Heart Hospital Journal, 2005, 3, 187-192.	0.2	10
364	Beyond statin therapy: why we need new thinking. Current Medical Research and Opinion, 2005, 21, S3-S8.	0.9	7
365	Global Risk Stratification to Improve Cardiovascular Prevention: Integration of Traditional Risk Factors, Emerging Risk Factors, and New, Noninvasive Cardiovascular Imaging. The American Heart Hospital Journal, 2005, 3, 265-268.	0.2	0
366	Metabolic Syndrome: Therapeutic Considerations. Handbook of Experimental Pharmacology, 2005, , 107-133.	0.9	32
367	Atorvastatin: An Update of Recent Clinical Trial Experience. Journal of Pharmacy Technology, 2005, 21, 197-202.	0.5	0
368	Lipoprotein-associated phospholipase A2: a novel marker of cardiovascular risk and potential therapeutic target. Expert Opinion on Investigational Drugs, 2005, 14, 671-679.	1.9	20
369	Efficacy and Safety of Lovastatin Therapy in Adolescent Girls With Heterozygous Familial Hypercholesterolemia. Pediatrics, 2005, 116, 682-688.	1.0	97
370	ATVB In Focus. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 480-481.	1.1	5
371	Should the NCEP III Guidelines Be Changed in Elderly and Younger Persons at High Risk for Cardiovascular Events?. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2005, 60, 591-592.	1.7	12
372	Drug therapy for prevention of cardiovascular disease – should surrogate measures be abandoned?. Clinical Medicine, 2005, 5, 282-286.	0.8	2
373	The contrOL of dYslipideMia in outPatlent clinics in GreeCe (Olympic) Study. Angiology, 2005, 56, 731-741.	0.8	19

#	ARTICLE	IF	CITATIONS
374	Atherosclerosis 2005. <i>Circulation</i> , 2005, 112, 3348-3353.	1.6	92
375	Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel. <i>Current Medical Research and Opinion</i> , 2005, 21, 665-682.	0.9	99
376	Medications for the treatment of acute coronary syndromes. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 2843-2854.	0.9	0
377	Rosuvastatin: a risk-benefit assessment for intensive lipid lowering. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 1897-1910.	0.9	10
378	The potential role of HDL and LDL cholesterol modulation in atheromatous plaque development. <i>Current Medical Research and Opinion</i> , 2005, 21, S17-S22.	0.9	14
379	Medical vs Surgical Management of Left Main Coronary Artery Disease. <i>JAMA - Journal of the American Medical Association</i> , 2005, 293, 1060.	3.8	0
380	Review: Treatment of lipids to reduce cardiovascular risk among people with the metabolic syndrome or type 2 diabetes. <i>British Journal of Diabetes and Vascular Disease</i> , 2005, 5, 315-319.	0.6	1
381	The IDEAL Cholesterol. <i>JAMA - Journal of the American Medical Association</i> , 2005, 294, 2492.	3.8	44
382	Short-Term Treatment With Atorvastatin Reduces Platelet CD40 Ligand and Thrombin Generation in Hypercholesterolemic Patients. <i>Circulation</i> , 2005, 111, 412-419.	1.6	159
383	Effect of Intensive Lipid Lowering, With or Without Antioxidant Vitamins, Compared With Moderate Lipid Lowering on Myocardial Ischemia in Patients With Stable Coronary Artery Disease. <i>Circulation</i> , 2005, 111, 1747-1755.	1.6	71
384	Treatment of Elevated Cholesterol. <i>Circulation</i> , 2005, 111, e360-3.	1.6	23
386	The Case for Medical Treatment in Chronic Stable Coronary Artery Disease. <i>Archives of Internal Medicine</i> , 2005, 165, 2587.	4.3	6
387	High-Dose Atorvastatin vs Usual-Dose Simvastatin for Secondary Prevention After Myocardial Infarction<SUBTITLE>The IDEAL Study: A Randomized Controlled Trial</SUBTITLE>. <i>JAMA - Journal of the American Medical Association</i> , 2005, 294, 2437.	3.8	1,401
389	Heat Shock Protein Antibody Titers Are Reduced by Statin Therapy in Dyslipidemic Subjects: A Pilot Study. <i>Angiology</i> , 2005, 56, 61-68.	0.8	20
391	Clinical Use and Pathogenetic Basis of Laboratory Tests for the Evaluation of Primary Arterial Hypertension. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2005, 42, 393-452.	2.7	5
392	Treatment with statins in the acute phase of ischemic stroke. <i>Expert Review of Neurotherapeutics</i> , 2005, 5, 211-221.	1.4	21
393	The Role of Statins in Oxidative Stress and Cardiovascular Disease. <i>Current Drug Targets Cardiovascular &amp; Haematological Disorders</i> , 2005, 5, 165-175.	2.0	9
394	Editorial: Emerging Pharmacological Strategies for the Prevention of Atherosclerotic Disease Progression. <i>Current Drug Targets Cardiovascular &amp; Haematological Disorders</i> , 2005, 5, 431-432.	2.0	0

#	ARTICLE	IF	CITATIONS
395	Cholesterol Absorption Blockade with Ezetimibe. <i>Current Drug Targets Cardiovascular &amp; Haematological Disorders</i> , 2005, 5, 455-462.	2.0	34
396	A Rationale for Combined Therapy with a Calcium Channel Blocker and a Statin: Evaluation of Basic and Clinical Evidence. <i>Current Drug Targets Cardiovascular &amp; Haematological Disorders</i> , 2005, 5, 489-501.	2.0	22
397	Influence of Different Lipid-Lowering Strategies on Plaque Volume and Plaque Composition in Patients with Coronary Artery Disease: Role of Intravascular Ultrasound Imaging. <i>Kidney and Blood Pressure Research</i> , 2005, 28, 290-294.	0.9	2
398	Impact of the Pravastatin or Atorvastatin Evaluation and Infection Therapy—Thrombolysis In Myocardial Infarction 22/Reversal of Atherosclerosis With Aggressive Lipid Lowering Trials on Trends in Intensive Versus Moderate Statin Therapy in Ontario, Canada. <i>Circulation</i> , 2005, 112, 1296-1300.	1.6	26
399	Real-world effectiveness of lipid-lowering therapy in male and female outpatients with coronary heart disease: relation to pre-treatment low-density lipoprotein-cholesterol, pre-treatment coronary heart disease risk, and other factors. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2005, 12, 37-45.	3.1	11
400	Lipophilic statins do not affect the antiplatelet potency of clopidogrel. <i>Platelets</i> , 2005, 16, 225-226.	1.1	2
401	The origins of age-related proinflammatory state. <i>Blood</i> , 2005, 105, 2294-2299.	0.6	770
402	Statin Therapy, LDL Cholesterol, C-Reactive Protein, and Coronary Artery Disease. <i>New England Journal of Medicine</i> , 2005, 352, 29-38.	13.9	1,234
403	Commentary. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2005, 60, 597-598.	1.7	0
404	Early Invasive versus Selectively Invasive Management for Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2005, 353, 1095-1104.	13.9	485
405	Effect of Combining Psyllium Fiber With Simvastatin in Lowering Cholesterol. <i>Archives of Internal Medicine</i> , 2005, 165, 1161.	4.3	104
406	High-Dose Statins in Acute Coronary Syndromes. <i>JAMA - Journal of the American Medical Association</i> , 2005, 293, 36.	3.8	0
407	Review: Defining the role of statins in diabetes. <i>British Journal of Diabetes and Vascular Disease</i> , 2005, 5, 55-62.	0.6	3
408	Managing Cardiovascular Risk in Patients With HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005, 38, 115-123.	0.9	52
409	In-Hospital Initiation of Statin Therapy in Acute Coronary Syndromes. <i>Chest</i> , 2005, 128, 3641-3651.	0.4	16
410	THE TREAT-TO-TARGET PARADIGM: A CROSS-SECTIONAL SURVEY OF CURRENT THERAPIES AND ACHIEVED METABOLIC CONTROL IN 800 TYPE 2 DIABETIC PATIENTS. <i>Acta Clinica Belgica</i> , 2005, 60, 79-85.	0.5	5
411	Statins, Ventricular Arrhythmias and Heart Rate Variability in Patients with Implantable Cardioverter Defibrillators and Coronary Heart Disease. <i>Cardiology</i> , 2005, 104, 210-214.	0.6	16
412	Intravascular ultrasound: defining plaque regression. <i>British Journal of Hospital Medicine (London,)</i> Tj ETQq1 1 0.784314 rgBT <sub>2</sub> /Overlook	0.2	

#	ARTICLE	IF	CITATIONS
413	Effect of combinations of drugs on all cause mortality in patients with ischaemic heart disease: nested case-control analysis. <i>BMJ: British Medical Journal</i> , 2005, 330, 1059-1063.	2.4	118
414	Loss of Imprinting of IGF2: A Common Epigenetic Modifier of Intestinal Tumor Risk. <i>Cancer Research</i> , 2005, 65, 11236-11240.	0.4	119
415	Hepatic and Cardiovascular Consequences of Familial Hypobetalipoproteinemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, 1979-1984.	1.1	103
416	Prevention and Health Services Delivery. <i>Stroke</i> , 2005, 36, 222-224.	1.0	0
417	Vitamin Intervention for Stroke Prevention Trial. <i>Stroke</i> , 2005, 36, 2404-2409.	1.0	235
418	Does intensive statin therapy lower mortality and cardiovascular event risk in patients with acute coronary syndrome?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2005, 2, 10-11.	3.3	2
419	Strategies to promote HDL-C: an emerging therapeutic target. <i>European Heart Journal</i> , 2005, 26, 853-855.	1.0	10
420	The statin studies: from targeting hypercholesterolaemia to targeting the high-risk patient. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2005, 98, 599-614.	0.2	44
421	Changing lipid-lowering guidelines: whom to treat and how low to go. <i>Country Review Ukraine</i> , 2005, 7, A12-A19.	0.8	5
422	Cardiovascular disease in HIV-positive patients. <i>Aids</i> , 2005, 19, 641-652.	1.0	67
423	Beneficial effect of early initiation of lipid-lowering therapy following renal transplantation. <i>Nephrology Dialysis Transplantation</i> , 2005, 20, 974-980.	0.4	72
424	Beyond LDL-cholesterol reduction: the way ahead in managing dyslipidaemia. <i>Country Review Ukraine</i> , 2005, 7, F56-F62.	0.8	12
425	The societal context of coronary artery disease. <i>Country Review Ukraine</i> , 2005, 7, A5-A11.	0.8	1
426	Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. <i>Lancet, The</i> , 2005, 366, 1267-1278.	6.3	6,113
427	Factores metab?licos de riesgo cardiovascular. Relevancia epidemiol?gica. Tratamiento farmacol?gico. Situaciones de especial relevancia. <i>Medicine</i> , 2005, 9, 3032-3043.	0.0	0
430	¿Hasta d?nde hay que reducir el colesterol en el paciente de alto riesgo cardiovascular?. <i>Hipertension</i> , 2005, 22, 318-331.	0.0	0
431	Implicaciones cl?nicas del estudio TNT. <i>Cl?nica E Investigaci?n En Arteriosclerosis</i> , 2005, 17, 249-254.	0.4	0
433	Thematic review series: The Immune System and Atherogenesis. The role of natural antibodies in atherogenesis. <i>Journal of Lipid Research</i> , 2005, 46, 1353-1363.	2.0	224

#	ARTICLE	IF	CITATIONS
434	Management of dyslipidemia in elderly diabetic patients. <i>Diabetes and Metabolism</i> , 2005, 31, 5S74-5S81.	1.4	6
436	Endothelium-ameliorating effects of statin therapy and coenzyme Q10 reductions in chronic heart failure. <i>Atherosclerosis</i> , 2005, 179, 201-206.	0.4	90
437	Effects of ezetimibe on plasma lipoproteins in severely hypercholesterolemic patients treated with regular LDL-apheresis and statins. <i>Atherosclerosis</i> , 2005, 180, 107-112.	0.4	23
438	High-density lipoprotein cholesterol in the cardiovascular equation: Does the "œgood" still count?. <i>Atherosclerosis</i> , 2005, 180, 217-223.	0.4	21
440	Diabetic dyslipidaemia: Effective management reduces cardiovascular risk. <i>Atherosclerosis Supplements</i> , 2005, 6, 37-43.	1.2	4
441	What is the most effective strategy for managing diabetic dyslipidaemia?. <i>Atherosclerosis Supplements</i> , 2005, 6, 21-27.	1.2	7
442	Integrated Management of Patients with Diabetes Mellitus and Ischemic Heart Disease: PCI, CABG, and Medical Therapy. <i>Current Problems in Cardiology</i> , 2005, 30, 583-617.	1.1	4
443	Non-High-Density Lipoprotein Cholesterol: Why Lower Is Better. <i>Preventive Cardiology</i> , 2005, 8, 173-177.	1.1	11
445	Role of Lipoprotein-Associated Phospholipase A 2 in Atherosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, 923-931.	1.1	430
446	Chronic Stable Angina. <i>New England Journal of Medicine</i> , 2005, 352, 2524-2533.	13.9	195
447	Rosuvastatin: A High-Potency HMG-CoA Reductase Inhibitor. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2005, 45, 503-513.	0.7	11
448	Discontinuing Cardiovascular Medications at the End of Life: Lipid-Lowering Agents. <i>Journal of Palliative Medicine</i> , 2005, 8, 876-881.	0.6	47
449	A Randomized Trial of the Efficacy and Safety of Fenofibrate versus Pravastatin in HIV-Infected Subjects with Lipid Abnormalities: AIDS Clinical Trials Group Study 5087. <i>AIDS Research and Human Retroviruses</i> , 2005, 21, 757-767.	0.5	109
450	The Dyslipidemia of Diabetes Mellitus: Giving Triglycerides and High-Density Lipoprotein Cholesterol a Higher Priority?. <i>Endocrinology and Metabolism Clinics of North America</i> , 2005, 34, 27-48.	1.2	26
451	Updated National Cholesterol Education Program III guidelines. <i>Journal of the American Medical Directors Association</i> , 2005, 6, 160-161.	1.2	8
453	Getting There: Statin Plus Ezetimibe for Low-Density Lipoprotein Cholesterol Goals. <i>Mayo Clinic Proceedings</i> , 2005, 80, 585-586.	1.4	5
454	Cardiovascular risk prevention in peripheral artery disease. <i>Journal of Vascular Surgery</i> , 2005, 41, 1070-1073.	0.6	19
456	Chronic Kidney Disease: A Risk Factor for Cardiovascular Disease. <i>Cardiology Clinics</i> , 2005, 23, 343-362.	0.9	38

#	ARTICLE	IF	CITATIONS
457	The role of lipid management in diabetes. <i>Cardiology Clinics</i> , 2005, 23, 153-164.	0.9	0
458	Conversion to Atorvastatin in Patients Intolerant or Refractory to Simvastatin Therapy: The CAPISH Study. <i>Mayo Clinic Proceedings</i> , 2005, 80, 1163-1168.	1.4	22
459	The Safety of Rosuvastatin as Used in Common Clinical Practice. <i>Circulation</i> , 2005, 111, 3051-3057.	1.6	157
460	Dieci anni di utilizzo delle statine: adesione alla terapia e costi del trattamento farmacologico. <i>Pharmacoeconomics Italian Research Articles</i> , 2005, 7, 187-194.	0.2	4
461	The DISCOVERY PENTA study: a Direct Statin COmparison of LDLâ€™ Value â€™ an Evaluation of Rosuvastatin therapY compared with atorvastatin. <i>Current Medical Research and Opinion</i> , 2005, 21, 1307-1315.	0.9	30
463	Biomarkers in Angina. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2005, 65, 86-92.	0.6	5
464	Effective management of dyslipidaemia among patients with cardiovascular risk: Updated recommendations on identification and follow-up. <i>European Journal of General Practice</i> , 2005, 11, 68-75.	0.9	5
465	Adding clopidogrel to aspirin improves outcome in ST-elevation myocardial infarction patients receiving fibrinolytic therapy. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2005, 5, 751-761.	0.7	3
466	Berberine â€™ a novel approach to cholesterol lowering. <i>Expert Opinion on Investigational Drugs</i> , 2005, 14, 683-685.	1.9	60
467	Statins and LDLâ€™cholesterol lowering: an overview. <i>Current Medical Research and Opinion</i> , 2005, 21, S9-S16.	0.9	45
468	More support for high-dose atorvastatin in coronary artery disease. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 2365-2368.	0.9	0
469	Costâ€™effectiveness of HMG-CoA reductase inhibitors in the treatment of dyslipidemia and prevention of CHD. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2005, 5, 603-623.	0.7	0
470	Lipid-modifying therapy and attainment of cholesterol goals in Europe: the Return on Expenditure Achieved for Lipid Therapy (REALITY) study. <i>Current Medical Research and Opinion</i> , 2005, 21, 1389-1399.	0.9	76
471	The use of ezetimibe in achieving low density lipoprotein lowering goals in clinical practice: position statement of a United Kingdom consensus panel. <i>Current Medical Research and Opinion</i> , 2005, 21, 959-969.	0.9	68
472	Relating statin therapy to C-reactive protein levels. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 1597-1600.	0.9	9
473	Atherosclerosis and innate immune signaling. <i>Annals of Medicine</i> , 2005, 37, 130-140.	1.5	37
474	Fluvastatin: efficacy and safety in reducing cardiac events. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 1883-1895.	0.9	3
475	Statins and the Response to Myocardial Injury. <i>American Journal of Cardiovascular Drugs</i> , 2005, 5, 163-170.	1.0	13



#	ARTICLE	IF	CITATIONS
476	Industry Pulse. High Blood Pressure and Cardiovascular Prevention, 2005, 12, 53-56.	1.0	0
477	Adverse Effects of Statins. High Blood Pressure and Cardiovascular Prevention, 2005, 12, 141-148.	1.0	1
479	Atorvastatin. Expert Opinion on Pharmacotherapy, 2005, 6, 1191-1203.	0.9	18
480	Pathophysiology of Coronary Artery Disease. Circulation, 2005, 111, 3481-3488.	1.6	1,467
481	Management of Acute Coronary Syndromes. New England Journal of Medicine, 2005, 353, 2714-2718.	13.9	4
482	CARDS and A to Z. Preventive Cardiology, 2005, 8, 59-62.	1.1	2
483	Women's Health Study (Aspirin) and TNT. Preventive Cardiology, 2005, 8, 181-185.	1.1	0
484	Single-pill Therapy in the Treatment of Concomitant Hypertension and Dyslipidemia (The Tj ETQq1 1 0.784314 rgBT /Overlock 10 T 5	1.0	64
485	Differences between statins on clinical endpoints: a population-based cohort study. Current Medical Research and Opinion, 2005, 21, 1461-1468.	0.9	20
486	Targeting vascular risk in patients with metabolic syndrome but without diabetes. Metabolism: Clinical and Experimental, 2005, 54, 1065-1074.	1.5	66
487	A randomized, open-label study to evaluate the efficacy and safety of pitavastatin compared with simvastatin in Korean patients with hypercholesterolemia. Clinical Therapeutics, 2005, 27, 1074-1082.	1.1	49
488	Effects of simvastatin 20 mg/d on serum lipid profiles in Japanese hyperlipidemic patients: A prospective, open-label pilot study. Current Therapeutic Research, 2005, 66, 613-629.	0.5	3
489	C-reactive protein level as an independent risk factor of metabolic syndrome in the Korean population. Diabetes Research and Clinical Practice, 2005, 70, 126-133.	1.1	43
490	Long-term risk reduction: Who needs treatment?. Diabetes Research and Clinical Practice, 2005, 68, S15-S22.	1.1	5
491	Comparison of the effects of pravastatin and atorvastatin on fracture incidence in the PROVE IT-TIMI 22 trial—Secondary analysis of a randomized controlled trial. Bone, 2005, 37, 190-191.	1.4	19
492	Atorvastatin reduces thrombin generation after percutaneous coronary intervention independent of soluble tissue factor. Thrombosis Research, 2005, 115, 469-474.	0.8	9
493	Implications of emerging risk factors for therapeutic intervention. Nutrition, Metabolism and Cardiovascular Diseases, 2005, 15, 373-381.	1.1	27
495	Early initiation of lipid-lowering therapy for acute coronary syndromes improves compliance with guideline recommendations: Observations from the Orbofiban in Patients with Unstable Coronary Syndromes (OPUS—TIMI 16) trial. American Heart Journal, 2005, 149, 444-450.	1.2	30

#	ARTICLE	IF	CITATIONS
496	Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemia. <i>American Heart Journal</i> , 2005, 149, e1-e8.	1.2	51
497	Atorvastatin has an important acute anti-inflammatory effect in patients with acute coronary syndrome: Results of a randomized, double-blind, placebo-controlled study. <i>American Heart Journal</i> , 2005, 149, 451-457.	1.2	94
498	Revascularization of coronary atherosclerosis in patients with diabetes mellitusâ€”There is more to it than meets the image intensifier. <i>American Heart Journal</i> , 2005, 149, 190-193.	1.2	8
500	Statins in acute coronary syndromes: The sooner, the better?. <i>American Heart Journal</i> , 2005, 149, 377-380.	1.2	3
501	Association between lipid testing and statin therapy in acute myocardial infarction patients. <i>American Heart Journal</i> , 2005, 150, 419-425.	1.2	16
502	Simvastatin does not inhibit intimal hyperplasia and restenosis but promotes plaque regression in normocholesterolemic patients undergoing coronary stenting: A randomized study with intravascular ultrasound. <i>American Heart Journal</i> , 2005, 149, 520-526.	1.2	50
503	Plaque regressionâ€”A new target for antiatherosclerotic therapy. <i>American Heart Journal</i> , 2005, 149, 384-387.	1.2	6
504	Influence of clinical trial enrollment on the quality of care and outcomes for patients with nonâ€”ST-segment elevation acute coronary syndromes. <i>American Heart Journal</i> , 2005, 149, 474-481.	1.2	66
505	Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: The Vytorin Versus Atorvastatin (VYVA) Study. <i>American Heart Journal</i> , 2005, 149, 464-473.	1.2	237
506	A contemporary assessment of low-molecular-weight heparin for the treatment of acute coronary syndromes: Factoring in new trials and meta-analysis data. <i>American Heart Journal</i> , 2005, 149, S100-S106.	1.2	5
507	Early effects of statin therapy on endothelial function and microvascular reactivity in patients with coronary artery disease. <i>American Heart Journal</i> , 2005, 149, 1137.e9-1137.e16.	1.2	32
508	Should we measure C-reactive protein levels to ascertain the adequacy of statin therapy in patients who are at very high risk for a coronary heart disease event?. <i>American Heart Journal</i> , 2005, 150, 650-651.	1.2	2
509	Lipid-lowering therapy and the patient with multiple risk factors: what have we learned from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)?. <i>American Journal of Medicine</i> , 2005, 118, 3-9.	0.6	14
510	Statin use in a â€œreal-worldâ€”clinical setting: aggressive lipid lowering compared with usual care in the Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE) trial. <i>American Journal of Medicine</i> , 2005, 118, 16-21.	0.6	26
511	What impact will current trial data have on future guideline recommendations?. <i>American Journal of Medicine</i> , 2005, 118, 42-47.	0.6	5
512	Statin therapy in the treatment of Alzheimer disease: what is the rationale?. <i>American Journal of Medicine</i> , 2005, 118, 48-53.	0.6	41
513	Potential vascular benefits of statins. <i>American Journal of Medicine</i> , 2005, 118, 62-67.	0.6	22
514	Benefits of lipid-lowering therapy in patients with type 2 diabetes mellitus. <i>American Journal of Medicine</i> , 2005, 118, 10-15.	0.6	15

#	ARTICLE	IF	CITATIONS
515	Improved outcome after acute coronary syndromes with an intensive versus standard lipid-lowering regimen: results from the Pravastatin or Atorvastatin Evaluation and Infection Therapyâ€“Thrombolysis in Myocardial Infarction 22 (PROVE ITâ€“TIMI 22) trial. American Journal of Medicine, 2005, 118, 28-35.	0.6	60
516	Halting the progression of atherosclerosis with intensive lipid lowering: results from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial. American Journal of Medicine, 2005, 118, 22-27.	0.6	38
521	Pharmacological Strategies to Reduce Cardiovascular Risk in Type 2 Diabetes Mellitus. Drugs, 2005, 65, 433-445.	4.9	8
522	Angiotensin Antagonism in Coronary Artery Disease. Drugs, 2005, 65, 1073-1096.	4.9	14
523	Clinical utility of extended-release niacin: update and summary. Future Cardiology, 2005, 1, 571-578.	0.5	0
524	C-Reactive Protein Levels and Outcomes after Statin Therapy. New England Journal of Medicine, 2005, 352, 20-28.	13.9	2,103
525	Effect of Maximum Dose of Atorvastatin on Inflammation, Thrombogenesis, and Fibrinolysis in High-Risk Patients With Ischemic Heart Disease. Revista Espanola De Cardiologia (English Ed ), 2005, 58, 934-940.	0.4	4
526	New Insights Towards Catheter-Based Identification of Vulnerable Plaque. Revista Espanola De Cardiologia (English Ed ), 2005, 58, 1197-1206.	0.4	4
529	Effect of lipid-lowering therapy with atorvastatin on atherosclerotic aortic plaques detected by noninvasive magnetic resonance imaging. Journal of the American College of Cardiology, 2005, 45, 733-742.	1.2	141
530	Optimal lipids, statins, and dementia: Reply. Journal of the American College of Cardiology, 2005, 45, 964-965.	1.2	3
531	Optimal lipids, statins, and dementia. Journal of the American College of Cardiology, 2005, 45, 963-964.	1.2	6
532	The year in interventional cardiology. Journal of the American College of Cardiology, 2005, 45, 1117-1134.	1.2	47
533	Resistance to clopidogrel: A review of the evidence. Journal of the American College of Cardiology, 2005, 45, 1157-1164.	1.2	457
534	Relative Efficacy of Atorvastatin 80 mg and Pravastatin 40 mg in Achieving the Dual Goals of Low-Density Lipoprotein Cholesterol <70 mg/dl and C-Reactive Protein <2 mg/l. Journal of the American College of Cardiology, 2005, 45, 1644-1648.	1.2	219
535	Treatment of Asymptomatic Adults With Elevated Coronary Calcium Scores With Atorvastatin, Vitamin C, and Vitamin E. Journal of the American College of Cardiology, 2005, 46, 166-172.	1.2	380
536	Effects of Aggressive Versus Conventional Lipid-Lowering Therapy by Simvastatin on Human Atherosclerotic Lesions. Journal of the American College of Cardiology, 2005, 46, 106-112.	1.2	257
537	Early and Late Benefits of High-Dose Atorvastatin in Patients With Acute Coronary Syndromes. Journal of the American College of Cardiology, 2005, 46, 1405-1410.	1.2	313
538	Can Low-Density Lipoprotein Be Too Low? The Safety and Efficacy of Achieving Very Low Low-Density Lipoprotein With Intensive Statin Therapy. Journal of the American College of Cardiology, 2005, 46, 1411-1416.	1.2	306

#	ARTICLE	IF	CITATIONS
539	Suppression of Endothelial Progenitor Cells in Human Coronary Artery Disease by the Endogenous Nitric Oxide Synthase Inhibitor Asymmetric Dimethylarginine. <i>Journal of the American College of Cardiology</i> , 2005, 46, 1693-1701.	1.2	221
540	Stabilization of Carotid Atheroma Assessed by Quantitative Ultrasound Analysis in Nonhypercholesterolemic Patients With Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2005, 46, 2022-2030.	1.2	91
541	C-Reactive Protein Increase in Unstable Coronary Disease. <i>Journal of the American College of Cardiology</i> , 2005, 46, 1496-1502.	1.2	86
542	Pleiotropic Effects of Statins: Benefit Beyond Cholesterol Reduction?. <i>Journal of the American College of Cardiology</i> , 2005, 46, 1855-1862.	1.2	397
543	The Potential Relevance of the Multiple Lipid-Independent (Pleiotropic) Effects of Statins in the Management of Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2005, 46, 1425-1433.	1.2	248
544	Perspectives on Dyslipidemia and Coronary Heart Disease in Women. <i>Journal of the American College of Cardiology</i> , 2005, 46, 1628-1635.	1.2	67
545	The Year in Non-ST-Segment Elevation Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2005, 46, 906-919.	1.2	40
546	Evolving Concepts of Dyslipidemia, Atherosclerosis, and Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2005, 46, 1219-1224.	1.2	48
547	The Forgotten Majority. <i>Journal of the American College of Cardiology</i> , 2005, 46, 1225-1228.	1.2	345
548	Relationship Between Uncontrolled Risk Factors and C-Reactive Protein Levels in Patients Receiving Standard or Intensive Statin Therapy for Acute Coronary Syndromes in the PROVE IT-TIMI 22 Trial. <i>Journal of the American College of Cardiology</i> , 2005, 46, 1417-1424.	1.2	113
549	National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand. <i>Heart Lung and Circulation</i> , 2005, 14, 275-291.	0.2	115
550	Risk Factors for Atherosclerotic Vascular Disease. <i>Handbook of Experimental Pharmacology</i> , 2005, , 71-105.	0.9	21
551	PLEIOTROPIC EFFECTS OF STATINS. <i>Annual Review of Pharmacology and Toxicology</i> , 2005, 45, 89-118.	4.2	1,574
552	Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease. <i>New England Journal of Medicine</i> , 2005, 352, 1425-1435.	13.9	3,152
553	Atherosclerotic risk factor control in patients with peripheral arterial disease. <i>Journal of Vascular Surgery</i> , 2005, 41, 816-822.	0.6	88
555	Impact of Coaching Patients on Coronary Risk Factors. <i>Disease Management and Health Outcomes</i> , 2005, 13, 225-244.	0.3	13
556	The Performance Gap between Clinical Trials and Patient Treatment for Dyslipidemia. <i>Disease Management and Health Outcomes</i> , 2005, 13, 255-265.	0.3	3
557	Dyslipidemia and lipid-lowering therapy in the elderly. <i>Expert Review of Cardiovascular Therapy</i> , 2005, 3, 453-463.	0.6	2

#	ARTICLE	IF	CITATIONS
558	Current understanding of the role of high-density lipoproteins in atherosclerosis and senescence. Expert Review of Cardiovascular Therapy, 2005, 3, 1071-1086.	0.6	37
559	Atorvastatin and cardiovascular protection: a review and comparison of recent clinical trials. Expert Opinion on Pharmacotherapy, 2005, 6, 915-927.	0.9	20
560	Changes in lipids over twelve months after initiating protease inhibitor therapy among persons treated for HIV/AIDS. Lipids in Health and Disease, 2005, 4, 4.	1.2	27
561	Cardiovascular Biomarkers. , 2006, , .		5
562	The Effectiveness of Intensive Glycemic Control for the Prevention of Vascular Complications in Diabetes Mellitus. Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders, 2006, 5, 273-286.	1.8	25
563	Managing Hyperlipidaemia in the Elderly. Drugs and Aging, 2006, 23, 181-189.	1.3	13
564	Effectiveness of Ezetimibe Added to Ongoing Statin Therapy in Modifying Lipid Profiles and Low-Density Lipoprotein Cholesterol Goal Attainment in Patients of Different Races and Ethnicities: A Substudy of the Ezetimibe Add-On to Statin for Effectiveness Trial. Mayo Clinic Proceedings, 2006, 81, 1177-1185.	1.4	28
565	Assessment and Management of Lipid Disorders in Men. Primary Care - Clinics in Office Practice, 2006, 33, 93-114.	0.7	1
566	Pathogenesis and Early Management of Non-“ST-segment Elevation Acute Coronary Syndromes. Cardiology Clinics, 2006, 24, 19-35.	0.9	5
567	Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction. Expert Review of Cardiovascular Therapy, 2006, 4, 461-476.	0.6	44
568	Diabetic Dyslipidemia and the Heart. Heart Failure Clinics, 2006, 2, 37-52.	1.0	1
569	Primary and secondary prevention of heart failure with statins. Expert Review of Cardiovascular Therapy, 2006, 4, 917-926.	0.6	13
570	Lipid Management and Cholesterol Goal Attainment in Norway. American Journal of Cardiovascular Drugs, 2006, 6, 121-128.	1.0	16
571	The Role of Oral Antiplatelet Agents in Atherothrombotic Disease. American Journal of Cardiovascular Drugs, 2006, 6, 149-157.	1.0	16
572	Intensive Reduction of Low-Density Lipoprotein-Cholesterol. American Journal of Cardiovascular Drugs, 2006, 6, 367-371.	1.0	7
573	The A-SACT (Achievement in Singapore of Cholesterol Targets) Study in Patients with Coronary Heart Disease. American Journal of Cardiovascular Drugs, 2006, 6, 383-391.	1.0	23
574	Treatment of High-Risk Hypertensive Patients. High Blood Pressure and Cardiovascular Prevention, 2006, 13, 13-19.	1.0	0
576	Ezetimibe/simvastatin single tablet versus rosuvastatin in patients with hypercholesterolemia. Current Medical Research and Opinion, 2006, 22, 2037-2039.	0.9	7

#	ARTICLE	IF	CITATIONS
577	Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe. <i>Current Medical Research and Opinion</i> , 2006, 22, 511-528.	0.9	54
579	The effect of high dose simvastatin on, platelet size in patients with, type 2 diabetes mellitus. <i>Platelets</i> , 2006, 17, 292-295.	1.1	2
581	Colesevelam hydrochloride in the management of dyslipidemia. <i>Expert Review of Cardiovascular Therapy</i> , 2006, 4, 283-291.	0.6	18
582	Paraoxonase-2 Deficiency Aggravates Atherosclerosis in Mice Despite Lower Apolipoprotein-B-containing Lipoproteins. <i>Journal of Biological Chemistry</i> , 2006, 281, 29491-29500.	1.6	149
583	The potential for CETP inhibition to reduce cardiovascular disease risk. <i>Current Medical Research and Opinion</i> , 2006, 22, 2467-2478.	0.9	10
584	Influence of Statins on Perioperative Outcomes. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2006, 20, 251-258.	0.6	15
585	Management of Dyslipidemia with Statins in the Patient with Peripheral Arterial Disease. <i>Techniques in Vascular and Interventional Radiology</i> , 2006, 9, 50-55.	0.4	3
587	Aggressive Very Low-Density Lipoprotein (VLDL) and LDL Lowering by Gene Transfer of the VLDL Receptor Combined with a Low-Fat Diet Regimen Induces Regression and Reduces Macrophage Content in Advanced Atherosclerotic Lesions in LDL Receptor-Deficient Mice. <i>American Journal of Pathology</i> , 2006, 168, 2064-2073.	1.9	42
589	Statin wars following coronary revascularization – Evidence-based clinical practice?. <i>Canadian Journal of Cardiology</i> , 2006, 22, 54-58.	0.8	8
590	Lower is better: Implications of the Treating to New Targets (TNT) study for Canadian patients. <i>Canadian Journal of Cardiology</i> , 2006, 22, 835-839.	0.8	9
591	Combination of statin and ezetimibe for the treatment of dyslipidemias and the prevention of coronary artery disease. <i>Canadian Journal of Cardiology</i> , 2006, 22, 863-868.	0.8	19
592	Canadian Cardiovascular Society position statement – Recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. <i>Canadian Journal of Cardiology</i> , 2006, 22, 913-927.	0.8	271
593	The clinical effect and tolerability of ezetimibe in high-risk patients managed in a specialty cardiovascular risk reduction clinic. <i>Canadian Journal of Cardiology</i> , 2006, 22, 939-945.	0.8	8
594	Efficacy and tolerability of ezetimibe 10 mg/day coadministered with statins in patients with primary hypercholesterolemia who do not achieve target LDL-C while on statin monotherapy: A Canadian, multicentre, prospective study – the Ezetrol® Add-On Study. <i>Canadian Journal of Cardiology</i> , 2006, 22, 1035-1044.	0.8	19
595	A comparison of Canadian and American guidelines for lipid management using data from the National Cholesterol Education Program Evaluation Project Utilizing Novel E-technology (NEPTUNE) II survey. <i>Canadian Journal of Cardiology</i> , 2006, 22, 315-322.	0.8	6
596	The use of lipid-lowering therapy for secondary prevention in patients undergoing percutaneous coronary intervention. <i>Canadian Journal of Cardiology</i> , 2006, 22, 419-423.	0.8	2
597	Non-ST segment elevation acute coronary syndromes: A simplified risk-oriented algorithm. <i>Canadian Journal of Cardiology</i> , 2006, 22, 663-677.	0.8	13
598	Profound regression of coronary atherosclerosis with statins. <i>Canadian Journal of Cardiology</i> , 2006, 22, 709.	0.8	1

#	ARTICLE	IF	CITATIONS
599	PROVE-IT proved it: Lower is better – Pro. Canadian Journal of Cardiology, 2006, 22, 91B-94B.	0.8	1
600	PROVE-IT proves that lower is better: A contrary view. Canadian Journal of Cardiology, 2006, 22, 95B-96B.	0.8	0
601	Prevention challenges: The era of atherosclerosis regression. Canadian Journal of Cardiology, 2006, 22, 27C-30C.	0.8	4
603	Tratamiento de los factores de riesgo cardiovascular en pacientes con accidente vascular cerebral. Clínica E Investigación En Arteriosclerosis, 2006, 18, 115-120.	0.4	0
604	Lipoproteínas clásicas, terapéuticas modernas. Farmacología de las lipoproteínas de alta densidad. Clínica E Investigación En Arteriosclerosis, 2006, 18, 10-19.	0.4	0
605	Controversies in stable coronary artery disease. Lancet, The, 2006, 367, 69-78.	6.3	56
606	Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet, The, 2006, 368, 1155-1163.	6.3	856
607	AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update. Journal of the American College of Cardiology, 2006, 47, 2130-2139.	1.2	526
608	Bioavailability of Amlodipine Besylate/Atorvastatin Calcium Combination Tablet. Journal of Clinical Pharmacology, 2006, 46, 1030-1037.	1.0	25
609	Effects of Early Treatment With Statins on Short-term Clinical Outcomes in Acute Coronary Syndromes. JAMA - Journal of the American Medical Association, 2006, 295, 2046.	3.8	146
610	The relationship between body fat and C-reactive protein in middle-aged Korean population. Atherosclerosis, 2006, 184, 171-177.	0.4	28
611	Long-term achievement of the therapeutic objectives of lipid-lowering agents in primary prevention patients and cardiovascular outcomes: An observational study. Atherosclerosis, 2006, 185, 58-64.	0.4	18
612	Estimating the fasting triglyceride concentration from the postprandial HDL-cholesterol and apolipoprotein CIII concentrations. Atherosclerosis, 2006, 184, 413-419.	0.4	14
613	The evolution of European guidelines: Changing the management of cholesterol levels. Atherosclerosis, 2006, 185, 12-20.	0.4	21
614	A triumvirate of targets in the prevention and treatment paradigm for cardiovascular disease. Atherosclerosis Supplements, 2006, 7, 21-29.	1.2	6
615	Raising high-density lipoprotein with cholesteryl ester transfer protein inhibitors. Current Opinion in Pharmacology, 2006, 6, 162-168.	1.7	26
616	Elevated Lipoprotein(a) – A Genetic Risk Factor for Premature Vascular Disease in People With and Without Standard Risk Factors: A Review. Disease-a-Month, 2006, 52, 5-50.	0.4	56
617	Long-term Care After Percutaneous Coronary Intervention: Focus on the Role of Antiplatelet Therapy. Mayo Clinic Proceedings, 2006, 81, 641-652.	1.4	49

#	ARTICLE	IF	CITATIONS
618	Epidemiologic Perspectives of Risk for Developing Diabetes and Diabetes Complications. <i>Nursing Clinics of North America</i> , 2006, 41, 487-498.	0.7	2
619	Les statines : intérêts en cardiologie, implications en anesthésie. <i>Praticien En Anesthésie Réanimation</i> , 2006, 10, 156-165.	0.0	0
620	Common Questions in Managing Hyperlipidemia. <i>Primary Care - Clinics in Office Practice</i> , 2006, 33, 903-921.	0.7	0
621	Angina Pectoris: Evaluation in the Office. <i>Medical Clinics of North America</i> , 2006, 90, 391-416.	1.1	3
622	Antithrombotic Therapy in Peripheral Arterial Disease. <i>Clinics in Geriatric Medicine</i> , 2006, 22, 183-198.	1.0	1
623	The Safety of Aggressive Statin Therapy: How Much Can Low-Density Lipoprotein Cholesterol Be Lowered?. <i>Mayo Clinic Proceedings</i> , 2006, 81, 1225-1231.	1.4	23
624	Is There Evidence for the Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women?. <i>Gender Medicine</i> , 2006, 3, 5-12.	1.4	0
625	Assessment of Progression and Regression of Coronary Atherosclerosis by Intravascular Ultrasound. A New Paradigm Shift?. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2006, 59, 57-66.	0.4	1
626	Overcoming Ageism Bias in the Treatment of Hypercholesterolaemia. <i>Drug Safety</i> , 2006, 29, 421-448.	1.4	48
627	Risk Factors for Rhabdomyolysis with Simvastatin and Atorvastatin. <i>Drug Safety</i> , 2006, 29, 1061-1067.	1.4	41
632	Efficacy and Safety of Atorvastatin in the Prevention of Cardiovascular End Points in Subjects With Type 2 Diabetes: The Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN). <i>Diabetes Care</i> , 2006, 29, 1478-1485.	4.3	501
633	Lp-PLA2: A New Kid on the Block. <i>Clinical Chemistry</i> , 2006, 52, 1645-1650.	1.5	59
634	Peripheral Arterial Disease in Patients With Diabetes. <i>Journal of the American College of Cardiology</i> , 2006, 47, 921-929.	1.2	430
635	Noninvasive Detection of Subclinical Coronary Atherosclerosis Coupled With Assessment of Changes in Plaque Characteristics Using Novel Invasive Imaging Modalities. <i>Journal of the American College of Cardiology</i> , 2006, 47, 1134-1142.	1.2	112
636	ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2006, 47, e1-e121.	1.2	435
637	New Opportunities for Identification and Reduction of Coronary Risk. <i>Journal of the American College of Cardiology</i> , 2006, 47, C2-C6.	1.2	38
638	The Year in Interventional Cardiology. <i>Journal of the American College of Cardiology</i> , 2006, 47, 1689-1706.	1.2	28
639	Intensive Statin Therapy and the Risk of Hospitalization for Heart Failure After an Acute Coronary Syndrome in the PROVE IT-TIMI 22 Study. <i>Journal of the American College of Cardiology</i> , 2006, 47, 2326-2331.	1.2	157



#	ARTICLE	IF	CITATIONS
640	Simvastatin Attenuates Plaque Inflammation. <i>Journal of the American College of Cardiology</i> , 2006, 48, 1825-1831.	1.2	636
641	Meta-Analysis of Cardiovascular Outcomes Trials Comparing Intensive Versus Moderate Statin Therapy. <i>Journal of the American College of Cardiology</i> , 2006, 48, 438-445.	1.2	668
642	Benefit of Early Invasive Therapy in Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2006, 48, 1319-1325.	1.2	496
643	Efficacy and Safety of Torcetrapib, a Novel Cholesteryl Ester Transfer Protein Inhibitor, in Individuals With Below-Average High-Density Lipoprotein Cholesterol Levels on a Background of Atorvastatin. <i>Journal of the American College of Cardiology</i> , 2006, 48, 1782-1790.	1.2	144
644	Efficacy and Safety of Torcetrapib, a Novel Cholesteryl Ester Transfer Protein Inhibitor, in Individuals With Below-Average High-Density Lipoprotein Cholesterol Levels. <i>Journal of the American College of Cardiology</i> , 2006, 48, 1774-1781.	1.2	130
645	An Initial Strategy of Intensive Medical Therapy Is Comparable to That of Coronary Revascularization for Suppression of Scintigraphic Ischemia in High-Risk But Stable Survivors of Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2006, 48, 2458-2467.	1.2	120
647	Effects of Statin Therapy on the Development and Progression of Heart Failure: Mechanisms and Clinical Trials. <i>Journal of Cardiac Failure</i> , 2006, 12, 664-674.	0.7	41
648	It is uncertain whether intensive lipid-lowering is more effective than standard atorvastatin therapy. <i>Evidence-based Cardiovascular Medicine</i> , 2006, 10, 103-105.	0.0	0
650	Pravastatin, simvastatin, and atorvastatin appear equally effective for preventing cardiovascular events. <i>Evidence-based Cardiovascular Medicine</i> , 2006, 10, 135-137.	0.0	2
652	Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). <i>European Heart Journal</i> , 2006, 28, 88-136.	1.0	1,144
653	Adherence to evidence-based statin guidelines reduces the risk of hospitalizations for acute myocardial infarction by 40%: a cohort study. <i>European Heart Journal</i> , 2006, 28, 154-159.	1.0	130
654	Examination of lower targets for low-density lipoprotein cholesterol and blood pressure in diabetes—the Stop Atherosclerosis in Native Diabetics Study (SANDS). <i>American Heart Journal</i> , 2006, 152, 867-875.	1.2	26
656	Regression of coronary artery outward remodeling in patients with non-ST-segment acute coronary syndromes: A longitudinal study using noninvasive magnetic resonance imaging. <i>American Heart Journal</i> , 2006, 152, 1123-1132.	1.2	13
657	Antihypertensive therapy and regression of coronary artery disease: Insights from the Comparison of Amlodipine versus Enalapril to Limit Occurrences of Thrombosis (CAMELOT) and Norvasc for Regression of Manifest Atherosclerotic Lesions by Intravascular Sonographic Evaluation (NORMALISE) trials. <i>American Heart Journal</i> , 2006, 152, 1059-1063.	1.2	40
658	Contemporary Management of Dyslipidemia in High-Risk Patients: Targets Still Not Met. <i>American Journal of Medicine</i> , 2006, 119, 676-683.	0.6	148
659	Clinical Perspectives of Statin-Induced Rhabdomyolysis. <i>American Journal of Medicine</i> , 2006, 119, 400-409.	0.6	210
660	Tolerability of atorvastatin in a population aged ≥65 years: A retrospective pooled analysis of results from fifty randomized clinical trials. <i>American Journal of Geriatric Pharmacotherapy</i> , 2006, 4, 112-122.	3.0	25
661	Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention. <i>American Heart Journal</i> , 2006, 151, 273-281.	1.2	105

#	ARTICLE	IF	CITATIONS
662	Coronary plaque composition of nonculprit lesions, assessed by in vivo intracoronary ultrasound radio frequency data analysis, is related to clinical presentation. American Heart Journal, 2006, 151, 1020-1024.	1.2	87
663	A pharmacoepidemiology study of the interaction between atorvastatin and clopidogrel after percutaneous coronary intervention. American Heart Journal, 2006, 152, 263-269.	1.2	48
664	Statin use in heart failure: A cause for concern?. American Heart Journal, 2006, 152, 39-49.	1.2	42
665	Highlights from the American Heart Association Scientific Sessions, November 13 to 16, 2005, Dallas, TX. American Heart Journal, 2006, 151, 295-307.	1.2	12
666	Clopidogrel-statin interaction: A mountain or a mole hill?. American Heart Journal, 2006, 152, 200-203.	1.2	27
667	Evaluation of a novel anti-ischemic agent in acute coronary syndromes: Design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non- $\sigma$ ST-elevation acute coronary syndromes (MERLIN)-TIMI 36 trial. American Heart Journal, 2006, 151, 1186.e1-1186.e9.	1.2	63
668	Pharmacologic management of ischemic stroke: Relevance to stem cell therapy. Experimental Neurology, 2006, 199, 28-36.	2.0	22
669	The effect of different doses of fluvastatin on inflammatory markers in the early phase of acute coronary syndrome. Clinica Chimica Acta, 2006, 368, 183-187.	0.5	15
670	Impact of rosuvastatin use on costs and outcomes in patients at high risk for cardiovascular disease in US managed care and medicare populations: A data analysis. Clinical Therapeutics, 2006, 28, 1425-1442.	1.1	7
671	Improving the management of patients after myocardial infarction, from admission to discharge. Clinical Therapeutics, 2006, 28, 1509-1539.	1.1	8
672	Expanding options with a wider range of rosuvastatin doses. Clinical Therapeutics, 2006, 28, 1747-1763.	1.1	6
673	Role of lipoprotein-associated phospholipase A2 in atherosclerosis and its potential as a therapeutic target. Current Opinion in Pharmacology, 2006, 6, 154-161.	1.7	58
674	Effect of rosuvastatin or atorvastatin on urinary albumin excretion and renal function in type 2 diabetic patients. Diabetes Research and Clinical Practice, 2006, 72, 81-87.	1.1	27
675	Early invasive strategy may have no benefit over conservative strategy after one year. Evidence-based Cardiovascular Medicine, 2006, 10, 41-43.	0.0	0
677	Primary prevention in high-risk dyslipidemic patients without an established cardiovascular disease: Undertreatment and rationale for lipid-lowering therapy. European Journal of Internal Medicine, 2006, 17, 495-499.	1.0	12
678	Rationale for Intensive Statin Treatment in High-Risk Patients. Preventive Cardiology, 2006, 9, 91-95.	1.1	5
679	The IDEAL Trial: Less Is More. Preventive Cardiology, 2006, 9, 66-66.	1.1	0
680	Lower Is Better-The Contemporary Concept of Low-Density Lipoprotein Lowering in the Preventive Management of Cardiovascular Risk: Does This Apply to All Patients?. Preventive Cardiology, 2006, 9, 219-227.	1.1	0

#	ARTICLE	IF	CITATIONS
681	IDEAL and FIELD. Preventive Cardiology, 2006, 9, 115-120.	1.1	0
682	Niacin-ER/Statin Combination for the Treatment of Dyslipidemia: Focus on Low High-Density Lipoprotein Cholesterol. Journal of Clinical Hypertension, 2006, 8, 493-501.	1.0	9
683	Efficacy and Safety of Coadministered Amlodipine and Atorvastatin in Patients With Hypertension and Dyslipidemia: Results of the AVALON Trial. Journal of Clinical Hypertension, 2006, 8, 571-583.	1.0	51
684	Effects of early administration of atorvastatin treatment on thrombotic process in normocholesterolemic patients with unstable angina. International Journal of Cardiology, 2006, 106, 333-337.	0.8	23
685	Reduced risks of death and CHF are associated with statin therapy administered acutely within the first 24 h of AMI. International Journal of Cardiology, 2006, 108, 314-319.	0.8	19
686	The impact of early administration of low-dose atorvastatin treatment on inflammatory process, in patients with unstable angina and low cholesterol level. International Journal of Cardiology, 2006, 109, 48-52.	0.8	38
687	Reducing cardiovascular risk in diabetes: Beyond glycemic and blood pressure control. International Journal of Cardiology, 2006, 110, 137-145.	0.8	16
688	Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? Rationale and design for an international, open-label program to assess the effectiveness of a single pill (amlodipine/atorvastatin) to attain recommended target levels for blood pressure and lipids (The JEWEL Program). International Journal of Cardiology, 2006, 110, 242-250.	0.8	25
689	Short-term effects of low-dose atorvastatin on inflammatory status and lipid profiles in perimenopausal hypercholesterolemic, hypertriglyceridemic women. International Journal of Cardiology, 2006, 113, 66-75.	0.8	5
690	Rosuvastatin versus atorvastatin in achieving lipid goals in patients at high risk for cardiovascular disease in clinical practice: A randomized, open-label, parallel-group, multicenter study (DISCOVERY) Tj ETQq1 1 0.784314 rgB8 /Over	0.8	14
691	Is it time to reassess the approach to statin therapy?. Prevention and Control: the Official Journal of the World Heart Federation, 2006, 2, 27-29.	0.3	0
692	Impact of LDL-C lowering on recurrent cardiovascular events and hospitalization in secondary prevention in German clinical practice. Prevention and Control: the Official Journal of the World Heart Federation, 2006, 2, 5-14.	0.3	1
693	The impact of lipid-lowering treatment patterns on LDL-C reduction and goal attainment in secondary prevention in Germany. Prevention and Control: the Official Journal of the World Heart Federation, 2006, 2, 15-26.	0.3	2
694	Cholesterol lowering and mortality: Time for a new paradigm?. Nutrition, Metabolism and Cardiovascular Diseases, 2006, 16, 387-390.	1.1	14
697	Thyrotoxicosis as a Risk Factor for Pulmonary Arterial Hypertension. Annals of Internal Medicine, 2006, 144, 222.	2.0	1
698	Undisclosed Conflicts of Interest. Annals of Internal Medicine, 2006, 144, 225.	2.0	1
699	Acute Exacerbations in Idiopathic Pulmonary Fibrosis. Annals of Internal Medicine, 2006, 144, 218.	2.0	0
700	Presentation of Diagnostic Test Accuracy. Annals of Internal Medicine, 2006, 144, 220.	2.0	0

#	ARTICLE	IF	CITATIONS
701	Efficacy of a Low Dose of Pitavastatin Compared with Atorvastatin in Primary Hyperlipidemia: Results of a 12-week, open label study. <i>Journal of Atherosclerosis and Thrombosis</i> , 2006, 13, 108-113.	0.9	18
702	Effects of simvastatin in abdominal sepsis in rats. <i>Acta Cirurgica Brasileira</i> , 2006, 21, 8-12.	0.3	25
703	Presentation of Diagnostic Test Accuracy. <i>Annals of Internal Medicine</i> , 2006, 144, 221.	2.0	1
704	Forecasting Cholesterol Management-End of the Statin Gold Rush?. <i>Journal of Managed Care Pharmacy</i> , 2006, 12, 479-485.	2.2	2
705	Estatinas na sepse: nova arma terapêutica no arsenal da medicina intensiva?. <i>Revista Brasileira De Terapia Intensiva</i> , 2006, 18, 402-406.	0.1	0
706	Liver Transplantation in HIV-Seropositive Individuals. <i>Annals of Internal Medicine</i> , 2006, 144, 223.	2.0	6
708	Processing of Amyloid Precursor Protein as a Biochemical Link Between Atherosclerosis and Alzheimers Disease. <i>Cardiovascular &amp; Hematological Disorders Drug Targets</i> , 2006, 6, 21-34.	0.2	26
709	Treatment of Hyperlipidemia from Japanese Evidence. <i>Journal of Atherosclerosis and Thrombosis</i> , 2006, 13, 267-280.	0.9	20
710	Statins: Beneficial or Adverse for Glucose Metabolism. <i>Journal of Atherosclerosis and Thrombosis</i> , 2006, 13, 123-129.	0.9	79
711	Vascular imaging and the clinical development of new pharmaceuticals. , 2006, , 418-429.		0
712	Monitoring pharmaceutical interventions with IVUS. , 2006, , 451-463.		0
713	Molecular imaging of carotid artery disease. , 2006, , 471-483.		0
714	Quality of Care for Vulnerable Older Patients. <i>Annals of Internal Medicine</i> , 2006, 144, 219.	2.0	0
715	Savings from Canadian Internet Pharmacies Are Limited. <i>Annals of Internal Medicine</i> , 2006, 144, 224.	2.0	0
717	A dual approach to cholesterol targets. <i>Practice Nursing</i> , 2006, 17, 144-148.	0.1	0
719	Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome (JAPAN-ACS) Rationale and Design. <i>Circulation Journal</i> , 2006, 70, 1624-1628.	0.7	33
720	Cross-Over Trial of Intensive Monotherapy With Atorvastatin and Combined Therapy With Atorvastatin and Colestimide for Japanese Familial Hypercholesterolemia. <i>Circulation Journal</i> , 2006, 70, 14-20.	0.7	8
722	Lipid-lowering therapy with statins in postmenopausal women: a few answered and many unanswered questions. <i>Future Lipidology</i> , 2006, 1, 375-379.	0.5	1

#	ARTICLE	IF	CITATIONS
723	HDL/apoA-I infusion for atherosclerosis management: an emerging therapeutic paradigm. <i>Future Lipidology</i> , 2006, 1, 55-64.	0.5	3
724	Future approaches to reducing low-density lipoprotein cholesterol. <i>Future Lipidology</i> , 2006, 1, 463-476.	0.5	1
725	Narrative Review: Lack of Evidence for Recommended Low-Density Lipoprotein Treatment Targets: A Solvable Problem. <i>Annals of Internal Medicine</i> , 2006, 145, 520.	2.0	148
726	Selective Compensatory Induction of Hepatic HMG-CoA Reductase in Response to Inhibition of Cholesterol Absorption. <i>Experimental Biology and Medicine</i> , 2006, 231, 559-565.	1.1	19
727	Non-ST Segment Elevation Acute Coronary Syndromes: A Comprehensive Review. <i>Southern Medical Journal</i> , 2006, 99, 1103-1110.	0.3	6
728	Stable Angina. , 2006, , 135-153.		0
729	Effect of Lipid Levels and Lipid-Lowering Therapy on Restenosis after Coronary Artery Stenting. <i>American Journal of the Medical Sciences</i> , 2006, 331, 270-273.	0.4	11
730	Acute Exacerbations in Idiopathic Pulmonary Fibrosis. <i>Annals of Internal Medicine</i> , 2006, 144, 218.	2.0	4
731	Intensive Versus Moderate Lipid Lowering With Statins After Acute Coronary Syndromes. <i>Yearbook of Vascular Surgery</i> , 2006, 2006, 89-91.	0.0	1
732	A Systematic Approach to Improve Lipids in Coronary Artery Disease Patients Participating in a Cardiac Rehabilitation Program. <i>Journal of Cardiopulmonary Rehabilitation and Prevention</i> , 2006, 26, 355-360.	0.5	3
733	Hospital discharge treatments after an acute event: evidence for a systems approach to prevention. <i>Coronary Artery Disease</i> , 2006, 17, 239-241.	0.3	3
734	Statins Are Associated With Better Outcomes After Carotid Endarterectomy in Symptomatic Patients. <i>Perspectives in Vascular Surgery and Endovascular Therapy</i> , 2006, 18, 79-80.	0.6	1
735	Potential benefit of statins for vascular disease in systemic sclerosis. <i>Current Opinion in Rheumatology</i> , 2006, 18, 594-600.	2.0	24
736	Cardiovascular Disease. <i>Journal of Cardiovascular Nursing</i> , 2006, 21, S20-S42.	0.6	7
737	Eating, vascular biology, and atherosclerosis: a lot to chew onThe opinions expressed in this article are not necessarily those of the Editors of the <i>European Heart Journal</i> or of the <i>European Society of Cardiology</i> .. <i>European Heart Journal</i> , 2006, 27, 13-14.	1.0	21
739	Statin-Associated Pleiotropy: Possible Beneficial Effects Beyond Cholesterol Reduction. <i>Pharmacotherapy</i> , 2006, 26, 85S-97S.	1.2	47
740	High-Density Lipoprotein Cholesterol-Raising Strategies. <i>Journal of Cardiovascular Pharmacology</i> , 2006, 47, 196-204.	0.8	12
741	The gap between theory and practice: what do the trials tell us?. <i>Country Review Ukraine</i> , 2006, 8, F10-F16.	0.8	0

#	ARTICLE	IF	CITATIONS
742	Evidence to support aggressive management of HDL-cholesterol: implications of recent trials. Country Review Ukraine, 2006, 8, F74-F80.	0.8	2
743	C-Reactive Protein Levels and Outcomes After Statin Therapy. Yearbook of Endocrinology, 2006, 2006, 95-97.	0.0	0
744	Ezetimibe: one step beyond in the battle against atherosclerosis. Future Lipidology, 2006, 1, 255-266.	0.5	2
745	The ACTIVATE study: lessons for the future of atherosclerotic therapy. Future Lipidology, 2006, 1, 421-428.	0.5	0
746	Treating dyslipidemia in the elderly. Current Opinion in Lipidology, 2006, 17, 54-57.	1.2	2
747	Statin therapy for prevention and treatment of acute and chronic cardiovascular disease: update on recent trials and metaanalyses. Current Opinion in Internal Medicine, 2006, 5, 29-33.	1.5	9
748	The safety and efficacy of achieving very low LDL-cholesterol concentrations with high dose statin therapy. Current Opinion in Lipidology, 2006, 17, 626-630.	1.2	24
749	Managing cholesterol in the elderly. Aging Health, 2006, 2, 623-638.	0.3	0
750	Possible mechanisms for statin myopathy and its relationship to physical exercise. Future Lipidology, 2006, 1, 143-151.	0.5	5
751	The dyslipidemia of chronic renal disease: effects of statin therapy. Current Opinion in Lipidology, 2006, 17, 659-666.	1.2	11
752	Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Current Opinion in Cardiology, 2006, 21, 400-404.	0.8	59
753	Statins in the intensive care unit. Current Opinion in Critical Care, 2006, 12, 309-314.	1.6	32
755	Lipid Abnormalities in Women. Cardiology in Review, 2006, 14, 276-280.	0.6	15
756	Prevention is better than cure. Current Opinion in Lipidology, 2006, 17, 188-191.	1.2	1
757	Statins: are any questions unanswered?. Current Opinion in Lipidology, 2006, 17, 418-425.	1.2	10
758	Safety Issues with Statin Therapy. Journal of the American Pharmacists Association: JAPhA, 2006, 46, 479-490.	0.7	54
759	Regression of Cutaneous and Gastrointestinal Telangiectasia with Sirolimus and Aspirin in a Patient with Hereditary Hemorrhagic Telangiectasia. Annals of Internal Medicine, 2006, 144, 226.	2.0	40
760	Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins. Cardiovascular Diabetology, 2006, 5, 20.	2.7	72

#	ARTICLE	IF	CITATIONS
761	A randomized trial to assess the impact of opinion leader endorsed evidence summaries on the use of secondary prevention strategies in patients with coronary artery disease: the ESP-CAD trial protocol [NCT00175240]. <i>Implementation Science</i> , 2006, 1, 11.	2.5	17
762	Results from a rosuvastatin historical cohort study in more than 45â€‰%000 Dutch statin users, a PHARMO study. <i>Pharmacoepidemiology and Drug Safety</i> , 2006, 15, 435-443.	0.9	34
763	The comparative safety of rosuvastatin: a retrospective matched cohort study in over 48â€‰%000 initiators of statin therapy. <i>Pharmacoepidemiology and Drug Safety</i> , 2006, 15, 444-453.	0.9	51
764	Management and outcomes of acute coronary syndrome with minimal myocardial necrosis: analysis of a large prospective registry from a non-interventional centre*. <i>International Journal of Clinical Practice</i> , 2006, 60, 383-390.	0.8	1
765	Statins and the acute coronary syndrome: â€˜the early bird catches the wormâ€™™. <i>International Journal of Clinical Practice</i> , 2006, 60, 716-727.	0.8	4
766	ASTEROID - when spinning a star leads to a collision with reality. <i>International Journal of Clinical Practice</i> , 2006, 60, 505-505.	0.8	0
767	Is Rosuvastatin Really a More Efficient Therapeutic Option than Atorvastatin?. <i>Value in Health</i> , 2006, 9, 276-277.	0.1	0
768	Use of an indirect effect model to describe the LDL cholesterol-lowering effect by statins in hypercholesterolaemic patients. <i>Fundamental and Clinical Pharmacology</i> , 2006, 20, 321-330.	1.0	22
769	Influence of Genetic Variation in the C-Reactive Protein Gene on the Inflammatory Response During and After Acute Coronary Ischemia. <i>Annals of Human Genetics</i> , 2006, 70, 705-716.	0.3	61
770	Update in perioperative medicine. <i>Journal of General Internal Medicine</i> , 2006, 21, 1329-1337.	1.3	2
771	C-Reactive Protein (CRP)-Lowering Agents. <i>Cardiovascular Drug Reviews</i> , 2006, 24, 33-50.	4.4	228
772	Hydroxymethylglutaryl-CoA Reductase Inhibitors in Older Persons with Acute Myocardial Infarction: Evidence for an Age-Dependent Statin Interaction. <i>Journal of the American Geriatrics Society</i> , 2006, 54, 421-430.	1.3	71
773	Efficacy, safety and LDL-C goal attainment of ezetimibe 10â€‰fmg-simvastatin 20â€‰fmg vs. placebo-simvastatin 20â€‰fmg in UK-based adults with coronary heart disease and hypercholesterolaemia. <i>International Journal of Clinical Practice</i> , 2006, 60, 914-921.	0.8	24
774	The Role of Statins in Reversing Atherosclerosis: What the Latest Regression Studies Show. <i>Journal of Interventional Cardiology</i> , 2006, 19, 3-9.	0.5	22
775	Studying Coronary Plaque Regression with IVUS: A Critical Review of Recent Studies. <i>Journal of Interventional Cardiology</i> , 2006, 19, 11-15.	0.5	24
776	Levels of dyslipidaemia and improvement in its management in England: results from the Health Survey for England 2003. <i>Clinical Endocrinology</i> , 2006, 64, 292-298.	1.2	38
777	Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. <i>Journal of Internal Medicine</i> , 2006, 259, 247-258.	2.7	405
778	Who should receive a statin these days? Lessons from recent clinical trials. <i>Journal of Internal Medicine</i> , 2006, 260, 305-319.	2.7	46

#	ARTICLE	IF	CITATIONS
779	Application of intravascular ultrasound in anti-atherosclerotic drug development. <i>Nature Reviews Drug Discovery</i> , 2006, 5, 485-492.	21.5	43
780	Effects of chronic treatment with statins and fenofibrate on rat skeletal muscle: a biochemical, histological and electrophysiological study. <i>British Journal of Pharmacology</i> , 2006, 149, 909-919.	2.7	50
781	RNAi-mediated gene silencing in non-human primates. <i>Nature</i> , 2006, 441, 111-114.	13.7	1,275
782	Statins: another class of antihypertensive agents?. <i>Journal of Human Hypertension</i> , 2006, 20, 320-335.	1.0	55
783	“Hypertension”™ and “microalbuminuria”™: The bell tolls for thee. <i>Kidney International</i> , 2006, 69, 22-28.	2.6	64
784	The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease. <i>Kidney International</i> , 2006, 70, 2021-2030.	2.6	227
785	Intestinal expression of P-glycoprotein (ABCB1), multidrug resistance associated protein 2 (ABCC2), and uridine diphosphate–glucuronosyltransferase 1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetimibe in humans. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 79, 206-217.	2.3	94
786	Recent trends in coronary intravascular ultrasound: Tracking atherosclerosis, pursuit of vulnerable plaques, and beyond. <i>Journal of Nuclear Cardiology</i> , 2006, 13, 91-96.	1.4	6
788	Lipid-Lowering Therapy in High-Risk Persons. <i>Comprehensive Therapy</i> , 2006, 32, 68-73.	0.2	3
789	Statins: the evidence, side-effects and interactions in older people. <i>The Prescriber</i> , 2006, 17, 20-28.	0.1	2
790	Lipid-lowering treatment: today's recommended management. <i>The Prescriber</i> , 2006, 17, 33-44.	0.1	1
791	Cholesterol, C-reactive protein, and cerebrovascular events following intensive and moderate statin therapy. <i>Journal of Thrombosis and Thrombolysis</i> , 2006, 22, 71-76.	1.0	24
792	Possible mechanisms of drug-induced aspirin and clopidogrel resistance. <i>Journal of Thrombosis and Thrombolysis</i> , 2006, 22, 139-150.	1.0	22
793	Atherosclerosis Imaging with Intravascular Ultrasound. <i>International Journal of Cardiovascular Imaging</i> , 2006, 22, 615-618.	0.7	0
795	Low density lipoprotein cholesterol, statins and cardiovascular events: a meta-analysis. <i>Clinical Research in Cardiology</i> , 2006, 95, 393-404.	1.5	57
798	Statins: the next step in adjuvant therapy for sepsis?. <i>Intensive Care Medicine</i> , 2006, 32, 11-14.	3.9	26
799	Effects of simvastatin on cardiohemodynamic responses to ischemia–reperfusion in isolated rat hearts. <i>Heart and Vessels</i> , 2006, 21, 116-123.	0.5	13
800	The effect of early statin treatment on inflammation and cardiac events in acute coronary syndrome patients with low-density lipoprotein cholesterol. <i>Heart and Vessels</i> , 2006, 21, 291-297.	0.5	24



#	ARTICLE	IF	CITATIONS
801	Impact of high dose statin trials on hospital prescribers. <i>European Journal of Clinical Pharmacology</i> , 2006, 63, 65-72.	0.8	2
803	Low-density lipoprotein cholesterol lowering in the prevention of CHD: How low should we go?. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2006, 8, 289-297.	0.4	7
804	Implications of changing national cholesterol education program goals for the treatment and control of hypercholesterolemia. <i>Journal of General Internal Medicine</i> , 2006, 21, 171-176.	1.3	24
807	Statin therapy for coronary heart disease and its effect on stroke. <i>Current Atherosclerosis Reports</i> , 2006, 8, 337-342.	2.0	3
809	Are lower levels of low-density lipoprotein cholesterol beneficial? A review of recent data. <i>Current Atherosclerosis Reports</i> , 2006, 8, 382-389.	2.0	1
810	Optimal low-density lipoprotein levels: Evidence from epidemiology and clinical trials. <i>Current Atherosclerosis Reports</i> , 2006, 8, 157-162.	2.0	3
812	Low-density lipoprotein reduction: Is the risk worth the benefit?. <i>Current Atherosclerosis Reports</i> , 2006, 8, 19-25.	2.0	1
813	New strategies in the medical treatment of carotid artery disease. <i>Current Cardiology Reports</i> , 2006, 8, 33-37.	1.3	4
814	Noninvasive monitoring of medical therapy. <i>Current Cardiology Reports</i> , 2006, 8, 139-146.	1.3	0
815	Expanding the definition of hypertension to incorporate global cardiovascular risk. <i>Current Hypertension Reports</i> , 2006, 8, 384-390.	1.5	6
816	Review article: The role of statins in reducing perioperative cardiac risk: physiologic and clinical perspectives. <i>Canadian Journal of Anaesthesia</i> , 2006, 53, 1126-1147.	0.7	17
817	The Debate Over Anticoagulation in Patients With Heart Failure. <i>Congestive Heart Failure</i> , 2006, 12, 285-287.	2.0	0
818	REPORT: Obesity, Dyslipidemias and Erectile Dysfunction: A Report of a Subcommittee of the Sexual Medicine Society of North America. <i>Journal of Sexual Medicine</i> , 2006, 3, 778-786.	0.3	70
819	High Cardiovascular Risk in Patients With Diabetes and the Cardiometabolic Syndrome: Mandate for Statin Therapy. <i>Journal of the Cardiometabolic Syndrome</i> , 2006, 1, 178-183.	1.7	8
820	Novel non-systemic inhibitor of ileal apical Na <sup>+</sup> -dependent bile acid transporter reduces serum cholesterol levels in hamsters and monkeys. <i>European Journal of Pharmacology</i> , 2006, 539, 89-98.	1.7	33
821	Comparative Safety of Atorvastatin 80 mg Versus 10 mg Derived from Analysis of 49 Completed Trials in 14,236 Patients. <i>American Journal of Cardiology</i> , 2006, 97, 61-67.	0.7	203
822	Association Between Time of Statin Initiation After Hospital Discharge from Acute Myocardial Infarction and Risk of Recurrence and Mortality in Patients ≥65 Years of Age. <i>American Journal of Cardiology</i> , 2006, 97, 155-159.	0.7	5
823	The Metabolic Syndrome: Inflammation, Diabetes Mellitus, and Cardiovascular Disease. <i>American Journal of Cardiology</i> , 2006, 97, 3-11.	0.7	457

#	ARTICLE	IF	CITATIONS
824	Statin Safety and Drug Interactions: Clinical Implications. American Journal of Cardiology, 2006, 97, S27-S31.	0.7	152
825	Cholesterol Management: Targeting a Lower Low-Density Lipoprotein Cholesterol Concentration Increases Adult Treatment Panel-III Goal Attainment. American Journal of Cardiology, 2006, 97, 1667-1669.	0.7	6
826	Coronary Artery Disease Prognosis and C-Reactive Protein Levels Improve in Proportion to Percent Lowering of Low-Density Lipoprotein. American Journal of Cardiology, 2006, 98, 135-139.	0.7	13
827	What the Statin Trials Have Taught Us. American Journal of Cardiology, 2006, 98, 129-134.	0.7	29
828	Statement of the Problem. American Journal of Cardiology, 2006, 97, 3-8.	0.7	267
829	Outcome of Percutaneous Coronary Intervention in Unstable Angina Pectoris Versus Stable Angina Pectoris in Two Different Time Periods. American Journal of Cardiology, 2006, 98, 447-452.	0.7	10
830	Impact of Low High-Density Lipoproteins on In-Hospital Events and One-Year Clinical Outcomes in Patients With Non-ST-Elevation Myocardial Infarction Acute Coronary Syndrome Treated With Drug-Eluting Stent Implantation. American Journal of Cardiology, 2006, 98, 711-717.	0.7	72
831	Relation Between Soluble Intercellular Adhesion Molecule-1, Statin Therapy, and Long-Term Risk of Clinical Cardiovascular Events in Patients With Previous Acute Coronary Syndrome (from PROVE) Tj ETQq1 1 0.784314 rgBT 43 Overloc	0.7	43
832	Usefulness of Follow-Up Low-Density Lipoprotein Cholesterol Level as an Independent Predictor of Changes of Coronary Atherosclerotic Plaque Size as Determined by Intravascular Ultrasound Analysis After Statin (Atorvastatin or Simvastatin) Therapy. American Journal of Cardiology, 2006, 98, 866-870.	0.7	23
833	The Editor's Roundtable: Diabetes Mellitus and Coronary Heart Disease. American Journal of Cardiology, 2006, 98, 842-856.	0.7	4
834	Identifying Patients for Aggressive Cholesterol Lowering: The Risk Curve Concept. American Journal of Cardiology, 2006, 98, 1405-1408.	0.7	43
835	Relation Between Plaque Progression and Low-Density Lipoprotein Cholesterol During Aging as Assessed With Serial Long-Term (12 Months) Follow-Up Intravascular Ultrasound of the Left Main Coronary Artery. American Journal of Cardiology, 2006, 98, 1419-1423.	0.7	19
836	Beyond Lipid Lowering: What Have We Learned About the Benefits of Statins from the Acute Coronary Syndromes Trials?. American Journal of Cardiology, 2006, 98, S18-S25.	0.7	61
837	Plaque Stabilization: Can We Turn Theory into Evidence?. American Journal of Cardiology, 2006, 98, S26-S33.	0.7	56
838	Molecular Basis of Differences Among Statins and a Comparison with Antioxidant Vitamins. American Journal of Cardiology, 2006, 98, S34-S41.	0.7	51
839	Atherosclerosis: Its Cause and Its Prevention. American Journal of Cardiology, 2006, 98, 1550-1555.	0.7	17
840	Pathophysiology, Diagnosis, and Management of Dyslipidemia. Current Problems in Cardiology, 2006, 31, 445-486.	1.1	29
844	Beneficios de la terapia combinada en la hiperlipemia. Revista Espanola De Cardiologia Suplementos, 2006, 6, 63G-71G.	0.2	1

#	ARTICLE	IF	CITATIONS
845	How Safe Is Aggressive Statin Therapy?. <i>Progress in Cardiovascular Nursing</i> , 2006, 21, 140-145.	0.5	9
846	Interventions to improve guideline compliance following coronary artery bypass grafting. <i>Surgery</i> , 2006, 140, 541-552.	1.0	24
847	Preoperative statin therapy is associated with reduced cardiac mortality after coronary artery bypass graft surgery. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2006, 132, 392-400.e1.	0.4	136
848	Latent plaque rupture in a patient undergoing stenting for acute coronary syndrome and diffuse coronary disease: A case report and review of literature. <i>Catheterization and Cardiovascular Interventions</i> , 2006, 67, 241-245.	0.7	1
849	Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment. <i>Hepatology</i> , 2006, 44, 335-340.	3.6	107
850	Admission ECG predicts long-term outcome in acute coronary syndromes without ST elevation. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2006, 99, 601-607.	0.2	7
851	Benefits of achieving the NCEP optional LDL-C goal among elderly patients with ACS. <i>European Heart Journal</i> , 2006, 27, 2310-2316.	1.0	57
852	Niaspan® in the management of dyslipidaemia: the evidence. <i>Country Review Ukraine</i> , 2006, 8, F60-F67.	0.8	10
853	METABOLIC (GLYCAEMIC, LIPIDIC) AND BLOOD PRESSURE CONTROL IN 101 TYPE 2 DIABETIC PATIENTS ON FIRST ADMISSION TO DIABETES CENTRES. <i>Acta Clinica Belgica</i> , 2006, 61, 127-133.	0.5	1
854	NITRIC OXIDE-DEPENDENT ENDOTHELIAL FUNCTION AND CARDIOVASCULAR DISEASE. <i>Acta Clinica Belgica</i> , 2006, 61, 326-334.	0.5	77
855	Reported Outcomes in Major Cardiovascular Clinical Trials Funded by For-Profit and Not-for-Profit Organizations: 2000-2005. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 2270.	3.8	249
856	Update on lipid-lowering therapy and LDL-cholesterol targets. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2006, 3, 424-436.	3.3	8
858	Prognostic significance of serum cholesterol levels in patients with idiopathic dilated cardiomyopathy. <i>European Heart Journal</i> , 2006, 27, 691-699.	1.0	38
859	Rapid immunomodulation by rosuvastatin in patients with acute coronary syndrome. <i>European Heart Journal</i> , 2006, 27, 2945-2955.	1.0	85
860	Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin. <i>European Heart Journal</i> , 2006, 28, 1448-1453.	1.0	50
861	Apolipoproteins as markers and managers of coronary risk. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2006, 99, 277-287.	0.2	84
862	Intensive statin therapy for treating acute coronary syndromes. <i>Expert Opinion on Investigational Drugs</i> , 2006, 15, 1151-1159.	1.9	3
863	Pharmacoeconomic considerations with statin therapy. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 1291-1304.	0.9	6

#	ARTICLE	IF	CITATIONS
864	Statins: Are They All the Same?. <i>Current Drug Therapy</i> , 2006, 1, 157-172.	0.2	0
865	Are we lowering LDL cholesterol sufficiently?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2006, 3, 290-291.	3.3	7
866	How low to target LDL?. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2006, 2, 414-415.	2.9	1
867	Chronic Obstructive Pulmonary Disease, Risk Factors, and Outcome Trials: Comparisons with Cardiovascular Disease. <i>Proceedings of the American Thoracic Society</i> , 2006, 3, 635-640.	3.5	34
868	Carotid intima-media thickness as a surrogate marker for cardiovascular disease in intervention studies. <i>Current Medical Research and Opinion</i> , 2006, 22, 2181-2190.	0.9	99
869	How and When Do We Alter Inflammatory Mechanisms in Stroke? Will It Help?. <i>Seminars in Neurology</i> , 2006, 26, 075-087.	0.5	1
870	Clinical implications of vulnerable plaque. <i>Future Cardiology</i> , 2006, 2, 721-731.	0.5	0
871	Reducing residual cardiovascular risk: the relevance of raising high-density lipoprotein cholesterol in patients on cholesterol-lowering treatment. <i>Diabetes and Vascular Disease Research</i> , 2006, 3, S1-S12.	0.9	13
872	Atorvastatin: beyond lipid-lowering effects in the diabetic population. <i>Future Cardiology</i> , 2006, 2, 527-533.	0.5	0
873	Management of Dyslipidemia in Special Populations. <i>Journal of Pharmacy Practice</i> , 2006, 19, 63-78.	0.5	1
874	Standards of training. <i>Cmaj</i> , 2006, 174, 502-503.	0.9	0
875	Predictive factors of stroke in patients undergoing coronary bypass grafting: statins are protective. <i>European Journal of Cardio-thoracic Surgery</i> , 2006, 30, 300-304.	0.6	45
876	An evaluation of class effect. <i>Cmaj</i> , 2006, 174, 502-502.	0.9	0
877	An evaluation of class effect. <i>Cmaj</i> , 2006, 174, 502-502.	0.9	0
878	Drug Insight: immunomodulatory effects of statins—potential benefits for renal patients?. <i>Nature Clinical Practice Nephrology</i> , 2006, 2, 378-387.	2.0	31
879	Trends in the Prevalence, Awareness, Treatment, and Control of Cardiovascular Disease Risk Factors among Noninstitutionalized Patients with a History of Myocardial Infarction and Stroke. <i>American Journal of Epidemiology</i> , 2006, 163, 913-920.	1.6	88
881	How safe are very low LDL cholesterol levels?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2006, 3, 306-307.	3.3	1
882	The Changing Face of Dyslipidemia Therapies. <i>Journal of Pharmacy Practice</i> , 2006, 19, 79-93.	0.5	0

#	ARTICLE	IF	CITATIONS
883	Atherosclerosis is an Inflammatory Disorder After All. <i>Current Topics in Medicinal Chemistry</i> , 2006, 6, 93-102.	1.0	11
884	Novel Concepts of Statin Therapy for Cardiovascular Risk Reduction in Hypertension. <i>Current Pharmaceutical Design</i> , 2006, 12, 1593-1609.	0.9	16
885	Cyclophilin A Is Secreted by a Vesicular Pathway in Vascular Smooth Muscle Cells. <i>Circulation Research</i> , 2006, 98, 811-817.	2.0	204
886	Lovastatin Enhances Clearance of Apoptotic Cells (Efferocytosis) with Implications for Chronic Obstructive Pulmonary Disease. <i>Journal of Immunology</i> , 2006, 176, 7657-7665.	0.4	200
887	Achieving 2003 European lipid goals with rosuvastatin and comparator statins in 6743 patients in real-life clinical practice: DISCOVERY meta-analysis. <i>Current Medical Research and Opinion</i> , 2006, 22, 1181-1191.	0.9	12
888	Effects of a global risk educational tool on primary coronary prevention: the Atherosclerosis Assessment Via Total Risk (AVIATOR) study. <i>Current Medical Research and Opinion</i> , 2006, 22, 1065-1073.	0.9	26
889	Lipid Testing and Lipid-Lowering Therapy in Hospitalized Ischemic Stroke and Transient Ischemic Attack Patients. <i>Stroke</i> , 2006, 37, 44-49.	1.0	32
890	Differential effects of short-term lipid lowering with ezetimibe and statins on endothelial function in patients with CAD: clinical evidence for "pleiotropic" functions of statin therapy. <i>European Heart Journal</i> , 2006, 27, 1182-1190.	1.0	134
891	Statin Therapy for Native and Peri-Interventional Coronary Heart Disease. <i>Current Molecular Medicine</i> , 2006, 6, 589-602.	0.6	8
892	Evidence-Based Prescribing of Statins: A Developing World Perspective. <i>PLoS Medicine</i> , 2006, 3, e50.	3.9	10
893	Incidental Renal Artery Stenosis Is an Independent Predictor of Mortality in Patients with Peripheral Vascular Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, 2069-2074.	3.0	79
895	The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes. <i>Circulation</i> , 2006, 114, 2871-2891.	1.6	109
896	Primary Prevention of Ischemic Stroke. <i>Stroke</i> , 2006, 37, 1583-1633.	1.0	1,100
897	Intravascular Ultrasound in Cardiovascular Medicine. <i>Circulation</i> , 2006, 114, e55-9.	1.6	49
898	Management of Dyslipidemias in Patients with Diabetes and Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006, 1, 1090-1099.	2.2	54
899	A 39-Year-Old Woman With Hypercholesterolemia. <i>JAMA - Journal of the American Medical Association</i> , 2006, 296, 319.	3.8	0
900	High-Dose Statins and the IDEAL Study. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 2476.	3.8	4
901	Quality Assessment of Dyslipidemia in Managed Care: Current Best Evidence Should Be Used to Benchmark Quality. <i>Annals of Pharmacotherapy</i> , 2006, 40, 124-127.	0.9	4

#	ARTICLE	IF	CITATIONS
902	Unanswered Questions for Management of Acute Coronary Syndrome. Archives of Internal Medicine, 2006, 166, 1391.	4.3	168
903	Coronary revascularization and medical management of coronary artery disease: changing paradigms and perceptions. European Journal of Cardiovascular Prevention and Rehabilitation, 2006, 13, 669-673.	3.1	5
904	Effect of Intensive Versus Standard Lipid-Lowering Treatment With Atorvastatin on the Progression of Calcified Coronary Atherosclerosis Over 12 Months. Circulation, 2006, 113, 427-437.	1.6	245
905	Adherence and Persistence with Single-Dosage Form Extended-Release Niacin/Lovastatin Compared with Statins Alone or in Combination with Extended-Release Niacin. Annals of Pharmacotherapy, 2006, 40, 1274-1279.	0.9	23
906	Direct Comparison of the A to Z and PROVE IT Trials. Circulation, 2006, 113, 1382-1384.	1.6	9
907	Emerging Therapies Targeting High-Density Lipoprotein Metabolism and Reverse Cholesterol Transport. Circulation, 2006, 113, 1140-1150.	1.6	93
908	Variable Impact of Combining Fatal and Nonfatal End Points in Heart Failure Trials. Circulation, 2006, 114, 2298-2303.	1.6	34
909	The Effect of Early, Intensive Statin Therapy on Acute Coronary Syndrome. Archives of Internal Medicine, 2006, 166, 1814.	4.3	169
910	Can a Potent Statin Actually Regress Coronary Atherosclerosis?. JAMA - Journal of the American Medical Association, 2006, 295, 1583.	3.8	20
911	International Prevalence, Recognition, and Treatment of Cardiovascular Risk Factors in Outpatients With Atherothrombosis. JAMA - Journal of the American Medical Association, 2006, 295, 180.	3.8	1,353
912	Effect of Very High-Intensity Statin Therapy on Regression of Coronary Atherosclerosis. JAMA - Journal of the American Medical Association, 2006, 295, 1556.	3.8	1,759
913	Rethinking Primary Prevention of Atherosclerosis-Related Diseases. Circulation, 2006, 114, 2517-2527.	1.6	88
914	Statins, Diet, and Low Cholesterolâ€”Reply. JAMA - Journal of the American Medical Association, 2006, 295, 2479.	3.8	0
915	High-Dose Statins and the IDEAL Study. JAMA - Journal of the American Medical Association, 2006, 295, 2476.	3.8	1
916	Case Studies in Lipid Management. , 0, , .		1
917	Coronary Artery Calcium. Circulation, 2006, 113, 336-337.	1.6	23
918	Role of the Pharmacist in the Management of Dyslipidemia. Journal of Pharmacy Practice, 2006, 19, 94-102.	0.5	6
919	AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update. Circulation, 2006, 113, 2363-2372.	1.6	1,742

#	ARTICLE	IF	CITATIONS
920	Statins, Diet, and Low Cholesterol. JAMA - Journal of the American Medical Association, 2006, 295, 2479.	3.8	0
921	Cardiology in Family Practice. , 2006, , .		0
922	Ezetimibe added to ongoing statin therapy improves LDL-C goal attainment and lipid profile in patients with diabetes or metabolic syndrome. Diabetes and Vascular Disease Research, 2006, 3, 93-102.	0.9	65
923	Assessing and Reducing the Cardiac Risk of Noncardiac Surgery. Circulation, 2006, 113, 1361-1376.	1.6	134
924	Determinants of Arterial Wall Remodeling During Lipid-Lowering Therapy. Circulation, 2006, 113, 2826-2834.	1.6	145
925	Liver X Receptor Activation and High-Density Lipoprotein Biology. Circulation, 2006, 113, 5-8.	1.6	19
926	Lipoprotein-Associated Phospholipase A 2 and Its Association With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 50 1745-1752.	1.6	209
927	ACC/AHA/SCAI Practice Guidelines, February 21, 2006. Circulation, 2006, 113, e166-286.	1.6	525
928	Statins, cholesterol, and the prevention of coronary heart disease. FASEB Journal, 2006, 20, 200-201.	0.2	10
929	Gap between guidelines and practice: attainment of treatment targets in patients with primary hypercholesterolemia starting statin therapy. Results of the 4E-Registry (Efficacy Calculation and) Tj ETQq1 1 0.784314 rgBT /Overlock 11 33	3.1	33
930	Management of dyslipidaemias. Heart, 2006, 92, 1529-1534.	1.2	5
931	What's New? Guidelines and Goals. Journal of Pharmacy Practice, 2006, 19, 103-112.	0.5	0
932	The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes. Circulation, 2006, 114, 2850-2870.	1.6	346
933	Inhibition of CETP as a novel therapeutic strategy for reducing the risk of atherosclerotic disease. European Heart Journal, 2006, 28, 5-12.	1.0	46
934	Dyslipidemia in Older Adults. The American Journal of Geriatric Cardiology, 2006, 15, 239-244.	0.7	2
935	Treatment of Non?ST-Elevation Acute Coronary Syndrome in the Elderly: Current Practice and Future Opportunities. The American Journal of Geriatric Cardiology, 2006, 15, 42-49.	0.7	10
936	Lipid Therapy in the Elderlyâ€”Emphasis on Clinical Event Reduction and Safety. The American Journal of Geriatric Cardiology, 2006, 15, 245-247.	0.7	4
937	Drug Insight: statin use in the elderly. Nature Clinical Practice Cardiovascular Medicine, 2006, 3, 318-328.	3.3	13

#	ARTICLE	IF	CITATIONS
938	Acute coronary syndromes and diabetes: is intensive lipid lowering beneficial? Results of the PROVE IT-TIMI 22 trial. <i>European Heart Journal</i> , 2006, 27, 2323-2329.	1.0	88
939	Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. <i>Current Medical Research and Opinion</i> , 2006, 22, 2041-2053.	0.9	101
940	The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. <i>Current Medical Research and Opinion</i> , 2006, 22, 2243-2250.	0.9	291
941	Active Metabolite of Atorvastatin Inhibits Membrane Cholesterol Domain Formation by an Antioxidant Mechanism. <i>Journal of Biological Chemistry</i> , 2006, 281, 9337-9345.	1.6	79
942	Vascular Protection of Dual Therapy (Atorvastatin-Amlodipine) in Hypertensive Patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, S189-S193.	3.0	11
943	A Tale of Two Trials. <i>Circulation</i> , 2006, 113, 1406-1414.	1.6	84
944	Variations on a Gene: Rare and Common Variants in ABCA1 and Their Impact on HDL Cholesterol Levels and Atherosclerosis. <i>Annual Review of Nutrition</i> , 2006, 26, 105-129.	4.3	139
945	Amlodipine/atorvastatin single pill for the management of hypertensive patients with additional cardiovascular risk factors. <i>Future Cardiology</i> , 2006, 2, 145-159.	0.5	1
946	Statins in stroke: prevention, protection and recovery. <i>Expert Review of Neurotherapeutics</i> , 2006, 6, 195-202.	1.4	22
948	Drug Insight: the role of statins in combination with ezetimibe to lower LDL cholesterol. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2006, 3, 664-672.	3.3	18
949	Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. <i>European Heart Journal</i> , 2006, 27, 1153-1158.	1.0	268
950	The ASTEROID trial: coronary plaque regression with high-dose statin therapy. <i>Future Cardiology</i> , 2006, 2, 651-654.	0.5	21
951	Coronary Heart Disease Risk Equivalence in Diabetes Depends on Concomitant Risk Factors. <i>Diabetes Care</i> , 2006, 29, 391-397.	4.3	163
952	Effect of Lowering LDL Cholesterol Substantially Below Currently Recommended Levels in Patients With Coronary Heart Disease and Diabetes: The Treating to New Targets (TNT) study. <i>Diabetes Care</i> , 2006, 29, 1220-1226.	4.3	493
953	Standards of Medical Care in Diabetes--2007. <i>Diabetes Care</i> , 2007, 30, S4-S41.	4.3	1,296
954	Effect of Intensive Lipid Lowering with Atorvastatin on Renal Function in Patients with Coronary Heart Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2007, 2, 1131-1139.	2.2	246
955	Economic impacts attributable to the early clinical benefit of atorvastatin therapy â€” a US managed care perspective. <i>Current Medical Research and Opinion</i> , 2007, 23, 1517-1529.	0.9	13
957	Emerging drugs for acute and chronic heart failure: current and future developments. <i>Expert Opinion on Emerging Drugs</i> , 2007, 12, 75-95.	1.0	5



#	ARTICLE	IF	CITATIONS
958	Farnesyltransferase Inhibitor, Manumycin A, Prevents Atherosclerosis Development and Reduces Oxidative Stress in Apolipoprotein E-Deficient Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007, 27, 1390-1395.	1.1	33
959	Enhanced sensitivity to IGF-II signaling links loss of imprinting of <i>IGF2</i> to increased cell proliferation and tumor risk. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 20926-20931.	3.3	97
960	The Use of Statins in Pediatrics: Knowledge Base, Limitations, and Future Directions. <i>Pediatrics</i> , 2007, 119, 370-380.	1.0	58
961	ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction. <i>Circulation</i> , 2007, 116, e148-304.	1.6	1,247
962	Potential of non-antiarrhythmic drugs to provide an innovative upstream approach to the pharmacological prevention of sudden cardiac death. <i>Expert Opinion on Investigational Drugs</i> , 2007, 16, 605-623.	1.9	16
963	Exploring the natural history of atherosclerosis with intravascular ultrasound. <i>Expert Review of Cardiovascular Therapy</i> , 2007, 5, 295-306.	0.6	7
964	Effects of Reconstituted High-Density Lipoprotein Infusions on Coronary Atherosclerosis<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>. <i>JAMA - Journal of the American Medical Association</i> , 2007, 297, 1675.	3.8	652
965	Use of maximum-dose simvastatin or atorvastatin in an ethnically diverse population. <i>American Journal of Health-System Pharmacy</i> , 2007, 64, 767-772.	0.5	1
967	Circulating chemokines accurately identify individuals with clinically significant atherosclerotic heart disease. <i>Physiological Genomics</i> , 2007, 31, 402-409.	1.0	60
968	Effects of Intensive Versus Moderate Lipid-Lowering Therapy on Myocardial Ischemia in Older Patients With Coronary Heart Disease. <i>Circulation</i> , 2007, 115, 700-707.	1.6	213
969	Long-Term Prognostic Value of Neopterin. <i>Circulation</i> , 2007, 115, 3071-3078.	1.6	125
970	Restoring the Dysfunctional Endothelium. <i>Current Pharmaceutical Design</i> , 2007, 13, 1053-1068.	0.9	35
971	Nutritional and nutraceutical considerations for dyslipidemia. <i>Future Lipidology</i> , 2007, 2, 313-339.	0.5	14
972	Impact of C-reactive protein on treatment of patients with cardiovascular disease. <i>American Journal of Health-System Pharmacy</i> , 2007, 64, 2009-2016.	0.5	10
973	Apolipoprotein A-I/HDL Infusion Therapy for Plaque Stabilization-Regression: A Novel Therapeutic Approach. <i>Current Pharmaceutical Design</i> , 2007, 13, 1031-1038.	0.9	34
974	Pleiotropic Effects of Statins: Stabilization of the Vulnerable Atherosclerotic Plaque?. <i>Current Pharmaceutical Design</i> , 2007, 13, 1003-1012.	0.9	32
975	Which statin, what dose?. <i>Drug and Therapeutics Bulletin</i> , 2007, 45, 33-37.	0.3	4
976	Serotonin transporter protein in pulmonary hypertensive rats treated with atorvastatin. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2007, 293, L630-L638.	1.3	39

#	ARTICLE	IF	CITATIONS
977	Influence of Statin Use on Endothelial Function: From Bench to Clinics. <i>Current Pharmaceutical Design</i> , 2007, 13, 1771-1786.	0.9	53
978	Diabetes and Mortality Following Acute Coronary Syndromes. <i>JAMA - Journal of the American Medical Association</i> , 2007, 298, 765.	3.8	569
979	Primary PCI for Myocardial Infarction with ST-Segment Elevation. <i>New England Journal of Medicine</i> , 2007, 356, 47-54.	13.9	170
980	Incremental Benefit and Cost-Effectiveness of High-Dose Statin Therapy in High-Risk Patients With Coronary Artery Disease. <i>Circulation</i> , 2007, 115, 2398-2409.	1.6	68
981	Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials. <i>Heart</i> , 2007, 93, 914-921.	1.2	108
982	Biases in the Identification of Risk Factor Thresholds and J-Curves. <i>American Journal of Epidemiology</i> , 2007, 166, 824-831.	1.6	35
983	Is There a True Beneficial Effect of Statin Therapy in the Acute Phase of Unstable Angina or Myocardial Infarction?. <i>Current Vascular Pharmacology</i> , 2007, 5, 221-225.	0.8	4
984	Atherosclerosis imaging in statin intervention trials. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2007, 100, 253-262.	0.2	8
985	Does Preventive PCI Work?. <i>New England Journal of Medicine</i> , 2007, 356, 1572-1574.	13.9	49
986	Clinical Application of C-Reactive Protein Across the Spectrum of Acute Coronary Syndromes. <i>Clinical Chemistry</i> , 2007, 53, 1800-1807.	1.5	72
987	Risk factor status and vascular events in patients with symptomatic intracranial stenosis. <i>Neurology</i> , 2007, 69, 2063-2068.	1.5	155
988	Coronary atherosclerosis, low-density lipoproteins and markers of thrombosis, inflammation and endothelial dysfunction. <i>International Journal of Angiology</i> , 2007, 16, 12-16.	0.2	8
989	Alanine to Serine Polymorphism at Position 986 of the Calcium-Sensing Receptor Associated with Coronary Heart Disease, Myocardial Infarction, All-Cause, and Cardiovascular Mortality. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 2363-2369.	1.8	69
990	Mechanisms of action of statins in stroke. <i>Expert Opinion on Therapeutic Targets</i> , 2007, 11, 273-278.	1.5	14
991	Plasminogen Activator Inhibitor-1 in Vascular Thrombosis. <i>Current Drug Targets</i> , 2007, 8, 996-1002.	1.0	62
992	Serum lipid profile on admission for ischemic stroke: Failure to meet National Cholesterol Education Program Adult Treatment Panel (NCEP-ATPIII) guidelines. <i>Neurology</i> , 2007, 68, 660-665.	1.5	25
993	Impact of statins on atherosclerotic plaque. <i>Future Cardiology</i> , 2007, 3, 157-164.	0.5	1
995	Pitavastatin: efficacy and safety in intensive lipid lowering. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 2315-2327.	0.9	54

#	ARTICLE	IF	CITATIONS
996	Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). <i>European Heart Journal Supplements</i> , 2007, 9, C3-C74.	0.0	40
997	Statin therapy in South-Asian patients: clinical implications beyond lipid lowering?. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 1235-1243.	0.9	8
998	Atorvastatin Treatment and Vaccination Efficacy. <i>Journal of Clinical Pharmacology</i> , 2007, 47, 1022-1027.	1.0	17
999	Biomarkers in the Prevention and Treatment of Atherosclerosis: Need, Validation, and Future. <i>Pharmacological Reviews</i> , 2007, 59, 40-53.	7.1	61
1000	A multicentre, open study to assess the effect of individualizing starting doses of atorvastatin according to baseline LDL-C levels on achieving cholesterol targets: the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST-2) study. <i>Current Medical Research and Opinion</i> , 2007, 23, 1945-1956.	0.9	12
1001	Targeting High-Density Lipoprotein Cholesterol in the Management of Cardiovascular Disease. <i>The American Heart Hospital Journal</i> , 2007, 5, 210-216.	0.2	4
1002	Efficacy of Atorvastatin Therapy in Ischaemic Heart Disease – Effects on Oxidized Low-density Lipoprotein and Adiponectin. <i>Journal of International Medical Research</i> , 2007, 35, 534-539.	0.4	25
1003	ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-“ST-Elevation Myocardial Infarction: Executive Summary. <i>Circulation</i> , 2007, 116, 803-877.	1.6	177
1004	Acute Coronary Care in the Elderly, Part II. <i>Circulation</i> , 2007, 115, 2570-2589.	1.6	489
1005	The Evaluation of Cardiac and Peripheral Arterial Disease in Patients with Diabetes Mellitus. <i>Endocrine Research</i> , 2007, 32, 109-142.	0.6	3
1006	State of the Art Reviews: Relationship Between Diet/ Physical Activity and Health. <i>American Journal of Lifestyle Medicine</i> , 2007, 1, 457-481.	0.8	14
1007	The Unique Character of Cardiovascular Disease in Chronic Kidney Disease and Its Implications for Treatment with Lipid-Lowering Drugs. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2007, 2, 766-785.	2.2	30
1008	Effects of Ranolazine on Recurrent Cardiovascular Events in Patients With Non-“ST-Elevation Acute Coronary Syndromes<SUBTITLE>The MERLIN-TIMI 36 Randomized Trial</SUBTITLE>. <i>JAMA - Journal of the American Medical Association</i> , 2007, 297, 1775.	3.8	448
1009	Lifestyle Medicine Strategies for Risk Factor Reduction, Prevention, and Treatment of Coronary Heart Disease: Part II. <i>American Journal of Lifestyle Medicine</i> , 2007, 1, 79-90.	0.8	6
1010	Endocrine Disorders and the Heart. , 2007, , 2295-2330.		1
1012	Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 weeks controlled trial. <i>Rheumatology</i> , 2007, 46, 1560-1565.	0.9	104
1013	Statins, High-Density Lipoprotein Cholesterol, and Regression of Coronary Atherosclerosis. <i>JAMA - Journal of the American Medical Association</i> , 2007, 297, 499.	3.8	654
1014	High-Density Lipoprotein as a Therapeutic Target. <i>JAMA - Journal of the American Medical Association</i> , 2007, 298, 786.	3.8	415

#	ARTICLE	IF	CITATIONS
1015	Statin Therapy and the Elderly. <i>Circulation</i> , 2007, 115, 681-683.	1.6	27
1016	Effects of Statins on Blood Pressure: A Review of the Experimental and Clinical Evidence.. <i>Current Vascular Pharmacology</i> , 2007, 5, 155-161.	0.8	10
1017	Averting a pandemic health crisis in Europe by 2020: what physicians need to know regarding cholesterol management. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2007, 14, 340-345.	3.1	0
1018	Comparison of intensive and low-dose atorvastatin therapy in the reduction of carotid intimal-medial thickness in patients with coronary heart disease. <i>Heart</i> , 2007, 93, 933-939.	1.2	62
1019	Statins in elderly patients with acute coronary syndrome: an analysis of dose and class effects in typical practice. <i>Heart</i> , 2007, 93, 945-951.	1.2	23
1020	Baseline Characteristics of Patients with Cerebrovascular Disease in the REACH Registry: The Spanish Contribution. <i>Cerebrovascular Diseases</i> , 2007, 24, 89-95.	0.8	6
1021	Statin Use in Patients With Extremely Low Low-Density Lipoprotein Levels Is Associated With Improved Survival. <i>Circulation</i> , 2007, 116, 613-618.	1.6	63
1022	Successful Intensive Lipid-lowering Therapy Using Atorvastatin Stabilizes Coronary Artery Plaque as Assessed by Multi-detector Row Computed Tomography. <i>Internal Medicine</i> , 2007, 46, 859-863.	0.3	3
1024	Usefulness of Hydrophilic vs Lipophilic Statins After Acute Myocardial Infarction Subanalysis of MUSASHI-AMI. <i>Circulation Journal</i> , 2007, 71, 1348-1353.	0.7	50
1025	Rationale and Design of a Study to Examine Lower Targets for Low-Density Lipoprotein-Cholesterol and Blood Pressure in Coronary Artery Disease Patients The Japanese Coronary Artery Disease Study II (JCADII). <i>Circulation Journal</i> , 2007, 72, 515-520.	0.7	4
1026	Outcomes of Using High- or Low-Dose Atorvastatin in Patients 65 Years of Age or Older with Stable Coronary Heart Disease. <i>Annals of Internal Medicine</i> , 2007, 147, 1.	2.0	124
1027	<b>Cardiovascular Medication Prescribing in Older Adults with Psychiatric Disorders Research and Reports</b>. <i>The Consultant Pharmacist</i> , 2007, 22, 660-668.	0.4	0
1028	Î²-Blockers and Progression of Coronary Atherosclerosis: Pooled Analysis of 4 Intravascular Ultrasonography Trials. <i>Annals of Internal Medicine</i> , 2007, 147, 10.	2.0	83
1029	Antisense Apolipoprotein B-100 As Novel Treatment For Hypercholesterolemia: Focus On Isis 301012. <i>Future Lipidology</i> , 2007, 2, 387-393.	0.5	6
1030	Pharmacotherapeutic decisions in menopausal women with cardiovascular risk. <i>Future Lipidology</i> , 2007, 2, 197-210.	0.5	2
1031	Differential Impact of Atorvastatin vs Pravastatin on Progressive Insulin Resistance and Left Ventricular Diastolic Dysfunction in a Rat Model of Type II Diabetes. <i>Circulation Journal</i> , 2007, 71, 144-152.	0.7	42
1032	Randomized Evaluation of Atorvastatin in Patients With Coronary Heart Disease A Serial Intravascular Ultrasound Study. <i>Circulation Journal</i> , 2007, 71, 1845-1850.	0.7	23
1033	Effect of Statins and Calcium Channel Blockers on All-Cause Mortality and Cardiovascular and Cerebrovascular Disease Mortality in 958 Chinese Hospitalized Patients with Peripheral Arterial Disease after 13 Months of Follow-up. <i>Journal of Health Science</i> , 2007, 53, 226-233.	0.9	3

#	ARTICLE	IF	CITATIONS
1034	Impact of Lipid-Lowering Therapy With Pitavastatin, a New HMG-CoA Reductase Inhibitor, on Regression of Coronary Atherosclerotic Plaque A 3-Dimensional Intravascular Ultrasound Study. <i>Circulation Journal</i> , 2007, 71, 1678-1684.	0.7	36
1035	Effects of Medication on Cardiovascular Events in the Japanese Coronary Artery Disease (JCAD) Study. <i>Circulation Journal</i> , 2007, 71, 1835-1840.	0.7	29
1036	Rationale and Design for a Study Using Intravascular Ultrasound to Evaluate Effects of Rosuvastatin on Coronary Artery Atheroma in Japanese Subjects COSMOS Study (Coronary Atherosclerosis Study) <i>Tj ETQq0 0 0 reBT /Overlock 10 Tf Journal</i> , 2007, 71, 271-275.	0.7	26
1037	Impact of Newly Diagnosed Abnormal Glucose Tolerance on Long-Term Prognosis in Patients With Acute Myocardial Infarction. <i>Circulation Journal</i> , 2007, 71, 834-841.	0.7	49
1038	Effect of Colestimide Therapy for Glycemic Control in Type 2 Diabetes Mellitus with Hypercholesterolemia. <i>Endocrine Journal</i> , 2007, 54, 53-58.	0.7	74
1041	Atherosclerosis imaging as a benchmark in the development of novel cardiovascular drugs. <i>Current Opinion in Lipidology</i> , 2007, 18, 613-621.	1.2	26
1042	Reducing Myocardial Injury by Minimizing Imbalance between Oxygen Supply and Demand. <i>Anesthesiology</i> , 2007, 107, 161-163.	1.3	1
1043	Cardiovascular Drug Therapy in the Elderly. <i>Cardiology in Review</i> , 2007, 15, 195-215.	0.6	32
1044	Evaluation of Proton Pump Inhibitor Use in Patients With Acute Coronary Syndromes Based on Risk Factors for Gastrointestinal Bleed. <i>Critical Pathways in Cardiology</i> , 2007, 6, 169-172.	0.2	10
1045	Statin Therapy. <i>Critical Care Nursing Quarterly</i> , 2007, 30, 154-160.	0.4	8
1046	Use of statins in the elderly. <i>Future Lipidology</i> , 2007, 2, 9-13.	0.5	0
1047	Impact Of Statin Therapy On The Artery Wall In The Low-Risk Patient: Implications From The METEOR Study. <i>Future Lipidology</i> , 2007, 2, 595-601.	0.5	0
1048	Statins and perioperative myocardial infarction. <i>Southern African Journal of Anaesthesia and Analgesia</i> , 2007, 13, 15-20.	0.1	1
1049	Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease. <i>Yearbook of Vascular Surgery</i> , 2007, 2007, 90-92.	0.0	0
1050	Identifying and Attaining LDL-C Goals: Mission Accomplished? Next Target: New Therapeutic Options to Raise HDL-C Levels. <i>Current Drug Targets</i> , 2007, 8, 483-488.	1.0	27
1051	Low-density lipoprotein lowering in type 2 diabetes mellitus: how to know how low to go. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2007, 14, 116-123.	1.2	7
1052	Statin therapy and stroke prevention: what was known, what is new and what is next?. <i>Current Opinion in Lipidology</i> , 2007, 18, 622-625.	1.2	8
1053	Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. <i>Yearbook of Endocrinology</i> , 2007, 2007, 108-110.	0.0	0

#	ARTICLE	IF	CITATIONS
1054	High-Dose Atorvastatin vs Usual-Dose Simvastatin for Secondary Prevention After Myocardial Infarction: The IDEAL Study: A Randomized Controlled Trial. <i>Yearbook of Medicine</i> , 2007, 2007, 521-523.	0.1	0
1057	Reply to Drs Vos, Ravnskov, Mascitelli and Pezzetta. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2007, 17, e21-e23.	1.1	0
1058	Optimal Treatment of Dyslipidemia in High-Risk Patients: Intensive Statin Treatment or Combination Therapy?. <i>Preventive Cardiology</i> , 2007, 10, 31-35.	1.1	4
1059	Intensive Statin Treatment or Combination Therapy in High-Risk Patients. <i>Preventive Cardiology</i> , 2007, 10, 7-8.	1.1	0
1060	Statins and C-reactive Protein Levels. <i>Journal of Clinical Hypertension</i> , 2007, 9, 622-628.	1.0	46
1061	Mechanisms of Disease: HDL metabolism as a target for novel therapies. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2007, 4, 102-109.	3.3	59
1062	Framingham risk score and prediction of coronary heart disease death in young men. <i>American Heart Journal</i> , 2007, 154, 80-86.	1.2	131
1063	Testing the hypothesis of atherosclerotic plaque lipid depletion during lipid therapy by magnetic resonance imaging: Study design of Carotid Plaque Composition Study. <i>American Heart Journal</i> , 2007, 154, 239-246.	1.2	42
1064	Intensity of lipid-lowering therapy and low-density lipoprotein cholesterol goal attainment among the elderly before and after the 2004 National Cholesterol Education Program Adult Treatment Panel III update. <i>American Heart Journal</i> , 2007, 154, 554-560.	1.2	24
1065	Statin therapy in heart failure: Prognostic effects and potential mechanisms. <i>American Heart Journal</i> , 2007, 154, 617-623.	1.2	22
1066	Study of the effectiveness of additional reductions in cholesterol and homocysteine (SEARCH): Characteristics of a randomized trial among 12064 myocardial infarction survivors. <i>American Heart Journal</i> , 2007, 154, 815-823.e6.	1.2	88
1067	Management of Post-Myocardial Infarction Patients with Left Ventricular Systolic Dysfunction. <i>American Journal of Medicine</i> , 2007, 120, 109-120.	0.6	16
1068	Active Lipid Management In Coronary Artery Disease (ALMICAD) Study. <i>American Journal of Medicine</i> , 2007, 120, 734.e11-734.e17.	0.6	3
1069	Impact of Statin Dosing Intensity on Transaminase and Creatine Kinase. <i>American Journal of Medicine</i> , 2007, 120, 706-712.	0.6	55
1070	Achievement of optimal combined lipid values in a managed care setting: Is a new treatment paradigm needed?. <i>Clinical Therapeutics</i> , 2007, 29, 196-209.	1.1	11
1071	A dose-specific meta-analysis of lipid changes in randomized controlled trials of atorvastatin and simvastatin. <i>Clinical Therapeutics</i> , 2007, 29, 242-252.	1.1	32
1072	Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy. <i>Clinical Therapeutics</i> , 2007, 29, 253-260.	1.1	179
1073	Cholesterol reduction yields clinical benefits: meta-analysis including recent trials. <i>Clinical Therapeutics</i> , 2007, 29, 778-794.	1.1	116

#	ARTICLE	IF	CITATIONS
1074	Does Statin Therapy Initiation Increase the Risk for Myopathy? An Observational Study of 32,225 Diabetic and Nondiabetic Patients. <i>Clinical Therapeutics</i> , 2007, 29, 1761-1770.	1.1	158
1075	On the association between statin and fracture: A Bayesian consideration. <i>Bone</i> , 2007, 40, 813-820.	1.4	21
1076	Is lipid lowering treatment aiming for very low LDL levels safe in terms of the synthesis of steroid hormones?. <i>Medical Hypotheses</i> , 2007, 69, 104-112.	0.8	13
1077	Current questions regarding the use of statins in patients with coronary heart disease. <i>International Journal of Cardiology</i> , 2007, 122, 188-194.	0.8	16
1078	Serial intravascular ultrasound evidence of both plaque stabilization and lesion progression in patients with ruptured coronary plaques: Effects of statin therapy on ruptured coronary plaque. <i>Atherosclerosis</i> , 2007, 191, 107-114.	0.4	39
1079	Effect of individualizing starting doses of a statin according to baseline LDL-cholesterol levels on achieving cholesterol targets: The Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST) study. <i>Atherosclerosis</i> , 2007, 191, 135-146.	0.4	30
1080	To statin or to non-statin in coronary disease—considering absolute risk is the answer. <i>Atherosclerosis</i> , 2007, 195, 1-6.	0.4	38
1081	Efficacy and safety of rosuvastatin 40mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: Results of the POLARIS study. <i>Atherosclerosis</i> , 2007, 194, e154-e164.	0.4	48
1082	Cholesterol lowering in patients with CHD and metabolic syndrome. <i>Lancet, The</i> , 2007, 369, 27.	6.3	24
1083	The safety of statins in clinical practice. <i>Lancet, The</i> , 2007, 370, 1781-1790.	6.3	705
1084	Guías de práctica clínica sobre diabetes, prediabetes y enfermedades cardiovasculares: versión resumida. <i>Revista Española De Cardiología</i> , 2007, 60, 525.e1-525.e64.	0.6	13
1085	Dislipemia del síndrome metabólico. Documento sumario del Foro-HDL. <i>Clínica E Investigación En Arteriosclerosis</i> , 2007, 19, 252-263.	0.4	1
1087	Reducing cardiovascular risk by targeting high-density lipoprotein cholesterol. <i>Current Atherosclerosis Reports</i> , 2007, 9, 81-88.	2.0	10
1088	Letter to the editor. <i>Canadian Journal of Cardiology</i> , 2007, 23, 481-482.	0.8	1
1089	The effect of intensified lipid-lowering therapy on long-term prognosis in patients with peripheral arterial disease. <i>Journal of Vascular Surgery</i> , 2007, 45, 936-943.	0.6	89
1090	Atorvastatin in prevention of stroke and transient ischaemic attack. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 2789-2797.	0.9	9
1091	Acute Coronary Syndromes in the Elderly. <i>Drugs and Aging</i> , 2007, 24, 901-912.	1.3	9
1092	Rosuvastatin in Elderly Patients. <i>Drugs and Aging</i> , 2007, 24, 933-944.	1.3	7

#	ARTICLE	IF	CITATIONS
1093	The GALAXY Program: an update on studies investigating efficacy and tolerability of rosuvastatin for reducing cardiovascular risk. <i>Expert Review of Cardiovascular Therapy</i> , 2007, 5, 177-193.	0.6	28
1094	Atorvastatin. <i>Drugs</i> , 2007, 67, 3-15.	4.9	61
1095	Atorvastatin Efficacy in the Primary and Secondary Prevention of Cardiovascular Events. <i>Drugs</i> , 2007, 67, 29-42.	4.9	41
1096	Atorvastatin Efficacy in the Prevention of Cardiovascular Events in Patients with Diabetes Mellitus and/or Metabolic Syndrome. <i>Drugs</i> , 2007, 67, 43-54.	4.9	30
1097	Medical Treatment of Stable Angina. , 2007, , 911-936.		0
1098	Prevalence of Adequate and of Optimal Control of Serum Low-Density Lipoprotein Cholesterol in an Academic Nursing Home. <i>Journal of the American Medical Directors Association</i> , 2007, 8, 604-606.	1.2	19
1099	Efficacy and safety of ezetimibe co-administered with atorvastatin in untreated patients with primary hypercholesterolaemia and coronary heart disease. <i>Current Medical Research and Opinion</i> , 2007, 23, 767-775.	0.9	25
1100	Atorvastatin. <i>Pharmacoeconomics</i> , 2007, 25, 1031-1053.	1.7	22
1101	Management of Dyslipidemia in the Metabolic Syndrome. <i>American Journal of Cardiovascular Drugs</i> , 2007, 7, 39-58.	1.0	54
1102	Evidence-Based Medical Therapy of Patients with Acute Coronary Syndromes. <i>American Journal of Cardiovascular Drugs</i> , 2007, 7, 95-116.	1.0	15
1103	Long-Term Benefit of Statin Therapy Initiated during Hospitalization for an Acute Coronary Syndrome. <i>American Journal of Cardiovascular Drugs</i> , 2007, 7, 135-141.	1.0	44
1104	Lipoprotein-Associated Phospholipase A2. <i>Molecular Diagnosis and Therapy</i> , 2007, 11, 219-226.	1.6	19
1105	Atorvastatin and statins in the treatment of heart failure. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 3061-3068.	0.9	17
1106	Efficacy and safety of extended-release fluvastatin in Turkish patients with hypercholesterolaemia: TULIPS (Turkish Lipid Study). <i>Current Medical Research and Opinion</i> , 2007, 23, 1093-1102.	0.9	7
1107	Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin. <i>Current Medical Research and Opinion</i> , 2007, 23, 2183-2192.	0.9	82
1108	Update on Dyslipidemia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 1581-1589.	1.8	102
1109	A Randomized, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Pharmacodynamic Interaction of Coadministered Amlodipine and Atorvastatin in 1660 Patients With Concomitant Hypertension and Dyslipidemia: The Respond Trial. <i>Journal of Clinical Pharmacology</i> , 2007, 47, 1555-1569.	1.0	53
1110	Clopidogrel anti-platelet effect: An evaluation by optical aggregometry, impedance aggregometry, and the Platelet Function Analyzer (PFA-100). <i>Platelets</i> , 2007, 18, 491-496.	1.1	50



#	ARTICLE	IF	CITATIONS
1111	The safety of rosuvastatin: effects on renal and hepatic function. <i>Expert Opinion on Drug Safety</i> , 2007, 6, 573-581.	1.0	15
1112	Designs of RADIANCE 1 and 2: carotid ultrasound studies comparing the effects of torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis. <i>Current Medical Research and Opinion</i> , 2007, 23, 885-894.	0.9	35
1113	Chapter 12 Recent Trends in HDL Modulating Therapies. <i>Annual Reports in Medicinal Chemistry</i> , 2007, , 177-191.	0.5	2
1114	Acute Coronary Syndromes in the Elderly. <i>Clinics in Geriatric Medicine</i> , 2007, 23, 425-440.	1.0	13
1116	Clinical Use of Carotid Intima-Media Thickness: Review of the Literature. <i>Journal of the American Society of Echocardiography</i> , 2007, 20, 907-914.	1.2	102
1117	Management of Antiretroviral Treatment-Related Complications. <i>Infectious Disease Clinics of North America</i> , 2007, 21, 103-132.	1.9	16
1118	Statins: An essential component in the management of carotid artery disease. <i>Journal of Vascular Surgery</i> , 2007, 46, 373-386.e9.	0.6	79
1119	Management of non-ST-Segment Elevation Myocardial Infarction. <i>Medical Clinics of North America</i> , 2007, 91, 683-700.	1.1	3
1120	Acute Coronary Syndromes: Unstable Angina/Non-ST Elevation Myocardial Infarction. <i>Critical Care Clinics</i> , 2007, 23, 709-735.	1.0	10
1121	Implication of the New Low-Density Lipoprotein Goals in Dyslipidemia Management of Patients With Acute Coronary Syndrome. <i>Mayo Clinic Proceedings</i> , 2007, 82, 551-555.	1.4	7
1123	Regression or Reduction in Progression of Atherosclerosis, and Avoidance of Coronary Events, With Lovastatin in Patients With or at High Risk of Cardiovascular Disease. <i>Clinical Drug Investigation</i> , 2007, 27, 591-604.	1.1	18
1124	Lipid-Modifying Therapy and Attainment of Cholesterol Goals in Hungary. <i>Clinical Drug Investigation</i> , 2007, 27, 647-660.	1.1	19
1125	Effect of Cardiovascular Risk Factors on Long-Term Morbidity and Mortality Following Acute Myocardial Infarction. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2007, 60, 703-713.	0.4	3
1126	Cholesterol ester transfer protein (CETP) and atherosclerosis. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2007, 4, 137-145.	0.5	4
1127	Global cardiovascular risk: The benefits of a precocious, aggressive treatment strategy. <i>International Congress Series</i> , 2007, 1303, 113-120.	0.2	1
1128	Intravascular Ultrasound for the Evaluation of Therapies Targeting Coronary Atherosclerosis. <i>Journal of the American College of Cardiology</i> , 2007, 49, 925-932.	1.2	82
1129	Coronary Heart Disease in Patients With Diabetes. <i>Journal of the American College of Cardiology</i> , 2007, 49, 631-642.	1.2	132
1130	Atherosclerosis Regression, Vascular Remodeling, and Plaque Stabilization—Editorials published in the <i>Journal of the American College of Cardiology</i> reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology. <i>Journal of the American College of Cardiology</i> , 2007, 49, 271-273.	1.2	35

#	ARTICLE	IF	CITATIONS
1131	Depression and Heart Failure: Why the Link Continues to Elude Us. <i>Journal of the American College of Cardiology</i> , 2007, 49, 1503-1504.	1.2	2
1133	Safety of Aggressive Lipid Management. <i>Journal of the American College of Cardiology</i> , 2007, 49, 1753-1762.	1.2	144
1134	ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-“ST-Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2007, 50, e1-e157.	1.2	1,587
1135	ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-“ST-Elevation Myocardial Infarction” Executive Summary. <i>Journal of the American College of Cardiology</i> , 2007, 50, 652-726.	1.2	252
1136	Role of Endothelial Shear Stress in the Natural History of Coronary Atherosclerosis and Vascular Remodeling. <i>Journal of the American College of Cardiology</i> , 2007, 49, 2379-2393.	1.2	1,211
1137	Effect of the Magnitude of Lipid Lowering on Risk of Elevated Liver Enzymes, Rhabdomyolysis, and Cancer. <i>Journal of the American College of Cardiology</i> , 2007, 50, 409-418.	1.2	224
1139	Clopidogrel-“Statin Interaction. <i>Journal of the American College of Cardiology</i> , 2007, 50, 296-298.	1.2	50
1140	Beyond Low-Density Lipoprotein Cholesterol. <i>Journal of the American College of Cardiology</i> , 2007, 50, 1735-1741.	1.2	115
1141	Effect of drugs on high-density lipoprotein. <i>Journal of Clinical Lipidology</i> , 2007, 1, 74-87.	0.6	3
1142	Implications of recent statin trials for primary care practice. <i>Journal of Clinical Lipidology</i> , 2007, 1, 182-190.	0.6	5
1143	Efficacy and tolerability of fixed-dose combination of simvastatin plus ezetimibe in patients with primary hypercholesterolemia: Results of a multicentric trial from India. <i>Journal of Clinical Lipidology</i> , 2007, 1, 264-270.	0.6	3
1144	Effects of adding extended-release niacin and colesvelam to statin therapy on lipid levels in subjects with atherosclerotic disease. <i>Journal of Clinical Lipidology</i> , 2007, 1, 620-625.	0.6	19
1145	Beneficial Effects of Statin Therapy on Survival in Hypertensive Patients With Acute Myocardial Infarction: Data From the RICO Survey&lt;xref ref-type="author-notes" id="fn1"&gt;&lt;sup&gt;*&lt;/sup&gt;&lt;/xref&gt;&lt;sub&gt;title /&gt;. <i>American Journal of Hypertension</i> , 2007, 20, 1133-9.	1.0	6
1146	Effect of Torcetrapib on Carotid Atherosclerosis in Familial Hypercholesterolemia. <i>New England Journal of Medicine</i> , 2007, 356, 1620-1630.	13.9	613
1147	Statins and Stroke Prevention. <i>Cerebrovascular Diseases</i> , 2007, 24, 170-182.	0.8	61
1148	Stroke and Other Neurovascular Disorders. , 2007, , 1019-1051.		4
1149	Comparison of Efficacy and Safety after Administering High Potency Statin to High Risk Patients: Rosuvastatin 10 mg versus Atorvastatin 20 mg. <i>Korean Circulation Journal</i> , 2007, 37, 154.	0.7	13
1150	Tools for Assessment of Cardiovascular Tests and Therapies. , 2007, , 1-34.		0

#	ARTICLE	IF	CITATIONS
1152	Integrated Primary Prevention of Cardiovascular Disease. , 0, , 129-189.		0
1153	Primary Prevention of Ischemic Heart Disease. , 2007, , 178-220.		1
1154	Efficacy and tolerability of 12-weeks treatment with lipanthyl supra or trichol in Indonesian patients with dyslipidemia. Medical Journal of Indonesia, 0, , 159.	0.2	0
1155	GUIDELINES ON DIABETES, PRE-DIABETES, AND CARDIOVASCULAR DISEASES. Rational Pharmacotherapy in Cardiology, 2007, 3, 71-99.	0.3	20
1156	Update in Perioperative Medicine. Annals of Internal Medicine, 2007, 147, 263.	2.0	11
1157	Effect of Conventional Dose of Simvastatin on Plaque Regression and Vascular Remodeling in the Persistent Reference Segments of Normocholesterolemic Patients: A Serial Intravascular Ultrasound Assessment. Korean Circulation Journal, 2007, 37, 483.	0.7	2
1158	Comprehensive Coronary Artery Disease Care in a Safety-Net Hospital: Results of Get With The Guidelines Quality Improvement Initiative. Journal of Managed Care Pharmacy, 2007, 13, 319-325.	2.2	16
1159	Colesevelam Hydrochloride-Ezetimibe Combination Lipid-Lowering Therapy in Patients with Diabetes or Metabolic Syndrome and a History of Statin Intolerance. Endocrine Practice, 2007, 13, 11-16.	1.1	48
1160	Prospective Study to Evaluate the Efficacy and Safety of Pitavastatin in Patients with Risk Factor of Cardiovascular Disease(PEACE Study). Korean Circulation Journal, 2007, 37, 16.	0.7	1
1161	In-Hospital Outcome According to the Initial Management and the "Thrombolysis in Myocardial Infarction Risk Score" of Acute Non-ST Segment Elevation Myocardial Infarction. Korean Circulation Journal, 2007, 37, 550.	0.7	0
1162	Effect of Early Versus Late In-Hospital Initiation of Statin Therapy on the Clinical Outcomes of Patients With Acute Coronary Syndrome. International Heart Journal, 2007, 48, 677-688.	0.5	15
1163	Non ST-Elevation Acute Coronary Syndromes. , 2007, , 221-245.		0
1164	Lipid-Lowering Therapy. , 2007, , 1087-1099.		1
1165	Prevention of sudden cardiac death. , 0, , 449-462.		0
1171	Preventing another event: Role of the hospitalist in discharge stroke prevention. Journal of Hospital Medicine, 2007, 2, 31-38.	0.7	1
1172	Design and synthesis of hepatoselective, pyrrole-based HMG-CoA reductase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 4538-4544.	1.0	50
1173	Pyrazole inhibitors of HMG-CoA reductase: An attempt to dramatically reduce synthetic complexity through minimal analog re-design. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 5567-5572.	1.0	15
1174	Risk stratification after acute myocardial infarction: Is it time to reassess? Implications from the INSPIRE trial. Journal of Nuclear Cardiology, 2007, 14, 282-292.	1.4	3

#	ARTICLE	IF	CITATIONS
1175	Fluvastatin ameliorates endotoxin induced multiple organ failure in conscious rats. Resuscitation, 2007, 74, 166-174.	1.3	33
1176	Renin-angiotensin-aldosterone system polymorphisms: a role or a hole in occurrence and long-term prognosis of acute myocardial infarction at young age. BMC Medical Genetics, 2007, 8, 27.	2.1	25
1177	Effectiveness of two statin prescribing strategies with respect to adherence and cardiovascular outcomes: observational study. Pharmacoepidemiology and Drug Safety, 2007, 16, 385-392.	0.9	35
1178	The impact of over-the-counter simvastatin on the number of statin prescriptions in the United Kingdom: a view from the General Practice Research Database. Pharmacoepidemiology and Drug Safety, 2007, 16, 1-4.	0.9	51
1179	Cardiovascular metabolic syndrome ? an interplay of, obesity, inflammation, diabetes and coronary heart disease. Diabetes, Obesity and Metabolism, 2007, 9, 218-232.	2.2	163
1180	Efficacy of ezetimibe/simvastatin 10/20 and 10/40 mg compared with atorvastatin 20 mg in patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism, 2007, 9, 575-584.	2.2	40
1181	Myocardial infarction: contemporary management strategies. Journal of Internal Medicine, 2007, 262, 59-77.	2.7	15
1182	Co-administration of ezetimibe and simvastatin in acute myocardial infarction. European Journal of Clinical Investigation, 2007, 37, 357-363.	1.7	15
1183	A perioperative statin update for noncardiac surgery. Part I: The effects of statin therapy on atherosclerotic disease and lessons learnt from statin therapy in medical (non-surgical) patients. Anaesthesia, 2008, 63, 52-64.	1.8	22
1184	Reduced Mortality Rates after Intensive Statin Therapy in Managed-Care Patients. Value in Health, 2007, 10, 161-169.	0.1	18
1185	Plaque progression and regression in atherothrombosis. Journal of Thrombosis and Haemostasis, 2007, 5, 292-299.	1.9	50
1186	Modifying Women's Risk for Cardiovascular Disease. JOGNN - Journal of Obstetric, Gynecologic, and Neonatal Nursing, 2007, 36, 116-124.	0.2	6
1187	Statin utilisation - recognising the role of the invisible hand. International Journal of Clinical Practice, 2007, 61, 3-6.	0.8	9
1188	Lighting the vascular fuse - late surgical attrition in older patients. International Journal of Clinical Practice, 2007, 61, 718-720.	0.8	0
1189	Role of imaging end points in atherosclerosis trials: focus on intravascular ultrasound. International Journal of Clinical Practice, 2007, 61, 951-962.	0.8	5
1190	A global survey of physicians' perceptions on cholesterol management: the From The Heart study. International Journal of Clinical Practice, 2007, 61, 1078-1085.	0.8	27
1191	Recent trials of lipid lowering. International Journal of Clinical Practice, 2007, 61, 1145-1159.	0.8	13
1192	Secondary prevention for coronary heart disease in the United Kingdom, low-density lipoprotein cholesterol goals and statin switching-an expression of concern. International Journal of Clinical Practice, 2007, 61, 1608-1611.	0.8	1

#	ARTICLE	IF	CITATIONS
1193	Absence of policy on how to use statins in England and Wales: do not let JBS2 fill the void. <i>International Journal of Clinical Practice</i> , 2007, 61, 1967-1970.	0.8	1
1194	Importance of Intensive Lipid Lowering in Acute Coronary Syndrome and Percutaneous Coronary Intervention. <i>Journal of Interventional Cardiology</i> , 2007, 20, 447-457.	0.5	14
1195	Non-ST segment elevation acute coronary syndromes: Treatment guidelines for the nurse practitioner. <i>Journal of the American Academy of Nurse Practitioners</i> , 2007, 19, 277-289.	1.4	2
1196	Heart Health: Does Diet Still Matter?. <i>Journal of the American Dietetic Association</i> , 2007, 107, 185.	1.3	1
1197	Comparison of Drug-Eluting Versus Bare Metal Stents on Later Frequency of Acute Myocardial Infarction and Death. <i>American Journal of Cardiology</i> , 2007, 99, 333-338.	0.7	28
1199	Efficacy and Safety of Rosuvastatin 40 mg Alone or in Combination With Ezetimibe in Patients at High Risk of Cardiovascular Disease (Results from the EXPLORER Study). <i>American Journal of Cardiology</i> , 2007, 99, 673-680.	0.7	168
1200	Role of C-Reactive Protein in Coronary Risk Reduction: Focus on Primary Prevention. <i>American Journal of Cardiology</i> , 2007, 99, 718-725.	0.7	38
1201	Global Risk Management in Patients with Type 2 Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2007, 99, 41-50.	0.7	33
1202	Effect of Early Statin Treatment at Standard Doses on Long-Term Clinical Outcomes in Patients With Acute Myocardial Infarction (The Heart Institute of Japan, Department of Cardiology Statin Evaluation) <i>Tj ETQq0 0 0rgBT /Overlock 10 T</i>		
1203	Efficacy of Drug Therapy in the Secondary Prevention of Cardiovascular Disease and Stroke. <i>American Journal of Cardiology</i> , 2007, 99, S1-S35.	0.7	20
1204	Low-Density Lipoprotein Cholesterol Reduction: The End Is More Important Than the Means. <i>American Journal of Cardiology</i> , 2007, 100, 240-242.	0.7	55
1205	Prevention of Cardiovascular Disease in Persons with Type 2 Diabetes Mellitus: Current Knowledge and Rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. <i>American Journal of Cardiology</i> , 2007, 99, S4-S20.	0.7	189
1206	Evolution of the Lipid Trial Protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. <i>American Journal of Cardiology</i> , 2007, 99, S56-S67.	0.7	87
1207	Safety and Efficacy of Atorvastatin-Induced Very Low-Density Lipoprotein Cholesterol Levels in Patients With Coronary Heart Disease (a Post Hoc Analysis of the Treating to New Targets [TNT]) <i>Tj ETQq1 1 0.784314 rgBT /Overlock 10 T</i>	0.7	143
1208	Comparison of Utilization of Statin Therapy at Hospital Discharge and Six-Month Outcomes in Patients With an Acute Coronary Syndrome and Serum Low-Density Lipoprotein $\geq 100$ mg/dl Versus $< 100$ mg/dl. <i>American Journal of Cardiology</i> , 2007, 100, 913-918.	0.7	23
1209	Effect of Intensive Lipid-Lowering Therapy on Mortality After Acute Coronary Syndrome (a) <i>Tj ETQq1 1 0.784314 rgBT /Overlock 10 T</i> 2007. 100. 1047-1051.	0.7	69
1210	Prevalence of Low High-Density Lipoprotein Cholesterol in Patients With Documented Coronary Heart Disease or Risk Equivalent and Controlled Low-Density Lipoprotein Cholesterol. <i>American Journal of Cardiology</i> , 2007, 100, 1499-1501.	0.7	64
1211	High-Density Lipoprotein Metabolism: Potential Therapeutic Targets. <i>American Journal of Cardiology</i> , 2007, 100, S32-S40.	0.7	65

#	ARTICLE	IF	CITATIONS
1212	A Cardiologist's Perspective on Cardiometabolic Risk. <i>American Journal of Cardiology</i> , 2007, 100, S3-S6.	0.7	23
1214	Statins and the endothelium. <i>Vascular Pharmacology</i> , 2007, 46, 1-9.	1.0	110
1215	Low-Density Lipoprotein Cholesterol in High-Risk Asymptomatic Individuals. <i>Journal of the Cardiometabolic Syndrome</i> , 2007, 2, 49-52.	1.7	1
1216	Protective effects of a squalene synthase inhibitor, lapaquistat acetate (TAK-475), on statin-induced myotoxicity in guinea pigs. <i>Toxicology and Applied Pharmacology</i> , 2007, 223, 39-45.	1.3	33
1217	Reduced mitochondrial coenzyme Q10 levels in HepG2 cells treated with high-dose simvastatin: A possible role in statin-induced hepatotoxicity?. <i>Toxicology and Applied Pharmacology</i> , 2007, 223, 173-179.	1.3	59
1218	Endocannabinoid Antagonism: Blocking the Excess in the Treatment of High-Risk Abdominal Obesity. <i>Trends in Cardiovascular Medicine</i> , 2007, 17, 35-43.	2.3	20
1219	The association between saphenous vein endothelial function, systemic inflammation, and statin therapy in patients undergoing coronary artery bypass surgery. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2007, 134, 335-341.	0.4	23
1220	Cardiovascular disease and modifiable cardiometabolic risk factors. <i>Clinical Cornerstone</i> , 2007, 8, 11-28.	1.0	122
1221	Can Intensive Statin Therapy Halt the Progression of Atherosclerosis? Recent Evidence and Potential Implications for Patient Management. <i>Progress in Cardiovascular Nursing</i> , 2007, 22, 207-213.	0.5	4
1222	Intensive statins post-MI: best practice vs cost-effective prescribing. <i>The Prescriber</i> , 2007, 18, 9-10.	0.1	0
1223	Rosuvastatin: the most efficient treatment option for patients with dyslipidemia. <i>Future Lipidology</i> , 2007, 2, 127-141.	0.5	0
1224	Rosuvastatin: a highly potent statin for the prevention and management of coronary artery disease. <i>Expert Review of Cardiovascular Therapy</i> , 2007, 5, 161-175.	0.6	25
1225	Evolution of Anticoagulant and Antiplatelet Therapy: Benefits and Risks of Contemporary Pharmacologic Agents and Their Implications for Myonecrosis and Bleeding in Percutaneous Coronary Intervention. <i>Clinical Cardiology</i> , 2007, 30, II4-II15.	0.7	3
1226	Management of coronary artery disease in patients with type 2 diabetes mellitus. <i>Current Cardiology Reports</i> , 2007, 9, 264-271.	1.3	7
1227	Aggressive statin therapy for acute coronary syndromes. <i>Current Cardiology Reports</i> , 2007, 9, 298-302.	1.3	0
1228	Residual risk in statin-treated patients: Future therapeutic options. <i>Current Cardiology Reports</i> , 2007, 9, 499-505.	1.3	23
1230	Statin therapy: Is the percent reduction or the attained low-density lipoprotein cholesterol level more important?. <i>Current Atherosclerosis Reports</i> , 2007, 9, 10-17.	2.0	4
1231	Statin therapy in cardiovascular diseases other than atherosclerosis. <i>Current Atherosclerosis Reports</i> , 2007, 9, 25-32.	2.0	6

#	ARTICLE	IF	CITATIONS
1233	Immediate effect of fluvastatin on lipid levels in acute coronary syndrome. <i>Molecular and Cellular Biochemistry</i> , 2007, 306, 19-23.	1.4	5
1234	Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection. <i>Heart Failure Reviews</i> , 2007, 12, 217-234.	1.7	436
1235	The Effect of Aggressive Versus Conventional Lipid-lowering Therapy on Markers of Inflammatory and Oxidative Stress. <i>Cardiovascular Drugs and Therapy</i> , 2007, 21, 91-97.	1.3	25
1236	Statin Pleiotropy: A Popular Concept but Clinical Significance Unclear. <i>Cardiovascular Drugs and Therapy</i> , 2007, 21, 81-83.	1.3	3
1237	The Importance of Managing Hypertension and Dyslipidemia to Decrease Cardiovascular Disease. <i>Cardiovascular Drugs and Therapy</i> , 2007, 21, 297-309.	1.3	49
1238	Reinforcing a Continuum of Care: In-Hospital Initiation of Long-Term Secondary Prevention Following Acute Coronary Syndromes. <i>Cardiovascular Drugs and Therapy</i> , 2007, 21, 375-388.	1.3	14
1241	Genetic determinants of C-reactive protein. <i>Current Atherosclerosis Reports</i> , 2007, 9, 195-203.	2.0	32
1242	Atherosclerosis regression: Is low-density lipoprotein or high-density lipoprotein the answer?. <i>Current Atherosclerosis Reports</i> , 2007, 9, 266-273.	2.0	11
1243	SPARCL: The glimmer of statins for stroke risk reduction. <i>Current Atherosclerosis Reports</i> , 2007, 9, 347-351.	2.0	4
1244	Dyslipidemia in type 2 diabetes mellitus. <i>Current Diabetes Reports</i> , 2007, 7, 228-234.	1.7	47
1245	COX-2 and the vasculature: Angel or evil?. <i>Current Hypertension Reports</i> , 2007, 9, 73-80.	1.5	5
1246	Atherosclerotic renovascular disease and renal impairment: Can we predict the effect of intervention?. <i>Current Hypertension Reports</i> , 2007, 9, 140-147.	1.5	3
1247	Intensive management of risk factors for accelerated atherosclerosis: the role of multiple interventions. <i>Current Neurology and Neuroscience Reports</i> , 2007, 7, 42-48.	2.0	31
1248	Combination therapy of dyslipidemia. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2007, 9, 249-258.	0.4	8
1249	Organizing services for cardiovascular prevention. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2007, 9, 278-286.	0.4	9
1250	Treatment goals for the management of lipids and inflammation for patients with coronary artery disease. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2007, 9, 3-10.	0.4	1
1251	Lipid-independent pleiotropic effects of statins in the management of acute coronary coronary syndromes. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2007, 9, 46-51.	0.4	7
1252	Intensive lipid lowering in the cardiovascular patient: Who, how low, and for how long?. <i>Current Cardiovascular Risk Reports</i> , 2007, 1, 290-295.	0.8	0

#	ARTICLE	IF	CITATIONS
1253	Mevalonate pathway: A review of clinical and therapeutical implications. <i>Clinical Biochemistry</i> , 2007, 40, 575-584.	0.8	471
1254	Glucose-6-phosphate dehydrogenase deficiency protects against coronary heart disease. <i>Journal of Inherited Metabolic Disease</i> , 2008, 31, 412-417.	1.7	54
1255	Effects of Statins on High-Density Lipoproteins: A Potential Contribution to Cardiovascular Benefit. <i>Cardiovascular Drugs and Therapy</i> , 2008, 22, 321-338.	1.3	134
1256	Cardiovascular Prevention in Patients with Diabetes and Prediabetes. <i>Herz</i> , 2008, 33, 170-177.	0.4	16
1257	Informational lobbying under the shadow of political pressure. <i>Social Choice and Welfare</i> , 2008, 30, 531-559.	0.4	55
1258	High-dose statin use does not impair aerobic capacity or skeletal muscle function in older adults. <i>Age</i> , 2008, 30, 283-291.	3.0	42
1259	Oral Nanoparticulate Atorvastatin Calcium is More Efficient and Safe in Comparison to Lipicure <sup>®</sup> in Treating Hyperlipidemia. <i>Lipids</i> , 2008, 43, 231-241.	0.7	35
1261	What is the evidence in favor of low-dose statin therapy in 2008?. <i>Current Atherosclerosis Reports</i> , 2008, 10, 33-38.	2.0	2
1262	Adjunctive interventions in myocardial infarction: The role of statin therapy. <i>Current Atherosclerosis Reports</i> , 2008, 10, 142-148.	2.0	8
1263	Intensive statin therapy in acute coronary syndromes. <i>Current Atherosclerosis Reports</i> , 2008, 10, 158-163.	2.0	5
1264	Role of lipoprotein-associated phospholipase A2 in atherosclerosis. <i>Current Atherosclerosis Reports</i> , 2008, 10, 230-235.	2.0	23
1265	The evolving role of medical therapy for chronic stable angina. <i>Current Cardiology Reports</i> , 2008, 10, 263-271.	1.3	5
1266	Lipid management: Considerations in acute coronary syndrome. <i>Current Cardiology Reports</i> , 2008, 10, 334-341.	1.3	0
1267	Putting the benefits of percutaneous coronary revascularization into perspective: From trials to guidelines. <i>Current Cardiology Reports</i> , 2008, 10, 393-401.	1.3	0
1268	New strategies in the medical treatment of carotid artery disease. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2008, 10, 156-163.	0.4	2
1269	Atherosclerosis regression. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2008, 10, 187-194.	0.4	1
1270	Therapeutic options for premature coronary artery disease. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2008, 10, 294-303.	0.4	2
1272	Vulnerable plaque intervention: State of the art. <i>Catheterization and Cardiovascular Interventions</i> , 2008, 71, 367-374.	0.7	9



#	ARTICLE	IF	CITATIONS
1273	Prevalence, Predictors, and Impact of Conservative Medical Management for Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Who Have Angiographically Documented Significant Coronary Disease. <i>JACC: Cardiovascular Interventions</i> , 2008, 1, 369-378.	1.1	48
1274	Substituted oxazolidinones as novel NPC1L1 ligands for the inhibition of cholesterol absorption. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 546-553.	1.0	21
1275	Optimal Management of Combined Dyslipidemia: What Have We Behind Statins Monotherapy?. <i>Advances in Cardiology</i> , 2008, 45, 127-153.	2.6	31
1276	Lipid-altering efficacy of ezetimibe/simvastatin 10/40mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: the INFORCE study. <i>International Journal of Clinical Practice</i> , 2008, 62, 539-554.	0.8	29
1277	Subclinical atherosclerosis: what it is, what it means and what we can do about it. <i>International Journal of Clinical Practice</i> , 2008, 62, 1246-1254.	0.8	135
1278	Statin safety and chronic liver disease. <i>International Journal of Clinical Practice</i> , 2008, 62, 1831-1835.	0.8	6
1279	Vulnerable Plaque: Scope of the Problem. <i>Journal of Interventional Cardiology</i> , 2008, 21, 443-451.	0.5	5
1280	The influence of obesity and consequent insulin resistance on coronary risk factors in medically treated patients with coronary disease. <i>International Journal of Obesity</i> , 2008, 32, 967-974.	1.6	14
1281	Cholesterol—When Is Lower Better?. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 83, 777-780.	2.3	8
1282	Influence of OATP1B1 Genotype on the Pharmacokinetics of Rosuvastatin in Koreans. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 83, 251-257.	2.3	111
1283	Estrogen Receptor Genotypes, Menopausal Status, and the Lipid Effects of Tamoxifen. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 83, 702-710.	2.3	36
1284	Comparison of Effects of Pitavastatin and Atorvastatin on Plasma Coenzyme Q10 in Heterozygous Familial Hypercholesterolemia: Results From a Crossover Study. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 83, 731-739.	2.3	32
1285	Statin Cost-Effectiveness Comparisons Using Real-World Effectiveness Data: Formulary Implications. <i>Value in Health</i> , 2008, 11, 1061-1069.	0.1	15
1286	Cholesterol Goal Attainment in Patients with Coronary Heart Disease and Elevated Coronary Risk: Results of the Hong Kong Hospital Audit Study. <i>Value in Health</i> , 2008, 11, S91-S98.	0.1	22
1287	Atorvastatin attenuates mitochondrial toxin-induced striatal degeneration, with decreasing iNOS levels and activating ERK/Akt pathways. <i>Journal of Neurochemistry</i> , 2008, 104, 1190-1200.	2.1	29
1288	EFFECTS OF ATORVASTATIN AND PRAVASTATIN ON GLUCOSE TOLERANCE, ADIPOKINE LEVELS AND INFLAMMATORY MARKERS IN HYPERCHOLESTEROLAEMIC PATIENTS. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2008, 35, 1012-1017.	0.9	26
1289	Variability of lipids in patients with Type 2 diabetes taking statin treatment: implications for target setting. <i>Diabetic Medicine</i> , 2008, 25, 909-915.	1.2	12
1290	Ovariectomy increases vascular calcification via the OPG/RANKL cytokine signalling pathway. <i>European Journal of Clinical Investigation</i> , 2008, 38, 211-217.	1.7	24

#	ARTICLE	IF	CITATIONS
1291	Combination therapy in the management of mixed dyslipidaemia. <i>Journal of Internal Medicine</i> , 2008, 263, 353-365.	2.7	30
1292	Cholesterol complacency in Australia: time to revisit the basics of cardiovascular disease prevention. <i>Journal of Clinical Nursing</i> , 2009, 18, 678-686.	1.4	5
1294	Switching Statin Therapy Using a Pharmacist-Managed Therapeutic Conversion Program versus Usual Care Conversion Among Indigent Patients. <i>Pharmacotherapy</i> , 2008, 28, 553-561.	1.2	29
1295	Dyslipidemia Control in Indigent Patients Receiving Medication Assistance Compared with Insured Patients. <i>Pharmacotherapy</i> , 2008, 28, 562-569.	1.2	11
1296	Effect of Statin Therapy Before Q-Wave Myocardial Infarction on Myocardial Perfusion. <i>American Journal of Cardiology</i> , 2008, 101, 139-143.	0.7	19
1297	Nonprescription Statins: Not Ready for Prime Time. <i>American Journal of Cardiology</i> , 2008, 101, 745-746.	0.7	2
1298	Effect of Combination Angiotensin-Converting Enzyme and Angiotensin Receptor Blocker Therapy on Heart Failure Mortality and Morbidity. <i>American Journal of Cardiology</i> , 2008, 101, 744-745.	0.7	1
1299	The Editor's Roundtable: Psoriasis, Inflammation, and Coronary Artery Disease. <i>American Journal of Cardiology</i> , 2008, 101, 1119-1126.	0.7	30
1300	Factors Associated With Discharge Lipid-Lowering Drug Prescription in Patients Hospitalized for Coronary Artery Disease (from the Get With the Guidelines Database). <i>American Journal of Cardiology</i> , 2008, 101, 1242-1246.	0.7	11
1301	Outcomes by Optimizing Platelet Inhibition With Prasugrel (Preventing Clinical Events or Chasing) Tj ETQq1 1 0.784314 rgBT /Overlo compensation for U.S. Patent Application P-17232, "Method for Treating Vascular Diseases With Prasugrel," assigned to Eli Lilly and Company, Indianapolis, Indiana. He has received funding for research studies with clopidogrel. <i>American Journal of Cardiology</i> , 2008, 101, 1364-1366.	0.7	14
1302	Effect of Exercise Training in Supervised Cardiac Rehabilitation Programs on Prognostic Variables From the Exercise Tolerance Test. <i>American Journal of Cardiology</i> , 2008, 101, 1403-1407.	0.7	36
1303	Anti-Inflammatory Agents and Antioxidants as a Possible "Third Great Wave" in Cardiovascular Secondary Prevention. <i>American Journal of Cardiology</i> , 2008, 101, S4-S13.	0.7	44
1304	Reducing the Residual Risk of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor Therapy With Combination Therapy. <i>American Journal of Cardiology</i> , 2008, 101, S27-S35.	0.7	16
1305	Controlled Rosuvastatin Multinational Trial in Heart Failure (The Positive Negative Trial). <i>American Journal of Cardiology</i> , 2008, 101, 1808-1809.	0.7	2
1306	Effect of Intensive Atorvastatin Therapy on Prostaglandin E2 Levels and Metalloproteinase-9 Activity in the Plasma of Patients With Non-ST-Elevation Acute Coronary Syndrome Conflicts of interest: Drs. Egido and Tuñ�n have participated on advisory boards and have been invited speakers for Pfizer.. <i>American Journal of Cardiology</i> , 2008, 102, 12-18.	0.7	42
1307	A Perspective on the Efficacy and Safety of Intensive Antiplatelet Therapy in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel "Thrombolysis in Myocardial Infarction 38. <i>American Journal of Cardiology</i> , 2008, 101, 1367-1370.	0.7	10
1308	Lipoprotein-Associated Phospholipase A2: An Independent Predictor of Coronary Artery Disease Events in Primary and Secondary Prevention. <i>American Journal of Cardiology</i> , 2008, 101, S23-S33.	0.7	74
1309	Outcomes of Patients With Acute Coronary Syndrome and Previous Coronary Artery Bypass Grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the) Tj ETQq1 1 0.784314 rgBT /Overlo	0.7	14

#	ARTICLE	IF	CITATIONS
1310	Pleiotropic Effect of Lovastatin, With and Without Cholestyramine, in the Post Coronary Artery Bypass Graft (Post CABG) Trial. American Journal of Cardiology, 2008, 102, 1023-1027.	0.7	18
1311	Risk Stratification and Prognostic Factors in the Post-Myocardial Infarction Patient. American Journal of Cardiology, 2008, 102, 13G-20G.	0.7	13
1312	Relation Between Previous Lipid-Lowering Therapy and Infarct Size (Creatine Kinase-MB Level) in Patients Presenting With Acute Myocardial Infarction. American Journal of Cardiology, 2008, 102, 1119-1124.	0.7	6
1313	Comparison of Effectiveness of Atorvastatin 10 mg Versus 80 mg in Reducing Major Cardiovascular Events and Repeat Revascularization in Patients With Previous Percutaneous Coronary Intervention (Post Hoc Analysis of the Treating to New Targets [TNT] Study). American Journal of Cardiology, 2008, 102, 1571-1576.	0.7	40
1314	Intensive Lipid-Lowering Therapy for Patients With Aortic Stenosis. Conflicts of interest: Dr Pedersen has received research grants from Merck Sharp & Dohme, Norway; Merck/Schering-Plough, North Wales, Pennsylvania; and Pfizer, Inc., New York, New York, and consultant honoraria and speaker's fees from Merck Sharp & Dohme; Merck/Schering-Plough; Pfizer, Inc.; AstraZeneca, Wilmington, Delaware; and Merck KgaA, Darmstadt, Germany.. American Journal of Cardiology, 2008, 102, 1571-1576.	0.7	8
1315	Relation of Statin Therapy to Risk of Heart Failure After Acute Myocardial Infarction. American Journal of Cardiology, 2008, 102, 1706-1710.	0.7	11
1316	The Residual Risk Reduction Initiative: A Call to Action to Reduce Residual Vascular Risk in Patients with Dyslipidemia. American Journal of Cardiology, 2008, 102, 1K-34K.	0.7	371
1317	What Does "Best Medical Therapy" Really Mean?. European Journal of Vascular and Endovascular Surgery, 2008, 35, 139-144.	0.8	34
1318	Critical Missing Data on Erythropoiesis-Stimulating Agents in CKD: First Beat Placebo. American Journal of Kidney Diseases, 2008, 51, 366-369.	2.1	13
1319	Cardiovascular Disease and Modifiable Cardiometabolic Risk Factors. Clinical Cornerstone, 2008, 9, 24-41.	1.0	20
1320	The "Null Effect" of Low-Density Lipoprotein Cholesterol Lowering on a Modest Baseline Intima-Media Thickness: Lessons Learned From the ENHANCE Trial. Preventive Cardiology, 2008, 11, 177-178.	1.1	0
1321	The Benefits of Intensive Lipid Lowering in Patients With Stable Coronary Heart Disease With Normal or High Systolic Blood Pressure: An Analysis of the Treating to New Targets (TNT) Study. Journal of Clinical Hypertension, 2008, 10, 367-376.	1.0	13
1322	A Comparison of Cardiovascular Biomarkers in Patients Treated for Three Months with Etoricoxib, Celecoxib, Ibuprofen, and Placebo. Archives of Drug Information, 2008, 1, 4-13.	1.6	6
1323	Contemporary Approach to the Diagnosis and Management of Non-ST-Segment Elevation Acute Coronary Syndromes. Progress in Cardiovascular Diseases, 2008, 50, 311-351.	1.6	16
1324	Long-term effects of early statin therapy for patients with acute myocardial infarction treated with stent implantation. Journal of Cardiology, 2008, 51, 171-178.	0.8	13
1325	Cytogenetic status and oxidative DNA-damage induced by atorvastatin in human peripheral blood lymphocytes: Standard and Fpg-modified comet assay. Toxicology and Applied Pharmacology, 2008, 231, 85-93.	1.3	62
1326	Atorvastatin enhances hypothermia-induced neuroprotection after stroke. Journal of the Neurological Sciences, 2008, 275, 64-68.	0.3	22
1327	Drugs for Cardiovascular Disease Prevention in Women. Drugs, 2008, 68, 339-358.	4.9	5

#	ARTICLE	IF	CITATIONS
1328	Scientific Rationale for Combination of a Calcium Channel Antagonist and an HMG-CoA Reductase Inhibitor. <i>Drugs</i> , 2008, 68, 885-900.	4.9	6
1329	Rapid Change in Plaque Size, Composition, and Molecular Footprint After Recombinant Apolipoprotein A-IMilano (ETC-216) Administration. <i>Journal of the American College of Cardiology</i> , 2008, 51, 1104-1109.	1.2	122
1330	Polymorphism in KIF6 Gene and Benefit From Statins After Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2008, 51, 449-455.	1.2	146
1331	Impact of Triglyceride Levels Beyond Low-Density Lipoprotein Cholesterol After Acute Coronary Syndrome in the PROVE IT-TIMI 22 Trial. <i>Journal of the American College of Cardiology</i> , 2008, 51, 724-730.	1.2	534
1332	Lipid Levels After Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2008, 51, 1440-1445.	1.2	134
1333	The Effect of Darapladib on Plasma Lipoprotein-Associated Phospholipase A2 Activity and Cardiovascular Biomarkers in Patients With Stable Coronary Heart Disease or Coronary Heart Disease Risk Equivalent. <i>Journal of the American College of Cardiology</i> , 2008, 51, 1632-1641.	1.2	207
1334	ApoA-IMilano/Phospholipid Complex. <i>Journal of the American College of Cardiology</i> , 2008, 51, 1110-1111.	1.2	5
1335	Lipid Levels in the Post-Acute Coronary Syndrome Setting. <i>Journal of the American College of Cardiology</i> , 2008, 51, 1446-1447.	1.2	16
1336	In Search of the "Vulnerable Plaque". <i>Journal of the American College of Cardiology</i> , 2008, 51, 1539-1542.	1.2	58
1337	Intensive Lipid-Lowering With Atorvastatin for Secondary Prevention in Patients After Coronary Artery Bypass Surgery. <i>Journal of the American College of Cardiology</i> , 2008, 51, 1938-1943.	1.2	87
1338	The Influence of Pravastatin and Atorvastatin on Markers of Oxidative Stress in Hypercholesterolemic Humans. <i>Journal of the American College of Cardiology</i> , 2008, 51, 1653-1662.	1.2	104
1339	The Effects of Medications on Myocardial Perfusion. <i>Journal of the American College of Cardiology</i> , 2008, 52, 401-416.	1.2	84
1340	Baseline Low-Density Lipoprotein Cholesterol Is an Important Predictor of the Benefit of Intensive Lipid-Lowering Therapy. <i>Journal of the American College of Cardiology</i> , 2008, 52, 914-920.	1.2	64
1342	Primary Prevention of Cardiovascular Mortality and Events With Statin Treatments. <i>Journal of the American College of Cardiology</i> , 2008, 52, 1769-1781.	1.2	381
1343	Effect of ezetimibe/simvastatin versus atorvastatin or rosuvastatin on modifying lipid profiles in patients with diabetes, metabolic syndrome, or neither: Results of two subgroup analyses. <i>Journal of Clinical Lipidology</i> , 2008, 2, 91-105.	0.6	22
1344	Comparison of the efficacy and safety of a combination tablet of niacin extended-release and simvastatin with simvastatin 80 mg monotherapy: the SEACOAST II (high-dose) study. <i>Journal of Clinical Lipidology</i> , 2008, 2, 79-90.	0.6	37
1345	Plasma coenzyme Q10 predicts lipid-lowering response to high-dose atorvastatin. <i>Journal of Clinical Lipidology</i> , 2008, 2, 289-297.	0.6	17
1346	Benefits of statins beyond lipid lowering. <i>Drug Discovery Today Disease Mechanisms</i> , 2008, 5, e325-e331.	0.8	8

#	ARTICLE	IF	CITATIONS
1347	Effects of rosuvastatin and atorvastatin on the apolipoprotein B/apolipoprotein A-1 ratio in patients with an acute coronary syndrome: The CENTAURUS trial design. <i>Archives of Cardiovascular Diseases</i> , 2008, 101, 399-406.	0.7	10
1348	Antithrombotic Therapy in Peripheral Arterial Disease. <i>Cardiology Clinics</i> , 2008, 26, 289-298.	0.9	6
1349	Substituted Pyrazoles as Hepatoselective HMG-CoA Reductase Inhibitors: Discovery of (3 <i>R</i> )-5-[2-(4-Fluoro-phenyl)-4-isopropyl-5-(4-methyl-benzylcarbamoyl)-2 <i>H</i> -pyrazol-3-yl]-3,5-dihydroxyheptanoic Acid (PF-3052334) as a Candidate for the Treatment of Hypercholesterolemia. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 31-45.	2.9	59
1350	Niacin Increases HDL by Reducing Hepatic Expression and Plasma Levels of Cholesteryl Ester Transfer Protein in APOE*3Leiden.CETP Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, 2016-2022.	1.1	161
1352	Wild-Type Food in Health Promotion and Disease Prevention. , 2008, , .		15
1353	Cumulative clinical trial data on atorvastatin for reducing cardiovascular events: the clinical impact of atorvastatin. <i>Current Medical Research and Opinion</i> , 2008, 24, 1217-1229.	0.9	32
1354	Primary Prevention and Statins: Is It Just About Going to Class?. <i>Mayo Clinic Proceedings</i> , 2008, 83, 1313-1315.	1.4	2
1355	Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia. <i>New England Journal of Medicine</i> , 2008, 358, 1431-1443.	13.9	1,180
1356	Rosuvastatin: efficacy, safety and clinical effectiveness. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 2145-2160.	0.9	36
1358	Secondary Prevention of Coronary Heart Disease in Elderly Patients Following Myocardial Infarction. <i>Drugs and Aging</i> , 2008, 25, 649-664.	1.3	21
1359	Diagnosis and Treatment of Non-ST-Segment Elevation Myocardial Infarction. , 2008, , 60-72.		0
1361	Pleiotropic Effects of Atorvastatin in Heart Failure: Role in Oxidative Stress, Inflammation, Endothelial Function, and Exercise Capacity. <i>Journal of Heart and Lung Transplantation</i> , 2008, 27, 435-441.	0.3	62
1362	Coronary risk factors and coronary atheroma burden at severely narrowing segments. <i>International Journal of Cardiology</i> , 2008, 124, 124-126.	0.8	8
1363	The benefit of aspirin therapy in type 2 diabetes: What is the evidence?. <i>International Journal of Cardiology</i> , 2008, 129, 172-179.	0.8	14
1364	Effect of intensive vs standard statin therapy on endothelial progenitor cells and left ventricular function in patients with acute myocardial infarction: Statins for regeneration after acute myocardial infarction and PCI (STRAP) trial. <i>International Journal of Cardiology</i> , 2008, 130, 457-462.	0.8	69
1365	Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. <i>Trends in Molecular Medicine</i> , 2008, 14, 37-44.	3.5	522
1366	Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Therapy: Thrombolysis in Myocardial Infarction (PROVE IT-TIMI 22) trial. <i>American Heart Journal</i> , 2008, 155, 49-55.	1.2	151
1367	Effect of statin dose on incidence of atrial fibrillation: Data from the Pravastatin or Atorvastatin Evaluation and Infection Therapy Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) and Aggrastat to Zocor (A to Z) trials. <i>American Heart Journal</i> , 2008, 155, 298-302.	1.2	33

#	ARTICLE	IF	CITATIONS
1368	Noninvasive, medical management for non- $\sigma$ ST-elevation acute coronary syndromes. <i>American Heart Journal</i> , 2008, 155, 397-407.	1.2	20
1369	High-dose atorvastatin does not negatively influence clinical outcomes among clopidogrel treated acute coronary syndrome patients- $\sigma$ A Pravastatin or Atorvastatin Evaluation and Infection Therapy- $\sigma$ Thrombolysis in Myocardial Infarction 22 (PROVE IT- $\sigma$ TIMI 22) analysis. <i>American Heart Journal</i> , 2008, 155, 954-958.	1.2	33
1370	Statin Pretreatment Is Protective Despite an Association With Greater Coronary Artery Disease Burden in Patients Presenting With a First ST-Elevation Myocardial Infarction. <i>Preventive Cardiology</i> , 2008, 11, 21-25.	1.1	6
1371	Emerging antidyslipidemic drugs. <i>Expert Opinion on Emerging Drugs</i> , 2008, 13, 363-381.	1.0	14
1372	Statins in tumor suppression. <i>Cancer Letters</i> , 2008, 260, 11-19.	3.2	156
1373	A national study on lipid management. <i>European Journal of Internal Medicine</i> , 2008, 19, 356-361.	1.0	4
1374	Cardiac MRI of ischemic heart disease at 3T: Potential and challenges. <i>European Journal of Radiology</i> , 2008, 65, 15-28.	1.2	83
1375	Design of a nurse-run, telephone-based intervention to improve lipids in diabetics. <i>Contemporary Clinical Trials</i> , 2008, 29, 809-816.	0.8	4
1376	Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: A role for combination fibrate therapy. <i>Clinical Therapeutics</i> , 2008, 30, 294-306.	1.1	26
1377	A 52-Week, Randomized, Open-Label, Parallel-Group Comparison of the Tolerability and Effects of Pitavastatin and Atorvastatin on High-Density Lipoprotein Cholesterol Levels and Glucose Metabolism in Japanese Patients with Elevated Levels of Low-Density Lipoprotein Cholesterol and Glucose Intolerance. <i>Clinical Therapeutics</i> , 2008, 30, 1089-1101.	1.1	93
1378	Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: Economic analysis of the aggressive lipid-lowering initiation abates new cardiac events (ALLIANCE) study. <i>Clinical Therapeutics</i> , 2008, 30, 2204-2216.	1.1	16
1379	Tolerability and effects on lipids of ezetimibe coadministered with pravastatin or simvastatin for twelve months: Results from two open-label extension studies in hypercholesterolemic patients. <i>Clinical Therapeutics</i> , 2008, 30, 2280-2297.	1.1	7
1380	Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: Results of the CAP (Comparative Atorvastatin) Trial. <i>Overlook 10 1750 257 To</i>		
1381	Efficacy and Safety of Rosuvastatin in Taiwanese Patients. <i>Journal of the Chinese Medical Association</i> , 2008, 71, 113-118.	0.6	6
1382	Effects of the antioxidant succinobucol (AGI-1067) on human atherosclerosis in a randomized clinical trial. <i>Atherosclerosis</i> , 2008, 197, 480-486.	0.4	65
1383	Independent prognostic value of C-reactive protein and coronary artery disease extent in patients affected by unstable angina. <i>Atherosclerosis</i> , 2008, 196, 779-785.	0.4	45
1384	Modulation of arterial reactivity using amlodipine and atorvastatin measured by ultrasound examination (MARGAUX). <i>Atherosclerosis</i> , 2008, 197, 420-427.	0.4	13
1385	Atorvastatin increases HDL cholesterol by reducing CETP expression in cholesterol-fed APOE*3-Leiden.CETP mice. <i>Atherosclerosis</i> , 2008, 197, 57-63.	0.4	76

#	ARTICLE	IF	CITATIONS
1386	Association of circulating leukocyte count with coronary atherosclerosis regression after pravastatin treatment. <i>Atherosclerosis</i> , 2008, 198, 360-365.	0.4	21
1387	Do we need to consider inflammatory markers when we treat atherosclerotic disease?. <i>Atherosclerosis</i> , 2008, 200, 1-12.	0.4	79
1388	The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): Design and baseline characteristics. <i>Alzheimer's and Dementia</i> , 2008, 4, 145-153.	0.4	56
1390	Lipid management of cardiovascular disease. <i>International Journal of Cardiology</i> , 2008, 125, S20.	0.8	0
1391	The changes of Hs-CRP and WBC count after percutaneous coronary intervention in different types of coronary heart diseases. <i>Journal of Nanjing Medical University</i> , 2008, 22, 246-249.	0.1	1
1392	The Role of Antiphospholipid Syndrome in Cardiovascular Disease. <i>Hematology/Oncology Clinics of North America</i> , 2008, 22, 79-94.	0.9	46
1393	Is Carotid Intima-Media Thickness a Reliable Clinical Predictor?â€“Replyâ€“I. <i>Mayo Clinic Proceedings</i> , 2008, 83, 1300-1301.	1.4	3
1395	Evidence-Based Performance and Quality Improvement in the Acute Cardiac Care Setting. <i>Critical Care Clinics</i> , 2008, 24, 201-229.	1.0	10
1396	Women tolerate drug therapy for coronary artery disease as well as men do, but are treated less frequently with aspirin, $\beta$ -blockers, or statins. <i>Gender Medicine</i> , 2008, 5, 53-61.	1.4	46
1397	Aldosterone Receptor Blockade in Patients with Left Ventricular Systolic Dysfunction Following Acute Myocardial Infarction. <i>Cardiology Clinics</i> , 2008, 26, 91-105.	0.9	7
1398	Comparison of Cardiovascular Event Rates in Patients Without Cardiovascular Disease in Whom Atorvastatin or Simvastatin Was Newly Initiated. <i>Mayo Clinic Proceedings</i> , 2008, 83, 1316-1325.	1.4	22
1399	The Role of Statins in the Prevention of Heart Failure After Acute Coronary Syndrome. <i>Heart Failure Clinics</i> , 2008, 4, 129-139.	1.0	9
1400	Cholesteryl Ester Transfer Protein (CETP) Inhibitors: Is There Life After Torcetrapib?. <i>Cardiology Clinics</i> , 2008, 26, 537-546.	0.9	18
1401	Cost of care for new versus recurrent acute coronary syndrome patients. <i>Journal of Medical Economics</i> , 2008, 11, 81-99.	1.0	8
1402	Differences in cardiovascular event rates between atorvastatin and simvastatin among new users: managed-care experience. <i>Current Medical Research and Opinion</i> , 2008, 24, 2873-2882.	0.9	10
1403	Cholesterol lowering, sudden cardiac death and mortality. <i>Scandinavian Cardiovascular Journal</i> , 2008, 42, 264-267.	0.4	2
1404	Funding a Clinical Trial. <i>Pharmacoeconomics</i> , 2008, 26, 811-814.	1.7	1
1405	Amlodipine/Atorvastatin Fixed-Dose Combination. <i>American Journal of Cardiovascular Drugs</i> , 2008, 8, 51-67.	1.0	28

#	ARTICLE	IF	CITATIONS
1406	Current and Future Pharmacologic Options for the Management of Patients Unable to Achieve Low-Density Lipoprotein-Cholesterol Goals with Statins. <i>American Journal of Cardiovascular Drugs</i> , 2008, 8, 233-242.	1.0	23
1407	Candidate Mechanisms for Regression of Coronary Atherosclerosis with High-Dose Statins. <i>American Journal of Cardiovascular Drugs</i> , 2008, 8, 365-371.	1.0	11
1408	Measurement of carotid intima-media thickness to assess progression and regression of atherosclerosis. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2008, 5, 280-288.	3.3	221
1409	Persistence of atorvastatin and simvastatin among patients with and without prior cardiovascular diseases: a US managed care study. <i>Current Medical Research and Opinion</i> , 2008, 24, 1987-2000.	0.9	39
1410	Comparison of the Effect of Lipophilic and Hydrophilic Statins on Serum Adiponectin Levels in Patients with Mild Hypertension and Dyslipidemia: Kinki Adiponectin Interventional (KAI) Study. <i>Clinical and Experimental Hypertension</i> , 2008, 30, 530-540.	0.5	26
1411	Rosuvastatin. <i>American Journal of Cardiovascular Drugs</i> , 2008, 8, 127-146.	1.0	13
1412	Till death us do part? Postoperative statin discontinuation. <i>Southern African Journal of Anaesthesia and Analgesia</i> , 2008, 14, 7-12.	0.1	0
1413	Linoleic Acid-Enriched Phospholipids Act through Peroxisome Proliferator-Activated Receptors $\alpha$ To Stimulate Hepatic Apolipoprotein A-I Secretion. <i>Biochemistry</i> , 2008, 47, 1579-1587.	1.2	29
1414	Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy. <i>Pharmacogenomics</i> , 2008, 9, 1217-1227.	0.6	86
1415	Pretreatment With High-Dose Statin, But Not Low-Dose Statin, Ezetimibe, or the Combination of Low-Dose Statin and Ezetimibe, Limits Infarct Size in the Rat. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2008, 13, 72-79.	1.0	26
1416	The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS). <i>Diabetes and Vascular Disease Research</i> , 2008, 5, 177-183.	0.9	44
1417	Lipid Management to Reduce Cardiovascular Risk: A New Strategy Is Required. <i>Circulation</i> , 2008, 117, 560-568.	1.6	92
1418	LDL Cholesterol Lowering in Type 2 Diabetes: What Is the Optimum Approach?. <i>Clinical Diabetes</i> , 2008, 26, 8-13.	1.2	15
1419	Corporate Science and the Husbandry of Scientific and Medical Knowledge by the Pharmaceutical Industry. <i>BioSocieties</i> , 2008, 3, 355-382.	0.8	44
1420	Inflammation, Statin Therapy, and Risk of Stroke After an Acute Coronary Syndrome in the MIRACL Study. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, 142-147.	1.1	65
1421	Statin Potentiates Human Platelet eNOS Activity without Enhancing eNOS mRNA and Protein Levels. <i>Cerebrovascular Diseases</i> , 2008, 26, 190-198.	0.8	16
1422	Apolipoprotein CIII. <i>Circulation Research</i> , 2008, 103, 1348-1350.	2.0	13
1423	Overview of clinical trials on calcific aortic stenosis. <i>Country Review Ukraine</i> , 2008, 10, E31-E40.	0.8	4



#	ARTICLE	IF	CITATIONS
1424	Predictors of the first heart failure hospitalization in patients who are stable survivors of myocardial infarction complicated by pulmonary congestion and/or left ventricular dysfunction: a VALIANT study. <i>European Heart Journal</i> , 2008, 29, 748-756.	1.0	102
1425	Ultrasound imaging techniques for the evaluation of cardiovascular therapies. <i>European Heart Journal</i> , 2008, 29, 849-858.	1.0	69
1426	Statins do not adversely affect post-interventional residual platelet aggregation and outcomes in patients undergoing coronary stenting treated by dual antiplatelet therapy. <i>European Heart Journal</i> , 2008, 29, 1635-1643.	1.0	29
1427	Patterns and prognostic implications of low high-density lipoprotein levels in patients with non-ST-segment elevation acute coronary syndromes. <i>European Heart Journal</i> , 2008, 29, 2480-2488.	1.0	31
1428	From bone marrow to the arterial wall: the ongoing tale of endothelial progenitor cells. <i>European Heart Journal</i> , 2008, 30, 890-899.	1.0	143
1429	Non-Cardiovascular Mortality, Low-Density Lipoprotein Cholesterol and Statins: A Meta-Regression Analysis. <i>Cardiology</i> , 2008, 109, 110-116.	0.6	6
1430	The Impact of Statin Treatment on Presentation Mode and Early Outcomes in Acute Coronary Syndromes. <i>Cardiology</i> , 2008, 109, 156-162.	0.6	13
1431	JTT-705: is there still future for a CETP inhibitor after torcetrapib?. <i>Expert Opinion on Investigational Drugs</i> , 2008, 17, 1589-1597.	1.9	13
1432	Increased Adherence to Cardiac Standards of Care during Participation in Cardiac Disease Management Programs. <i>Disease Management: DM</i> , 2008, 11, 111-118.	1.0	7
1433	Novel Peroxisome Proliferator-Activated Receptor $\alpha$ Agonists Lower Low-Density Lipoprotein and Triglycerides, Raise High-Density Lipoprotein, and Synergistically Increase Cholesterol Excretion with a Liver X Receptor Agonist. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2008, 327, 716-726.	1.3	33
1434	Diabetes and vascular disease. <i>Expert Review of Cardiovascular Therapy</i> , 2008, 6, 127-138.	0.6	17
1435	Effects of the Direct Lipoprotein-Associated Phospholipase A <sub>2</sub> Inhibitor Darapladib on Human Coronary Atherosclerotic Plaque. <i>Circulation</i> , 2008, 118, 1172-1182.	1.6	492
1436	Effect of Cinnamon on Glucose Control and Lipid Parameters. <i>Diabetes Care</i> , 2008, 31, 41-43.	4.3	121
1437	Ezetimibe plus simvastatin cardiovascular outcomes study program. <i>Expert Review of Cardiovascular Therapy</i> , 2008, 6, 17-25.	0.6	3
1438	Common variation in the CETP gene and the implications for cardiovascular disease and its treatment: an updated analysis. <i>Pharmacogenomics</i> , 2008, 9, 747-763.	0.6	48
1439	Advances in the management of hyperlipidemia-induced atherosclerosis. <i>Expert Review of Cardiovascular Therapy</i> , 2008, 6, 369-383.	0.6	18
1440	Management of Lipids in the Prevention of Cardiovascular Events. <i>Annual Review of Medicine</i> , 2008, 59, 79-94.	5.0	21
1441	Therapy Insight: management of cardiovascular disease in patients with cancer and cardiac complications of cancer therapy. <i>Nature Clinical Practice Oncology</i> , 2008, 5, 655-667.	4.3	68

#	ARTICLE	IF	CITATIONS
1442	Colesevelam hydrochloride: a specifically engineered bile acid sequestrant. <i>Future Lipidology</i> , 2008, 3, 237-255.	0.5	15
1443	Standards of Medical Care in Diabetes—2008. <i>Diabetes Care</i> , 2008, 31, S12-S54.	4.3	1,509
1444	Is There a Problem With Ezetimibe or Just ENHANCED Hype?. <i>Angiology</i> , 2008, 59, 661-663.	0.8	7
1445	Disorders of Lipid Metabolism. <i>Fundamental and Clinical Cardiology</i> , 2008, , 159-178.	0.0	1
1446	The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials. <i>Cmaj</i> , 2008, 178, 576-584.	0.9	162
1447	Short-term effects of atorvastatin on hemorheologic parameters and endothelial dysfunction in patients with hypercholesterolemia. Lower is better?. <i>Clinical Hemorheology and Microcirculation</i> , 2008, 40, 325-326.	0.9	1
1448	Treatment of Diabetes in Long-Term Care Facilities: A Primary Care Approach. <i>Clinical Diabetes</i> , 2008, 26, 152-156.	1.2	11
1450	Quality of Lipid Management in Outpatient Care: A National Study Using Electronic Health Records. <i>American Journal of Medical Quality</i> , 2008, 23, 375-381.	0.2	10
1451	Cholesterol lowering is more important than pleiotropic effects of statins for endothelial function in patients with dysglycaemia and coronary artery disease. <i>European Heart Journal</i> , 2008, 29, 1753-1760.	1.0	87
1452	Evidence Mandating Earlier and More Aggressive Treatment of Hypercholesterolemia. <i>Circulation</i> , 2008, 118, 672-677.	1.6	90
1453	Statins in stroke prevention. <i>Future Lipidology</i> , 2008, 3, 319-325.	0.5	1
1454	Statins: established indications and controversial subgroups. <i>Heart</i> , 2008, 94, 1656-1662.	1.2	9
1455	Do People With Diabetes Need Statins?. <i>The Diabetes Educator</i> , 2008, 34, 664-673.	2.6	1
1456	Evidence-based medication and revascularization: powerful tools in the management of patients with diabetes and coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2008, 15, 216-223.	3.1	73
1457	The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients. <i>Diabetes and Vascular Disease Research</i> , 2008, 5, 319-335.	0.9	227
1458	Recent developments in acute coronary syndromes. <i>Clinical Medicine</i> , 2008, 8, 42-48.	0.8	2
1459	Progression of Nonculprit Plaque Stenosis Following Successful Percutaneous Intervention. <i>Angiology</i> , 2008, 59, 236-239.	0.8	0
1460	Statin-Dependent Suppression of the Akt/Mammalian Target of Rapamycin Signaling Cascade and Programmed Cell Death 4 Up-Regulation in Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2008, 14, 4640-4649.	3.2	64

#	ARTICLE	IF	CITATIONS
1461	Primary Prevention of Cardiovascular Disease and Type 2 Diabetes in Patients at Metabolic Risk: An Endocrine Society Clinical Practice Guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 3671-3689.	1.8	164
1463	Pravastatin: an evidence-based statin?. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2008, 4, 821-825.	1.5	8
1464	Clinical trials and health economics – A marriage of convenience or a marriage made in heaven?. <i>Journal of Medical Economics</i> , 2008, 11, 541-546.	1.0	1
1465	Continuum of Care in the Treatment of ST-Segment Elevation Myocardial Infarction (STEMI): Importance of Platelet and Coagulation Inhibition. <i>Postgraduate Medicine</i> , 2008, 120, 67-78.	0.9	1
1466	Cardiovascular disease prevention tailored for women. <i>Expert Review of Cardiovascular Therapy</i> , 2008, 6, 1123-1134.	0.6	13
1467	Late medical versus interventional therapy for stable ST-segment elevation myocardial infarction. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2008, 5, 42-52.	3.3	7
1468	Should we be targeting triglyceride as well as LDL cholesterol in the battle against coronary heart disease?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2008, 5, 438-439.	3.3	0
1469	Fibrates and future PPAR $\alpha$ agonists in the treatment of cardiovascular disease. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2008, 5, 542-553.	3.3	141
1470	A viewpoint on statin effects – benefits and problems. <i>International Journal of Angiology</i> , 2008, 17, 178-180.	0.2	2
1471	Effect of Lower Targets for Blood Pressure and LDL Cholesterol on Atherosclerosis in Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2008, 299, 1678.	3.8	217
1472	Treatment of ST-elevation myocardial infarction. <i>Future Cardiology</i> , 2008, 4, 391-397.	0.5	1
1473	The need for wider and appropriate utilization of aspirin and statins in the treatment and prevention of cardiovascular disease. <i>Expert Review of Cardiovascular Therapy</i> , 2008, 6, 95-107.	0.6	35
1474	Fenofibrate: treatment of hyperlipidemia and beyond. <i>Expert Review of Cardiovascular Therapy</i> , 2008, 6, 1319-1330.	0.6	81
1475	<i>SLCO1B1</i> Variants and Statin-Induced Myopathy – A Genomewide Study. <i>New England Journal of Medicine</i> , 2008, 359, 789-799.	13.9	1,860
1476	Metabolic complications of antiretroviral therapy in HIV-infected children. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2008, 4, 37-49.	1.5	12
1477	The Effects of Low-Dose Simvastatin and Ezetimibe Compared to High-Dose Simvastatin Alone on Post-Fat Load Endothelial Function in Patients With Metabolic Syndrome: A Randomized Double-Blind Crossover Trial. <i>Journal of Cardiovascular Pharmacology</i> , 2008, 52, 145-150.	0.8	41
1478	Silencing of Mouse Hepatic Lanosterol 14- $\alpha$ Demethylase Down-Regulated Plasma Low-Density Lipoprotein Cholesterol Levels by Short-Term Treatment of siRNA. <i>Biological and Pharmaceutical Bulletin</i> , 2008, 31, 1182-1191.	0.6	9
1479	Effect of Early Use of Low-Dose Pravastatin on Major Adverse Cardiac Events in Patients With Acute Myocardial Infarction. <i>Circulation Journal</i> , 2008, 72, 17-22.	0.7	49

#	ARTICLE	IF	CITATIONS
1480	Intensive Pharmacologic Treatment in Patients With Acute Non ST-Segment Elevation Myocardial Infarction Who Did Not Undergo Percutaneous Coronary Intervention. <i>Circulation Journal</i> , 2008, 72, 1403-1409.	0.7	5
1481	Better Survival With Statin Administration After Revascularization Therapy in Japanese Patients With Coronary Artery Disease Perspectives From the CREDO-Kyoto Registry. <i>Circulation Journal</i> , 2008, 72, 1937-1945.	0.7	27
1488	Investigation of Blood Lipid Levels and Statin Interventions in Outpatients With Coronary Heart Disease in China The China Cholesterol Education Program (CCEP). <i>Circulation Journal</i> , 2008, 72, 2040-2045.	0.7	15
1484	Regulation of Cholesterol Biosynthesis and Absorption: Ultimate Management of Dyslipidemia with Statin and Ezetimibe. <i>Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry</i> , 2008, 8, 177-182.	0.5	0
1485	Use of Vascular Ultrasound in Clinical Trials to Evaluate New Cardiovascular Therapies. <i>Journal of the National Medical Association</i> , 2008, 100, 222-229.	0.6	5
1487	Lipid lowering in diabetes mellitus. <i>Current Opinion in Lipidology</i> , 2008, 19, 579-584.	1.2	3
1488	Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition on serum matrix metalloproteinase-13 and tissue inhibitor matrix metalloproteinase-1 levels as a sign of plaque stabilization. <i>Journal of Cardiovascular Medicine</i> , 2008, 9, 1274-1278.	0.6	11
1489	Treatment of High-Risk Older Persons With Lipid-Lowering Drug Therapy. <i>American Journal of Therapeutics</i> , 2008, 15, 102-107.	0.5	17
1490	Inhibition of Macrophage Phagocytotic Activity by a Receptor-targeted Polymer Vesicle-based Drug Delivery Formulation of Pravastatin. <i>Journal of Cardiovascular Pharmacology</i> , 2008, 51, 246-252.	0.8	75
1492	Lipid-Lowering Therapy Today. <i>Journal of Cardiovascular Nursing</i> , 2008, 23, 414-421.	0.6	4
1493	Effects of Modifying Triglycerides and Triglyceride-rich Lipoproteins on Cardiovascular Outcomes. <i>Journal of Cardiovascular Pharmacology</i> , 2008, 51, 331-351.	0.8	44
1494	Exploring the gap between National Cholesterol Education Program guidelines and clinical practice in secondary care: results of a cross-sectional study involving over 10 000 patients followed in different specialty settings across Italy. <i>Journal of Cardiovascular Medicine</i> , 2008, 9, 878-887.	0.6	14
1495	Effect of ezetimibe coadministration with simvastatin in a Middle Eastern population: a prospective, multicentre, randomized, double-blind, placebo-controlled trial. <i>Journal of Cardiovascular Medicine</i> , 2008, 9, 688-693.	0.6	5
1496	Low high-density lipoprotein cholesterol: an important consideration in coronary heart disease risk assessment. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2008, 15, 175-181.	1.2	16
1497	Acute Ischemic Coronary Artery Disease and Ischemic Stroke: Similarities and Differences. <i>American Journal of Therapeutics</i> , 2008, 15, 137-149.	0.5	22
1499	Statin alternatives or just placebo: an objective review of omega-3, red yeast rice and garlic in cardiovascular therapeutics. <i>Chinese Medical Journal</i> , 2008, 121, 1588-1594.	0.9	9
1501	Pharmacotherapy: Improving the Lipid Profile. , 0, , 57-63.		0
1502	ACHIEVEMENT OF LIPID TARGET PLASMA LEVELS IN PATIENTS OF HIGH CARDIOVASCULAR RISK: IS MEDICINE CHOICE IMPORTANT?. <i>Rational Pharmacotherapy in Cardiology</i> , 2008, 4, 81-86.	0.3	0

#	ARTICLE	IF	CITATIONS
1503	Acute Coronary Syndromes and Acute Myocardial Infarction. , 2008, , 589-646.		0
1504	Relative safety profiles of high dose statin regimens. <i>Vascular Health and Risk Management</i> , 2008, Volume 4, 525-533.	1.0	37
1505	Atorvastatin and cardiovascular risk in the elderly &ndash; patient considerations. <i>Clinical Interventions in Aging</i> , 2008, Volume 3, 299-314.	1.3	15
1506	Epithelial Neutrophil-Activating Peptide (ENA-78), Acute Coronary Syndrome Prognosis, and Modulatory Effect of Statins. <i>PLoS ONE</i> , 2008, 3, e3117.	1.1	32
1507	High density lipoprotein cholesterol: an evolving target of therapy in the management of cardiovascular disease. <i>Vascular Health and Risk Management</i> , 0, Volume 4, 39-57.	1.0	19
1508	Targeting Low HDL-Cholesterol to Decrease Residual Cardiovascular Risk in the Managed Care Setting. <i>Journal of Managed Care Pharmacy</i> , 2008, 14, 1-31.	2.2	66
1509	Clinical efficacy and safety of statins in managing cardiovascular risk. <i>Vascular Health and Risk Management</i> , 2008, Volume 4, 341-353.	1.0	106
1510	The Early Treatment Gap of Dyslipidemia for Patients With Acute Myocardial Infarction. <i>Korean Circulation Journal</i> , 2008, 38, 419.	0.7	0
1511	Análise do perfil lipídico de mulheres idosas em Curitiba - Paraná. <i>Arquivos Brasileiros De Cardiologia</i> , 2008, 90, 299-304.	0.3	3
1512	DIABETES MELLITUS: OLD ASSUMPTIONS AND NEW REALITIES. , 2008, , 23-32.		0
1513	Síndromes coronarianas agudas: tratamento e estratificação de risco. <i>Revista Brasileira De Terapia Intensiva</i> , 2008, 20, 197-204.	0.1	4
1514	Experimental Therapies of the Vessel Wall. , 2009, , 553-567.		2
1515	New paradigm of treatment with statins in cardiovascular prevention. <i>Monaldi Archives for Chest Disease</i> , 2009, 72, .	0.3	0
1516	Lipid management in secondary prevention. <i>Practice Nursing</i> , 2009, 20, 592-595.	0.1	0
1517	Reducing morbidity and mortality in high risk patients with statins. <i>Vascular Health and Risk Management</i> , 2009, 5, 495.	1.0	6
1518	Lipid-Modifying and Antiatherosclerotic Drugs. , 2009, , 341-372.		2
1519	Effects of Atorvastatin on Nuclear Magnetic Resonance-Defined Lipoprotein Subclasses and Inflammatory Markers in Patients with Hypercholesterolemia. <i>Journal of Atherosclerosis and Thrombosis</i> , 2009, 16, 51-56.	0.9	22
1521	Mental Illness and the Criminal Justice System. , 2009, , 478-498.		11

#	ARTICLE	IF	CITATIONS
1522	The Measurement of Mental Disorder. , 0, , 20-45.		4
1523	Work and Unemployment as Stressors. , 2009, , 213-225.		9
1524	Marital Status and Mental Health. , 2009, , 306-320.		11
1525	Integrating Service Delivery Systems for Persons with a Severe Mental Illness. , 0, , 510-528.		1
1526	Psychological Approaches to Mental Illness. , 0, , 89-105.		8
1527	Fixed combination of amlodipine and atorvastatin in cardiovascular risk management: patient perspectives. <i>Vascular Health and Risk Management</i> , 2009, 5, 377.	1.0	30
1528	Prasugrel development “ Claims and achievements. <i>Thrombosis and Haemostasis</i> , 2009, 101, 14-22.	1.8	27
1529	Variabilidade interensaios de dislipidemias em pacientes hipertensos. <i>Jornal Brasileiro De Patologia E Medicina Laboratorial</i> , 2009, 45, 285-294.	0.3	0
1530	Efficacy, effectiveness and real life goal attainment of statins in managing cardiovascular risk. <i>Vascular Health and Risk Management</i> , 2009, 5, 369.	1.0	23
1531	A Randomized Controlled Study to Compare the Effects of Rosuvastatin 5mg and Atorvastatin10mg on the Plasma Lipid Profile in Japanese Patients with Hypercholesterolemia (ASTRO-2). <i>Annals of Vascular Diseases</i> , 2009, 2, 159-173.	0.2	9
1532	Marcadores inflamat3rios da doen3a cardiovascular em idosos. <i>Arquivos Brasileiros De Cardiologia</i> , 2009, 92, 233-240.	0.3	23
1534	Individualized initiation of statin therapy determined by baseline LDL-C: Are you more likely to achieve goal LDL-C?. <i>Risk Management and Healthcare Policy</i> , 2010, 3, 1.	1.2	2
1536	Mental Health and Terrorism. , 0, , 384-406.		13
1537	C-reactive protein and its role in coronary artery disease. <i>British Journal of Cardiac Nursing</i> , 2009, 4, 108-113.	0.0	0
1538	Facts and Ideas from Anywhere. <i>Baylor University Medical Center Proceedings</i> , 2009, 22, 178-187.	0.2	2
1539	Well-Being across the Life Course. , 2009, , 361-383.		8
1540	Review of the treatment of acute coronary syndrome in elderly patients. <i>Clinical Interventions in Aging</i> , 2009, 4, 435.	1.3	33
1541	African American Women and Mental Well-Being: The Triangulation of Race, Gender, and Socioeconomic Status. , 2009, , 291-305.		4

#	ARTICLE	IF	CITATIONS
1542	Platelet P2Y12 receptor inhibition by thienopyridines: status and future. Expert Opinion on Investigational Drugs, 2009, 18, 1317-1332.	1.9	20
1543	Disappointing Recent Cholesterol-Lowering Drug Trials: Is It Not Time for a Full Reappraisal of the Cholesterol Theory?. World Review of Nutrition and Dietetics, 2009, 100, 80-89.	0.1	3
1544	Adherence-adjusted efficacy with intensive versus standard statin therapy in patients with acute myocardial infarction in the IDEAL study. European Journal of Cardiovascular Prevention and Rehabilitation, 2009, 16, 315-320.	3.1	19
1545	Perspectives on low-density lipoprotein cholesterol goal achievement. Current Medical Research and Opinion, 2009, 25, 431-447.	0.9	39
1546	APOC3 Mutation, Serum Triglyceride Concentrations, and Coronary Heart Disease. Clinical Chemistry, 2009, 55, 1274-1276.	1.5	10
1547	Prognostic Utility of ApoB/AI, Total Cholesterol/HDL, Non-HDL Cholesterol, or hs-CRP as Predictors of Clinical Risk in Patients Receiving Statin Therapy After Acute Coronary Syndromes. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 424-430.	1.1	136
1548	Pharmacotherapy of coronary atherosclerosis. Expert Opinion on Pharmacotherapy, 2009, 10, 1587-1603.	0.9	26
1549	Statins. , 2009, , 253-280.		5
1550	ACCF/AHA/ACP 2009 Competence and Training Statement: A Curriculum on Prevention of Cardiovascular Disease. Circulation, 2009, 120, e100-26.	1.6	25
1551	A randomized, controlled trial of simvastatin versus rosuvastatin in patients with acute myocardial infarction: the Secondary Prevention of Acute Coronary Events "Reduction of Cholesterol to Key European Targets Trial. European Journal of Cardiovascular Prevention and Rehabilitation, 2009, 16, 712-721.	3.1	17
1552	Coadministered Amlodipine and Atorvastatin Produces Early Improvements in Arterial Wall Compliance in Hypertensive Patients With Dyslipidemia. American Journal of Hypertension, 2009, 22, 137-144.	1.0	34
1553	Colesevelam hydrochloride: usefulness of a specifically engineered bile acid sequestrant for lowering LDL-cholesterol. European Journal of Cardiovascular Prevention and Rehabilitation, 2009, 16, 1-9.	3.1	24
1554	Response to Letters Regarding Article, "Evidence for Statin Pleiotropy in Humans: Differential Effects of Statins and Ezetimibe on Rho-Associated Coiled-Coil Containing Protein Kinase Activity, Endothelial Function, and Inflammation". Circulation, 2009, 120, .	1.6	2
1555	Biomarkers for Prediction of Cardiovascular Events. JAMA - Journal of the American Medical Association, 2009, 302, 2089.	3.8	1
1557	An Open Pilot Study Exploring the Efficacy of Fluvastatin, Pegylated Interferon and Ribavirin in Patients with Hepatitis C Virus Genotype 1b in High Viral Loads. Intervirology, 2009, 52, 43-48.	1.2	77
1558	Vascular Disease Burden and In-Hospital Outcomes Among Patients Undergoing Percutaneous Coronary Intervention in New York State. Circulation: Cardiovascular Interventions, 2009, 2, 317-322.	1.4	14
1560	Does Simvastatin Cause More Myotoxicity Compared with Other Statins?. Annals of Pharmacotherapy, 2009, 43, 2012-2020.	0.9	44
1561	Concentrations of C-Reactive Protein and B-Type Natriuretic Peptide 30 Days after Acute Coronary Syndromes Independently Predict Hospitalization for Heart Failure and Cardiovascular Death. Clinical Chemistry, 2009, 55, 265-273.	1.5	54

#	ARTICLE	IF	CITATIONS
1562	Lipid goal achievement and trends in lipid-lowering therapy in veterans undergoing carotid endarterectomy. <i>Vascular Medicine</i> , 2009, 14, 21-27.	0.8	2
1563	Triglycerides and cardiovascular events in ACS: the need for combined lipid-altering therapies. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2009, 6, 98-100.	3.3	2
1564	Long-term trends in use of and expenditures for cardiovascular medications in Canada. <i>Cmaj</i> , 2009, 181, E19-E28.	0.9	24
1565	From Here to JUPITER. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2009, 2, 41-48.	0.9	48
1566	Intensive Lowering of Low-Density Lipoprotein Cholesterol Levels for Primary Prevention of Coronary Artery Disease. <i>Mayo Clinic Proceedings</i> , 2009, 84, 345-352.	1.4	37
1567	Low-Density Lipoprotein Cholesterol Reduction and Prevention of Cardiovascular Disease. <i>Mayo Clinic Proceedings</i> , 2009, 84, 307-309.	1.4	11
1568	Imaging outcomes in cardiovascular clinical trials. <i>Nature Reviews Cardiology</i> , 2009, 6, 524-531.	6.1	8
1570	Predicting benefit from statins by C-reactive protein, LDL-cholesterol or absolute cardiovascular risk. <i>Future Cardiology</i> , 2009, 5, 231-236.	0.5	7
1571	PLTP activity is a risk factor for subsequent cardiovascular events in CAD patients under statin therapy: the AtheroGene Study. <i>Journal of Lipid Research</i> , 2009, 50, 723-729.	2.0	35
1572	Rosuvastatin Induced Rhabdomyolysis in a Low Risk Patient: A Case Report and Review of the Literature. <i>Current Clinical Pharmacology</i> , 2009, 4, 1-3.	0.2	13
1573	Should All Diabetic Patients Be Treated With a Statin?. <i>Diabetes Care</i> , 2009, 32, S378-S383.	4.3	15
1574	Dyslipidemia and cardiovascular risk: the importance of early prevention. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2009, 102, 657-667.	0.2	108
1575	Impact of a compliance program on cholesterol control: results of the randomized ORBITAL study in 8108 patients treated with rosuvastatin. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2009, 16, 180-187.	3.1	12
1576	The Vytorin on Carotidâ€“Media Thickness and Overall Arterial Rigidity (VYCTOR) study. <i>Expert Review of Cardiovascular Therapy</i> , 2009, 7, 1057-1060.	0.6	1
1577	Coronary Microembolization. <i>Circulation</i> , 2009, 120, 1822-1836.	1.6	373
1578	Evidence for Statin Pleiotropy in Humans. <i>Circulation</i> , 2009, 119, 131-138.	1.6	208
1579	Adventures in Cardiovascular Research. <i>Circulation</i> , 2009, 120, 170-180.	1.6	22
1580	Use and cost of branded and generic drugs in patients with coronary heart disease--results from a prospective survey of 1008 patients in two London hospitals. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2009, 102, 843-849.	0.2	4



#	ARTICLE	IF	CITATIONS
1581	Renal Dysfunction Potentiates Foam Cell Formation by Repressing ABCA1. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009, 29, 1277-1282.	1.1	34
1582	The Influence of Treatment Effect Size on Willingness to Adopt a Therapy. <i>Medical Decision Making</i> , 2009, 29, 599-605.	1.2	2
1583	Oligonucleotide Delivery with Dendritic Poly(L-lysine) for Treatments of the Liver Disorders. <i>Materials Research Society Symposia Proceedings</i> , 2009, 1237, 1.	0.1	0
1584	Intensive statin therapy in coronary artery disease: is lower cholesterol better and safe?. <i>Future Cardiology</i> , 2009, 5, 129-139.	0.5	1
1585	Identification of Genetic Variants Associated With Response to Statin Therapy. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009, 29, 1310-1315.	1.1	83
1586	Efficacy of Ezetimibe/Simvastatin 10/40 mg Compared to Doubling the Dose of Low-, Medium- and High-Potency Statin Monotherapy in Patients with a Recent Coronary Event. <i>Cardiology</i> , 2009, 113, 89-97.	0.6	5
1587	LDL-Cholesterol is the King. <i>Angiology</i> , 2009, 60, 387-388.	0.8	0
1588	American Diabetes Association Indications for Statins in Diabetes. <i>Diabetes Care</i> , 2009, 32, S384-S391.	4.3	53
1589	The Spin Stops Here: Inhibition of Lipoprotein-Associated Phospholipase A2 – A Promising Target but a Negative Initial Trial?. <i>Clinical Chemistry</i> , 2009, 55, 21-23.	1.5	5
1590	Copayment Levels and Medication Adherence. <i>Circulation</i> , 2009, 119, 365-367.	1.6	14
1591	Adenoviral expression of human lecithin-cholesterol acyltransferase in nonhuman primates leads to an antiatherogenic lipoprotein phenotype by increasing high-density lipoprotein and lowering low-density lipoprotein. <i>Metabolism: Clinical and Experimental</i> , 2009, 58, 568-575.	1.5	40
1592	Clinical Insights From the Treating to New Targets Trial. <i>Progress in Cardiovascular Diseases</i> , 2009, 51, 487-502.	1.6	6
1593	Statin and cardioprotection – More than just lipid lowering?. , 2009, 122, 30-43.		164
1594	Statin for prevention of atrial fibrillation after cardiac surgery: A systematic literature review. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2009, 138, 678-686.e1.	0.4	124
1595	C-reactive protein predicts non-target lesion revascularization and cardiac events following percutaneous coronary intervention in patients with angina pectoris. <i>Journal of Cardiology</i> , 2009, 53, 388-395.	0.8	6
1596	Rationale and design of assessment of lipophilic vs. hydrophilic statin therapy in acute myocardial infarction (the ALPS-AMI) study. <i>Journal of Cardiology</i> , 2009, 54, 76-79.	0.8	10
1597	The impact of statins on health services utilization and mortality in older adults discharged from hospital with ischemic heart disease: a cohort study. <i>BMC Health Services Research</i> , 2009, 9, 198.	0.9	12
1598	Factors Associated with Recurrent Coronary Events Among Patients with Cardiovascular Disease. <i>Pharmacotherapy</i> , 2009, 29, 906-913.	1.2	8

#	ARTICLE	IF	CITATIONS
1599	JUPITER and ACCOMPLISH. Preventive Cardiology, 2009, 12, 114-119.	1.1	0
1600	Safety and Feasibility of Achieving Lower Systolic Blood Pressure Goals in Persons With Type 2 Diabetes: The SANDS Trial. Journal of Clinical Hypertension, 2009, 11, 540-548.	1.0	18
1601	Comparative Effectiveness Research: An Approach to Avoiding "Overgeneralized Medicine". Clinical and Translational Science, 2009, 2, 444-445.	1.5	1
1602	The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: An updated meta-analysis. Clinical Therapeutics, 2009, 31, 236-244.	1.1	144
1603	Relation of High-Density Lipoprotein Cholesterol to Mortality After Percutaneous Coronary Interventions in Patients With Low-Density Lipoprotein <70 mg/dl. American Journal of Cardiology, 2009, 103, 350-354.	0.7	9
1604	Seasonal Variation in Lipids in Patients Following Acute Coronary Syndrome on Fixed Doses of Pravastatin (40 mg) or Atorvastatin (80 mg) (from the Pravastatin or Atorvastatin Evaluation and Tolerability Study). American Journal of Cardiology, 2009, 103, 1056-1060.	0.7	31
1605	Evaluating Lipid-Lowering Trials in the Twenty-First Century. American Journal of Cardiology, 2009, 103, 1325-1328.	0.7	6
1606	Safety and Efficacy of Achieving Very Low Low-Density Lipoprotein Cholesterol Levels With Rosuvastatin 40 mg Daily (from the ASTEROID Study). American Journal of Cardiology, 2009, 104, 29-35.	0.7	20
1607	Comparison of Usefulness of Simvastatin 20 mg Versus 80 mg in Preventing Contrast-Induced Nephropathy in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. American Journal of Cardiology, 2009, 104, 519-524.	0.7	114
1608	Seasonal Variation in Lipids: Should We Consider It More?. American Journal of Cardiology, 2009, 104, 739-740.	0.7	1
1609	Acute Effects of Statin Therapy on Coronary Atherosclerosis Following an Acute Coronary Syndrome. American Journal of Cardiology, 2009, 104, 750-757.	0.7	22
1610	Effect of Atorvastatin on Platelet Thromboxane A2 Synthesis in Aspirin-Treated Patients With Acute Myocardial Infarction. American Journal of Cardiology, 2009, 104, 1618-1623.	0.7	50
1611	Meta-Analysis of Randomized Controlled Trials of Statins Versus Placebo in Patients With Heart Failure. American Journal of Cardiology, 2009, 104, 1708-1716.	0.7	93
1612	Low High-Density Lipoprotein Cholesterol and Increased Cardiovascular Disease Risk: An Analysis of Statin Clinical Trials. American Journal of Cardiology, 2009, 104, 3E-9E.	0.7	18
1613	High-Density Lipoprotein Cholesterol as a Risk Factor and Target of Therapy after Acute Coronary Syndrome. American Journal of Cardiology, 2009, 104, 46E-51E.	0.7	11
1614	Novel Targets that Affect High-Density Lipoprotein Metabolism: The Next Frontier. American Journal of Cardiology, 2009, 104, 52E-57E.	0.7	23
1615	Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurology, The, 2009, 8, 453-463.	4.9	537
1616	What is the Optimum Perioperative Drug Therapy Following Lower-Extremity Vein Bypass Surgery?. Seminars in Vascular Surgery, 2009, 22, 245-251.	1.1	3

#	ARTICLE	IF	CITATIONS
1617	Have newer cardiovascular drugs reduced hospitalization? Evidence from longitudinal country-level data on 20 OECD countries, 1995-2003. <i>Health Economics (United Kingdom)</i> , 2009, 18, 519-534.	0.8	25
1618	Cost-effectiveness of intensive atorvastatin therapy in secondary cardiovascular prevention in the United Kingdom, Spain, and Germany, based on the Treating to New Targets study. <i>European Journal of Health Economics</i> , 2009, 10, 255-265.	1.4	27
1619	Outcomes Among Patients With Non-ST-Segment Elevation Myocardial Infarction Presenting to Interventional Hospitals With and Without On-Site Cardiac Surgery. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 944-952.	1.1	17
1620	Achieving optimum lipid-lowering goals in patients with vascular disease. <i>Current Cardiovascular Risk Reports</i> , 2009, 3, 323-330.	0.8	0
1621	Should we treat all patients with coronary heart disease or the equivalent with statins?. <i>Current Atherosclerosis Reports</i> , 2009, 11, 28-35.	2.0	1
1622	The relationship of statins to rhabdomyolysis, malignancy, and hepatic toxicity: Evidence from clinical trials. <i>Current Atherosclerosis Reports</i> , 2009, 11, 100-104.	2.0	23
1623	Lipid management: Considerations in acute coronary syndrome. <i>Current Atherosclerosis Reports</i> , 2009, 11, 149-156.	2.0	1
1624	Lipid-lowering drugs and risk for cancer. <i>Current Atherosclerosis Reports</i> , 2009, 11, 350-357.	2.0	7
1625	The role of cholesterol and statins in stroke. <i>Current Cardiology Reports</i> , 2009, 11, 4-11.	1.3	14
1626	Lipid reduction in acute coronary syndrome: How much, when, and how?. <i>Current Cardiology Reports</i> , 2009, 11, 276-281.	1.3	0
1627	AURORA and JUPITER trials: Recognizing the limitations and expanding the benefits of statin treatment. <i>Current Cardiology Reports</i> , 2009, 11, 401-403.	1.3	1
1628	Managing diabetic dyslipidemia: Beyond statin therapy. <i>Current Diabetes Reports</i> , 2009, 9, 11-17.	1.7	19
1629	Statins in the prevention of heart failure after myocardial infarction. <i>Current Heart Failure Reports</i> , 2009, 6, 215-219.	1.3	2
1630	Cardiovascular risk reduction: What do recent trials with rosuvastatin tell us?. <i>Advances in Therapy</i> , 2009, 26, 469-487.	1.3	13
1631	Cardiovascular Prevention in Clinical Practice (ESC and German Guidelines 2007). <i>Herz</i> , 2009, 34, 4-14.	0.4	12
1632	Intensive cholesterol-lowering therapy improves large artery elasticity in acute myocardial infarction patients. <i>Heart and Vessels</i> , 2009, 24, 340-346.	0.5	14
1633	Update on statin-mediated anti-inflammatory activities in atherosclerosis. <i>Seminars in Immunopathology</i> , 2009, 31, 127-142.	2.8	79
1634	Atorvastatin modifies the protein profile of circulating human monocytes after an acute coronary syndrome. <i>Proteomics</i> , 2009, 9, 1982-1993.	1.3	23

#	ARTICLE	IF	CITATIONS
1635	Effectiveness of rosuvastatin compared to other statins for the prevention of cardiovascular events—a cohort study in 395 039 patients from clinical practice. <i>Pharmacoepidemiology and Drug Safety</i> , 2009, 18, 1214-1222.	0.9	9
1636	Effects of statins on the secretion of human serum albumin in cultured HepG2 cells. <i>Journal of Biomedical Science</i> , 2009, 16, 32.	2.6	23
1637	Regulation of different inflammatory diseases by impacting the mevalonate pathway. <i>Immunology</i> , 2009, 127, 18-25.	2.0	35
1638	Is There a Role for Statins in Atrial Fibrillation?. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2009, 32, 1063-1072.	0.5	9
1639	Preventing coronary heart disease and stroke with aggressive statin therapy in older adults using a team management model. <i>Journal of the American Academy of Nurse Practitioners</i> , 2009, 21, 47-53.	1.4	9
1640	Emerging concepts in cardiovascular disease risk assessment: Where do women fit in?. <i>Journal of the American Academy of Nurse Practitioners</i> , 2009, 21, 480-487.	1.4	3
1641	Identification of patients at risk of ischemic events for long-term secondary prevention. <i>Journal of the American Academy of Nurse Practitioners</i> , 2009, 21, 677-689.	1.4	5
1642	Association of low cholesterol with primary intracerebral haemorrhage: a case control study. <i>Acta Neurologica Scandinavica</i> , 2009, 119, 151-154.	1.0	12
1643	Targeting triglycerides in secondary prevention: should we bother?. <i>International Journal of Clinical Practice</i> , 2009, 63, 15-18.	0.8	3
1644	Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study. <i>International Journal of Clinical Practice</i> , 2009, 63, 547-559.	0.8	62
1645	Storms, tea cups and the adverse effects of statins. <i>International Journal of Clinical Practice</i> , 2009, 63, 1268-1270.	0.8	4
1646	Effects of Niacin on Cell Adhesion and Early Atherogenesis: Biochemical and Functional Findings in Endothelial Cells. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2009, 104, 206-210.	1.2	21
1647	EFFICACY AND SAFETY OF ATORVASTATIN DURING EARLY HOSPITALIZATION IN ELDERLY PATIENTS WITH UNSTABLE ANGINA. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2009, 36, 554-558.	0.9	9
1648	Serum cholesterol levels on admission and survival in patients with acute myocardial infarction treated with zofenopril: a post hoc analysis of the Survival of Myocardial Infarction Long-term Evaluation trial. <i>Fundamental and Clinical Pharmacology</i> , 2009, 23, 641-648.	1.0	13
1649	Statins, fibrates, nicotinic acid, cholesterol absorption inhibitors, anion-exchange resins, omega-3 fatty acids: which drugs for which patients?. <i>Fundamental and Clinical Pharmacology</i> , 2009, 23, 687-692.	1.0	30
1650	Effects of Statin Treatments on Coronary Plaques Assessed by Volumetric Virtual Histology Intravascular Ultrasound Analysis. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 679-688.	1.1	97
1651	Can Statins Alter Coronary Plaque Composition Assessed by Radiofrequency Backscatter Intravascular Ultrasound? Editorials published in <i>JACC: Cardiovascular Interventions</i> reflect the views of the authors and do not necessarily represent the views of <i>JACC: Cardiovascular Interventions</i> or the American College of Cardiology. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 697-700.	1.1	2
1652	Statins and coronary artery bypass graft surgery: preoperative and postoperative efficacy and safety. <i>Expert Opinion on Drug Safety</i> , 2009, 8, 559-571.	1.0	64

#	ARTICLE	IF	CITATIONS
1653	Cholesterol Goals: Moving from Numbers to Treatment. <i>Clinical Cardiology</i> , 2009, 32, 106-108.	0.7	0
1654	Impact of High-Dose Atorvastatin in Coronary Heart Disease Patients Age 65 to 78 Years. <i>Clinical Cardiology</i> , 2009, 32, 256-263.	0.7	19
1655	The Gender Differences in Baseline Characteristics and Statin Intervention Among Outpatients with Coronary Heart Disease in China: The China Cholesterol Education Program. <i>Clinical Cardiology</i> , 2009, 32, 308-314.	0.7	15
1656	Hypercholesterolemia Paradox in Relation to Mortality in Acute Coronary Syndrome. <i>Clinical Cardiology</i> , 2009, 32, E22-8.	0.7	66
1657	Statin Therapy in Patients with Diastolic Heart Failure. <i>Clinical Cardiology</i> , 2010, 33, E1-5.	0.7	15
1658	Acute Coronary Syndrome in the Elderly. <i>Clinical Cardiology</i> , 2009, 32, 608-613.	0.7	18
1659	Reducing the risks of sudden death and heart failure post myocardial infarction: Utility of optimized pharmacotherapy. <i>Clinical Cardiology</i> , 2005, 28, 19-27.	0.7	7
1660	The patient with cardiovascular disease: Treatment strategies for preventing major events. <i>Clinical Cardiology</i> , 2009, 29, 4-12.	0.7	1
1661	In vivo siRNA delivery with dendritic poly(l-lysine) for the treatment of hypercholesterolemia. <i>Molecular BioSystems</i> , 2009, 5, 1306.	2.9	75
1662	Treatment strategies for peripheral artery disease. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 1571-1586.	0.9	11
1664	Markers of inflammation, thrombosis and endothelial activation correlate with carotid IMT regression in stable coronary disease after atorvastatin treatment. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2009, 19, 481-490.	1.1	29
1665	Cost-effectiveness of early versus selectively invasive strategy in patients with acute coronary syndromes without ST-segment elevation. <i>International Journal of Cardiology</i> , 2009, 131, 204-211.	0.8	9
1666	Lipid levels in patients hospitalized with coronary artery disease: An analysis of 136,905 hospitalizations in Get With The Guidelines. <i>American Heart Journal</i> , 2009, 157, 111-117.e2.	1.2	270
1667	Trends in the use of lipid-lowering medications at discharge in patients with acute myocardial infarction: 1998 to 2006. <i>American Heart Journal</i> , 2009, 157, 185-194.e2.	1.2	25
1668	Design of the DEFINE trial: Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib. <i>American Heart Journal</i> , 2009, 158, 513-519.e3.	1.2	85
1669	Rationale and design of China intensive lipid lowering with statins in acute coronary syndrome: The CHILLAS study. <i>American Heart Journal</i> , 2009, 158, 509-512.e1.	1.2	8
1670	Low- and high-density lipoprotein cholesterol goal attainment in dyslipidemic women: The Lipid Treatment Assessment Project (L-TAP) 2. <i>American Heart Journal</i> , 2009, 158, 860-866.	1.2	40
1671	Rationale and design of the dal-OUTCOMES trial: Efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. <i>American Heart Journal</i> , 2009, 158, 896-901.e3.	1.2	184

#	ARTICLE	IF	CITATIONS
1672	Long-term morbidity and mortality among medically managed patients with angina and multivessel coronary artery disease. <i>American Heart Journal</i> , 2009, 158, 933-940.	1.2	22
1673	The Pathology of Atherosclerosis: Plaque Development and Plaque Responses to Medical Treatment. <i>American Journal of Medicine</i> , 2009, 122, S3-S14.	0.6	422
1674	Low Levels of Low-Density Lipoprotein Cholesterol and Blood Pressure and Progression of Coronary Atherosclerosis. <i>Journal of the American College of Cardiology</i> , 2009, 53, 1110-1115.	1.2	63
1675	Meta-Analysis of the Relationship Between Non-HDL Cholesterol Reduction and Coronary Heart Disease Risk. <i>Journal of the American College of Cardiology</i> , 2009, 53, 316-322.	1.2	327
1676	Effect of Intensive Statin Therapy on Regression of Coronary Atherosclerosis in Patients With Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2009, 54, 293-302.	1.2	332
1677	The SLCO1B1*5 Genetic Variant Is Associated With Statin-Induced Side Effects. <i>Journal of the American College of Cardiology</i> , 2009, 54, 1609-1616.	1.2	452
1678	Statins in Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2009, 54, 1425-1433.	1.2	32
1679	ACCF/AHA/ACP 2009 Competence and Training Statement: A Curriculum on Prevention of Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2009, 54, 1336-1363.	1.2	50
1680	Early Statin Therapy in Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2009, 54, 1434-1437.	1.2	24
1681	Effect of Intensive Statin Therapy on Clinical Outcomes Among Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2009, 54, 2290-2295.	1.2	103
1682	Reduction in Recurrent Cardiovascular Events With Intensive Lipid-Lowering Statin Therapy Compared With Moderate Lipid-Lowering Statin Therapy After Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2009, 54, 2358-2362.	1.2	159
1683	Low-density lipoprotein cholesterol goal attainment in high-risk family medicine patients. <i>Journal of Clinical Lipidology</i> , 2009, 3, 195-200.	0.6	2
1684	Cost-effectiveness Considerations of Cardiovascular Therapeutics. <i>Heart Lung and Circulation</i> , 2009, 18, 118-122.	0.2	0
1686	The Cohort Study "Watchful Waiting." , 2009, , 23-30.		0
1687	Statins and stroke prevention. <i>Expert Review of Cardiovascular Therapy</i> , 2009, 7, 1231-1243.	0.6	20
1688	Lowering Low-Density Lipoprotein Cholesterol: Statins, Ezetimibe, Bile Acid Sequestrants, and Combinations: Comparative Efficacy and Safety. <i>Endocrinology and Metabolism Clinics of North America</i> , 2009, 38, 79-97.	1.2	84
1689	Acute Coronary Syndromes: Diagnosis and Management, Part I. <i>Mayo Clinic Proceedings</i> , 2009, 84, 917-938.	1.4	310
1690	Comparison of incidences of cardiovascular events among new users of different statins: a retrospective observational cohort study. <i>Current Medical Research and Opinion</i> , 2009, 25, 2621-2629.	0.9	7

#	ARTICLE	IF	CITATIONS
1691	Standards of Medical Care in Diabetes—2009. <i>Diabetes Care</i> , 2009, 32, S13-S61.	4.3	1,606
1692	Lipid Management in the Geriatric Patient. <i>Endocrinology and Metabolism Clinics of North America</i> , 2009, 38, 185-206.	1.2	5
1693	Prevalence of cardiovascular comorbidities and utilization of evidence-based treatment strategies among statin users in a Medicare and commercial health plan. <i>Current Medical Research and Opinion</i> , 2009, 25, 205-213.	0.9	6
1694	Treatment with Statins in High-Risk Patients. <i>American Journal of Cardiovascular Drugs</i> , 2009, 9, 211-212.	1.0	2
1695	Are High-Risk Hypertensive Patients being Prescribed Concomitant Statin Therapy?. <i>American Journal of Cardiovascular Drugs</i> , 2009, 9, 299-308.	1.0	5
1696	Clinical review: Impact of statin substitution policies on patient outcomes. <i>Annals of Medicine</i> , 2009, 41, 242-256.	1.5	24
1697	Limitations of statin monotherapy for the treatment of dyslipidemia: a projection based on the Canadian lipid study – observational. <i>Current Medical Research and Opinion</i> , 2009, 25, 47-55.	0.9	7
1698	Low-Density Lipoprotein Cholesterol Reduction and Goal Achievement With Ezetimibe/Simvastatin Versus Atorvastatin or Rosuvastatin in Patients With Diabetes, Metabolic Syndrome, or Neither Disease, Stratified by National Cholesterol Education Program Risk Category. <i>Metabolic Syndrome and Related Disorders</i> , 2009, 7, 601-610.	0.5	9
1699	Are intensive lipid-lowering regimens an optimal economic strategy in patients with ACS? An acute and chronic perspective. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2009, 9, 423-433.	0.7	4
1700	Quantification of serial changes in plaque burden using multi-detector computed tomography in experimental atherosclerosis. <i>Atherosclerosis</i> , 2009, 202, 185-191.	0.4	19
1701	Molecular basis of statin-associated myopathy. <i>Atherosclerosis</i> , 2009, 202, 18-28.	0.4	102
1702	Patterns of statin prescription in acute myocardial infarction. <i>Atherosclerosis</i> , 2009, 204, 491-496.	0.4	16
1703	Statins inhibit Rho kinase activity in patients with atherosclerosis. <i>Atherosclerosis</i> , 2009, 205, 517-521.	0.4	119
1704	Statin prevents plaque disruption in apoE-knockout mouse model through pleiotropic effect on acute inflammation. <i>Atherosclerosis</i> , 2009, 206, 355-361.	0.4	56
1705	Coronary artery endothelial dysfunction is positively correlated with low density lipoprotein and inversely correlated with high density lipoprotein subclass particles measured by nuclear magnetic resonance spectroscopy. <i>Atherosclerosis</i> , 2009, 207, 111-115.	0.4	27
1706	Prognostic Value of High-Sensitivity C-Reactive Protein in Heart Failure: A Systematic Review. <i>Journal of Cardiac Failure</i> , 2009, 15, 256-266.	0.7	120
1707	Methods of plaque quantification and characterization by cardiac computed tomography. <i>Journal of Cardiovascular Computed Tomography</i> , 2009, 3, S91-S98.	0.7	19
1708	Bridging science and health policy in cardiovascular disease: focus on lipid management. <i>Atherosclerosis Supplements</i> , 2009, 10, 3-21.	1.2	10

#	ARTICLE	IF	CITATIONS
1709	Perioperative Statin Therapy Is Associated With a Significant and Dose-Dependent Reduction of Adverse Cardiovascular Outcomes After Coronary Artery Bypass Graft Surgery. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2009, 23, 633-638.	0.6	39
1710	A winter's tale: Report from the First Annual Canadian Biomarkers and Surrogate Endpoints Symposium. <i>Canadian Journal of Cardiology</i> , 2009, 25, 527-532.	0.8	2
1711	2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendations. <i>Canadian Journal of Cardiology</i> , 2009, 25, 567-579.	0.8	653
1712	Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. <i>Lancet</i> , The, 2009, 373, 1175-1182.	6.3	886
1713	Non-adherence to statin therapy: a major challenge for preventive cardiology. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 2973-2985.	0.9	114
1714	Low-Density Lipoprotein Cholesterol Reduction and Prevention of Cardiovascular Disease. <i>Mayo Clinic Proceedings</i> , 2009, 84, 307-309.	1.4	5
1715	Carotid Intima-Media Thickness and Coronary Artery Calcium Score as Indications of Subclinical Atherosclerosis. <i>Mayo Clinic Proceedings</i> , 2009, 84, 229-233.	1.4	89
1716	Lipid Management in Chronic Kidney Disease, Hemodialysis, and Transplantation. <i>Endocrinology and Metabolism Clinics of North America</i> , 2009, 38, 223-234.	1.2	8
1717	Other Therapies for Reducing Low-Density Lipoprotein Cholesterol: Medications in Development. <i>Endocrinology and Metabolism Clinics of North America</i> , 2009, 38, 99-119.	1.2	31
1718	Individualized Approach to the Management of Coronary Heart Disease. <i>Journal of the American College of Cardiology</i> , 2009, 53, 331-333.	1.2	7
1719	Diabetes and Cardiovascular Disease Prevention in Older Adults. <i>Clinics in Geriatric Medicine</i> , 2009, 25, 607-641.	1.0	44
1720	Intensive Lowering of Low-Density Lipoprotein Cholesterol Levels for Primary Prevention of Coronary Artery Disease. <i>Mayo Clinic Proceedings</i> , 2009, 84, 345-352.	1.4	28
1721	Clinical evidence from ONTARGET: the value of an angiotensin II receptor blocker and an angiotensin-converting enzyme inhibitor. <i>Journal of Hypertension</i> , 2009, 27, S23-S29.	0.3	13
1722	Role of ezetimibe in the management of patients with atherosclerosis. <i>Coronary Artery Disease</i> , 2009, 20, 169-174.	0.3	7
1723	Relationship between LDL, HDL, blood pressure and atheroma progression in the coronaries. <i>Current Opinion in Lipidology</i> , 2009, 20, 491-496.	1.2	16
1724	Insufficient Statin Therapy in Coronary Heart Disease Is Related to the Time of the Last Coronary Angiography. <i>Journal of Cardiovascular Pharmacology</i> , 2009, 53, 215-222.	0.8	0
1725	The role of low endothelial shear stress in the conversion of atherosclerotic lesions from stable to unstable plaque. <i>Current Opinion in Cardiology</i> , 2009, 24, 580-590.	0.8	106
1726	Approach to the diagnosis and management of lipoprotein disorders. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2009, 16, 132-140.	1.2	19



#	ARTICLE	IF	CITATIONS
1727	Myalgia in Patients on High-Dose and Low-to-Moderate Dose Statin Therapy. <i>Journal of Pharmacy Practice and Research</i> , 2009, 39, 202-206.	0.5	1
1728	New Insights into the Pleiotropic Effects of Statins for Stroke Prevention. <i>Mini-Reviews in Medicinal Chemistry</i> , 2009, 9, 794-804.	1.1	14
1729	Prevention of Perioperative Myocardial Infarction. <i>International Anesthesiology Clinics</i> , 2009, 47, 13-36.	0.3	3
1730	Evidence-Based Guidelines for Cardiovascular Risk Reduction. <i>Journal of Cardiovascular Nursing</i> , 2009, 24, 429-438.	0.6	7
1731	An Elective Course on Landmark Trials to Improve Pharmacy Students' Literature Evaluation and Therapeutic Application Skills. <i>American Journal of Pharmaceutical Education</i> , 2009, 73, 31.	0.7	11
1732		0.0	0
1733	1. Pathophysiology and Treatment of Acute Coronary Syndrome. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2009, 98, 595-600.	0.0	0
1734	Post-Hospitalization Care of Patients with Acute Coronary Syndrome. , 2009, , 173-208.		0
1735	An Overview of Sociological Perspectives on the Definitions, Causes, and Responses to Mental Health and Illness. , 0, , 6-19.		6
1736	Linking diabetes and atherosclerosis. <i>Expert Review of Endocrinology and Metabolism</i> , 2009, 4, 603-624.	1.2	8
1737	The Role of Statins for the Primary and Secondary Prevention of Coronary Heart Disease in Women. <i>Current Pharmaceutical Design</i> , 2009, 15, 1054-1062.	0.9	21
1738	On the road to better dyslipidemia outcomes. <i>Nurse Practitioner</i> , 2009, 34, 14-21.	0.2	0
1739	Early Effect of Lipid-Lowering Therapy With Pitavastatin on Regression of Coronary Atherosclerotic Plaque Comparison With Atorvastatin. <i>Circulation Journal</i> , 2009, 73, 1466-1472.	0.7	74
1740	Qualitative and Quantitative Changes in Coronary Plaque Associated With Atorvastatin Therapy. <i>Circulation Journal</i> , 2009, 73, 718-725.	0.7	98
1741	Treatment With Statin on Atheroma Regression Evaluated by Intravascular Ultrasound With Virtual Histology (TRUTH Study) Rationale and Design. <i>Circulation Journal</i> , 2009, 73, 352-355.	0.7	21
1742	The Impact of Pravastatin Therapy on Long-Term Outcome in Patients With Metabolic Syndrome Undergoing Complete Coronary Revascularization. <i>Circulation Journal</i> , 2009, 73, 2104-2109.	0.7	12
1743	Serial Intravascular Ultrasound Assessment of Atherosclerosis Progression and Regression State-of-the-Art and Limitations. <i>Circulation Journal</i> , 2009, 73, 1557-1560.	0.7	22
1744	Unstable Angina and Non-ST-Elevation Myocardial Infarction. , 2009, , 37-78.		0

#	ARTICLE	IF	CITATIONS
1745	C-Reactive Protein and Cardiovascular Diseases—Is it Ready for Primetime?. <i>American Journal of the Medical Sciences</i> , 2009, 338, 486-492.	0.4	74
1746	Statins and Cardiovascular Diseases: From Cholesterol Lowering to Pleiotropy. <i>Current Pharmaceutical Design</i> , 2009, 15, 467-478.	0.9	232
1747	Pleiotropic Effects of Statins - Clinical Evidence. <i>Current Pharmaceutical Design</i> , 2009, 15, 479-489.	0.9	144
1748	Role of Statins in Diabetes Complications. <i>Current Diabetes Reviews</i> , 2009, 5, 165-170.	0.6	9
1749	Enhancing cardiovascular disease risk reduction: raising high-density lipoprotein levels. <i>Current Opinion in Cardiology</i> , 2009, 24, 473-482.	0.8	34
1750	Combination regimens with statin, niacin, and intestinally active LDL-lowering drugs: alternatives to high-dose statin therapy?. <i>Current Opinion in Lipidology</i> , 2010, 21, 372-377.	1.2	10
1751	The Failure of Immunomodulation Therapy in Heart Failure: Does the Statins &#x201C;Paradigm&#x201D; Prove the Rule?. <i>Current Vascular Pharmacology</i> , 2010, 8, 114-121.	0.8	5
1752	Variation in the Net Benefit of Aggressive Cardiovascular Risk Factor Control Across the US Population of Patients With Diabetes Mellitus. <i>Archives of Internal Medicine</i> , 2010, 170, 1037.	4.3	52
1753	ESVS Guidelines: Section A - Prevention in Patients with Carotid Stenosis. <i>Current Vascular Pharmacology</i> , 2010, 8, 673-681.	0.8	34
1754	Method of LDL Cholesterol Measurement Influences Classification of LDL Cholesterol Treatment Goals. <i>Journal of Investigative Medicine</i> , 2010, 58, 945-949.	0.7	27
1755	High-density lipoprotein subclasses are a potential intermediary between alcohol intake and reduced risk of cardiovascular disease: The Rancho Bernardo Study. <i>British Journal of Nutrition</i> , 2010, 104, 1034-1042.	1.2	36
1756	Secondary Stroke Prevention: Practice Patterns in a Tertiary Care Stroke Service. <i>Canadian Journal of Neurological Sciences</i> , 2010, 37, 245-251.	0.3	6
1757	Acute Effects of Statin Therapy on Coronary Atherosclerosis Following an Acute Coronary Syndrome. <i>Yearbook of Endocrinology</i> , 2010, 2010, 43-47.	0.0	0
1759	Physicians' perception of guideline-recommended low-density lipoprotein target values: characteristics of misclassified patients. <i>European Heart Journal</i> , 2010, 31, 1266-1273.	1.0	16
1760	Editorial: why inhibition of lipoprotein-associated phospholipase A2 has the potential to improve patient outcomes. <i>Current Opinion in Cardiology</i> , 2010, 25, 299-301.	0.8	13
1761	Practical Implications of ACC/AHA 2007 Guidelines for the Management of Unstable Angina/Non-ST Elevation Myocardial Infarction. <i>American Journal of Therapeutics</i> , 2010, 17, e24-e40.	0.5	8
1762	Intensive statin therapy: a goal worth targeting. <i>Interventional Cardiology</i> , 2010, 2, 103-105.	0.0	0
1763	Management of Hypercholesterolemia in Older Persons for the Prevention of Cardiovascular Disease. <i>Cardiology in Review</i> , 2010, 18, 132-140.	0.6	18

#	ARTICLE	IF	CITATIONS
1764	Statins and inflammation: an update. <i>Current Opinion in Cardiology</i> , 2010, 25, 399-405.	0.8	92
1765	Cholesterol and Triglyceride Management. <i>Journal of Cardiovascular Nursing</i> , 2010, 25, 241-246.	0.6	6
1766	Impact of the attainment of current recommended low-density lipoprotein cholesterol goal of less than 70 mg/dl on clinical outcomes in very high-risk patients treated with drug-eluting stents. <i>Coronary Artery Disease</i> , 2010, 21, 182-188.	0.3	7
1767	Do structural differences in statins correlate with clinical efficacy?. <i>Current Opinion in Lipidology</i> , 2010, 21, 298-304.	1.2	31
1768	Should we change our lipid management strategies to focus on non-high-density lipoprotein cholesterol?. <i>Current Opinion in Cardiology</i> , 2010, 25, 622-626.	0.8	8
1769	Statin myopathy: a review of recent progress. <i>Current Opinion in Rheumatology</i> , 2010, 22, 644-650.	2.0	69
1770	Simultaneous Determination of Prazosin, Atorvastatin, Rosuvastatin and Simvastatin in API, Dosage Formulations and Human Serum by RP-HPLC. <i>Journal of the Chinese Chemical Society</i> , 2010, 57, 1286-1292.	0.8	16
1771	Statin loading for acute coronary syndromes. <i>Current Opinion in Cardiology</i> , 2010, 25, 373-378.	0.8	9
1772	Colesevelam: an improved bile acid sequestrant for treating hypercholesterolemia and improving diabetes. <i>Expert Review of Endocrinology and Metabolism</i> , 2010, 5, 825-834.	1.2	2
1773	Cost effectiveness of a general practice chronic disease management plan for coronary heart disease in Australia. <i>Australian Health Review</i> , 2010, 34, 162.	0.5	15
1774	99, 473-479.	0.0	0
1775	Meta-analysis: Statin Therapy Does Not Alter the Association Between Low Levels of High-Density Lipoprotein Cholesterol and Increased Cardiovascular Risk. <i>Annals of Internal Medicine</i> , 2010, 153, 800.	2.0	93
1776	Cellular and Mitochondrial Effects of Alcohol Consumption. <i>International Journal of Environmental Research and Public Health</i> , 2010, 7, 4281-4304.	1.2	209
1777	Controlling lipids in a high-risk population with documented coronary artery disease for secondary prevention: are we doing enough?. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2010, 17, 556-561.	3.1	2
1778	Nonoptimal Lipids Commonly Present in Young Adults and Coronary Calcium Later in Life: The CARDIA (Coronary Artery Risk Development in Young Adults) Study. <i>Annals of Internal Medicine</i> , 2010, 153, 137.	2.0	93
1779	Targeting Residual Risk: The Rationale for the Use of Non-HDL Cholesterol. <i>Southern Medical Journal</i> , 2010, 103, 434-439.	0.3	7
1780	The Vulnerable Atherosclerotic Plaque: Scope of the Literature. <i>Annals of Internal Medicine</i> , 2010, 153, 387.	2.0	97
1781	Atorvastatin: a review of its pharmacological properties and use in familial hypercholesterolemia. <i>Clinical Lipidology</i> , 2010, 5, 615-625.	0.4	7

#	ARTICLE	IF	CITATIONS
1782	Darapladib and its potential for plaque stabilization and prevention of cardiac events. <i>Clinical Lipidology</i> , 2010, 5, 465-476.	0.4	2
1783	"Just Make It Lower" Is an Alternative Strategy of Lipid-Lowering Therapy With Statins in Japanese Patients - LDL-Cholesterol: The Lower, the Better; Is It True for Asians? (Con) -. <i>Circulation Journal</i> , 2010, 74, 1731-1741.	0.7	30
1784	Diabetes Mellitus Is a Major Negative Determinant of Coronary Plaque Regression During Statin Therapy in Patients With Acute Coronary Syndrome - Serial Intravascular Ultrasound Observations From the Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome Trial (the Tj ETQq0 0 0 rBT /Overlock 10 Tf 5	0.7	186
1785	Stabilization and Regression of Coronary Plaques Treated With Pitavastatin Proven by Angioscopy and Intravascular Ultrasound - The TOGETHAR Trial -. <i>Circulation Journal</i> , 2010, 74, 1922-1928.	0.7	58
1786	Clinical Significance of Intensive Lipid-Lowering Therapy Using Statins in Patients With Coronary Artery Disease. <i>Circulation Journal</i> , 2010, 74, 1718-1730.	0.7	26
1787	Ezetimibe/Simvastatin or Atorvastatin for the Treatment of Hypercholesterolemia in Patients with the Metabolic Syndrome: The VYMET Study. <i>Current Diabetes Reports</i> , 2010, 10, 173-175.	1.7	5
1788	Receipt of Cardiac Medications Upon Discharge Among Men and Women With Acute Coronary Syndrome and Nonobstructive Coronary Artery Disease. <i>Clinical Cardiology</i> , 2010, 33, 36-41.	0.7	22
1789	A Very High Prevalence of Low HDL Cholesterol in Spanish Patients With Acute Coronary Syndromes. <i>Clinical Cardiology</i> , 2010, 33, 418-423.	0.7	26
1790	RhoA/Rho-kinase and vascular diseases: what is the link?. <i>Cellular and Molecular Life Sciences</i> , 2010, 67, 3823-3836.	2.4	138
1792	Effect of ezetimibe+simvastatine over endothelial dysfunction in dyslipidemic patients: Assessment by 13N-ammonia positron emission tomography. <i>Journal of Nuclear Cardiology</i> , 2010, 17, 1015-1022.	1.4	21
1793	Do We Know When and How to Lower Lipoprotein(a)?. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2010, 12, 396-407.	0.4	8
1794	Recent Developments with Lipoprotein-Associated Phospholipase A2 Inhibitors. <i>Current Atherosclerosis Reports</i> , 2010, 12, 43-47.	2.0	12
1795	New Evidence Extending the Benefit of Treating LDL-C Beyond the Current Guidelines. <i>Current Atherosclerosis Reports</i> , 2010, 12, 1-4.	2.0	0
1796	Statin Effects on Both Low-Density Lipoproteins and High-Density Lipoproteins: Is There a Dual Benefit?. <i>Current Atherosclerosis Reports</i> , 2010, 12, 14-19.	2.0	4
1797	A Multicenter, Eight-Week Treatment, Single-Step Titration, Open-Label Study Assessing the Percentage of Korean Dyslipidemic Patients Achieving LDL Cholesterol Target with Atorvastatin Starting Doses of 10Åmg, 20Åmg and 40Åmg. <i>Cardiovascular Drugs and Therapy</i> , 2010, 24, 181-188.	1.3	2
1798	Atherosclerotic Plaque Regression: Fact or Fiction?. <i>Cardiovascular Drugs and Therapy</i> , 2010, 24, 311-317.	1.3	19
1799	Secondary prevention strategies for coronary heart disease. <i>Journal of Thrombosis and Thrombolysis</i> , 2010, 29, 8-24.	1.0	24
1800	Association between percutaneous coronary intervention and long-term C-reactive protein levels in patients with acute coronary syndromes. <i>Journal of Thrombosis and Thrombolysis</i> , 2010, 30, 10-13.	1.0	5

#	ARTICLE	IF	CITATIONS
1801	The epidemiology and management of elderly patients with myocardial infarction or heart failure. <i>Heart Failure Reviews</i> , 2010, 15, 407-413.	1.7	9
1802	Design and rationale of a study in Asia of atorvastatin pretreatment in patients undergoing percutaneous coronary intervention for non-ST elevation acute coronary syndromes. <i>Journal of Cardiology</i> , 2010, 55, 303-308.	0.8	4
1805	Low-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio as a useful marker for early-stage carotid atherosclerosis. <i>Metabolism: Clinical and Experimental</i> , 2010, 59, 653-657.	1.5	29
1806	Management of ST-elevation myocardial infarction. <i>Medicine</i> , 2010, 38, 431-437.	0.2	0
1807	Primary and secondary prevention. <i>Medicine</i> , 2010, 38, 409-413.	0.2	1
1808	Impact of genetic and acquired alteration in cytochrome P450 system on pharmacologic and clinical response to clopidogrel. , 2010, 125, 249-259.		39
1809	Niacin and fibrates in atherogenic dyslipidemia: Pharmacotherapy to reduce cardiovascular risk. , 2010, 126, 314-345.		196
1810	Prevalence of lipid abnormalities before and after introduction of lipid modifying therapy among Swedish patients with dyslipidemia (PRIMUM). <i>BMC Public Health</i> , 2010, 10, 737.	1.2	10
1811	Statin-associated muscle-related adverse effects: A case series of 354 patients. <i>Pharmacotherapy</i> , 2010, 30, 541-553.	1.2	95
1812	Meta-analysis of comparative efficacy of increasing dose of atorvastatin versus rosuvastatin versus simvastatin on lowering levels of atherogenic lipids (from VOYAGER). <i>American Journal of Cardiology</i> , 2010, 105, 69-76.	0.7	206
1813	Distribution of traditional and novel risk factors and their relation to subsequent cardiovascular events in patients with acute coronary syndromes (from the PROVE IT-TIMI 22 trial). <i>American Journal of Cardiology</i> , 2010, 105, 619-623.	0.7	12
1814	Comparison of atorvastatin 80 mg/day versus simvastatin 20 to 40 mg/day on frequency of cardiovascular events late (five years) after acute myocardial infarction (from the incremental Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 55). <i>Cardiology</i> , 2010, 106, 354-359.	0.7	35
1815	On-statin cholesteryl ester transfer protein mass and risk of recurrent coronary events (from the Tj ETQq0 0 0 rgBT /Overlock 10 Tf 55). <i>Cardiology</i> , 2010, 106, 354-359.	0.7	37
1816	Should statin therapy be allocated on the basis of global risk or on the basis of randomized trial evidence?. <i>American Journal of Cardiology</i> , 2010, 106, 905-909.	0.7	5
1817	KIF6 polymorphism as a predictor of risk of coronary events and of clinical event reduction by statin therapy. <i>American Journal of Cardiology</i> , 2010, 106, 994-998.	0.7	48
1818	Intravascular ultrasound imaging for assessing regression and progression in coronary artery disease. <i>American Journal of Cardiology</i> , 2010, 106, 1735-1746.	0.7	20
1819	Alternative strategies for the management of chronic stable angina. <i>Current Problems in Cardiology</i> , 2010, 35, 384-446.	1.1	6
1820	ARBITER-6 HALTS and lipid concentrations and heart failure incidence: Framingham Heart Study. <i>Preventive Cardiology</i> , 2010, 13, 141-4.	1.1	1

#	ARTICLE	IF	CITATIONS
1821	Statin-associated myopathy and its exacerbation with exercise. <i>Muscle and Nerve</i> , 2010, 42, 469-479.	1.0	84
1822	Design of a novel class of biphenyl CETP inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 7469-7472.	1.0	15
1823	The seed of abundance and misery. <i>Economics and Human Biology</i> , 2010, 8, 145-152.	0.7	17
1824	"If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study. <i>Cardiovascular Diabetology</i> , 2010, 9, 24.	2.7	27
1825	Fluvastatin in the first-line therapy of acute coronary syndrome: results of the multicenter, randomized, double-blind, placebo-controlled trial (the FACS-trial). <i>Trials</i> , 2010, 11, 61.	0.7	22
1826	Noninferiority trial designs for odds ratios and risk differences. <i>Statistics in Medicine</i> , 2010, 29, 982-993.	0.8	15
1827	OUTCOME AFTER PRIMARY ANGIOPLASTY FOR ACUTE MYOCARDIAL INFARCTION IN OLD AGE. <i>Journal of the American Geriatrics Society</i> , 2010, 58, 2236-2237.	1.3	0
1828	Projected Cost-Effectiveness of Ezetimibe/Simvastatin Compared with Doubling the Statin Dose in the United Kingdom: Findings from the INFORCE Study. <i>Value in Health</i> , 2010, 13, 726-734.	0.1	20
1829	Role of drugs and devices in patients at risk of sudden cardiac death. <i>Fundamental and Clinical Pharmacology</i> , 2010, 24, 575-594.	1.0	15
1830	Is Apolipoprotein E codon 112 Polymorphisms Associated with Recurrent Pregnancy Loss?. <i>American Journal of Reproductive Immunology</i> , 2010, 64, 87-92.	1.2	5
1831	Effects of atorvastatin on circulating CD34+/CD133+/ CD45 <sup>low</sup> progenitor cells and indices of angiogenesis (vascular endothelial growth factor and the angiopoietins 1 and 2) in atherosclerotic vascular disease and diabetes mellitus. <i>Journal of Internal Medicine</i> , 2010, 267, 385-393.	2.7	42
1832	Inflammation reduces HDL protection against primary cardiac risk. <i>European Journal of Clinical Investigation</i> , 2010, 40, 483-489.	1.7	64
1833	A systematic review and meta-analysis on the therapeutic equivalence of statins. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2010, 35, 139-151.	0.7	272
1834	Low density lipoprotein cholesterol variability in patients with type 2 diabetes taking atorvastatin compared to simvastatin: justification for direct measurement?. <i>Diabetes, Obesity and Metabolism</i> , 2010, 12, 540-544.	2.2	7
1835	"For Me There Is No Substitute" Authenticity, Uniqueness, and the Lessons of Lipitor. <i>AMA Journal of Ethics</i> , 2010, 12, 818-823.	0.4	1
1836	Fenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia. <i>Vascular Health and Risk Management</i> , 2010, 6, 351.	1.0	27
1837	Prescribing in lipid management. <i>NursePrescribing</i> , 2010, 8, 115-121.	0.1	0
1838	Effects of Combined Therapy with Ezetimibe Plus Simvastatin After Drug-Eluting Stent Implantation in a Porcine Coronary Restenosis Model. <i>Journal of Korean Medical Science</i> , 2010, 25, 716.	1.1	4

#	ARTICLE	IF	CITATIONS
1839	Diagnosis and Management of Coronary Artery Disease. , 2010, , 286-294.		0
1840	Challenges in Initiating Antiretroviral Therapy in 2010. Canadian Journal of Infectious Diseases and Medical Microbiology, 2010, 21, 1C-15C.	0.7	1
1841	Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid. Vascular Health and Risk Management, 2010, 6, 525.	1.0	44
1842	High Dose Statins: Is it Beneficial over Conventional Dose of Statin in Acute Coronary Syndrome?. Cardiovascular Journal, 2010, 2, 245-251.	0.0	0
1843	HDL Mimetic Peptides. , 2010, , 179-197.		1
1844	More Intensive Lipid Lowering is Associated with Regression of Coronary Atherosclerosis in Diabetic Patients with Acute Coronary Syndrome –Sub-Analysis of JAPAN-ACS Study. Journal of Atherosclerosis and Thrombosis, 2010, 17, 1096-1107.	0.9	47
1845	Clinical utility of rosuvastatin and other statins for cardiovascular risk reduction among the elderly. Clinical Interventions in Aging, 2011, 6, 27.	1.3	16
1846	Cholesterol-lowering phytosterols: factors affecting their use and efficacy. Nutrition and Dietary Supplements, 0, , 59.	0.7	29
1847	COMPARATIVE EFFICACY OF THE STATINS IN PREVENTING AND TREATING OF THE CORONARY HEART DISEASE. Rational Pharmacotherapy in Cardiology, 2010, 6, 865-869.	0.3	2
1848	Long-Term Clinical Outcomes according to Initial Management and Thrombolysis In Myocardial Infarction Risk Score in Patients with Acute Non-ST-Segment Elevation Myocardial Infarction. Yonsei Medical Journal, 2010, 51, 58.	0.9	5
1849	RNAi-mediated Rab5a suppression inhibits proliferation and migration of vascular smooth muscle cells. Acta Cardiologica, 2010, 65, 507-514.	0.3	6
1850	Dyslipidemia Management in Women and Men. , 2010, , 175-185.		0
1851	Recent cholesterol-lowering drug trials: New data, new questions. Journal of Lipid Nutrition, 2010, 19, 65-92.	0.1	2
1852	Changes in attainment of lipid goals by general practitioners and specialists in patients at high cardiovascular risk in Hungary during 2004-2008. Archives of Medical Science, 2010, 5, 695-700.	0.4	16
1853	Low high-density lipoprotein cholesterol: current status and future strategies for management. Vascular Health and Risk Management, 2010, 6, 979.	1.0	26
1854	Medical Management of Unstable Angina and Non-“ST Segment Elevation Myocardial Infarction. , 2010, , 183-195.		0
1855	<i>Klf15</i> Deficiency Is a Molecular Link Between Heart Failure and Aortic Aneurysm Formation. Science Translational Medicine, 2010, 2, 26ra26.	5.8	94
1856	Treatment With 5-Lipoxygenase Inhibitor VIA-2291 (Atreleuton) in Patients With Recent Acute Coronary Syndrome. Circulation: Cardiovascular Imaging, 2010, 3, 298-307.	1.3	129

#	ARTICLE	IF	CITATIONS
1857	Residual risk for secondary ischemic events in patients with atherothrombotic disease: Opportunity for future improvements in patient care. <i>Annals of Medicine</i> , 2010, 42, 19-35.	1.5	23
1858	Low-dose versus moderate-dose atorvastatin after acute myocardial infarction: 8-month effects on coronary flow reserve and angiogenic cell mobilisation. <i>Heart</i> , 2010, 96, 756-764.	1.2	25
1859	New evidence on pitavastatin: efficacy and safety in clinical studies. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 817-828.	0.9	49
1860	Statin loading before percutaneous coronary intervention: proposed mechanisms and applications. <i>Future Cardiology</i> , 2010, 6, 579-589.	0.5	9
1861	No accord for the ACCORD-Lipid trial results. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2010, 1, 47-49.	1.4	0
1862	LDL-C Goal Attainment in Patients who Remain on Atorvastatin or Switch to Equivalent or Non-equivalent Doses of Simvastatin: A Retrospective Matched Cohort Study in Clinical Practice. <i>Postgraduate Medicine</i> , 2010, 122, 16-24.	0.9	31
1863	Clinical Approach to Sudden Cardiac Death Syndromes. , 2010, , .		5
1864	What Is the Optimal Blood Pressure in Patients After Acute Coronary Syndromes?. <i>Circulation</i> , 2010, 122, 2142-2151.	1.6	207
1865	Efficacy of experimental treatments compared with standard treatments in non-inferiority trials: a meta-analysis of randomized controlled trials. <i>International Journal of Epidemiology</i> , 2010, 39, 1567-1581.	0.9	25
1866	Comparative Effectiveness And Personalized Medicine: Evolving Together Or Apart?. <i>Health Affairs</i> , 2010, 29, 1783-1787.	2.5	17
1867	Letter by Superko and King Regarding Article, "Lipid Treatment Assessment Project 2: A Multinational Survey to Evaluate the Proportion of Patients Achieving Low-Density Lipoprotein Cholesterol Goals". <i>Circulation</i> , 2010, 121, e233.	1.6	2
1868	Impact of Increases in High-Density Lipoprotein Cholesterol on Cardiovascular Outcomes During the Armed Forces Regression Study. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2010, 15, 380-383.	1.0	4
1869	Preprocedural Statin Therapy to Prevent Myocardial Damage in Percutaneous Coronary Intervention. <i>Critical Pathways in Cardiology</i> , 2010, 9, 19-22.	0.2	4
1870	Centralized Pan-European Survey on the Undertreatment of Hypercholesterolemia in Patients Using Lipid Lowering Drugs" The CEPHEUS-Greece Survey. <i>Angiology</i> , 2010, 61, 465-474.	0.8	19
1871	Current cardiovascular risk management patterns with special focus on lipid lowering in daily practice in Switzerland. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2010, 17, 363-372.	3.1	11
1872	Office-based Global Cardiometabolic Risk Assessment. <i>Critical Pathways in Cardiology</i> , 2010, 9, 156-159.	0.2	2
1873	Basic Science Review Section: Statin Therapy"Part II: Clinical Considerations for Cardiovascular Disease. <i>Vascular and Endovascular Surgery</i> , 2010, 44, 421-433.	0.3	19
1874	Evaluation of a Pharmacist-Managed Telephone Lipid Clinic at a Veterans Affairs Medical Center. <i>Annals of Pharmacotherapy</i> , 2010, 44, 50-56.	0.9	6



#	ARTICLE	IF	CITATIONS
1875	Use of Statin Therapy to Reduce Cardiovascular Risk in Older Patients. <i>Current Gerontology and Geriatrics Research</i> , 2010, 2010, 1-9.	1.6	10
1876	Safety of Simvastatin and Goal Attainment for Low-Density Lipoprotein Cholesterol in Sultan Qaboos University Hospital. <i>Oman Medical Journal</i> , 2010, 25, 264-8.	0.3	4
1877	Diabetes in Women. , 2010, , .		2
1878	Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease. <i>New England Journal of Medicine</i> , 2010, 363, 2406-2415.	13.9	697
1879	Non-LDL-related dyslipidaemia and coronary risk: a case-control study. <i>Diabetes and Vascular Disease Research</i> , 2010, 7, 204-212.	0.9	21
1880	Pleiotropic Effects of Atorvastatin on Monocytes in Atherosclerotic Patients. <i>Journal of Clinical Pharmacology</i> , 2010, 50, 311-319.	1.0	28
1881	The Association Between Achieving Low-Density Lipoprotein Cholesterol (LDL-C) Goal and Statin Treatment in an Employee Population. <i>Population Health Management</i> , 2010, 13, 1-8.	0.8	11
1882	Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. <i>European Heart Journal</i> , 2010, 31, 149-164.	1.0	256
1883	Inflammatory markers, cholesterol and statins: pathophysiological role and clinical importance. <i>Clinical Chemistry and Laboratory Medicine</i> , 2010, 48, 1685-1691.	1.4	62
1884	High Density Lipoproteins, Dyslipidemia, and Coronary Heart Disease. , 2010, , .		6
1885	Statin-fibrate combination for mixed dyslipidaemia: a limited option?. <i>Current Medical Research and Opinion</i> , 2010, 26, 2137-2140.	0.9	7
1886	Lipid lowering goals: back to nature?. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2010, 4, 185-191.	1.0	13
1887	Effects of amlodipine plus atorvastatin association in hypertensive hypercholesterolemic patients. <i>Expert Review of Cardiovascular Therapy</i> , 2010, 8, 835-843.	0.6	15
1888	Effects of Atorvastatin 20 mg, Rosuvastatin 10 mg, and Atorvastatin/Ezetimibe 5 mg/5 mg on Lipoproteins and Glucose Metabolism. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2010, 15, 167-174.	1.0	35
1889	Cost-effectiveness analysis of the use of a high-intensity statin compared to a low-intensity statin in the management of patients with familial hypercholesterolaemia. <i>Current Medical Research and Opinion</i> , 2010, 26, 529-536.	0.9	45
1890	Effect of increasing doses of Rosuvastatin and Atorvastatin on apolipoproteins, enzymes and lipid transfer proteins involved in lipoprotein metabolism and inflammatory parameters. <i>Current Medical Research and Opinion</i> , 2010, 26, 2301-2313.	0.9	23
1891	Cardiovascular Clinical Trials in Patients With Diabetes Mellitus. <i>Circulation</i> , 2010, 121, 2453-2455.	1.6	4
1892	The Tsim Tsoum Approaches for Prevention of Cardiovascular Disease. <i>Cardiology Research and Practice</i> , 2010, 2010, 1-18.	0.5	19

#	ARTICLE	IF	CITATIONS
1893	Impact of anti-apoptotic and anti-oxidative effects of bone marrow mesenchymal stem cells with transient overexpression of heme oxygenase-1 on myocardial ischemia. American Journal of Physiology - Heart and Circulatory Physiology, 2010, 298, H1320-H1329.	1.5	93
1894	Vitamin D Levels and Lipid Response to Atorvastatin. International Journal of Endocrinology, 2010, 2010, 1-4.	0.6	32
1895	Eugene Braunwald. Circulation Research, 2010, 106, 1668-1671.	2.0	4
1896	Cost-effectiveness of rosuvastatin versus ezetimibe/simvastatin in managing dyslipidemic patients in Mexico. Current Medical Research and Opinion, 2010, 26, 1075-1081.	0.9	4
1897	C-reactive protein improves risk prediction in patients with acute coronary syndromes. European Heart Journal, 2010, 31, 290-297.	1.0	55
1898	Potent anti-ischaemic effects of statins in chronic stable angina: incremental benefit beyond lipid lowering?. European Heart Journal, 2010, 31, 2650-2659.	1.0	23
1899	Imaging of coronary atherosclerosis: intravascular ultrasound. European Heart Journal, 2010, 31, 2456-2469.	1.0	194
1900	Barriers to cardiovascular disease risk scoring and primary prevention in Europe. QJM - Monthly Journal of the Association of Physicians, 2010, 103, 727-739.	0.2	80
1901	Guidelines on myocardial revascularization. European Journal of Cardio-thoracic Surgery, 2010, 38, S1-S52.	0.6	405
1903	Low-Fat Versus Low-Carbohydrate Diets, Weight Loss, Vascular Health, and Prevention of Coronary Artery Disease. Nutrition in Clinical Practice, 2010, 25, 528-541.	1.1	9
1904	Simvastatin reduces sympathetic activity in men with hypertension and hypercholesterolemia. Hypertension Research, 2010, 33, 1038-1043.	1.5	37
1905	Findings of clinical trials that evaluate the impact of medical therapies on progression of atherosclerosis. Current Medical Research and Opinion, 2010, 26, 745-751.	0.9	1
1906	Statin loading in patients undergoing percutaneous coronary intervention for acute coronary syndromes: a new pleiotropic effect?. Current Medical Research and Opinion, 2010, 26, 839-842.	0.9	22
1907	Association between HDL-C concentration and risk for a major cardiovascular event. Current Medical Research and Opinion, 2010, 26, 933-941.	0.9	7
1908	The Utility of Observational Studies in Clinical Decision Making: Lessons Learned from Statin Trials. Postgraduate Medicine, 2010, 122, 222-229.	0.9	9
1909	Niacin's role in the statin era. Expert Opinion on Pharmacotherapy, 2010, 11, 2291-2300.	0.9	13
1910	Diabetes, Cardiovascular Risk and Nephropathy. Cardiology Clinics, 2010, 28, 467-475.	0.9	26
1911	Men Presenting for Radical Prostatectomy on Preoperative Statin Therapy Have Reduced Serum Prostate Specific Antigen. Journal of Urology, 2010, 183, 118-125.	0.2	42

#	ARTICLE	IF	CITATIONS
1912	Issues in Data Analysis. , 2010, , 345-398.		5
1914	Noninferiority of Pitavastatin in Intravascular Ultrasound Findings. Journal of the American College of Cardiology, 2010, 55, 262-263.	1.2	0
1916	Efficacy and Safety of Rosuvastatin Therapy for Children With Familial Hypercholesterolemia. Journal of the American College of Cardiology, 2010, 55, 1121-1126.	1.2	136
1917	Intensive Multifactorial Intervention for Stable Coronary Artery Disease. Journal of the American College of Cardiology, 2010, 55, 1348-1358.	1.2	96
1918	Baseline and On-Treatment High-Density Lipoprotein Cholesterol and the Risk of Cancer in Randomized Controlled Trials of Lipid-Altering Therapy. Journal of the American College of Cardiology, 2010, 55, 2846-2854.	1.2	145
1919	High-Density Lipoprotein and Coronary Heart Disease. Journal of the American College of Cardiology, 2010, 55, 1283-1299.	1.2	190
1920	Clinical Predictors of Plaque Progression Despite Very Low Levels of Low-Density Lipoprotein Cholesterol. Journal of the American College of Cardiology, 2010, 55, 2736-2742.	1.2	143
1921	Evidence of Pre-Procedural Statin Therapy. Journal of the American College of Cardiology, 2010, 56, 1099-1109.	1.2	161
1922	Prior Aspirin Use and Outcomes in Acute Coronary Syndromes. Journal of the American College of Cardiology, 2010, 56, 1376-1385.	1.2	39
1923	The Year in Non-“ST-Segment Elevation Acute Coronary Syndrome. Journal of the American College of Cardiology, 2010, 56, 2126-2138.	1.2	31
1924	Attainment of low-density lipoprotein cholesterol goals in coronary artery disease. Journal of Clinical Lipidology, 2010, 4, 173-180.	0.6	33
1925	Nonoptimal high-density lipoprotein cholesterol levels are highly prevalent in patients presenting with acute coronary syndromes and well-controlled low-density lipoprotein cholesterol levels. Journal of Clinical Lipidology, 2010, 4, 265-271.	0.6	6
1926	The Year in Molecular Imaging. JACC: Cardiovascular Imaging, 2010, 3, 1181-1195.	2.3	14
1927	Comparison of the efficacy of rosuvastatin versus atorvastatin in reducing apolipoprotein B/apolipoprotein A-1 ratio in patients with acute coronary syndrome: Results of the CENTAURUS study. Archives of Cardiovascular Diseases, 2010, 103, 160-169.	0.7	24
1928	Drug Treatment of Hyperlipidaemia. Drugs, 2010, 70, 1363-1379.	4.9	42
1929	Amlodipine/Atorvastatin. Drugs, 2010, 70, 191-213.	4.9	28
1930	Risk Factors and Drug Interactions Predisposing to Statin-Induced Myopathy. Drug Safety, 2010, 33, 171-187.	1.4	167
1931	Increasing High-Density Lipoprotein as a Therapeutic Target in Atherothrombotic Disease. Revista Espanola De Cardiologia (English Ed ), 2010, 63, 323-333.	0.4	8

#	ARTICLE	IF	CITATIONS
1932	Therapeutic Goals in Patients With Refractory Chronic Angina. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2010, 63, 571-582.	0.4	2
1933	Mortality and morbidity of newly diagnosed heart failure treated with statins. <i>International Journal of Cardiology</i> , 2010, 140, 210-218.	0.8	12
1934	Effect of atorvastatin on circulating hsCRP concentrations: A sub-study of the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST) study. <i>International Journal of Cardiology</i> , 2010, 142, 257-264.	0.8	14
1935	Antilipidemic adherence post-coronary artery disease diagnosis among those with and without an ICD-9 diagnosis of depression. <i>Journal of Psychosomatic Research</i> , 2010, 69, 169-174.	1.2	35
1938	Differing effect of statins on insulin sensitivity in non-diabetics: A systematic review and meta-analysis. <i>Diabetes Research and Clinical Practice</i> , 2010, 87, 98-107.	1.1	164
1939	Israeli guidelines for the management of hypercholesterolemia in children and adolescents. Report of the pediatric association expert group. <i>European E-journal of Clinical Nutrition and Metabolism</i> , 2010, 5, e132-e143.	0.4	2
1940	Prior simvastatin treatment is associated with reduced thrombin generation and platelet activation in patients with acute ST-segment elevation myocardial infarction. <i>Thrombosis Research</i> , 2010, 125, 382-386.	0.8	23
1941	Relative spatial distributions of coronary artery bypass graft insertion and acute thrombosis: A model for protection from acute myocardial infarction. <i>American Heart Journal</i> , 2010, 160, 195-201.	1.2	23
1942	Predicting chronic left ventricular dysfunction 90 days after ST-segment elevation myocardial infarction: An Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Substudy. <i>American Heart Journal</i> , 2010, 160, 272-278.	1.2	29
1943	Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: An analysis of 65,396 hospitalizations from 344 hospitals participating in Get With The Guidelines (GWTG). <i>American Heart Journal</i> , 2010, 160, 1130-1136.e3.	1.2	33
1944	Lipid-lowering intensification and low-density lipoprotein cholesterol achievement from hospital admission to 1-year follow-up after an acute coronary syndrome event: Results from the Medications Applied and Sustained Over Time (MAINTAIN) registry. <i>American Heart Journal</i> , 2010, 160, 1121-1129.e1.	1.2	38
1946	Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands. <i>Atherosclerosis</i> , 2010, 209, 189-194.	0.4	250
1947	Incremento de las HDL como arma terapéutica en la aterotrombosis. <i>Revista Espanola De Cardiologia</i> , 2010, 63, 323-333.	0.6	18
1948	Metas terapéuticas en pacientes con angina refractaria crónica. <i>Revista Espanola De Cardiologia</i> , 2010, 63, 571-582.	0.6	4
1951	Efficacy and benefits of lipid-lowering drug therapy. The new European guidelines for cardiovascular disease prevention. <i>Clínica E Investigaci3n En Arteriosclerosis</i> , 2010, 22, 48-51.	0.4	0
1952	Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2010, 375, 998-1006.	6.3	813
1953	Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12064 survivors of myocardial infarction: a double-blind randomised trial. <i>Lancet, The</i> , 2010, 376, 1658-1669.	6.3	501
1954	Dissociating HDL cholesterol from cardiovascular risk. <i>Lancet, The</i> , 2010, 376, 305-306.	6.3	5

#	ARTICLE	IF	CITATIONS
1955	Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. <i>Lancet</i> , 2010, 376, 1670-1681.	6.3	5,162
1956	Effect of different loading doses of atorvastatin on percutaneous coronary intervention for acute coronary syndromes. <i>Canadian Journal of Cardiology</i> , 2010, 26, 481-485.	0.8	15
1957	Statins before stents: Does an ounce of prevention improve outcomes?. <i>Canadian Journal of Cardiology</i> , 2010, 26, 486-487.	0.8	0
1958	Standards of Medical Care in Diabetes 2010. <i>Diabetes Care</i> , 2010, 33, S11-S61.	4.3	2,863
1959	Fundamentals of Clinical Trials. , 2010, , .		284
1961	Vulnerable Plaque: Definition, Diagnosis, and Treatment. <i>Cardiology Clinics</i> , 2010, 28, 1-30.	0.9	89
1962	Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). <i>European Heart Journal</i> , 2010, 31, 2501-2555.	1.0	2,649
1963	The Anesthesia Patient with Acute Coronary Syndrome. <i>Anesthesiology Clinics</i> , 2010, 28, 55-66.	0.6	0
1964	Atorvastatin: safety and tolerability. <i>Expert Opinion on Drug Safety</i> , 2010, 9, 667-674.	1.0	38
1965	Are post-treatment low-density lipoprotein subclass pattern analyses potentially misleading?. <i>Lipids in Health and Disease</i> , 2010, 9, 136.	1.2	24
1966	Immediate effect of intensive atorvastatin therapy on lipid parameters in patients with acute coronary syndrome. <i>Lipids in Health and Disease</i> , 2010, 9, 71.	1.2	15
1968	Adjunctive Pharmacologic Therapies in Acute Myocardial Infarction. , 2010, , 145-182.		1
1969	Efficacy and Safety of Rosuvastatin and Fenofibric Acid Combination Therapy versus Simvastatin Monotherapy in Patients with Hypercholesterolemia and Hypertriglyceridemia. <i>American Journal of Cardiovascular Drugs</i> , 2010, 10, 175-186.	1.0	32
1970	The Risk for Significant Creatine Kinase Elevation with Statins. <i>American Journal of Cardiovascular Drugs</i> , 2010, 10, 187-192.	1.0	15
1971	Darapladib. <i>Expert Opinion on Investigational Drugs</i> , 2010, 19, 161-168.	1.9	14
1972	Efficacia clinica e costo-efficacia di atorvastatina a elevati dosaggi nella prevenzione degli eventi cardiocerebrovascolari. <i>Giornale Italiano Di Health Technology Assessment</i> , 2011, 4, 17-31.	0.1	0
1973	Prevalence of low high-density lipoprotein cholesterol (HDL-C) as a marker of residual cardiovascular risk among acute coronary syndrome patients from Oman. <i>Current Medical Research and Opinion</i> , 2011, 27, 879-885.	0.9	12
1974	AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update. <i>Circulation</i> , 2011, 124, 2458-2473.	1.6	1,369

#	ARTICLE	IF	CITATIONS
1975	Is prevention a fantasy, or the future of medicine? A panoramic view of recent data, status, and direction in cardiovascular prevention. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2011, 5, 61-81.	1.0	37
1976	Intensive statin therapy compared with moderate dosing for prevention of cardiovascular events: a meta-analysis of >40 000 patients. <i>European Heart Journal</i> , 2011, 32, 1409-1415.	1.0	128
1977	The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the UK. <i>European Heart Journal</i> , 2011, 32, 2525-2532.	1.0	110
1978	Growth Differentiation Factor-15 and Risk of Recurrent Events in Patients Stabilized After Acute Coronary Syndrome. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011, 31, 203-210.	1.1	138
1980	Extreme All-Cause Mortality in JUPITER Requires Reexamination of Vital Records. <i>Cardiology</i> , 2011, 120, 84-88.	0.6	3
1981	LDL cholesterol goals and cardiovascular risk during statin treatment: the IDEAL study. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2011, 18, 262-269.	3.1	10
1982	Lipid-Lowering Therapy with Statins for the Primary and Secondary Prevention of Cardiovascular Disease. <i>Cardiology Clinics</i> , 2011, 29, 87-103.	0.9	37
1984	The REALIST (REsidual risk, Lipids and Standard Therapies) study: an analysis of residual risk attributable to lipid profile in acute coronary syndrome. <i>Endocrinología Y Nutrición (English)</i> Tj ETQq1 1 0.784310.8BT / Overlock 10T	0.8	10
1985	Therapeutic approach to dyslipidemia and goal achievement in a Spanish population with type 2 diabetes without cardiovascular disease. <i>Endocrinología Y Nutrición (English Edition)</i> , 2011, 58, 283-290.	0.5	2
1987	2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2011, 57, e215-e367.	1.2	420
1988	Non-High-Density Lipoprotein Cholesterol Versus Apolipoprotein B in Cardiovascular Risk Stratification. <i>Journal of the American College of Cardiology</i> , 2011, 58, 457-463.	1.2	132
1989	Benefit of Early Statin Therapy in Patients With Acute Myocardial Infarction Who Have Extremely Low Low-Density Lipoprotein Cholesterol. <i>Journal of the American College of Cardiology</i> , 2011, 58, 1664-1671.	1.2	99
1990	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary. <i>Journal of the American College of Cardiology</i> , 2011, 58, 2550-2583.	1.2	114
1991	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2011, 58, e44-e122.	1.2	2,027
1992	2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: Executive Summary. <i>Journal of the American College of Cardiology</i> , 2011, 58, 2584-2614.	1.2	76
1993	2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery. <i>Journal of the American College of Cardiology</i> , 2011, 58, e123-e210.	1.2	665
1994	On-Clopidogrel Platelet Reactivity. <i>Journal of the American College of Cardiology</i> , 2011, 58, 1955-1957.	1.2	0
1995	AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update. <i>Journal of the American College of Cardiology</i> , 2011, 58, 2432-2446.	1.2	700

#	ARTICLE	IF	CITATIONS
1996	Clinical utility of inflammatory markers and advanced lipoprotein testing: Advice from an expert panel of lipid specialists. <i>Journal of Clinical Lipidology</i> , 2011, 5, 338-367.	0.6	235
1999	Statins and myocardial remodelling: cell and molecular pathways. <i>Expert Reviews in Molecular Medicine</i> , 2011, 13, e22.	1.6	44
2000	Statins for acute coronary syndrome. , 2011, , CD006870.		16
2001	Pharmacological strategies for lowering LDL cholesterol: statins and beyond. <i>Nature Reviews Cardiology</i> , 2011, 8, 253-265.	6.1	90
2002	Clinical Implications of Pharmacogenetic Variation on the Effects of Statins. <i>Drug Safety</i> , 2011, 34, 1-19.	1.4	60
2003	Novel 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors: a patent review. <i>Expert Opinion on Therapeutic Patents</i> , 2011, 21, 187-203.	2.4	12
2004	Comprehensive Cardiovascular Medicine in the Primary Care Setting. , 2011, , .		0
2005	Lipid control in patients with diabetes mellitus. <i>Nature Reviews Cardiology</i> , 2011, 8, 278-290.	6.1	38
2006	Pharmacogenomic Testing in Current Clinical Practice. , 2011, , .		2
2007	A Prospective Natural-History Study of Coronary Atherosclerosis. <i>New England Journal of Medicine</i> , 2011, 364, 226-235.	13.9	2,721
2009	Effects of rosuvastatin on the coordinated proteomic response of human coronary smooth muscle cells to low density lipoproteins. <i>Cl�nica E Investigaci�n En Arteriosclerosis</i> , 2011, 23, 191-200.	0.4	0
2010	Riesgo residual vascular de origen lip�dico. Estrategias para el tratamiento del riesgo residual por dislipidemia aterog�nica. <i>Cl�nica E Investigaci�n En Arteriosclerosis</i> , 2011, 23, 230-239.	0.4	0
2011	The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol. <i>American Heart Journal</i> , 2011, 161, 471-477.e2.	1.2	80
2012	Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: An analysis of 65,396 hospitalizations from 344 hospitals participating in Get With The Guidelines (GWTG). <i>American Heart Journal</i> , 2011, 161, 418-424.e3.	1.2	35
2013	Peripheral artery disease, biomarkers, and darapladib. <i>American Heart Journal</i> , 2011, 161, 972-978.	1.2	20
2014	Assessment of adiponectin and the risk of recurrent cardiovascular events in patients presenting with an acute coronary syndrome: Observations from the Pravastatin Or atorVastatin Evaluation and Infection Trial�Thrombolysis in Myocardial Infarction 22 (PROVE IT�TIMI 22). <i>American Heart Journal</i> , 2011, 161, 1147-1155.e1.	1.2	46
2015	Effects of atorvastatin pretreatment on infarct size in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. <i>American Heart Journal</i> , 2011, 162, 1026-1033.	1.2	46
2016	Outcomes of Hospitalized Patients with Non-Acute Coronary Syndrome and Elevated Cardiac Troponin Level. <i>American Journal of Medicine</i> , 2011, 124, 630-635.	0.6	46

#	ARTICLE	IF	CITATIONS
2017	A hybrid approach to predicting events in clinical trials with time-to-event outcomes. <i>Contemporary Clinical Trials</i> , 2011, 32, 755-759.	0.8	13
2018	Statin-Associated Rhabdomyolysis: Is There a Dose-Response Relationship?. <i>Canadian Journal of Cardiology</i> , 2011, 27, 146-151.	0.8	64
2019	Differential regulation of human apolipoprotein AI and high-density lipoprotein by fenofibrate in hapoAI and hapoAI $\alpha$ CIII $\alpha$ IV transgenic mice. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2011, 1811, 76-83.	1.2	3
2020	Trimerized apolipoprotein A-I (TripA) forms lipoproteins, activates lecithin:cholesterol acyltransferase, elicits lipid efflux, and is transported through aortic endothelial cells. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2011, 1811, 1115-1123.	1.2	12
2021	Probabilistic cost-effectiveness analysis of cascade screening for familial hypercholesterolaemia using alternative diagnostic and identification strategies. <i>Heart</i> , 2011, 97, 1175-1181.	1.2	125
2022	Current status of statin therapy for stroke prevention. <i>Expert Review of Cardiovascular Therapy</i> , 2011, 9, 1305-1314.	0.6	14
2023	Hypercholesterolemia and hypo adiponectinemia are associated with necrotic core-rich coronary plaque. <i>International Journal of Cardiology</i> , 2011, 147, 371-376.	0.8	28
2024	Statins, cholesterol depletion and risk of incident diabetes. <i>International Journal of Cardiology</i> , 2011, 152, 275-276.	0.8	3
2025	ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2011, 32, 2999-3054.	1.0	2,995
2026	Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: where are we now?. <i>Trends in Pharmacological Sciences</i> , 2011, 32, 694-699.	4.0	24
2027	ApoB/apoA-I ratio is better than LDL-C in detecting cardiovascular risk. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2011, 21, 406-411.	1.1	36
2029	Introduction. <i>Atherosclerosis Supplements</i> , 2011, 12, 265-266.	1.2	8
2030	Pitavastatin: An overview. <i>Atherosclerosis Supplements</i> , 2011, 12, 271-276.	1.2	48
2031	Impact of statins on progression of atherosclerosis: rationale and design of SATURN (Study of Tj ETQq1 1 0.784314 rgBT /Overlock 10). <i>Current Medical Research and Opinion</i> , 2011, 27, 1119-1129.	0.9	43
2032	Cardiovascular drug therapy in the elderly: benefits and challenges. <i>Nature Reviews Cardiology</i> , 2011, 8, 13-28.	6.1	148
2033	Drug safety evaluation of rosuvastatin. <i>Expert Opinion on Drug Safety</i> , 2011, 10, 969-986.	1.0	27
2034	Prevalence of Metabolic Syndrome and its Components in Patients With Acute Coronary Syndrome. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2011, 64, 579-586.	0.4	20
2035	Impact of age on treatment and outcomes after acute myocardial infarction, particularly in very elderly patients. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2011, 30, 897-903.	0.2	15



#	ARTICLE	IF	CITATIONS
2036	Atorvastatin and A $\beta$ 2(1â€“40): Not as Simple as Cholesterol Reduction in Brain and Relevance to Alzheimer Disease. <i>Experimental Neurology</i> , 2011, 228, 15-18.	2.0	9
2037	Long-term use of oral nicorandil stabilizes coronary plaque in patients with stable angina pectoris. <i>Atherosclerosis</i> , 2011, 214, 415-421.	0.4	35
2038	Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. <i>Lancet, The</i> , 2011, 378, 1547-1559.	6.3	479
2039	Higher Baseline LDL-C Levels Amplify the Short-Term Benefit of Early Intensive Statin Treatment in Acute Coronary Syndrome. <i>Journal of Atherosclerosis and Thrombosis</i> , 2011, 18, 42-48.	0.9	6
2040	Early Statin Therapy Within 48 Hours Decreased One-Year Major Adverse Cardiac Events in Patients With Acute Myocardial Infarction. <i>International Heart Journal</i> , 2011, 52, 1-6.	0.5	12
2041	LIPRIMARÂ®. FIFTEEN YEARS OF EVIDENCE. <i>Rational Pharmacotherapy in Cardiology</i> , 2011, 7, 231-240.	0.3	0
2042	Lipid-lowering therapy: who can benefit. <i>Vascular Health and Risk Management</i> , 2011, 7, 525.	1.0	31
2043	Efficacy of ezetimibe as monotherapy or combination therapy in hypercholesterolemic patients with and without diabetes. <i>Journal of Medical Investigation</i> , 2011, 58, 86-94.	0.2	17
2044	Treatment of dyslipidemia in the elderly. <i>Journal of Geriatric Cardiology</i> , 2011, 8, 55-64.	0.2	16
2045	Comparison of Clinical Outcomes of Hydrophilic and Lipophilic Statins in Patients with Acute Myocardial Infarction. <i>Korean Journal of Internal Medicine</i> , 2011, 26, 294.	0.7	40
2046	Statins: Cardiovascular Risk Reduction in Percutaneous Coronary Interventionâ€”Basic and Clinical Evidence of Hyperacute Use of Statins. <i>International Journal of Hypertension</i> , 2011, 2011, 1-12.	0.5	9
2047	Prevalence, Predictors, and Impact of Low High-Density Lipoprotein Cholesterol on in-Hospital Outcomes Among Acute Coronary Syndrome Patients in the Middle East. <i>Open Cardiovascular Medicine Journal</i> , 2011, 5, 203-209.	0.6	13
2048	Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey. <i>Drug Design, Development and Therapy</i> , 2011, 5, 325.	2.0	201
2049	Estatinas nas sÃ¢ndromes coronarianas agudas. <i>Arquivos Brasileiros De Cardiologia</i> , 2011, 97, 350-356.	0.3	5
2050	Comparison of Ezetimibe/Simvastatin 10/20 mg Versus Atorvastatin 20 mg in Achieving a Target Low Density Lipoprotein-Cholesterol Goal for Patients With Very High Risk. <i>Korean Circulation Journal</i> , 2011, 41, 149.	0.7	10
2051	Inhibition of Lipoprotein-Associated Phospholipase A2 Ameliorates Inflammation and Decreases Atherosclerotic Plaque Formation in ApoE-Deficient Mice. <i>PLoS ONE</i> , 2011, 6, e23425.	1.1	40
2052	Statins Enhance Clonal Growth of Late Outgrowth Endothelial Progenitors and Increase Myocardial Capillary Density in the Chronically Ischemic Heart. <i>PLoS ONE</i> , 2011, 6, e24868.	1.1	16
2053	Cardiac protection and pharmacologic management of myocardial ischemia. , 0, , 1091-1105.		0

#	ARTICLE	IF	CITATIONS
2054	Stabilisation of atherosclerotic plaques. <i>Thrombosis and Haemostasis</i> , 2011, 106, 1-19.	1.8	139
2055	Ezetimibe Combined With Simvastatin Compared With Simvastatin Alone Results in a Greater Suppression of Oxidative Stress and Enhanced Fibrinolysis in Patients After Acute Coronary Events. <i>Journal of Cardiovascular Pharmacology</i> , 2011, 58, 167-172.	0.8	23
2056	Treatment of acute coronary syndrome: Part 1: Non-ST-segment acute coronary syndrome. <i>Critical Care Medicine</i> , 2011, 39, 2346-2353.	0.4	18
2057	Prevalence, clinical characteristics and treatment patterns of low high-density lipoprotein cholesterol in the US population. <i>Journal of Cardiovascular Medicine</i> , 2011, 12, 714-722.	0.6	7
2058	Clinical predictors for progression of nonintervened nonculprit coronary lesions despite low-density lipoprotein cholesterol less than 1.8 mmol/l after successful stent implantation. <i>Coronary Artery Disease</i> , 2011, 22, 49-54.	0.3	5
2059	The effect of statins on high-risk atherosclerotic plaque associated with low endothelial shear stress. <i>Current Opinion in Lipidology</i> , 2011, 22, 358-364.	1.2	6
2060	Lipid Management for the Prevention of Cardiovascular Disease. <i>Current Pharmaceutical Design</i> , 2011, 17, 852-860.	0.9	24
2061	Pathophysiology of Atherosclerosis: The Role of Inflammation. <i>Current Pharmaceutical Design</i> , 2011, 17, 4089-4110.	0.9	96
2062	Cardiovascular Event Reduction and Adverse Events Among Subjects Attaining Low-Density Lipoprotein Cholesterol <50mg/dl With Rosuvastatin: The JUPITER Trial (Justification for the Use of Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.0	0
2063	Cardiovascular Event Reduction and Adverse Events Among Subjects Attaining Low-Density Lipoprotein Cholesterol <50mg/dl With Rosuvastatin: The JUPITER Trial (Justification for the Use of Tj ETQq1 1 0.784314 rgBT /Overlock 0.1 1	0.1	1
2064	Editorial [Hot topic:Vascular Protective Effects of Ezetimibe: Seeking New Therapeutic Possibilities of Ezetimibe in Vascular Disease (Guest Editor: Minako Yamaoka-Tojo)]. <i>Current Vascular Pharmacology</i> , 2011, 9, 61-61.	0.8	0
2065	Prognostic utility of neopterin and risk of heart failure hospitalization after an acute coronary syndrome. <i>European Heart Journal</i> , 2011, 32, 1390-1397.	1.0	23
2066	Anacetrapib: A New Weapon Against Dyslipidemia. <i>Current Clinical Pharmacology</i> , 2011, 6, 227-235.	0.2	1
2067	Anti-inflammatory Treatment of Acute Coronary Syndromes. <i>Current Pharmaceutical Design</i> , 2011, 17, 4172-4189.	0.9	21
2068	Gender-Specific Aspects in Primary and Secondary Prevention of Cardiovascular Disease. <i>Current Pharmaceutical Design</i> , 2011, 17, 1082-1089.	0.9	20
2069	Lipid-lowering intensification and low-density lipoprotein cholesterol achievement from hospital admission to 1-year follow-up after an acute coronary syndrome event: Results from the Medications Applied aNd SusTAINed Over Time (MAINTAIN) registry. <i>Yearbook of Endocrinology</i> , 2011, 2011, 48-50.	0.0	0
2070	Assessing the Comparative Effectiveness of Newly Marketed Medications: Methodological Challenges and Implications for Drug Development. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 90, 777-790.	2.3	157
2071	Is "Strict" Conventional Therapy Enough for the Treatment of Coronary Artery Disease?. <i>Circulation Journal</i> , 2011, 75, 2046-2047.	0.7	1

#	ARTICLE	IF	CITATIONS
2072	Comparison of Effects of Rosuvastatin and Atorvastatin on Plaque Regression in Korean Patients With Untreated Intermediate Coronary Stenosis. <i>Circulation Journal</i> , 2011, 75, 398-406.	0.7	40
2073	Comparison of Preventive Effect on Cardiovascular Events With Different Statins - The CIRCLE Study -. <i>Circulation Journal</i> , 2011, 75, 1951-1959.	0.7	37
2074	After the Triumph of Cardiovascular Medicine Over Acute Myocardial Infarction at the End of the 20th Century - Can We Predict the Onset of Acute Coronary Syndrome? (Con) -. <i>Circulation Journal</i> , 2011, 75, 2019-2026.	0.7	11
2075	Intensively Lowering Both Low-Density Lipoprotein Cholesterol and Blood Pressure Does Not Reduce Cardiovascular Risk in Japanese Coronary Artery Disease Patients. <i>Circulation Journal</i> , 2011, 75, 2062-2070.	0.7	8
2076	Comparative study between high-dose fluvastatin and low-dose fluvastatin and ezetimibe with regard to the effect on endothelial function in diabetic patients. <i>Endocrine Journal</i> , 2011, 58, 171-175.	0.7	24
2077	The IMPROVE-IT trial: current status and potential clinical implications of ezetimibe. <i>Clinical Investigation</i> , 2011, 1, 137-144.	0.0	0
2078	New considerations in the design of clinical trials for anti-atherosclerotic drugs. <i>Clinical Investigation</i> , 2011, 1, 795-803.	0.0	1
2079	Controlling lipids after acute coronary syndromes: what is the best strategy?. <i>Clinical Lipidology</i> , 2011, 6, 253-255.	0.4	0
2080	Encounter Frequency and Serum Glucose Level, Blood Pressure, and Cholesterol Level Control in Patients With Diabetes Mellitus. <i>Archives of Internal Medicine</i> , 2011, 171, 1542.	4.3	94
2081	Therapies for diabetic dyslipidaemia. <i>Diabetes, Obesity and Metabolism</i> , 2011, 13, 313-325.	2.2	31
2082	Inhibition of inositol monophosphatase by lithium chloride induces selective macrophage apoptosis in atherosclerotic plaques. <i>British Journal of Pharmacology</i> , 2011, 162, 1410-1423.	2.7	32
2083	â€Trig-onometryâ€™: non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia. <i>International Journal of Clinical Practice</i> , 2011, 65, 82-101.	0.8	17
2084	Use of high-intensity statin therapy with simvastatin 80â€mg and atorvastatin 80â€mg in primary care. <i>International Journal of Clinical Practice</i> , 2011, 65, 120-126.	0.8	4
2085	Meta-analysis of the cardiovascular benefits of intensive lipid lowering with statins. <i>Acta Neurologica Scandinavica</i> , 2011, 124, 188-195.	1.0	24
2086	Anti-inflammatory therapeutics for the treatment of atherosclerosis. <i>Nature Reviews Drug Discovery</i> , 2011, 10, 365-376.	21.5	246
2087	Progress and challenges in translating the biology of atherosclerosis. <i>Nature</i> , 2011, 473, 317-325.	13.7	3,058
2088	Effects of Statins on Progression of Coronary Artery Disease as Measured by Intravascular Ultrasound. <i>Journal of Clinical Hypertension</i> , 2011, 13, 492-496.	1.0	26
2089	Comorbidities of Diabetes and Hypertension: Mechanisms and Approach to Target Organ Protection. <i>Journal of Clinical Hypertension</i> , 2011, 13, 244-251.	1.0	333

#	ARTICLE	IF	CITATIONS
2090	Low-density lipoprotein cholesterol to apolipoprotein B ratio is independently associated with metabolic syndrome in Korean men. <i>Metabolism: Clinical and Experimental</i> , 2011, 60, 1136-1141.	1.5	9
2091	Impact of early statin initiation on secondary prevention in Japanese patients with coronary artery disease. <i>Journal of Cardiology</i> , 2011, 57, 172-180.	0.8	17
2093	Beneficio cl�nico de las estatinas: �hemos cubierto todo el espectro?. <i>Revista Espanola De Cardiologia Suplementos</i> , 2011, 11, 3-13.	0.2	2
2094	Eficacia de las estatinas en el manejo de la dislipemia. Un paso adelante. <i>Revista Espanola De Cardiologia Suplementos</i> , 2011, 11, 14-20.	0.2	0
2095	Valor de la dislipemia en el conjunto de los factores de riesgo cardiovascular. <i>Revista Espanola De Cardiologia Suplementos</i> , 2011, 11, 29-35.	0.2	1
2096	Exposure to statins and risk of common cancers: a series of nested case-control studies. <i>BMC Cancer</i> , 2011, 11, 409.	1.1	108
2097	Atorvastatin for the Treatment of Plaque�type Psoriasis. <i>Pharmacotherapy</i> , 2011, 31, 1045-1050.	1.2	23
2098	Combination Therapy With Ezetimibe/Simvastatin Versus Statin Monotherapy for Low-Density Lipoprotein Cholesterol Reduction and Goal Attainment in a Real-World Clinical Setting. <i>Clinical Therapeutics</i> , 2011, 33, 212-224.	1.1	23
2099	Pitavastatin Calcium: Clinical Review of a New Antihyperlipidemic Medication. <i>Clinical Therapeutics</i> , 2011, 33, 1023-1042.	1.1	12
2100	The Value of Atorvastatin Over the Product Life Cycle in the United States. <i>Clinical Therapeutics</i> , 2011, 33, 1433-1443.	1.1	13
2101	Achieving Optimal Lipid Goals in Patients With Coronary Artery Disease. <i>American Journal of Cardiology</i> , 2011, 107, 886-890.	0.7	42
2102	Relation of Fractional Flow Reserve After Drug-Eluting Stent Implantation to One-Year Outcomes. <i>American Journal of Cardiology</i> , 2011, 107, 1763-1767.	0.7	78
2103	The Editor's Roundtable: Role of Percutaneous Coronary Intervention and Drug-Eluting Stents in Patients With Stable Coronary Heart Disease. <i>American Journal of Cardiology</i> , 2011, 108, 1417-1425.	0.7	5
2104	Current Evidence for Perioperative Statins in Cardiac Surgery. <i>Annals of Thoracic Surgery</i> , 2011, 92, 372-379.	0.7	14
2105	Statin Therapy and Saphenous Vein Graft Disease After Coronary Bypass Surgery: Analysis From the CASCADE Randomized Trial. <i>Annals of Thoracic Surgery</i> , 2011, 92, 1284-1291.	0.7	82
2106	Effects of short-term anti-inflammatory therapy on endothelial function in patients with non-ST-segment elevation acute coronary syndrome. <i>Cardiovascular Revascularization Medicine</i> , 2011, 12, 2-9.	0.3	7
2108	Statins have an early antiplatelet effect in patients with acute myocardial infarction. <i>Platelets</i> , 2011, 22, 103-110.	1.1	25
2109	Expression of Apolipoprotein A-I in Rabbit Carotid Endothelium Protects Against Atherosclerosis. <i>Molecular Therapy</i> , 2011, 19, 1833-1841.	3.7	36

#	ARTICLE	IF	CITATIONS
2110	Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy. <i>New England Journal of Medicine</i> , 2011, 365, 2255-2267.	13.9	2,523
2111	Lack of an effect of anacetrapib on the pharmacokinetics of digoxin in healthy subjects. <i>Biopharmaceutics and Drug Disposition</i> , 2011, 32, 525-529.	1.1	11
2112	2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2013, 82, E266-355.	0.7	97
2113	Protective effects of resveratrol on calcium-induced oxidative stress in rat heart mitochondria. <i>Journal of Bioenergetics and Biomembranes</i> , 2011, 43, 101-107.	1.0	15
2114	Genetic variants in the KIF6 region and coronary event reduction from statin therapy. <i>Human Genetics</i> , 2011, 129, 17-23.	1.8	18
2115	Adherence of hospital-based cardiologists to lipid guidelines in patients at high risk for cardiovascular events (2L registry). <i>Clinical Research in Cardiology</i> , 2011, 100, 277-287.	1.5	9
2116	Treatment of cardiovascular diseases in cancer patients. <i>Herz</i> , 2011, 36, 340-345.	0.4	3
2118	Comprehensive Lipid Management in the Coronary Artery Disease Patient. <i>Current Cardiovascular Risk Reports</i> , 2011, 5, 399-406.	0.8	0
2119	Pitavastatin: a New 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor for the treatment of hyperlipidemia. <i>Advances in Therapy</i> , 2011, 28, 13-27.	1.3	10
2120	Lipoprotein associated phospholipase A2: role in atherosclerosis and utility as a biomarker for cardiovascular risk. <i>EPMA Journal</i> , 2011, 2, 27-38.	3.3	54
2121	The epidemiological concept of residual risk. <i>Internal and Emergency Medicine</i> , 2011, 6, 45-51.	1.0	30
2122	Residual cardiovascular risk in secondary prevention. <i>Internal and Emergency Medicine</i> , 2011, 6, 61-68.	1.0	6
2123	Statins in Combinations: From ARBITER-6 HALTS to ACCORDâ€”What Works?. <i>Current Atherosclerosis Reports</i> , 2011, 13, 4-8.	2.0	0
2124	Experimental Models for the Investigation of High-Density Lipoproteinâ€”Mediated Cholesterol Efflux. <i>Current Atherosclerosis Reports</i> , 2011, 13, 266-276.	2.0	45
2125	The JUPITER Trial: Myth or Reality?. <i>Current Atherosclerosis Reports</i> , 2011, 13, 413-421.	2.0	8
2126	Optimal Medical Therapy, Lifestyle Intervention, and Secondary Prevention Strategies for Cardiovascular Event Reduction in Ischemic Heart Disease. <i>Current Cardiology Reports</i> , 2011, 13, 287-295.	1.3	10
2127	Predictors of Statin Adherence. <i>Current Cardiology Reports</i> , 2011, 13, 553-558.	1.3	47
2128	Lipid-related residual risk and renal function for occurrence and prognosis among patients with first-event acute coronary syndrome and normal LDL cholesterol. <i>Lipids in Health and Disease</i> , 2011, 10, 215.	1.2	2

#	ARTICLE	IF	CITATIONS
2129	Red ginseng extract improves coronary flow reserve and increases absolute numbers of various circulating angiogenic cells in patients with first ST-segment elevation acute myocardial infarction. <i>Phytotherapy Research</i> , 2011, 25, 239-249.	2.8	32
2130	Prevalence and risk factors of muscle complications secondary to statins. <i>Muscle and Nerve</i> , 2011, 44, 877-881.	1.0	72
2131	Attainment of optional low-density lipoprotein cholesterol goal of less than 70 mg/dl and impact on prognosis of very high risk stable coronary patients: a 3-year follow-up. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 1481-1489.	0.9	12
2132	Cardiovascular disease in women. <i>Future Cardiology</i> , 2011, 7, 613-627.	0.5	3
2133	Options for the treatment of hyperlipidemia in Type 2 diabetes mellitus and hypothyroidism: lowering the cardiovascular risk. <i>Future Cardiology</i> , 2011, 7, 137-144.	0.5	5
2134	The beneficial effects of HDL-C on atherosclerosis: rationale and clinical results. <i>Clinical Lipidology</i> , 2011, 6, 181-208.	0.4	9
2135	Acute Myocardial Infarction with Severe ST Segment Elevation Treated with Percutaneous Coronary Intervention More than Two Days after Onset: A Case with Remarkable Recovery. <i>International Journal of Angiology</i> , 2011, 20, 103-106.	0.2	1
2136	Imaging Assessment of Cardiovascular Risk in Asymptomatic Adults. <i>American Journal of Roentgenology</i> , 2011, 197, W1046-W1051.	1.0	6
2137	Event reduction: revisiting why we treat with statins and harnessing current evidence towards optimal therapy. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 99-117.	0.9	5
2138	Statin myopathy: A common dilemma not reflected in clinical trials. <i>Cleveland Clinic Journal of Medicine</i> , 2011, 78, 393-403.	0.6	184
2139	Combination therapy with statin and fibrate in patients with dyslipidemia associated with insulin resistance, metabolic syndrome and type 2 diabetes mellitus. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 1429-1438.	0.9	16
2140	Statins and the risk of new-onset diabetes. <i>Current Opinion in Lipidology</i> , 2011, 22, 460-466.	1.2	93
2141	Should C-Reactive Protein Be a Target of Therapy?. <i>Diabetes Care</i> , 2011, 34, S155-S160.	4.3	24
2142	Does Pay for Performance Improve Cardiovascular Care in a "Real-World" Setting?. <i>American Journal of Medical Quality</i> , 2011, 26, 340-348.	0.2	8
2143	Impact of High-Dose Atorvastatin on Endothelial, Platelet, and Angiogenic Indices. <i>Angiology</i> , 2011, 62, 571-578.	0.8	11
2144	Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin Therapy. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 2556.	3.8	1,197
2145	Age and Outcomes in ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention. <i>Archives of Internal Medicine</i> , 2011, 171, 559-67.	4.3	54
2146	Statin Therapy Associated with Fatal Rhabdomyolysis. <i>Journal of the Intensive Care Society</i> , 2011, 12, 40-42.	1.1	6

#	ARTICLE	IF	CITATIONS
2147	2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery. <i>Circulation</i> , 2011, 124, e652-735.	1.6	590
2149	Benefit of Intensive Statin Therapy in Women. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2011, 4, 328-336.	0.9	61
2150	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary. <i>Circulation</i> , 2011, 124, 2574-2609.	1.6	500
2151	LDL-LOWERING INDEPENDENT EFFECTS OF EARLY PRE-TREATMENT WITH HIGH-DOSE STATINS IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTIONS. <i>The European Journal of Cardiovascular Medicine</i> , 2011, 1, .	1.0	0
2152	Recent Advances in the Treatment of Atherogenic Dyslipidemia in Type 2 Diabetes Mellitus. <i>Kidney and Blood Pressure Research</i> , 2011, 34, 209-217.	0.9	15
2153	Imaging Biomarkers in Atherosclerosis Trials. <i>Circulation: Cardiovascular Imaging</i> , 2011, 4, 319-333.	1.3	63
2154	Effectiveness of Preprocedural Statin Therapy on Clinical Outcomes for Patients With Stable Coronary Artery Disease After Percutaneous Coronary Interventions. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2011, 4, 459-466.	0.9	9
2155	Squalene Synthase Inhibitor Lapaquistat Acetate. <i>Circulation</i> , 2011, 123, 1925-1928.	1.6	21
2156	Commentary: 'The end of clinical freedom': relevance in the era of evidence-based medicine. <i>International Journal of Epidemiology</i> , 2011, 40, 855-858.	0.9	3
2157	How Many "Me-Too" Drugs Is Too Many?. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 711.	3.8	61
2158	Hyperlipidemia in Primary Care. , 2011, , .		2
2159	Significance of LDL-C lowering therapy in diabetic patients. <i>Clinical Lipidology</i> , 2011, 6, 389-399.	0.4	4
2160	Serial intravascular ultrasound assessment of changes in coronary atherosclerotic plaque dimensions and composition: an update. <i>European Journal of Echocardiography</i> , 2011, 12, 313-321.	2.3	33
2161	Intensifying statin therapy to maximize cardiovascular risk reduction: is 50 the new 70? Goals are getting old. <i>Clinical Lipidology</i> , 2011, 6, 131-136.	0.4	4
2162	Clinical Trial Subgroups. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2011, 4, 266-267.	0.9	1
2164	Lupus Atherosclerosis Prevention Study (LAPS). <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 760-765.	0.5	194
2165	Standards of Medical Care in Diabetes—2011. <i>Diabetes Care</i> , 2011, 34, S11-S61.	4.3	2,448
2166	The facts behind niacin. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2011, 5, 227-240.	1.0	20

#	ARTICLE	IF	CITATIONS
2167	HMG CoA Reduction in Patients with Average Cholesterol Concentrations. <i>Clinical Chemistry</i> , 2011, 57, 1072-1073.	1.5	2
2168	Expression of HMG-CoA reductase in human coronary atherosclerotic plaques and relationship to plaque destabilisation. <i>Heart</i> , 2011, 97, 715-720.	1.2	7
2169	Statin Use in Outpatients With Obstructive Coronary Artery Disease. <i>Circulation</i> , 2011, 124, 2405-2410.	1.6	62
2170	Statin Myopathy: Significant Problem With Minimal Awareness by Clinicians and no Emphasis by Clinical Investigators. <i>Angiology</i> , 2011, 62, 415-421.	0.8	19
2171	2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non- $\sigma$ ST-Elevation Myocardial Infarction. <i>Circulation</i> , 2011, 123, e426-579.	1.6	658
2172	Targeting Proteases in Atherosclerosis. <i>Circulation</i> , 2011, 124, 2480-2482.	1.6	2
2173	Atlas of Atherosclerosis and Metabolic Syndrome. , 2011, , .		5
2174	Emerging drugs for coronary artery disease. From past achievements and current needs to clinical promises. <i>Expert Opinion on Emerging Drugs</i> , 2011, 16, 203-233.	1.0	1
2175	Aborted Autophagy and Nonapoptotic Death Induced by Farnesyl Transferase Inhibitor and Lovastatin. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2011, 337, 65-74.	1.3	38
2176	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. <i>Circulation</i> , 2011, 124, e574-651.	1.6	1,946
2177	Epidemiology, risk analysis and clinical outcomes in acute myocardial infarction in Trinidad. <i>Anatolian Journal of Cardiology</i> , 2011, 11, 269-70.	0.4	2
2179	Intensive lipid lowering in patients with rheumatoid arthritis and previous myocardial infarction: an explorative analysis from the incremental decrease in endpoints through aggressive lipid lowering (IDEAL) trial. <i>Rheumatology</i> , 2011, 50, 324-329.	0.9	55
2180	2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: Executive Summary. <i>Circulation</i> , 2011, 124, 2610-2642.	1.6	451
2181	Atorvastatin and Low-Density Lipoprotein Cholesterol in Type 2 Diabetes Mellitus Patients on Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 1316-1325.	2.2	116
2182	Coronary Artery Wall Shear Stress Is Associated With Progression and Transformation of Atherosclerotic Plaque and Arterial Remodeling in Patients With Coronary Artery Disease. <i>Circulation</i> , 2011, 124, 779-788.	1.6	579
2183	Medical angioplasty - Hope and expectations: An optimistic overview. <i>Journal of Family and Community Medicine</i> , 2011, 18, 101.	0.5	0
2184	Remnant lipoprotein-cholesterol is a predictive biomarker for large artery atherosclerosis in apparently healthy women: usefulness as a parameter for annual health examinations. <i>Annals of Clinical Biochemistry</i> , 2011, 48, 332-337.	0.8	10
2185	Translating Cholesterol Guidelines Into Primary Care Practice: A Multimodal Cluster Randomized Trial. <i>Annals of Family Medicine</i> , 2011, 9, 528-537.	0.9	20



#	ARTICLE	IF	CITATIONS
2186	Cardio-Ankle Vascular Index Could Reflect Plaque Burden in the Coronary Artery. <i>Angiology</i> , 2011, 62, 401-408.	0.8	38
2187	Radiofrequency intravascular ultrasound and detection of the vulnerable plaque. <i>British Journal of Hospital Medicine</i> (London, England: 2005), 2012, 73, 682-686.	0.2	0
2188	Clinical Neuroprotective Drugs for Treatment and Prevention of Stroke. <i>International Journal of Molecular Sciences</i> , 2012, 13, 7739-7761.	1.8	22
2189	Effect of Statins on Venous Thromboembolic Events: A Meta-analysis of Published and Unpublished Evidence from Randomised Controlled Trials. <i>PLoS Medicine</i> , 2012, 9, e1001310.	3.9	78
2190	Use of Lipid-Lowering Medications and the Likelihood of Achieving Optimal LDL-Cholesterol Goals in Coronary Artery Disease Patients. <i>Cholesterol</i> , 2012, 2012, 1-7.	1.6	49
2191	Angina Pectoris and Stable Ischemic Heart Disease. , 2012, , 412-425.		2
2192	Efficacy of Short-Term High-Dose Statin in Preventing Contrast-Induced Nephropathy: A Meta-Analysis of Seven Randomized Controlled Trials. <i>PLoS ONE</i> , 2012, 7, e34450.	1.1	78
2193	The Effects of Statins on Prevention of Stroke and Dementia. <i>Journal of Cardiopulmonary Rehabilitation and Prevention</i> , 2012, 32, 240-249.	1.2	10
2194	Novel anti-inflammatory strategies in atherosclerosis. <i>Current Opinion in Lipidology</i> , 2012, 23, 532-539.	1.2	39
2195	Panel discussion 2. <i>Clinical Trials</i> , 2012, 9, 66-79.	0.7	0
2196	Low-density lipoprotein-lowering strategies. <i>Current Opinion in Cardiology</i> , 2012, 27, 405-411.	0.8	16
2197	Targeting HDL-cholesterol to reduce residual cardiovascular risk. <i>Current Opinion in Lipidology</i> , 2012, 23, 172-174.	1.2	7
2198	2012 Oman Heart Association Simplified Guidelines for the Management of Patients With Unstable Angina/Non-â€“ST-Elevation Myocardial Infarction. <i>Critical Pathways in Cardiology</i> , 2012, 11, 139-146.	0.2	4
2199	Predictive value of red cell distribution width in intrahospital mortality and postintervention thrombolysis in myocardial infarction flow in patients with acute anterior myocardial infarction. <i>Coronary Artery Disease</i> , 2012, 23, 450-454.	0.3	19
2200	Cardiac Disease Evaluation and Management Among Kidney and Liver Transplantation Candidates. <i>Circulation</i> , 2012, 126, 617-663.	1.6	255
2201	Lipid-Modifying Therapies and Risk of Pancreatitis. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 804.	3.8	140
2202	Acute Coronary Events. <i>Circulation</i> , 2012, 125, 1147-1156.	1.6	244
2203	Novel Strategies for Managing Dyslipidemia: Treatment beyond Statins. <i>Postgraduate Medicine</i> , 2012, 124, 43-54.	0.9	13

#	ARTICLE	IF	CITATIONS
2204	Contemporary Management of ST-Segment Elevation Myocardial Infarction. Hospital Practice (1995), 2012, 40, 224-231.	0.5	0
2205	Adding ezetimibe to statin treatment: is LDL-C lowering the only benefit?. Future Cardiology, 2012, 8, 813-817.	0.5	3
2206	ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal, 2012, 33, 2569-2619.	1.0	5,034
2207	Comparing the effectiveness of rosuvastatin and atorvastatin in preventing cardiovascular outcomes: estimates using the Archimedes model. Journal of Medical Economics, 2012, 15, 1118-1129.	1.0	16
2208	Potencialidad de los biomarcadores de inflamaci3n en la detecci3n precoz de la enfermedad cardiovascular. Revista M3dica Cl3nica Las Condes, 2012, 23, 666-671.	0.2	0
2209	Prevalence and Determinants of Hyperlipidemia in Moderate Altitude Areas of the Yunnan-Kweichow Plateau in Southwestern China. High Altitude Medicine and Biology, 2012, 13, 13-21.	0.5	24
2210	Cardiology in Family Practice. , 2012, , .		3
2211	The case for more intensive use of statins. Therapeutic Advances in Chronic Disease, 2012, 3, 201-210.	1.1	3
2212	Galectin-3 and the Development of Heart Failure after Acute Coronary Syndrome: Pilot Experience from PROVE IT-TIMI 22. Clinical Chemistry, 2012, 58, 267-273.	1.5	111
2213	Composition of Target Lesions by Near-Infrared Spectroscopy in Patients With Acute Coronary Syndrome Versus Stable Angina. Circulation: Cardiovascular Interventions, 2012, 5, 55-61.	1.4	99
2214	The Use of Combination Lipid Therapy in a County Health System. Journal of Pharmacy Technology, 2012, 28, 227-233.	0.5	0
2215	Rosuvastatin and Atorvastatin: Comparative Effects on Glucose Metabolism in Non-Diabetic Patients with Dyslipidaemia. Clinical Medicine Insights: Endocrinology and Diabetes, 2012, 5, CMED.S7591.	1.0	15
2216	A Randomized Trial Assessing the Effectiveness of Ezetimibe in South Asian Canadians with Coronary Artery Disease or Diabetes: The INFINITY Study. Advances in Preventive Medicine, 2012, 2012, 1-11.	1.1	8
2217	Effects of Statins on Cardiorenal Syndrome. International Journal of Vascular Medicine, 2012, 2012, 1-7.	0.4	9
2218	Lipid Disorders in Elderly Hypertensive Patients. International Journal of Hypertension, 2012, 2012, 1-3.	0.5	1
2219	Statin Loading Before Percutaneous Coronary Intervention to Reduce Periprocedural Myocardial Infarction. Cardiology in Review, 2012, 20, 319-324.	0.6	13
2220	Utility of Early High Dose Statins in Acute Coronary Syndrome. American Journal of Therapeutics, 2012, 19, 369-376.	0.5	4
2221	C-Reactive Protein Predicts the Severity of Coronary Artery Disease Beyond Low-Density Lipoprotein Cholesterol. Angiology, 2012, 63, 218-222.	0.8	9

#	ARTICLE	IF	CITATIONS
2222	Effect of a Multifaceted Intervention on Use of Evidence-Based Therapies in Patients With Acute Coronary Syndromes in Brazil. <i>JAMA - Journal of the American Medical Association</i> , 2012, 307, 2041-9.	3.8	70
2223	2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease. <i>Circulation</i> , 2012, 126, e354-471.	1.6	675
2224	Statin Therapy and the Risk of Intracerebral Hemorrhage. <i>Stroke</i> , 2012, 43, 2149-2156.	1.0	266
2225	Evaluation of C-reactive protein prior to and on-treatment as a predictor of benefit from atorvastatin: observations from the Anglo-Scandinavian Cardiac Outcomes Trial. <i>European Heart Journal</i> , 2012, 33, 486-494.	1.0	48
2226	A new approach to managing the 'statin-intolerant' patient?. <i>European Heart Journal</i> , 2012, 33, 1040-1043.	1.0	6
2227	Creating controversy where none exists: the important role of C-reactive protein in the CARE, AFCAPS/TexCAPS, PROVE IT, REVERSAL, A to Z, JUPITER, HEART PROTECTION, and ASCOT trials. <i>European Heart Journal</i> , 2012, 33, 430-432.	1.0	59
2228	Treatment of acute coronary syndrome. <i>Critical Care Medicine</i> , 2012, 40, 1939-1945.	0.4	12
2229	The Modification of Serum Lipids after Acute Coronary Syndrome and Importance in Clinical Practice. <i>Current Cardiology Reviews</i> , 2012, 7, 272-276.	0.6	33
2230	Impacts of conventional coronary risk factors, diabetes and hypertension, on coronary atherosclerosis during statin therapy. <i>Coronary Artery Disease</i> , 2012, 23, 239-244.	0.3	3
2231	Statins and Cardiovascular Risk in Rheumatic Diseases. <i>International Journal of Immunopathology and Pharmacology</i> , 2012, 25, 25-30.	1.0	0
2232	Attainment of combined optimal lipid values with the use of niacin: has AIM-HIGH closed the book on this debate?. <i>Clinical Lipidology</i> , 2012, 7, 389-396.	0.4	0
2234	Small dense low-density lipoprotein particles: priority as a treatment target in Type 2 diabetes?. <i>Diabetes Management</i> , 2012, 2, 65-74.	0.5	1
2235	Diagnosis of Stable Ischemic Heart Disease: Summary of a Clinical Practice Guideline From the American College of Physicians/American College of Cardiology Foundation/American Heart Association/American Association for Thoracic Surgery/Preventive Cardiovascular Nurses Association/Society of Thoracic Surgeons. <i>Annals of Internal Medicine</i> , 2012, 157, 729.	2.0	78
2236	Chromosome 9p21 Single Nucleotide Polymorphisms Are Not Associated With Recurrent Myocardial Infarction in Patients With Established Coronary Artery Disease. <i>Circulation Journal</i> , 2012, 76, 950-956.	0.7	24
2237	Impact of Diabetes Mellitus on Coronary Atherosclerosis and Plaque Composition Under Statin Therapy. <i>Circulation Journal</i> , 2012, 76, 2188-2196.	0.7	22
2238	Intensity of Statin Therapy, Achieved Low-Density Lipoprotein Cholesterol Levels and Cardiovascular Outcomes in Japanese Patients After Coronary Revascularization. <i>Circulation Journal</i> , 2012, 76, 1369-1379.	0.7	49
2239	Clustering of Metabolic Syndrome Components Attenuates Coronary Plaque Regression During Intensive Statin Therapy in Patients With Acute Coronary Syndrome. <i>Circulation Journal</i> , 2012, 76, 2840-2847.	0.7	10
2240	Novel Functional Risk Factors for the Prediction of Cardiovascular Events in Vulnerable Patients Following Acute Coronary Syndrome. <i>Circulation Journal</i> , 2012, 76, 778-783.	0.7	43

#	ARTICLE	IF	CITATIONS
2241	Virtual Histology Findings and Effects of Varying Doses of Atorvastatin on Coronary Plaque Volume and Composition in Statin-Naive Patients. <i>Circulation Journal</i> , 2012, 76, 2662-2672.	0.7	24
2242	The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. <i>Lancet, The</i> , 2012, 380, 581-590.	6.3	2,250
2243	Statins in acute coronary syndrome: very early initiation and benefits. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2012, 6, 163-174.	1.0	20
2244	Very early initiation of statin therapy and mortality in patients with acute coronary syndrome. <i>Acute Cardiac Care</i> , 2012, 14, 34-39.	0.2	10
2245	Myocardial infarction accelerates atherosclerosis. <i>Nature</i> , 2012, 487, 325-329.	13.7	874
2246	2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease. <i>Journal of the American College of Cardiology</i> , 2012, 60, e44-e164.	1.2	1,423
2247	Lipidâ€Altering Efficacy of Ezetimibe/Simvastatin 10/20 mg Compared to Rosuvastatin 10 mg in Highâ€Risk Patients with and without Type 2 Diabetes Mellitus Inadequately Controlled Despite Prior Statin Monotherapy. <i>Cardiovascular Therapeutics</i> , 2012, 30, 61-74.	1.1	15
2248	Is lower and lower better and better? A re-evaluation of the evidence from the Cholesterol Treatment Trialistsâ€™ Collaboration meta-analysis for low-density lipoprotein lowering. <i>Journal of Clinical Lipidology</i> , 2012, 6, 303-309.	0.6	42
2249	The Thrombolysis in Myocardial Infarction (TIMI) Study Group experience. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2012, 144, 762-770.	0.4	14
2250	ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2012, 65, 173.	0.4	183
2251	Risk Factors for Non-calcified Plaques in Asymptomatic Population. <i>Academic Radiology</i> , 2012, 19, 548-553.	1.3	7
2252	Rosuvastatin-induced high-density lipoprotein changes in patients who underwent percutaneous coronary intervention for non-ST-segment elevation acute coronary syndrome. <i>Journal of Cardiology</i> , 2012, 60, 383-388.	0.8	9
2253	Suboptimal Attainment of Cardiovascular Disease Prevention Guideline Goals in Korean Women. <i>Asian Nursing Research</i> , 2012, 6, 49-54.	0.7	4
2255	Dysfunctional High-Density Lipoprotein in Patients on Chronic Hemodialysis. <i>Journal of the American College of Cardiology</i> , 2012, 60, 2372-2379.	1.2	172
2256	Identification of a potent and metabolically stable series of fluorinated diphenylpyridylethanamine-based cholesteryl ester transfer protein inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 6503-6508.	1.0	18
2257	Triglycerides: How Much Credit Do They Deserve?. <i>Medical Clinics of North America</i> , 2012, 96, 39-55.	1.1	16
2258	Lowâ€Density Lipoprotein Cholesterol and Highâ€Sensitivity Câ€Reactive Protein Lowering With Atorvastatin in Patients of South Asian Compared With European Origin: Insights From the Achieve Cholesterol Targets Fast With Atorvastatin Stratified Titration (ACTFAST) Study. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 850-858.	1.0	15
2259	Effect of statins on ventricular tachyarrhythmia, cardiac arrest, and sudden cardiac death: a meta-analysis of published and unpublished evidence from randomized trials. <i>European Heart Journal</i> , 2012, 33, 1571-1581.	1.0	41

#	ARTICLE	IF	CITATIONS
2260	Standards of Medical Care in Diabetes—2012. <i>Diabetes Care</i> , 2012, 35, S11-S63.	4.3	1,956
2262	Supplementing claims data with outpatient laboratory test results to improve confounding adjustment in effectiveness studies of lipid-lowering treatments. <i>BMC Medical Research Methodology</i> , 2012, 12, 180.	1.4	33
2263	Guía de práctica clínica de la ESC para el manejo del síndrome coronario agudo en pacientes sin elevación persistente del segmento ST. <i>Revista Española De Cardiología</i> , 2012, 65, 173.e1-173.e55.	0.6	31
2264	Statin treatment for coronary artery plaque composition based on intravascular ultrasound radiofrequency data analysis. <i>American Heart Journal</i> , 2012, 163, 191-199.e1.	1.2	78
2265	The impact of high-density lipoprotein cholesterol levels on long-term outcomes after non-ST-elevation myocardial infarction. <i>American Heart Journal</i> , 2012, 163, 705-713.	1.2	20
2267	Updated evidence on early statin therapy for acute coronary syndromes: Meta-analysis of 18 randomized trials involving over 14,000 patients. <i>International Journal of Cardiology</i> , 2012, 158, 93-100.	0.8	23
2268	Pleiotropic effects of ezetimibe/simvastatin vs. high dose simvastatin. <i>International Journal of Cardiology</i> , 2012, 158, 400-404.	0.8	42
2269	The importance of atrial fibrillation/flutter as a cause of ischemic stroke. <i>International Journal of Cardiology</i> , 2012, 158, 143-144.	0.8	8
2270	Effectiveness of statin therapy for elderly acute myocardial infarction patients with normal levels of low-density lipoprotein cholesterol. <i>International Journal of Cardiology</i> , 2012, 158, 139-143.	0.8	3
2271	Effect of statin therapy on the progression of coronary atherosclerosis. <i>BMC Cardiovascular Disorders</i> , 2012, 12, 70.	0.7	57
2272	Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction. <i>Cardiovascular Diabetology</i> , 2012, 11, 125.	2.7	128
2273	Efficacy, safety and tolerability of ongoing statin plus ezetimibe versus doubling the ongoing statin dose in hypercholesterolemic Taiwanese patients: an open-label, randomized clinical trial. <i>BMC Research Notes</i> , 2012, 5, 251.	0.6	10
2274	What Is the Role of Advanced Lipoprotein Analysis in Practice?. <i>Journal of the American College of Cardiology</i> , 2012, 60, 2607-2615.	1.2	19
2275	Relationships between HMG-CoA reductase inhibitors (statin) use and strength, balance and falls in older people. <i>Internal Medicine Journal</i> , 2012, 42, 1329-1334.	0.5	27
2276	The Burden and Management of Dyslipidemia: Practical Issues. <i>Population Health Management</i> , 2012, 15, 302-308.	0.8	7
2277	Dyslipidemia: Management Using Optimal Lipid-Lowering Therapy. <i>Annals of Pharmacotherapy</i> , 2012, 46, 1368-1381.	0.9	28
2279	LDL Cholesterol: The Lower the Better. <i>Medical Clinics of North America</i> , 2012, 96, 13-26.	1.1	73
2280	Management of Type 2 Diabetes Mellitus. , 2012, , 167-191.		0

#	ARTICLE	IF	CITATIONS
2281	The Study Of LoSmapiomod treatment on inflammation and InfarCtSize (SOLSTICE): Design and rationale. American Heart Journal, 2012, 164, 646-653.e3.	1.2	24
2282	Registry of Lipid Control and the Use of Lipid-lowering Drugs for Secondary Prevention of Cardiovascular Events in Patients with Established Atherosclerotic Disease in Taiwan: Rationality and Methods. International Journal of Gerontology, 2012, 6, 241-246.	0.7	13
2283	Cardiac Disease Evaluation and Management Among Kidney and Liver Transplantation Candidates. Journal of the American College of Cardiology, 2012, 60, 434-480.	1.2	328
2284	The differential effect of statins on oxidative stress and endothelial function: Atorvastatin versus pravastatin. Journal of Clinical Lipidology, 2012, 6, 42-49.	0.6	61
2285	Residual Plaque Burden in Patients With Acute Coronary Syndromes After Successful Percutaneous Coronary Intervention. JACC: Cardiovascular Imaging, 2012, 5, S76-S85.	2.3	40
2286	Effect of Si-Miao-Yong-An on the stability of atherosclerotic plaque in a diet-induced rabbit model. Journal of Ethnopharmacology, 2012, 143, 241-248.	2.0	27
2287	Meta-Analysis of Comparison of Effectiveness of Lowering Apolipoprotein B Versus Low-Density Lipoprotein Cholesterol and Nonhigh-Density Lipoprotein Cholesterol for Cardiovascular Risk Reduction in Randomized Trials. American Journal of Cardiology, 2012, 110, 1468-1476.	0.7	108
2288	Acute Coronary Syndrome in Patients with Diabetes Mellitus: Perspectives of an Interventional Cardiologist. American Journal of Cardiology, 2012, 110, 13B-23B.	0.7	15
2290	Pharmacologic Risk Mitigation ( $\beta$ -Blockers, Statins, $\beta$ -2-Agonists). Hospital Medicine Clinics, 2012, 1, e427-e442.	0.2	0
2291	Preoperative statin therapy for patients undergoing cardiac surgery. , 2012, , CD008493.		76
2292	Translating the effects of statins: From redox regulation to suppression of vascular wall inflammation. Thrombosis and Haemostasis, 2012, 108, 840-848.	1.8	61
2293	Dyslipidemias in the Prevention of Cardiovascular Disease: Risks and Causality. Current Cardiology Reports, 2012, 14, 709-720.	1.3	93
2294	Drugs Targeting High-Density Lipoprotein Cholesterol for Coronary Artery Disease Management. Canadian Journal of Cardiology, 2012, 28, 667-677.	0.8	6
2295	Low-dose atorvastatin reduces ambulatory blood pressure in patients with mild hypertension and hypercholesterolaemia: a double-blind, randomized, placebo-controlled study. Journal of Human Hypertension, 2012, 26, 577-584.	1.0	17
2297	Statin-Induced Muscle Toxicity. , 2012, , 945-954.		0
2299	Cardioprotection. , 2012, , 369-388.		1
2300	Achieving Secondary Prevention Low-Density Lipoprotein Particle Concentration Goals Using Lipoprotein Cholesterol-Based Data. PLoS ONE, 2012, 7, e33692.	1.1	20
2301	Cardiovascular Events in Patients Received Combined Fibrate/Statin Treatment versus Statin Monotherapy: Acute Coronary Syndrome Israeli Surveys Data. PLoS ONE, 2012, 7, e35298.	1.1	24

#	ARTICLE	IF	CITATIONS
2302	Relationship between Coronary Artery Disease and Non-HDL-C, and Effect of Highly Purified EPA on the Risk of Coronary Artery Disease in Hypercholesterolemic Patients Treated with Statins: Sub-Analysis of the Japan EPA Lipid Intervention Study (JELIS). <i>Journal of Atherosclerosis and Thrombosis</i> , 2012, 19, 194-204.	0.9	32
2303	Ezetimibe therapy: mechanism of action and clinical update. <i>Vascular Health and Risk Management</i> , 2012, 8, 415.	1.0	169
2304	Disorders of Lipid Metabolism. , 2012, , 1346-1354.		2
2305	Double-Blind Randomized Clinical Trial of the Effects of Ezetimibe on Postprandial Hyperlipidaemia and Hyperglycaemia. <i>Journal of Atherosclerosis and Thrombosis</i> , 2012, 19, 1093-1101.	0.9	33
2306	Lipoproteins Impact Increasing Cardiovascular Mortality. , 2012, , .		0
2307	Dyslipidemia and Cardiovascular Risk: Lipid Ratios as Risk Factors for Cardiovascular Disease. , 0, , .		9
2308	Payer Perspectives on Health Technology Assessment. <i>Journal of Managed Care Pharmacy</i> , 2012, 18, 265-267.	2.2	3
2309	Atherosclerosis: from biology to pharmacological treatment. <i>Journal of Geriatric Cardiology</i> , 2012, 9, 305-317.	0.2	46
2310	Dyslipidemia: evidence of efficacy of the pharmacological and non-pharmacological treatment in the elderly. <i>Journal of Geriatric Cardiology</i> , 2012, 9, 83-90.	0.2	4
2311	Inflammatory Targets for the Treatment of Atherosclerosis. <i>Annual Reports in Medicinal Chemistry</i> , 2012, 47, 223-235.	0.5	0
2312	The impact of initial statin treatment decisions on cardiovascular outcomes in clinical care settings: estimates using the Archimedes Model. <i>ClinicoEconomics and Outcomes Research</i> , 2012, 4, 337.	0.7	11
2313	Acute Coronary Syndrome. , 2012, , 425-434.		0
2314	Statins as Anti-Inflammatory Agents in Atherogenesis: Molecular Mechanisms and Lessons from the Recent Clinical Trials. <i>Current Pharmaceutical Design</i> , 2012, 18, 1519-1530.	0.9	349
2315	New Insights into the Assembly and Metabolism of ApoB-Containing Lipoproteins from in vivo Kinetic Studies: Results on Healthy Subjects and Patients with Chronic Kidney Disease. , 2012, , .		0
2316	Physician Perspectives on Comparative Effectiveness Research: Implications for Practice-based Evidence. <i>Global Advances in Health and Medicine</i> , 2012, 1, 32-36.	0.7	6
2317	Serum Lipid Profile status of Type 2 Diabetic Patients in the cross section population in Dhaka City of Bangladesh. <i>Bangladesh Journal of Medical Science</i> , 2012, 11, 121-125.	0.1	3
2318	The impact of statin therapy on long-term cardiovascular outcomes in an outpatient cardiology practice. <i>Archives of Medical Science</i> , 2012, 1, 53-56.	0.4	10
2319	Statins: Is There an Increased Risk of Diabetes?. <i>Hospital Pharmacy</i> , 2012, 47, 513-517.	0.4	1

#	ARTICLE	IF	CITATIONS
2320	Reduction in atherosclerotic events: a retrospective study in an outpatient cardiology practice. Archives of Medical Science, 2012, 1, 57-62.	0.4	18
2321	Dual role of lipoproteins in endothelial cell dysfunction in atherosclerosis. Cell and Tissue Research, 2012, 349, 433-446.	1.5	78
2322	A Tale of Coronary Artery Disease and Myocardial Infarction. New England Journal of Medicine, 2012, 366, 54-63.	13.9	815
2323	Dietary oats and modulation of atherogenic pathways. Molecular Nutrition and Food Research, 2012, 56, 1003-1013.	1.5	35
2324	Role of disease risk scores in comparative effectiveness research with emerging therapies. Pharmacoepidemiology and Drug Safety, 2012, 21, 138-147.	0.9	87
2325	Medical Management of Peripheral Arterial Disease. Circulation, 2012, 126, 1319-1321.	1.6	11
2326	Simultaneous determination of simvastatin, lovastatin and niacin in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. Biomedical Chromatography, 2012, 26, 476-484.	0.8	16
2327	Simultaneous determination of atorvastatin and niacin in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. Biomedical Chromatography, 2012, 26, 1436-1443.	0.8	12
2328	Intensive statin therapy for Chinese patients with coronary artery disease undergoing percutaneous coronary intervention (ISCAP study). Catheterization and Cardiovascular Interventions, 2012, 79, 967-971.	0.7	8
2329	2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: Executive Summary. Catheterization and Cardiovascular Interventions, 2012, 79, 453-495.	0.7	157
2330	Early statin treatment prior to primary PCI for acute myocardial infarction: REPERATOR, a randomized placebo-controlled pilot trial. Catheterization and Cardiovascular Interventions, 2012, 80, 756-765.	0.7	43
2331	Threshold Level of Low-Density Lipoprotein Cholesterol for the Short-Term Benefit of Statin Therapy in the Acute Phase of Myocardial Infarction. Clinical Cardiology, 2012, 35, 211-218.	0.7	4
2332	Individualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutions. Pharmacogenomics, 2012, 13, 579-594.	0.6	57
2333	LDL cholesterol targets – how low to go?. Current Opinion in Lipidology, 2012, 23, 265-270.	1.2	6
2334	Elevated concentration of placental growth factor (PIGF) and long term risk in patients with acute coronary syndrome in the PROVE IT-TIMI 22 trial. Journal of Thrombosis and Thrombolysis, 2012, 34, 222-228.	1.0	12
2335	The Role of Non-HDL Cholesterol in Risk Stratification for Coronary Artery Disease. Current Atherosclerosis Reports, 2012, 14, 130-134.	2.0	56
2336	The Role of Intravascular Ultrasound in the Determination of Progression and Regression of Coronary Artery Disease. Current Atherosclerosis Reports, 2012, 14, 175-185.	2.0	10
2338	Prospective, randomized, single-blind comparison of effects of 6-months' treatment with atorvastatin versus pravastatin on leptin and angiogenic factors in patients with coronary artery disease. Heart and Vessels, 2012, 27, 337-343.	0.5	32



#	ARTICLE	IF	CITATIONS
2339	Toll-like receptor 7 stimulation by imiquimod induces macrophage autophagy and inflammation in atherosclerotic plaques. <i>Basic Research in Cardiology</i> , 2012, 107, 269.	2.5	54
2340	Effects of combining simvastatin with rosiglitazone on inflammation, oxidant stress and ambulatory blood pressure in patients with the metabolic syndrome: the SIROCO study. <i>Diabetes, Obesity and Metabolism</i> , 2012, 14, 181-186.	2.2	18
2341	Simvastatin impairs ADP-stimulated respiration and increases mitochondrial oxidative stress in primary human skeletal myotubes. <i>Free Radical Biology and Medicine</i> , 2012, 52, 198-207.	1.3	104
2342	Frequency of Intensive Statin Therapy in Patients With Acute Coronary Syndrome Admitted to a Tertiary Care Center. <i>American Journal of Cardiology</i> , 2012, 109, 1-5.	0.7	8
2343	Comparison of Lipid-Modifying Efficacy of Rosuvastatin Versus Atorvastatin in Patients With Acute Coronary Syndrome (from the LUNAR Study). <i>American Journal of Cardiology</i> , 2012, 109, 1239-1246.	0.7	49
2344	Temporal Patterns of Lipid Testing and Statin Therapy in Acute Coronary Syndrome Patients (from the) Tj ETQq1 1 0.784314 rgBT /Over 0.7 18	0.7	18
2345	Modern Management of Acute Myocardial Infarction. <i>Current Problems in Cardiology</i> , 2012, 37, 237-310.	1.1	14
2346	SAR studies on the central phenyl ring of substituted biphenyl oxazolidinone-potent CETP inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 199-203.	1.0	9
2347	Predictors of Statin-Induced Regression of Left Anterior Descending Coronary Artery Wall Thickness as Measured by High-Resolution Transthoracic Echocardiography. <i>Echocardiography</i> , 2012, 29, 641-646.	0.3	2
2348	Optimal lipid targets for the new era of cardiovascular prevention. <i>Annals of the New York Academy of Sciences</i> , 2012, 1254, 106-114.	1.8	3
2349	LDL-cholesterol versus HDL-cholesterol in the atherosclerotic plaque: inflammatory resolution versus thrombotic chaos. <i>Annals of the New York Academy of Sciences</i> , 2012, 1254, 18-32.	1.8	138
2350	2011 ACCF/AHA guideline for coronary artery bypass graft surgery: Executive summary. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2012, 143, 4-34.	0.4	227
2351	Lack of a meaningful effect of anacetrapib on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2012, 74, 116-124.	1.1	8
2352	Residual Cardiovascular Risk Despite Optimal LDL Cholesterol Reduction with Statins: The Evidence, Etiology, and Therapeutic Challenges. <i>Current Atherosclerosis Reports</i> , 2012, 14, 1-10.	2.0	304
2353	Routine Invasive Versus Conservative Management Strategies in Acute Coronary Syndrome: Time for a "Hybrid" Approach. <i>Journal of Cardiovascular Translational Research</i> , 2012, 5, 30-40.	1.1	4
2354	Lipophilic versus hydrophilic statin therapy for heart failure: a protocol for an adjusted indirect comparison meta-analysis. <i>Systematic Reviews</i> , 2013, 2, 22.	2.5	21
2355	2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: Executive Summary. <i>Journal of the American College of Cardiology</i> , 2013, 61, 485-510.	1.2	905
2356	Protocolo terapéutico hospitalario del infarto de miocardio. <i>Medicine</i> , 2013, 11, 2275-2278.	0.0	0

#	ARTICLE	IF	CITATIONS
2357	Impact of post-challenge hyperglycemia on clinical outcomes in Japanese patients with stable angina undergoing percutaneous coronary intervention. <i>Cardiovascular Diabetology</i> , 2013, 12, 74.	2.7	24
2358	Accounting for Clinical Action Reduces Estimates of Gender Disparities in Lipid Management for Diabetic Veterans. <i>Journal of General Internal Medicine</i> , 2013, 28, 529-535.	1.3	29
2359	Defining the Role of High-Dose Statins in PCI. <i>American Journal of Cardiovascular Drugs</i> , 2013, 13, 189-197.	1.0	4
2360	GPR109A and Vascular Inflammation. <i>Current Atherosclerosis Reports</i> , 2013, 15, 325.	2.0	55
2361	Prospective Validation that Vulnerable Plaque Associated with Major Adverse Outcomes Have Larger Plaque Volume, Less Dense Calcium, and More Non-Calcified Plaque by Quantitative, Three-Dimensional Measurements Using Intravascular Ultrasound with Radiofrequency Backscatter Analysis. <i>Journal of Cardiovascular Translational Research</i> , 2013, 6, 762-771.	1.1	15
2362	CYP-Mediated Pharmacologic Interference with Optimal Platelet Inhibition. <i>Journal of Cardiovascular Translational Research</i> , 2013, 6, 404-410.	1.1	6
2363	Targeting the Unstable Plaque in Acute Coronary Syndromes. <i>Clinical Therapeutics</i> , 2013, 35, 1099-1107.	1.1	20
2364	Aggressive Statin Therapy and the Risk of Malignancy. <i>Current Atherosclerosis Reports</i> , 2013, 15, 316.	2.0	2
2365	Statin therapy in patients with atypical chest pain and mild-to-moderate coronary stenosis on 64-slice multidetector coronary computed tomography; a retrospective propensity score matching analysis. <i>European Radiology</i> , 2013, 23, 2954-2960.	2.3	2
2366	Urinary albumin concentration and long-term cardiovascular risk in acute coronary syndrome patients: a PROVE IT-TIMI 22 substudy. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 36, 233-239.	1.0	11
2367	LDL Cholesterol Goals in High-Risk Patients: How Low Do We Go and How Do We Get There?. <i>Drugs</i> , 2013, 73, 293-301.	4.9	20
2368	Dyslipidemia in Type 2 Diabetes: Prevalence, Pathophysiology, and Management. <i>Drugs</i> , 2013, 73, 327-339.	4.9	190
2369	Review of the Cost Effectiveness of Pharmacogenetic-Guided Treatment of Hypercholesterolaemia. <i>Pharmacoeconomics</i> , 2013, 31, 377-391.	1.7	15
2371	Intensification of Statin Therapy Results in a Rapid Reduction in Atherosclerotic Inflammation. <i>Journal of the American College of Cardiology</i> , 2013, 62, 909-917.	1.2	364
2372	Prevençã³n secundaria en el paciente coronario. <i>EMC - Tratado De Medicina</i> , 2013, 17, 1-8.	0.0	0
2373	Changes in serum cholesterol levels determine future risk of cardiovascular events in patients with acute coronary syndrome in the Japanese Coronary Artery Disease (JCAD) Study. <i>Journal of Cardiology</i> , 2013, 61, 387-392.	0.8	4
2374	Should We Measure Quality by the Dose?. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1802-1803.	1.2	0
2375	Gender Difference in Statin Intervention on Blood Lipid Control among Patients with Coronary Heart Disease. <i>International Journal of Gerontology</i> , 2013, 7, 116-121.	0.7	6

#	ARTICLE	IF	CITATIONS
2376	Impact of intensive statin use on the level of inflammation and platelet activation in stable angina after percutaneous coronary intervention: A clinical study. <i>Medicina Clínica</i> , 2013, 140, 532-536.	0.3	14
2377	Prevalence and severity of coronary artery calcium in young persons with diabetes. <i>Journal of Cardiovascular Computed Tomography</i> , 2013, 7, 241-247.	0.7	9
2378	Risk for recurrent coronary heart disease and all-cause mortality among individuals with chronic kidney disease compared with diabetes mellitus, metabolic syndrome, and cigarette smokers. <i>American Heart Journal</i> , 2013, 166, 373-380.e2.	1.2	45
2379	Validating the benefits of lipid modifying therapies upon atherosclerotic plaque by computed tomography angiography: Should we trust our eyes? Commentary on the study of Zeb et al.. <i>Atherosclerosis</i> , 2013, 231, 189-190.	0.4	0
2380	Pleiotropic vascular protective effects of statins in perioperative medicine. <i>Acta Anaesthesiologica Taiwanica</i> , 2013, 51, 120-126.	1.0	17
2381	Protein Engineering for Cardiovascular Therapeutics. <i>Circulation Research</i> , 2013, 113, 933-943.	2.0	42
2382	Acute myocardial infarction leads to acceleration of atherosclerosis. <i>Atherosclerosis</i> , 2013, 229, 18-22.	0.4	21
2383	Assessment of Low-Density Lipoprotein Targets. <i>Angiology</i> , 2013, 64, 411-416.	0.8	11
2384	Statin-associated autoimmune myopathy and anti-HMGCR autoantibodies. <i>Muscle and Nerve</i> , 2013, 48, 477-483.	1.0	115
2385	Effects of Aggressive Statin Therapy on Patients With Coronary Saphenous Vein Bypass Grafts: A Systematic Review and Meta-Analysis of Randomized, Controlled Trials. <i>Clinical Therapeutics</i> , 2013, 35, 1125-1136.	1.1	21
2386	Low-Density Lipoprotein Cholesterol: How Low Can We Go?. <i>American Journal of Cardiovascular Drugs</i> , 2013, 13, 225-232.	1.0	10
2387	Are there differences in LDL-C target value attainment in Austrian federal states? Yes!. <i>Wiener Medizinische Wochenschrift</i> , 2013, 163, 528-535.	0.5	3
2388	First-line treatment patterns and lipid target levels attainment in very high cardiovascular risk outpatients. <i>Lipids in Health and Disease</i> , 2013, 12, 170.	1.2	12
2389	Cardiovascular risk and lipid management beyond statin therapy: the potential role of omega-3 polyunsaturated fatty acid ethyl esters. <i>Clinical Lipidology</i> , 2013, 8, 329-344.	0.4	5
2390	Comparison of pitavastatin with atorvastatin in increasing HDL-cholesterol and adiponectin in patients with dyslipidemia and coronary artery disease: The COMPACT-CAD study. <i>Journal of Cardiology</i> , 2013, 62, 87-94.	0.8	33
2391	Coronary Artery Disease. <i>Primary Care - Clinics in Office Practice</i> , 2013, 40, 1-16.	0.7	50
2392	High-Dose Atorvastatin Reduces Periodontal Inflammation. <i>Journal of the American College of Cardiology</i> , 2013, 62, 2382-2391.	1.2	103
2393	Cost Effectiveness of Targeted High-dose Atorvastatin Therapy Following Genotype Testing in Patients with Acute Coronary Syndrome. <i>Pharmacoeconomics</i> , 2013, 31, 519-531.	1.7	11

#	ARTICLE	IF	CITATIONS
2394	AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism. <i>Journal of Lipid Research</i> , 2013, 54, 134-151.	2.0	178
2395	Extended-release niacin/laropiprant for lipid management: observational study in clinical practice. <i>International Journal of Clinical Practice</i> , 2013, 67, 527-535.	0.8	2
2396	Current Ways of Treating Dyslipidemias to Prevent Atherosclerosis. <i>Therapeutic Apheresis and Dialysis</i> , 2013, 17, 125-129.	0.4	1
2397	Reduction in First and Recurrent Cardiovascular Events With Ticagrelor Compared With Clopidogrel in the PLATO Study. <i>Circulation</i> , 2013, 127, 673-680.	1.6	72
2398	Sympathetic Nervous System. <i>Circulation Research</i> , 2013, 112, 13-16.	2.0	4
2399	2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2013, 61, e78-e140.	1.2	2,612
2400	Non-ST-Segment Elevation Acute Coronary Syndromes. , 2013, , 153-177.		0
2401	Forbidden Fruit: On the Analysis of Recurrent Events in Randomized Clinical Trials. <i>American Journal of Cardiology</i> , 2013, 111, 1530-1536.	0.7	6
2402	Impact of statin dose on major cardiovascular events: A mixed treatment comparison meta-analysis involving more than 175,000 patients. <i>International Journal of Cardiology</i> , 2013, 166, 431-439.	0.8	31
2403	The safety of therapeutic monoclonal antibodies: Implications for cardiovascular disease and targeting the PCSK9 pathway. <i>Atherosclerosis</i> , 2013, 228, 18-28.	0.4	119
2404	2012 ACCF/AHA Focused Update Incorporated Into the ACCF/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2013, 61, e179-e347.	1.2	370
2405	Emerging Clinical Challenges in the Use of Statins. <i>American Journal of Medicine</i> , 2013, 126, 663-664.	0.6	3
2406	High-Potency Statins and Acute Kidney Injury-Associated Hospitalizations. <i>American Journal of Kidney Diseases</i> , 2013, 62, 877-879.	2.1	2
2407	Substituting non-HDL cholesterol with LDL as a guide for lipid-lowering therapy increases the number of patients with indication for therapy. <i>Atherosclerosis</i> , 2013, 226, 471-475.	0.4	17
2408	Prognostic significance of elevated lipoprotein(a) in coronary artery revascularization patients. <i>International Journal of Cardiology</i> , 2013, 167, 1990-1994.	0.8	17
2409	Effects of pravastatin on serum adiponectin levels in female patients with type 2 diabetes mellitus. <i>Atherosclerosis</i> , 2013, 227, 355-359.	0.4	12
2410	Effects of the simultaneous use of drug-eluting stents and statins in an atherosclerotic animal model. <i>Clínica e Investigação em Arteriosclerosis</i> , 2013, 25, 16-24.	0.4	0
2411	The prognostic value of very low admission LDL-cholesterol levels in ST-segment elevation myocardial infarction compared in statin-pretreated and statin-naïve patients undergoing primary percutaneous coronary intervention. <i>International Journal of Cardiology</i> , 2013, 167, 458-463.	0.8	20

#	ARTICLE	IF	CITATIONS
2412	A combination of increased Rho kinase activity and N-terminal pro-B-type natriuretic peptide predicts worse cardiovascular outcome in patients with acute coronary syndrome. <i>International Journal of Cardiology</i> , 2013, 167, 2813-2819.	0.8	16
2413	The lipid-lowering effect of atorvastatin in Taiwanese diabetic patients with hyperlipidemia. <i>Tzu Chi Medical Journal</i> , 2013, 25, 168-174.	0.4	0
2414	Low Levels of High-Density Lipoprotein Cholesterol and Increased Risk of Cardiovascular Events in Stable Ischemic Heart Disease Patients. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1826-1833.	1.2	84
2415	Effect of Intensive Versus Moderate Lipid-Lowering Therapy on Epicardial Adipose Tissue in Hyperlipidemic Post-Menopausal Women. <i>Journal of the American College of Cardiology</i> , 2013, 61, 1956-1961.	1.2	142
2416	The Current State of Niacin in Cardiovascular Disease Prevention. <i>Journal of the American College of Cardiology</i> , 2013, 61, 440-446.	1.2	168
2417	Beyond Medication Prescription as Performance Measures. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1791-1801.	1.2	102
2418	Relationship between low-density lipoprotein levels on admission and 1-year outcome in patients with acute ST-segment-elevation myocardial infarction. <i>Kaohsiung Journal of Medical Sciences</i> , 2013, 29, 206-213.	0.8	4
2420	A Simple Mnemonic for the Acute and Continued Medical Treatment of ST-elevation Myocardial Infarctions. <i>Journal of Emergency Medicine</i> , 2013, 45, 258-259.	0.3	1
2421	Effect of lipid-modifying drug therapy on survival after abdominal aortic aneurysm repair. <i>Journal of Vascular Surgery</i> , 2013, 58, 355-363.	0.6	15
2422	Traitement hypolipidémiant en prévention secondaire. <i>Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique</i> , 2013, 2013, 17-24.	0.0	0
2423	Fat lowers fat: Purified phospholipids as emerging therapies for dyslipidemia. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2013, 1831, 887-893.	1.2	33
2424	Statin Treatment Improves Plasma Lipid Levels but not HDL Subclass Distribution in Patients Undergoing Percutaneous Coronary Intervention. <i>Lipids</i> , 2013, 48, 127-137.	0.7	6
2425	Does it Make Sense to Combine Statins with Other Lipid-Altering Agents Following AIM-HIGH, SHARP and ACCORD?. <i>Current Atherosclerosis Reports</i> , 2013, 15, 290.	2.0	3
2426	Is Atherosclerosis Regression a Realistic Goal of Statin Therapy and What Does That Mean?. <i>Current Atherosclerosis Reports</i> , 2013, 15, 294.	2.0	20
2427	Is the Future of Statins Aligned with New Novel Lipid Modulation Therapies?. <i>Current Atherosclerosis Reports</i> , 2013, 15, 300.	2.0	5
2428	LDL Lowering After Acute Coronary Syndrome: Is Lower Better?. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2013, 15, 33-40.	0.4	6
2429	Medical emergencies: atrial fibrillation and myocardial infarction. <i>Anaesthesia</i> , 2013, 68, 84-101.	1.8	8
2430	Meta-Analysis of Impact of Different Types and Doses of Statins on New-Onset Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2013, 111, 1123-1130.	0.7	239

#	ARTICLE	IF	CITATIONS
2431	Safety and Effect of Very Low Levels of Low-Density Lipoprotein Cholesterol on Cardiovascular Events. <i>American Journal of Cardiology</i> , 2013, 111, 1221-1229.	0.7	35
2432	Primary prevention with statins and incident diabetes in hypertensive patients at high cardiovascular risk. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2013, 23, 1101-1106.	1.1	16
2433	Exploring the Ticagrelor-Statin Interplay in the PLATO Trial. <i>Cardiology</i> , 2013, 124, 105-107.	0.6	17
2434	Reduction of platelet cytosolic phospholipase A2 activity by atorvastatin and simvastatin: Biochemical regulatory mechanisms. <i>Thrombosis Research</i> , 2013, 131, e154-e159.	0.8	30
2435	Beyond Statins: Lipid Management to Reduce Cardiovascular Risk. <i>Pharmacotherapy</i> , 2013, 33, 754-764.	1.2	13
2436	Pharmacokinetic interaction studies of co-administration of ticagrelor and atorvastatin or simvastatin in healthy volunteers. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 477-487.	0.8	52
2437	2012 Update of the Canadian Cardiovascular Society Guidelines for the Diagnosis and Treatment of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. <i>Canadian Journal of Cardiology</i> , 2013, 29, 151-167.	0.8	680
2438	Standards of Medical Care in Diabetes—2013. <i>Diabetes Care</i> , 2013, 36, S11-S66.	4.3	3,076
2439	A Reappraisal of the Risks and Benefits of Treating to Target with Cholesterol Lowering Drugs. <i>Drugs</i> , 2013, 73, 1025-1054.	4.9	30
2440	Emerging anti-inflammatory drugs for atherosclerosis. <i>Expert Opinion on Emerging Drugs</i> , 2013, 18, 193-205.	1.0	30
2441	HDL particle functionality as a primary pharmacological target for HDL-based therapies. <i>Biochemical Pharmacology</i> , 2013, 85, 1575-1578.	2.0	27
2442	A systematic review of economic evaluations of the detection and treatment of familial hypercholesterolemia. <i>International Journal of Cardiology</i> , 2013, 167, 2391-2396.	0.8	62
2443	Risk Factors and Prevention, Including Hyperlipidemia. , 2013, , 405-418.		0
2444	Stable Angina. , 2013, , 419-438.		0
2445	Unstable Angina and Non-ST Segment Elevation Myocardial Infarction (Acute Coronary Syndromes). , 2013, , 439-457.		0
2446	Rosuvastatin calcium in acute coronary syndromes. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 1215-1227.	0.9	17
2447	When Choosing Statin Therapy. <i>JAMA Internal Medicine</i> , 2013, 173, 229.	2.6	20
2448	Cardiovascular event rates in atorvastatin patients versus patients switching from atorvastatin to simvastatin. <i>Current Medical Research and Opinion</i> , 2013, 29, 773-781.	0.9	2

#	ARTICLE	IF	CITATIONS
2449	Modifiable factors associated with failure to attain low-density lipoprotein cholesterol goal at 6 months after acute myocardial infarction. <i>American Heart Journal</i> , 2013, 165, 26-33.e3.	1.2	25
2451	An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia. <i>Journal of Clinical Lipidology</i> , 2013, 7, 561-565.	0.6	147
2452	Safety and Efficacy of Statins in Patients With End-Stage Renal Disease. <i>Annals of Pharmacotherapy</i> , 2013, 47, 1321-1329.	0.9	10
2453	Comparative study of high-dose Xuezhikang and low-dose Xuezhikang plus ezetimibe on pro- and anti-inflammatory markers. <i>Clinical Lipidology</i> , 2013, 8, 151-157.	0.4	2
2454	Lipid management: maximising reduction of cardiac risk. <i>Clinical Medicine</i> , 2013, 13, 618-620.	0.8	3
2455	Statins in the treatment of asthma. <i>American Journal of Health-System Pharmacy</i> , 2013, 70, 1661-1669.	0.5	8
2456	Factors underlying regression of coronary atheroma with potent statin therapy. <i>European Heart Journal</i> , 2013, 34, 1818-1825.	1.0	61
2457	Incidence of Musculoskeletal and Neoplastic Diseases in Patients on Statin Therapy: Results of a Retrospective Cohort Analysis. <i>American Journal of the Medical Sciences</i> , 2013, 345, 343-348.	0.4	21
2458	Subclinical Carotid Atherosclerosis: Short-term Natural History of Lipid-rich Necrotic Core in a Multicenter Study with MR Imaging. <i>Radiology</i> , 2013, 268, 61-68.	3.6	59
2459	Lipoprotein(a): epidemiology, atherogenic activity and impact on cardiovascular risk. <i>Clinical Lipidology</i> , 2013, 8, 195-203.	0.4	2
2460	Problems and Possible Solutions for Therapy with Statins. <i>International Journal of Angiology</i> , 2013, 22, 075-082.	0.2	12
2461	Coronary atheroma volume and cardiovascular events during maximally intensive statin therapy. <i>European Heart Journal</i> , 2013, 34, 3182-3190.	1.0	86
2462	2012 ACCF/AHA Focused Update Incorporated Into the ACCF/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction. <i>Circulation</i> , 2013, 127, e663-828.	1.6	219
2463	Diabetes Mellitus and Cardiovascular Events in Older Patients With Myocardial Infarction Prescribed Intensive-Dose and Moderate-Dose Statins. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2013, 6, 315-322.	0.9	37
2464	Implication of Low HDL-c Levels in Patients with Average LDL-c Levels: A Focus on Oxidized LDL, Large HDL Subpopulation, and Adiponectin. <i>Mediators of Inflammation</i> , 2013, 2013, 1-12.	1.4	21
2465	Lipoprotein(a): A Promising Marker for Residual Cardiovascular Risk Assessment. <i>Disease Markers</i> , 2013, 35, 551-559.	0.6	39
2466	The Importance of Functional Tests in Personalized Medicine. <i>Rambam Maimonides Medical Journal</i> , 2013, 4, e0014.	0.4	1
2467	Journey in guidelines for lipid management: From adult treatment panel (ATP)-I to ATP-III and what to expect in ATP-IV. <i>Indian Journal of Endocrinology and Metabolism</i> , 2013, 17, 628.	0.2	25

#	ARTICLE	IF	CITATIONS
2468	Baseline LDL-C and Lp(a) Elevations Portend a High Risk of Coronary Revascularization in Patients after Stent Placement. <i>Disease Markers</i> , 2013, 35, 857-862.	0.6	20
2469	Safety of statins. <i>Indian Journal of Endocrinology and Metabolism</i> , 2013, 17, 636.	0.2	70
2470	Venous Thrombosis Associated with HMG-CoA Reductase Inhibitors. <i>Seminars in Thrombosis and Hemostasis</i> , 2013, 39, 515-532.	1.5	36
2471	Effects of Atorvastatin on Systemic and Renal Nitric Oxide in Healthy Man. <i>Clinical and Experimental Hypertension</i> , 2013, 35, 148-157.	0.5	7
2472	The Effect of Sodium Tanshinone IIA Sulfate and Simvastatin on Elevated Serum Levels of Inflammatory Markers in Patients with Coronary Heart Disease: A Study Protocol for a Randomized Controlled Trial. <i>Evidence-based Complementary and Alternative Medicine</i> , 2013, 2013, 1-8.	0.5	28
2473	Recent clinical trials evaluating benefit of drug therapy for modification of HDL cholesterol. <i>Current Opinion in Cardiology</i> , 2013, 28, 389-398.	0.8	34
2474	Lipoprotein Kinetics in Male Hemodialysis Patients Treated with Atorvastatin. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 1319-1326.	2.2	2
2475	Statins and beyond: Concurrent strategies for prevention of cardiovascular disease in patients with type 2 diabetes. <i>Diabetes and Vascular Disease Research</i> , 2013, 10, 99-114.	0.9	7
2476	Importance of high-density lipoprotein quality. <i>Current Opinion in Nephrology and Hypertension</i> , 2013, 22, 259-265.	1.0	14
2477	The Need for a Systematic Approach to Statin Switching. <i>Journal of Cardiovascular Nursing</i> , 2013, 28, 565-572.	0.6	4
2478	Should $\beta$ -blockers still be routine after myocardial infarction?. <i>Current Opinion in Cardiology</i> , 2013, 28, 399-404.	0.8	8
2479	Stabilization of atherosclerotic plaques: an update. <i>European Heart Journal</i> , 2013, 34, 3251-3258.	1.0	101
2480	Increasing Doses of Simvastatin Versus Combined Ezetimibe/Simvastatin. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2013, 18, 447-452.	1.0	9
2481	Assessing Appropriateness of Lipid Management Among Patients With Diabetes Mellitus. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2013, 6, 66-74.	0.9	24
2482	The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol. <i>Drug Design, Development and Therapy</i> , 2013, 7, 1135.	2.0	40
2483	Stable Ischemic Heart Disease/Chronic Stable Angina. , 2013, , 131-152.		0
2484	ST-Segment Elevation Myocardial Infarction. , 2013, , 178-213.		3
2485	Drugs for Elevated Low-Density Lipoprotein Cholesterol. , 2013, , 421-433.		0



#	ARTICLE	IF	CITATIONS
2486	Effect of intensive statin therapy on regression of carotid intima-media thickness in patients with subclinical carotid atherosclerosis (a prospective, randomized trial: PEACE (Pitavastatin Evaluation) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50 of Preventive Cardiology, 2013, 20, 1069-1079.	0.8	21
2487	A review of statin use in patients with acute coronary syndrome in Western and Japanese populations. Journal of International Medical Research, 2013, 41, 523-536.	0.4	13
2488	Effects of Statins on Serum n-3 to n-6 Polyunsaturated Fatty Acid Ratios in Patients With Coronary Artery Disease. Journal of Cardiovascular Pharmacology and Therapeutics, 2013, 18, 320-326.	1.0	12
2489	2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: Executive Summary. Circulation, 2013, 127, 529-555.	1.6	2,051
2490	2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. Circulation, 2013, 127, e362-425.	1.6	2,639
2491	Results From a Carotid Intima-Media Thickness Trial as a Decision Tool for Launching a Large-Scale Morbidity and Mortality Trial. Circulation: Cardiovascular Imaging, 2013, 6, 20-25.	1.3	23
2492	The Chain of Survival for ST-Segment Elevation Myocardial Infarction. Critical Pathways in Cardiology, 2013, 12, 154-160.	0.2	1
2493	Time course of statin-induced changes in coronary atherosclerosis using intravascular ultrasound with virtual histology. Coronary Artery Disease, 2013, 24, 481-486.	0.3	7
2494	Chlamydia pneumoniae Infection in Atherosclerotic Lesion Development through Oxidative Stress: A Brief Overview. International Journal of Molecular Sciences, 2013, 14, 15105-15120.	1.8	35
2495	A comparative study of efficacy of atorvastatin alone and its combination with fenofibrate on lipid profile in type 2 diabetes mellitus patients with hyperlipidemia. Journal of Advanced Pharmaceutical Technology and Research, 2013, 4, 166.	0.4	11
2496	Impact of Treatment With Statins on Prostate-Specific Antigen and Prostate Volume in Patients With Benign Prostatic Hyperplasia. Korean Journal of Urology, 2013, 54, 750.	1.2	15
2497	Lipid Goal Attainment and Prescription Behavior in Asian Patients with Acute Coronary Syndromes: Experience from a Tertiary Hospital. Clinical Medicine Insights: Cardiology, 2013, 7, CMC.S11488.	0.6	15
2498	Association of Medicare Part D Medication Out-of-Pocket Costs with Utilization of Statin Medications. Health Services Research, 2013, 48, 1311-1333.	1.0	15
2499	Implementation of standardized assessment and reporting of myocardial infarction in contemporary randomized controlled trials: a systematic review. European Heart Journal, 2013, 34, 894-902.	1.0	21
2500	Management of Cardiovascular Disease Risk Factors in Older Adults with Type 2 Diabetes Mellitus: 2002-2012 Literature Review. Journal of the American Geriatrics Society, 2013, 61, 2027-2037.	1.3	56
2501	Effects of patient-tailored atorvastatin therapy on ameliorating the levels of atherogenic lipids and inflammation beyond lowering low-density lipoprotein cholesterol in patients with type 2 diabetes. Journal of Diabetes Investigation, 2013, 4, 466-474.	1.1	10
2502	Effectiveness of a Pharmacy Care Management Program for Veterans with Dyslipidemia. Pharmacotherapy, 2013, 33, 736-743.	1.2	18
2503	Management of the patient with diabetes and coronary artery disease: a contemporary review. Future Cardiology, 2013, 9, 387-403.	0.5	8

#	ARTICLE	IF	CITATIONS
2504	Comparative Tolerability and Harms of Individual Statins. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2013, 6, 390-399.	0.9	236
2505	2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>Catheterization and Cardiovascular Interventions</i> , 2013, 82, E1-27.	0.7	368
2506	A Clinician's Guide to the <scp>ABCs</scp> of Cardiovascular Disease Prevention: The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease and American College of Cardiology Cardiosource Approach to the Million Hearts Initiative. <i>Clinical Cardiology</i> , 2013, 36, 383-393.	0.7	45
2507	C-Reactive Protein, but not Low-Density Lipoprotein Cholesterol Levels, Associate With Coronary Atheroma Regression and Cardiovascular Events After Maximally Intensive Statin Therapy. <i>Circulation</i> , 2013, 128, 2395-2403.	1.6	109
2508	High-Dose Statin Therapy in Patients With Stable Coronary Artery Disease. <i>Circulation</i> , 2013, 127, 2485-2493.	1.6	38
2509	The Role of Statins in Diabetes Treatment. <i>Diabetes Spectrum</i> , 2013, 26, 156-164.	0.4	8
2510	Intensive-Dose Atorvastatin Regimen Halts Progression of Atherosclerotic Plaques in New-onset Unstable Angina With Borderline Vulnerable Plaque Lesions. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2013, 18, 119-125.	1.0	10
2511	Therapeutic Approaches to the Regulation of Metabolism of High-Density Lipoprotein. <i>Circulation Journal</i> , 2013, 77, 2651-2663.	0.7	31
2512	Differences in Action of Atorvastatin and Ezetimibe in Lowering Low-Density Lipoprotein Cholesterol and Effect on Endothelial Function. <i>Circulation Journal</i> , 2013, 77, 1791-1798.	0.7	22
2513	Association Between Serum Levels of n-3 Polyunsaturated Fatty Acids and Coronary Plaque Detected by Coronary Computed Tomography Angiography in Patients Receiving Statin Therapy. <i>Circulation Journal</i> , 2013, 77, 2578-2585.	0.7	17
2514	Lack of Goal Attainment Regarding the Low-density Lipoprotein Cholesterol Level in the Management of Type 2 Diabetes Mellitus. <i>Internal Medicine</i> , 2013, 52, 2409-2415.	0.3	4
2515	A Simple Method for Increasing Levels of High-Density Lipoprotein Cholesterol: A Pilot Study of Combination Aerobic- and Resistance-Exercise Training. <i>International Journal of Sport Nutrition and Exercise Metabolism</i> , 2013, 23, 271-281.	1.0	23
2516	Cholesterol Levels and the Association of Statins With In-Hospital Mortality of Myocardial Infarction Patients Insights From a Chilean Registry of Myocardial Infarction. <i>Clinical Cardiology</i> , 2013, 36, 305-311.	0.7	3
2517	C-reactive protein and its role in coronary artery disease. <i>British Journal of Cardiac Nursing</i> , 2013, 8, 193-197.	0.0	0
2519	Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes. <i>Vascular Health and Risk Management</i> , 2013, 9, 617.	1.0	71
2520	Contemporary Management and Attainment of Cholesterol Targets for Patients with Dyslipidemia in China. <i>PLoS ONE</i> , 2013, 8, e47681.	1.1	22
2522	Does Combination Therapy with Statins and Fibrates Prevent Cardiovascular Disease in Diabetic Patients with Atherogenic Mixed Dyslipidemia?. <i>Review of Diabetic Studies</i> , 2013, 10, 171-190.	0.5	31
2523	State of the art paper Treatment of non-ST-elevation myocardial infarction and ST-elevation myocardial infarction in patients with chronic kidney disease. <i>Archives of Medical Science</i> , 2013, 6, 1019-1027.	0.4	25

#	ARTICLE	IF	CITATIONS
2524	Management of dyslipidemia and hyperglycemia with a fixed-dose combination of sitagliptin and simvastatin. <i>Vascular Health and Risk Management</i> , 2013, 9, 273.	1.0	7
2525	Treatment of lipid disorders: targets and thresholds. <i>Italian Journal of Medicine</i> , 2013, , 75-77.	0.2	0
2526	Provider Compliance With Guidelines for Management of Cardiovascular Risk in HIV-Infected Patients. <i>Preventing Chronic Disease</i> , 2013, 10, E10.	1.7	42
2527	Early Differential Changes in Coronary Plaque Composition According to Plaque Stability Following Statin Initiation in Acute Coronary Syndrome: Classification and Analysis by Intravascular Ultrasound-Virtual Histology. <i>Yonsei Medical Journal</i> , 2013, 54, 336.	0.9	18
2528	Postoperative Care and Follow-Up After Coronary Stenting. <i>Deutsches A&amp;#x0308;rztblatt International</i> , 2013, 110, 72-81; quiz 82.	0.6	14
2529	Statins in heart failure: do we need another trial?. <i>Vascular Health and Risk Management</i> , 2013, 9, 303.	1.0	25
2530	Effects of the <i>Cynanchum wilfordii</i> Ethanol Extract on the Serum Lipid Profile in Hypercholesterolemic Rats. <i>Preventive Nutrition and Food Science</i> , 2013, 18, 157-162.	0.7	25
2531	Trends in Low-Density Lipoprotein Cholesterol Goal Achievement in High Risk United States Adults: Longitudinal Findings from the 1999â€“2008 National Health and Nutrition Examination Surveys. <i>PLoS ONE</i> , 2013, 8, e59309.	1.1	17
2532	Xanthine Oxidase Inhibitor Febuxostat as a Novel Agent Postulated to Act Against Vascular Inflammation. <i>Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry</i> , 2013, 12, 94-99.	1.1	43
2533	Role of Statins in Coronary Artery Disease. <i>Chonnam Medical Journal</i> , 2013, 49, 1.	0.5	30
2534	Emergent Biomarkers of Residual Cardiovascular Risk in Patients with Low HDL-c and/or High Triglycerides and Average LDL-c Concentrations: Focus on HDL Subpopulations, Oxidized LDL, Adiponectin, and Uric Acid. <i>Scientific World Journal, The</i> , 2013, 2013, 1-16.	0.8	7
2535	Lipoprotein-Associated Phospholipase A2 (Lp-PLA <sub>2</sub> ): A Novel and Promising Biomarker for Cardiovascular Risks Assessment. <i>Disease Markers</i> , 2013, 34, 323-331.	0.6	48
2536	STATINS AND THE RISK OF DIABETES MELLITUS. <i>Rational Pharmacotherapy in Cardiology</i> , 2013, 9, 444-447.	0.3	3
2537	Calpain and Atherosclerosis. <i>Journal of Atherosclerosis and Thrombosis</i> , 2013, 20, 228-237.	0.9	37
2538	REAL PRACTICE OF STATINS USE AND ITS DEPENDENCE ON FOLLOW-UP IN THE SPECIALIZED MEDICAL CENTRE IN PATIENTS WITH HIGH CARDIOVASCULAR RISK (ACCORDING TO THE PROFILE REGISTER). <i>Rational Pharmacotherapy in Cardiology</i> , 2013, 9, 362-367.	0.3	8
2539	Anacetrapib: potential for the prevention and treatment of coronary heart disease. <i>Research Reports in Clinical Cardiology</i> , 2013, , 39.	0.2	0
2540	NORVASCÂ® IN RUSSIA 20 YEARS LATER: CONTINUATION OF THE HISTORY. <i>Rational Pharmacotherapy in Cardiology</i> , 2013, 9, 448-454.	0.3	0
2541	STATIN THERAPY IN THE MANAGEMENT OF DIABETES MELLITUS; HOW RELEVANT?. <i>American Medical Journal</i> , 2013, 4, 36-42.	1.0	1

#	ARTICLE	IF	CITATIONS
2542	STATINS IN PREVENTION OF ISCHEMIC STROKE. Rational Pharmacotherapy in Cardiology, 2013, 9, 409-416.	0.3	1
2543	Coronary Artery Disease. Journal of Atherosclerosis and Thrombosis, 2014, 21, 86-92.	0.9	11
2544	Suppressive Effects of Standard-dose Rosuvastatin Therapy on the Progression of Coronary Atherosclerosis in Japanese Patients: The APOLLO Study. Journal of Atherosclerosis and Thrombosis, 2014, 21, 1298-1307.	0.9	3
2545	Statin Discontinuation after Achieving a Target Low Density Lipoprotein Cholesterol Level in Type 2 Diabetic Patients without Cardiovascular Disease: A Randomized Controlled Study. Diabetes and Metabolism Journal, 2014, 38, 64.	1.8	17
2546	Inpatient Coronary Angiography and Revascularisation following Non-ST-Elevation Acute Coronary Syndrome in Patients with Renal Impairment: A Cohort Study Using the Myocardial Ischaemia National Audit Project. PLoS ONE, 2014, 9, e99925.	1.1	14
2547	All-Cause Mortality in Patients with Type 2 Diabetes in Association with Achieved Hemoglobin A1c, Systolic Blood Pressure, and Low-Density Lipoprotein Cholesterol Levels. PLoS ONE, 2014, 9, e109501.	1.1	18
2548	Management of acute coronary syndrome in special subgroups: female, older, diabetic and Indigenous patients. Medical Journal of Australia, 2014, 201, S91-6.	0.8	1
2549	Dyslipidemia in women: etiology and management. International Journal of Women's Health, 2014, 6, 185.	1.1	57
2550	Posicionamiento del Comit� Esp�ol Interdisciplinario de Prevenci�n Cardiovascular y la Sociedad Espa�ola de Cardiolog�a en el tratamiento de las dislipemias: divergencia entre las gu�as europea y estadounidense. PEDIATRIA DE ATENCION PRIMARIA, 2014, 16, e161-e172.	0.2	0
2551	THE FEATURES OF ANTIHYPERTENSIVE THERAPY IN PATIENTS WITH METABOLIC SYNDROME. Rational Pharmacotherapy in Cardiology, 2014, 10, 212-219.	0.3	1
2552	Pigment Epithelial-Derived Factor and Acute Coronary Syndrome: A Novel Protective Biomarker but Not for Routine Clinical Use at Present. Cardiology, 2014, 127, 28-30.	0.6	1
2553	STATINS AND PERCUTANEOUS CORONARY INTERVENTION. FOCUS ON THE ATORVASTATIN. Rational Pharmacotherapy in Cardiology, 2014, 10, 438-443.	0.3	1
2554	Optimising pharmacotherapy for secondary prevention of non�invasively managed acute coronary syndrome. Medical Journal of Australia, 2014, 201, S100-5.	0.8	1
2555	Eight challenges faced by general practitioners caring for patients after an acute coronary syndrome. Medical Journal of Australia, 2014, 201, S110-4.	0.8	1
2556	Statins, Diabetic Oxidative Stress and Vascular Tissue. , 2014, , 183-190.		2
2557	Statins: Definitive Translational Research. Molecular Medicine, 2014, 20, S20-S23.	1.9	7
2558	Effect of Statins on Endothelial Function in Patients With Acute Coronary Syndrome: A Prospective Study Using Adhesion Molecules and Flow-Mediated Dilatation. Journal of Clinical Medicine Research, 2014, 6, 354-61.	0.6	28
2559	Statins and their role in acute pancreatitis: Case report and literature review. World Journal of Gastrointestinal Pharmacology and Therapeutics, 2014, 5, 191.	0.6	9

#	ARTICLE	IF	CITATIONS
2560	Relationship between cholesterol crystals and culprit lesion characteristics in patients with stable coronary artery disease: an optical coherence tomography study. <i>Clinical Research in Cardiology</i> , 2014, 103, 1015-1021.	1.5	22
2561	The correlation between serum lipid profile with carotid intima-media thickness and plaque. <i>BMC Cardiovascular Disorders</i> , 2014, 14, 181.	0.7	46
2562	High-Density Lipoproteins and Coronary Artery Disease. <i>Angiology</i> , 2014, 65, 696-702.	0.8	11
2563	Consensus statement on management of dyslipidemia in Indian subjects. <i>Indian Heart Journal</i> , 2014, 66, S1-S51.	0.2	47
2564	LDL cholesterol: should guidelines include targets?. <i>Expert Review of Cardiovascular Therapy</i> , 2014, 12, 285-290.	0.6	1
2565	Acute Myocardial Infarction During Pregnancy. <i>Clinical Obstetrics and Gynecology</i> , 2014, 57, 835-843.	0.6	13
2566	The good and bad effects of statins on insulin sensitivity and secretion. <i>Endocrine Research</i> , 2014, 39, 137-143.	0.6	27
2567	National Trends in Recurrent AMI Hospitalizations 1 Year After Acute Myocardial Infarction in Medicare Beneficiaries: 1999-2010. <i>Journal of the American Heart Association</i> , 2014, 3, e001197.	1.6	41
2568	New cholesterol guidelines and the secondary prevention of cardiovascular disease – A commentary on epistemic aspects. <i>Preventive Medicine</i> , 2014, 69, 314-316.	1.6	4
2569	Statins after acute coronary syndrome: a missed opportunity. <i>Heart</i> , 2014, 100, 752-753.	1.2	1
2570	Effects of atorvastatin loading prior to primary percutaneous coronary intervention on endothelial function and inflammatory factors in patients with ST-segment elevation myocardial infarction. <i>Experimental and Therapeutic Medicine</i> , 2014, 7, 316-322.	0.8	7
2571	Protective Role of Statins in Patients With Acute Coronary Syndrome Aged ≥75 Years With Low LDL-C Who Underwent Percutaneous Coronary Intervention. <i>Angiology</i> , 2014, 65, 590-595.	0.8	2
2572	Clinician's Guide to the Updated ABCs of Cardiovascular Disease Prevention. <i>Journal of the American Heart Association</i> , 2014, 3, e001098.	1.6	24
2573	Varespladib and Cardiovascular Events in Patients With an Acute Coronary Syndrome. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 252.	3.8	270
2574	Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial. <i>European Heart Journal</i> , 2014, 35, 3277-3286.	1.0	214
2575	Imaging of atherosclerotic plaques in obesity: excessive fat accumulation, plaque progression and vulnerability. <i>Expert Review of Cardiovascular Therapy</i> , 2014, 12, 1471-1489.	0.6	6
2576	Antithrombotic selection and risk factor management in ischemic stroke and transient ischemic attack. <i>Neurosurgical Focus</i> , 2014, 36, E10.	1.0	2
2577	Changes in Low-Density Lipoprotein Cholesterol Levels After Discharge for Acute Myocardial Infarction in a Real-World Patient Population. <i>American Journal of Epidemiology</i> , 2014, 179, 1293-1300.	1.6	7

#	ARTICLE	IF	CITATIONS
2578	Update on the efficacy of statin treatment in acute coronary syndromes. <i>European Journal of Clinical Investigation</i> , 2014, 44, 501-515.	1.7	20
2579	Resurgence of targets and compounds to treat dyslipidaemia. <i>Nature Reviews Cardiology</i> , 2014, 11, 629-631.	6.1	7
2580	Combination Therapy with Statins. <i>Endocrinology and Metabolism Clinics of North America</i> , 2014, 43, 993-1006.	1.2	1
2581	Sigmoidal Maximal Effect Modeling of Low-Density Lipoprotein Cholesterol Concentration and Annual Incidence of Coronary Heart Disease Events in Secondary Prevention Trials. <i>Pharmacotherapy</i> , 2014, 34, 452-463.	1.2	6
2582	New cholesterol guidelines: Worth the wait?. <i>Cleveland Clinic Journal of Medicine</i> , 2014, 81, 11-19.	0.6	25
2583	Plaque regression and progenitor cell mobilization with intensive lipid elimination regimen (PREMIER) trial design. <i>Journal of Clinical Apheresis</i> , 2014, 29, 97-106.	0.7	7
2584	Methodological issues of retrospective studies assessing health outcomes of potential clopidogrel-statin interaction. <i>International Journal of Pharmacy Practice</i> , 2014, 22, 360-362.	0.3	0
2585	Impact of aspirin and statins on long-term survival in patients hospitalized with acute myocardial infarction complicated by heart failure: an analysis of 1706 patients. <i>European Journal of Heart Failure</i> , 2014, 16, 95-102.	2.9	10
2586	Rationale and Design of LAPLACE-2: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Evolocumab in Subjects With Hypercholesterolemia on Background Statin Therapy. <i>Clinical Cardiology</i> , 2014, 37, 195-203.	0.7	12
2587	National Lipid Association Annual Summary of Clinical Lipidology 2015. <i>Journal of Clinical Lipidology</i> , 2014, 8, S1-S36.	0.6	64
2588	Genotoxicity evaluation of HMG CoA reductase inhibitor rosuvastatin. <i>Drug and Chemical Toxicology</i> , 2014, 37, 316-321.	1.2	7
2589	2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes. <i>Circulation</i> , 2014, 130, e344-426.	1.6	928
2590	Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial. <i>American Heart Journal</i> , 2014, 168, 682-689.e1.	1.2	365
2591	Effect of Alogliptazar on Cardiovascular Outcomes After Acute Coronary Syndrome in Patients With Type 2 Diabetes Mellitus. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 1515.	3.8	206
2592	The clinical burden of type 2 diabetes in patients with acute coronary syndromes: Prognosis and implications for short- and long-term management. <i>Diabetes and Vascular Disease Research</i> , 2014, 11, 395-409.	0.9	15
2593	Impact of prior chronic statin therapy and high-intensity statin therapy at discharge on circulating endothelial progenitor cell levels in patients with acute myocardial infarction: a prospective observational study. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 1181-1193.	0.8	6
2594	Rosuvastatin Activates ATP-Binding Cassette Transporter A1-Dependent Efflux Ex Vivo and Promotes Reverse Cholesterol Transport in Macrophage Cells in Mice Fed a High-Fat Diet. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 2246-2253.	1.1	29
2595	Efficacy and safety of ezetimibe plus atorvastatin therapy. <i>Clinical Lipidology</i> , 2014, 9, 441-470.	0.4	7

#	ARTICLE	IF	CITATIONS
2596	Evidence of Sample Use Among New Users of Statins. <i>Medical Care</i> , 2014, 52, 773-780.	1.1	33
2597	LDL-cholesterol reduction in patients with hypercholesterolemia by modulation of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase. <i>Current Opinion in Lipidology</i> , 2014, 25, 309-315.	1.2	33
2598	Effect of Cardiovascular Drugs on Cardiovascular Events in 1599 Patients Followed in an Academic Outpatient Cardiology Practice. <i>American Journal of Therapeutics</i> , 2014, 21, 68-72.	0.5	0
2599	Anacetrapib. <i>Cardiology in Review</i> , 2014, 22, 253-261.	0.6	3
2600	Loss of One Copy of Zfp148 Reduces Lesional Macrophage Proliferation and Atherosclerosis in Mice by Activating p53. <i>Circulation Research</i> , 2014, 115, 781-789.	2.0	30
2601	National Trends in Recurrent AMI Hospitalizations 1 Year After Acute Myocardial Infarction in Medicare Beneficiaries: 1999-2010. <i>Journal of the American Heart Association</i> , 2014, 3, .	1.6	0
2602	The Incidence of Kidney Injury for Patients Treated With a High-Potency Versus Moderate-Potency Statin Regimen After an Acute Coronary Syndrome. <i>Journal of the American Heart Association</i> , 2014, 3, e000784.	1.6	12
2603	2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes: Executive Summary. <i>Circulation</i> , 2014, 130, 2354-2394.	1.6	938
2604	Effect of Evolocumab or Ezetimibe Added to Moderate- or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 1870.	3.8	422
2605	Evaluating the Impact of Treatment Effectiveness and Side Effects in Prescribing Choices. <i>International Series in Quantitative Marketing</i> , 2014, , 171-187.	0.5	1
2606	Computed tomography angiography for the interventional cardiologist. <i>European Heart Journal Cardiovascular Imaging</i> , 2014, 15, 842-854.	0.5	14
2607	Atherosclerotic cardiovascular disease risk and evidence-based management of cholesterol. <i>North American Journal of Medical Sciences</i> , 2014, 6, 191.	1.7	22
2608	HPS2-THRIVE, AIM-HIGH and dal-OUTCOMES: HDL-cholesterol under attack. <i>Global Cardiology Science &amp; Practice</i> , 2014, 2014, 37.	0.3	3
2609	Time course changes of cystatin C and inflammatory and biochemical markers in non-ST-elevation acute coronary syndromes. <i>Journal of Cardiovascular Medicine</i> , 2014, 15, 42-47.	0.6	9
2610	Safety and effectiveness of the association ezetimibe-statin (E-S) versus high dose rosuvastatin after acute coronary syndrome: The SAFE-ES study. <i>Annales De Cardiologie Et D'Angiologie</i> , 2014, 63, 222-227.	0.3	7
2611	Use of ezetimibe results in more patients reaching lipid targets without side effects. <i>Cor Et Vasa</i> , 2014, 56, e128-e132.	0.1	3
2612	Peripheral microvascular dysfunction predicts residual risk in coronary artery disease patients on statin therapy. <i>Atherosclerosis</i> , 2014, 232, 186-190.	0.4	27
2613	Comparison of Statin Alone Versus Bezafibrate and Statin Combination in Patients With Diabetes Mellitus and Acute Coronary Syndrome. <i>American Journal of Cardiology</i> , 2014, 113, 12-16.	0.7	12

#	ARTICLE	IF	CITATIONS
2614	Stabilizing effect of combined eicosapentaenoic acid and statin therapy on coronary thin-cap fibroatheroma. <i>Atherosclerosis</i> , 2014, 234, 114-119.	0.4	108
2615	Lipid-Lowering Therapy in Patients 75 Years and Older: Clinical Priority or Superfluous Therapy?. <i>Progress in Cardiovascular Diseases</i> , 2014, 57, 187-196.	1.6	10
2616	LDL-C Levels in US Patients at High Cardiovascular Risk Receiving Rosuvastatin Monotherapy. <i>Clinical Therapeutics</i> , 2014, 36, 792-799.	1.1	3
2617	Merits and potential downsides of the 2013 ACC/AHA cholesterol management guidelines. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2014, 24, 573-576.	1.1	7
2618	Acute Coronary Syndrome. , 2014, , 49-66.		3
2619	Impacts of age on coronary atherosclerosis and vascular response to statin therapy. <i>Heart and Vessels</i> , 2014, 29, 456-463.	0.5	27
2620	Accelerated decline in renal function after acute myocardial infarction in patients with high low-density lipoprotein-cholesterol to high-density lipoprotein-cholesterol ratio. <i>Heart and Vessels</i> , 2014, 29, 7-14.	0.5	4
2621	Low serum docosahexaenoic acid is associated with progression of coronary atherosclerosis in statin-treated patients with diabetes mellitus: results of the treatment with statin on atheroma regression evaluated by intravascular ultrasound with virtual histology (TRUTH) study. <i>Cardiovascular Diabetology</i> . 2014. 13. 13.	2.7	14
2622	An Update on the Clinical Development of Proprotein Convertase Subtilisin Kexin 9 Inhibitors, Novel Therapeutic Agents for Lowering Low-density Lipoprotein Cholesterol. <i>Cardiovascular Therapeutics</i> , 2014, 32, 82-88.	1.1	16
2623	Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease. , 2014, 143, 87-110.		131
2624	Patterns and Predictors of Intensive Statin Therapy Among Patients With Diabetes Mellitus After Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 2014, 113, 1267-1272.	0.7	12
2625	What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice. <i>European Journal of Preventive Cardiology</i> , 2014, 21, 464-474.	0.8	169
2626	Influence of High-Dose Highly Efficient Statins on Short-Term Mortality in Patients Undergoing Percutaneous Coronary Intervention With Stenting for Acute Coronary Syndromes. <i>American Journal of Cardiology</i> , 2014, 113, 1099-1104.	0.7	21
2627	Update in Therapeutic Approaches to Plaque Stabilization. <i>Current Atherosclerosis Reports</i> , 2014, 16, 392.	2.0	4
2628	Lipids, statins, and clinical outcomes in heart failure: rethinking the data. <i>Heart Failure Reviews</i> , 2014, 19, 695-698.	1.7	4
2629	Eicosapentaenoic Acid Combined with Optimal Statin Therapy Improves Endothelial Dysfunction in Patients with Coronary Artery Disease. <i>Cardiovascular Drugs and Therapy</i> , 2014, 28, 53-59.	1.3	33
2630	Statins and Risk of New-Onset Diabetes Mellitus: is there a Rationale for Individualized Statin Therapy?. <i>American Journal of Cardiovascular Drugs</i> , 2014, 14, 79-87.	1.0	29
2631	Joint British Societiesâ€™ consensus recommendations for the prevention of cardiovascular disease (JBS3). <i>Heart</i> , 2014, 100, ii1-ii67.	1.2	441



#	ARTICLE	IF	CITATIONS
2632	An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia-Full report. <i>Journal of Clinical Lipidology</i> , 2014, 8, 29-60.	0.6	289
2633	Innate and Adaptive Inflammation as a Therapeutic Target in Vascular Disease. <i>Journal of the American College of Cardiology</i> , 2014, 63, 2491-2502.	1.2	155
2635	Nanoparticle-Mediated Delivery of Pitavastatin Inhibits Atherosclerotic Plaque Destabilization/Rupture in Mice by Regulating the Recruitment of Inflammatory Monocytes. <i>Circulation</i> , 2014, 129, 896-906.	1.6	137
2636	Use and misuse of statins after ACS: analysis of a prescription database of a community setting of 2,042,968 subjects. <i>European Journal of Preventive Cardiology</i> , 2014, 21, 1109-1116.	0.8	8
2637	Lipids and lipid management in diabetes. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2014, 28, 325-338.	2.2	72
2638	Meta-Analysis of Time-Related Benefits of Statin Therapy in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2014, 113, 1753-1764.	0.7	80
2639	2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. <i>Journal of the American College of Cardiology</i> , 2014, 63, 2889-2934.	1.2	3,414
2640	Pan coronary plaque vulnerability in patients with acute coronary syndrome and ruptured culprit plaque: A 3-vessel optical coherence tomography study. <i>American Heart Journal</i> , 2014, 167, 59-67.	1.2	74
2641	Evidence supporting primary prevention of cardiovascular diseases with statins: Gaps between updated clinical results and actual practice. <i>Archives of Cardiovascular Diseases</i> , 2014, 107, 188-200.	0.7	15
2642	Target-Attainment Rates of Low-Density Lipoprotein Cholesterol Using Lipid-Lowering Drugs One Year After Acute Myocardial Infarction in Sweden. <i>American Journal of Cardiology</i> , 2014, 113, 17-22.	0.7	10
2643	Statin Therapy in Patients With Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention (from the Evaluation of Drug Eluting Stents and Ischemic Events Registry). <i>American Journal of Cardiology</i> , 2014, 113, 621-625.	0.7	14
2644	Statin Treatment, New-Onset Diabetes, and Other Adverse Effects: A Systematic Review. <i>Current Cardiology Reports</i> , 2014, 16, 461.	1.3	45
2646	Lipoprotein(a) for Risk Assessment in Patients With Established Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2014, 63, 520-527.	1.2	152
2647	Effect of 24 Weeks of Statin Therapy on Systemic and Vascular Inflammation in HIV-Infected Subjects Receiving Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2014, 209, 1156-1164.	1.9	105
2648	Impact of Switching Treatment From Rosuvastatin to Atorvastatin on Rates of Cardiovascular Events. <i>Clinical Therapeutics</i> , 2014, 36, 58-69.	1.1	8
2649	Targeting inflammation—what has the VISTA-16 trial taught us?. <i>Nature Reviews Cardiology</i> , 2014, 11, 130-132.	6.1	7
2650	Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117 411 patients. <i>BMJ</i> , The, 2014, 349, g4379-g4379.	3.0	361
2651	Comparative effectiveness of rosuvastatin versus simvastatin in primary prevention among new users: a cohort study in the French national health insurance database. <i>Pharmacoepidemiology and Drug Safety</i> , 2014, 23, 240-250.	0.9	24

#	ARTICLE	IF	CITATIONS
2652	A Look at Statin Cost-Effectiveness in View of the 2013 ACC/AHA Cholesterol Management Guidelines. <i>Current Atherosclerosis Reports</i> , 2014, 16, 438.	2.0	15
2653	Mechanisms and assessment of statin-related muscular adverse effects. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 454-466.	1.1	88
2654	Spanish Interdisciplinary Committee for Cardiovascular Disease Prevention and the Spanish Society of Cardiology Position Statement on Dyslipidemia Management. Differences Between the European and American Guidelines. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2014, 67, 913-919.	0.4	5
2655	Lipid lowering with PCSK9 inhibitors. <i>Nature Reviews Cardiology</i> , 2014, 11, 563-575.	6.1	207
2656	Review of Clinical Practice Guidelines for the Management of LDL-Related Risk. <i>Journal of the American College of Cardiology</i> , 2014, 64, 196-206.	1.2	52
2657	Patterns of Statin Initiation, Intensification, and Maximization Among Patients Hospitalized With an Acute Myocardial Infarction. <i>Circulation</i> , 2014, 129, 1303-1309.	1.6	62
2658	The Therapeutic Role of Niacin in Dyslipidemia Management. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2014, 19, 141-158.	1.0	52
2659	Carbamylated low-density lipoprotein induces endothelial dysfunction. <i>European Heart Journal</i> , 2014, 35, 3021-3032.	1.0	114
2660	The Risk-Benefit Paradigm vs the Causal Exposure Paradigm: LDL as a primary cause of vascular disease. <i>Journal of Clinical Lipidology</i> , 2014, 8, 594-605.	0.6	11
2661	2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes: Executive Summary. <i>Journal of the American College of Cardiology</i> , 2014, 64, 2645-2687.	1.2	424
2663	Statins for acute coronary syndrome. <i>The Cochrane Library</i> , 2014, , CD006870.	1.5	32
2664	Management of ST-elevation myocardial infarction. <i>Medicine</i> , 2014, 42, 512-519.	0.2	1
2665	Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin. <i>Journal of Lipid Research</i> , 2014, 55, 2103-2112.	2.0	165
2666	Lipid pharmacotherapy for treatment of atherosclerosis. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 1119-1125.	0.9	13
2667	Global Perspective on Acute Coronary Syndrome. <i>Circulation Research</i> , 2014, 114, 1959-1975.	2.0	187
2668	2014 ESC/EACTS Guidelines on myocardial revascularization. <i>European Heart Journal</i> , 2014, 35, 2541-2619.	1.0	4,141
2669	Effect of Alirocumab, a Monoclonal Proprotein Convertase Subtilisin/Kexin 9 Antibody, on Lipoprotein(a) Concentrations (a Pooled Analysis of 150mg Every Two Weeks Dosing from Phase 2) <i>TJ ETQq0 0 0ogBT /Overtrck 10 Tf</i>	0.8	28
2670	HMG-CoA reductase inhibition prior reperfusion improves reparative fibrosis post-myocardial infarction in a preclinical experimental model. <i>International Journal of Cardiology</i> , 2014, 175, 528-538.	0.8	28

#	ARTICLE	IF	CITATIONS
2671	High-Intensity Statin Therapy Alters the Natural History of Diabetic Coronary Atherosclerosis: Insights From SATURN. <i>Diabetes Care</i> , 2014, 37, 3114-3120.	4.3	50
2672	Combination therapy in dyslipidemia: Where are we now?. <i>Atherosclerosis</i> , 2014, 237, 319-335.	0.4	39
2673	Sex-Related Differences of Coronary Atherosclerosis Regression Following Maximally Intensive Statin Therapy. <i>JACC: Cardiovascular Imaging</i> , 2014, 7, 1013-1022.	2.3	54
2674	Principles of Primary and Secondary Prevention of Cardiovascular Disease. , 2014, , 1-44.		0
2675	Lipoproteins as Biomarkers and Therapeutic Targets in the Setting of Acute Coronary Syndrome. <i>Circulation Research</i> , 2014, 114, 1880-1889.	2.0	38
2676	Antiatherosclerotic Effects of Long-Term Maximally Intensive Statin Therapy After Acute Coronary Syndrome. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 2465-2472.	1.1	41
2678	A Summary and Critical Assessment of the 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Disease Risk in Adults: Filling the Gaps. <i>Mayo Clinic Proceedings</i> , 2014, 89, 1257-1278.	1.4	35
2679	2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2014, 64, e139-e228.	1.2	2,746
2680	Standard and intensive lipid-lowering therapy with statins for the primary prevention of vascular diseases: a population-based study. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 99-108.	0.8	13
2681	Characteristics of plaque progression detected by serial coronary computed tomography angiography. <i>Heart and Vessels</i> , 2014, 29, 743-749.	0.5	17
2682	The Quality of Quality. <i>Circulation</i> , 2014, 129, 1270-1272.	1.6	2
2683	Standards of Medical Care in Diabetes—2014. <i>Diabetes Care</i> , 2014, 37, S14-S80.	4.3	3,893
2684	Low-Density Lipoprotein-Cholesterol-Induced Endothelial Dysfunction and Oxidative Stress: The Role of Statins. <i>Antioxidants and Redox Signaling</i> , 2014, 20, 1216-1237.	2.5	73
2685	A novel BET bromodomain inhibitor, RVX-208, shows reduction of atherosclerosis in hyperlipidemic ApoE deficient mice. <i>Atherosclerosis</i> , 2014, 236, 91-100.	0.4	106
2686	Benefit—Risk Assessment of Rosuvastatin in the Treatment of Atherosclerosis and Related Diseases. <i>Drug Safety</i> , 2014, 37, 481-500.	1.4	4
2687	Safety and Efficacy of Colesevelam HCl in the Treatment of Elderly Patients. <i>Drugs and Aging</i> , 2014, 31, 461-470.	1.3	7
2688	Baseline elevated Lp-PLA2 is associated with increased risk for re-stenosis after stent placement. <i>Lipids in Health and Disease</i> , 2014, 13, 41.	1.2	16
2689	The 2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol. <i>Circulation Research</i> , 2014, 114, 761-764.	2.0	17

#	ARTICLE	IF	CITATIONS
2690	2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. <i>Circulation</i> , 2014, 129, S1-45.	1.6	4,842
2691	Drug development: how academia, industry and authorities interact. <i>Nature Reviews Nephrology</i> , 2014, 10, 602-610.	4.1	4
2692	Effect of a hydrophilic and a hydrophobic statin on cardiac salvage after ST-elevated acute myocardial infarction – A pilot study. <i>Atherosclerosis</i> , 2014, 237, 251-258.	0.4	19
2693	High-potency statin and ezetimibe use and mortality in survivors of an acute myocardial infarction: a population-based study. <i>Heart</i> , 2014, 100, 867-872.	1.2	22
2694	Lipids in health and disease. <i>Nature</i> , 2014, 510, 47-47.	13.7	24
2695	Clinical Features of Heart Failure and Acute Coronary Syndromes. <i>Clinics in Laboratory Medicine</i> , 2014, 34, 15-30.	0.7	4
2696	Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: Final baseline characteristics of the IMPROVE-IT study population. <i>American Heart Journal</i> , 2014, 168, 205-212.e1.	1.2	93
2697	Preprocedural statin use in patients undergoing percutaneous coronary intervention. <i>American Heart Journal</i> , 2014, 168, 110-116.e3.	1.2	5
2698	Preloading with atorvastatin before percutaneous coronary intervention in statin-naïve Asian patients with non-ST elevation acute coronary syndromes: A randomized study. <i>Journal of Cardiology</i> , 2014, 63, 335-343.	0.8	34
2699	A users' guide to understanding therapeutic substitutions. <i>Journal of Clinical Epidemiology</i> , 2014, 67, 305-313.	2.4	3
2700	La arteriosclerosis en el siglo XXI. <i>Angiologia</i> , 2014, 66, 109-111.	0.0	0
2701	Temporal trends in clinical characteristics of patients without known cardiovascular disease with a first episode of myocardial infarction. <i>American Heart Journal</i> , 2014, 167, 480-488.e1.	1.2	18
2702	Metabolic syndrome and long-term cardiovascular outcomes in NSTEMI with unstable angina. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2014, 24, 176-182.	1.1	8
2703	The effect of moderate-dose versus double-dose statins on patients with acute coronary syndrome in China: Results of the CHILLAS trial. <i>Atherosclerosis</i> , 2014, 233, 707-712.	0.4	61
2704	Dietary modulators of statin efficacy in cardiovascular disease and cognition. <i>Molecular Aspects of Medicine</i> , 2014, 38, 1-53.	2.7	13
2705	Statin and the Risk of Renal-Related Serious Adverse Events: Analysis from the IDEAL, TNT, CARDS, ASPEN, SPARCL, and Other Placebo-Controlled Trials. <i>American Journal of Cardiology</i> , 2014, 113, 2018-2020.	0.7	36
2706	Putting the diabetes risk due to statins in perspective: A re-evaluation using the complementary outcome. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2014, 24, 705-708.	1.1	2
2707	Combination therapy of eicosapentaenoic acid and pitavastatin for coronary plaque regression evaluated by integrated backscatter intravascular ultrasonography (CHERRY study) – Rationale and design. <i>Journal of Cardiology</i> , 2014, 64, 236-239.	0.8	9

#	ARTICLE	IF	CITATIONS
2708	Lipid-lowering effects of Danhong injection on hyperlipidemia rats. <i>Journal of Ethnopharmacology</i> , 2014, 154, 437-442.	2.0	45
2709	Five-Year Prognosis After Endovascular Therapy in Claudicant Patients With Iliofemoral Artery Disease. <i>Journal of Endovascular Therapy</i> , 2014, 21, 381-388.	0.8	15
2710	Frequency-Domain Optical Coherence Tomographic Analysis of Plaque Microstructures at Nonculprit Narrowings in Patients Receiving Potent Statin Therapy. <i>American Journal of Cardiology</i> , 2014, 114, 549-554.	0.7	37
2711	Are statin trials in diabetes representative of real-world diabetes care: a population-based study on statin initiators in Finland. <i>BMJ Open</i> , 2014, 4, e005402-e005402.	0.8	19
2712	Effects of statin treatment in patients with coronary artery disease and chronic kidney disease. <i>Heart and Vessels</i> , 2014, 29, 21-28.	0.5	28
2713	Relationships between the Serum Cholesterol Levels, Production of Monocyte Proinflammatory Cytokines and Long-term Prognosis in Patients with Chronic Heart Failure. <i>Internal Medicine</i> , 2014, 53, 2415-2424.	0.3	24
2714	The Combination of the Ankle Brachial Index and Brachial Ankle Pulse Wave Velocity Exhibits a Superior Association with Outcomes in Diabetic Patients. <i>Internal Medicine</i> , 2014, 53, 2425-2431.	0.3	21
2715	Assessment of Lipophilic vs. Hydrophilic Statin Therapy in Acute Myocardial Infarction. <i>Circulation Journal</i> , 2014, 79, 161-168.	0.7	37
2716	Risk of statin-induced rhabdomyolysis in patients with hepatic impairment. <i>BMJ Case Reports</i> , 2014, 2014, bcr2014204013-bcr2014204013.	0.2	1
2717	CVD and type 2 diabetes: The nurse prescriber's role. <i>British Journal of Cardiac Nursing</i> , 2014, 9, 325-329.	0.0	0
2718	Adding Coronary Computed Tomography Angiography to Invasive Coronary Angiography Improves Prediction of Cardiac Events. <i>Circulation Journal</i> , 2014, 78, 2735-2740.	0.7	10
2719	Do Statins Have a Specific Drug Effect Beyond Low-Density Lipoprotein-Cholesterol-Lowering in the Secondary Prevention of Coronary Artery Disease?. <i>Circulation Journal</i> , 2014, 79, 49-50.	0.7	0
2720	Efficacy and Safety of Alirocumab as Add-on Therapy in High-risk Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Atorvastatin (20 or 40 mg) or Rosuvastatin (10 or 20 mg): Design and Rationale of the ODYSSEY OPTIONS Studies. <i>Clinical Cardiology</i> , 2014, 37, 597-604.	0.7	41
2721	Is High-intensity Statin Therapy Associated With Lower Statin Adherence Compared With Low-to Moderate-intensity Statin Therapy? Implications of the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guidelines. <i>Clinical Cardiology</i> , 2014, 37, 653-659.	0.7	53
2722	Review of Randomization Methods in Clinical Trials. , 2014, , 77-90.		0
2723	Effect of an Educational Program in Primary Care: The Case of Lipid Control in Cardio-Cerebrovascular Prevention. <i>International Journal of Immunopathology and Pharmacology</i> , 2014, 27, 351-363.	1.0	11
2726	Mortality in acute coronary syndromes: many small steps in the right direction. <i>Interventional Cardiology</i> , 2014, 6, 243-244.	0.0	0
2727	Perspectives: Direct and specific inhibition of factor Xa: an emerging therapeutic strategy for atherothrombotic disease. <i>European Heart Journal Supplements</i> , 2014, 16, A56-A60.	0.0	10

#	ARTICLE	IF	CITATIONS
2728	Impact of statin therapy on coronary plaque composition: a systematic review and meta-analysis of virtual histology intravascular ultrasound studies. <i>BMC Medicine</i> , 2015, 13, 229.	2.3	169
2730	Myopathy in older people receiving statin therapy: a systematic review and meta-analysis. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 363-371.	1.1	78
2731	Evacetrapib: in vitro and clinical disposition, metabolism, excretion, and assessment of drug interaction potential with strong CYP3A and CYP2C8 inhibitors. <i>Pharmacology Research and Perspectives</i> , 2015, 3, e00179.	1.1	9
2732	Dose optimisation following myocardial infarction. <i>The Prescriber</i> , 2015, 26, 29-31.	0.1	0
2733	MicroRNA-33a/b in Lipid Metabolism. <i>Circulation Journal</i> , 2015, 79, 278-284.	0.7	27
2734	Secondary Prevention Strategy of Cardiovascular Disease Using Endothelial Function Testing. <i>Circulation Journal</i> , 2015, 79, 685-694.	0.7	34
2735	High-Density Lipoprotein-Targeted Therapy and Apolipoprotein A-I Mimetic Peptides. <i>Circulation Journal</i> , 2015, 79, 2523-2528.	0.7	23
2736	Differential Effects of Strong and Regular Statins on the Clinical Outcome of Patients With Chronic Kidney Disease Following Coronary Stent Implantation – The Kumamoto Intervention Conference Study (KICS) Registry. <i>Circulation Journal</i> , 2015, 79, 1115-1124.	0.7	19
2737	Statin Adverse Events in Primary Prevention: Between Randomized Trials and Observational Studies. <i>American Journal of the Medical Sciences</i> , 2015, 350, 330-337.	0.4	15
2738	Intensity of statin therapy and new hospitalizations for heart failure in patients with type 2 diabetes. <i>BMJ Open Diabetes Research and Care</i> , 2015, 3, e000137.	1.2	5
2739	Familial hyperlipidaemia. <i>British Journal of Cardiac Nursing</i> , 2015, 10, 394-402.	0.0	0
2740	Targeted study to evaluate the cardiovascular risk factor status among patients and efficacy of statins in attaining goal lipid levels in a regional hospital in Sultanate of Oman. <i>Saudi Pharmaceutical Journal</i> , 2015, 23, 371-376.	1.2	1
2741	2015 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-segment Elevation. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2015, 68, 1125.	0.4	57
2742	Statin treatment alters serum n-3 to n-6 polyunsaturated fatty acids ratio in patients with dyslipidemia. <i>Lipids in Health and Disease</i> , 2015, 14, 67.	1.2	20
2743	Danish trends in pharmacotherapy, comorbidities, and demographics in patients referred for coronary angiography: what changed during a decade?. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015, 1, 157-165.	1.4	14
2744	How low should we target the LDL goal to improve survival for acute coronary syndrome patients in Hong Kong?. <i>BMC Cardiovascular Disorders</i> , 2015, 15, 117.	0.7	11
2745	Pathophysiology of Myocardial Infarction. , 2015, 5, 1841-1875.		437
2746	Association between daily glucose fluctuation and coronary plaque properties in patients receiving adequate lipid-lowering therapy assessed by continuous glucose monitoring and optical coherence tomography. <i>Cardiovascular Diabetology</i> , 2015, 14, 78.	2.7	40

#	ARTICLE	IF	CITATIONS
2747	Combined use of probucol and cilostazol with atorvastatin attenuates atherosclerosis in moderately hypercholesterolemic rabbits. <i>Lipids in Health and Disease</i> , 2015, 14, 82.	1.2	9
2748	Predictors of Beneficial Coronary Plaque Changes after Aerobic Exercise. <i>Medicine and Science in Sports and Exercise</i> , 2015, 47, 2251-2256.	0.2	3
2749	Expanding the Evidence Base. <i>American Journal of Therapeutics</i> , 2015, 22, e141-e150.	0.5	11
2750	Preoperative statin therapy for patients undergoing cardiac surgery. , 2015, , CD008493.		22
2751	Novel directions in inflammation as a therapeutic target in atherosclerosis. <i>Current Opinion in Lipidology</i> , 2015, 26, 580-585.	1.2	19
2752	Statins in Acute Ischemic Stroke: A Systematic Review. <i>Journal of Stroke</i> , 2015, 17, 282-301.	1.4	117
2753	Acute management of unstable angina and non-ST segment elevation myocardial infarction. <i>Einstein (Sao Paulo, Brazil)</i> , 2015, 13, 454-461.	0.3	19
2754	An Introduction to the Fundamentals of Randomized Controlled Trials in Pharmacy Research. <i>Canadian Journal of Hospital Pharmacy</i> , 2015, 68, 28-32.	0.1	13
2755	Position paper FADOI sulla prevenzione cardiovascolare nei pazienti complessi a rischio. <i>Italian Journal of Medicine</i> , 2015, 3, 309.	0.2	1
2756	An Update on Clinical Applications of Intravascular Ultrasound. <i>Journal of Cardiovascular Diseases &amp; Diagnosis</i> , 2015, 03, .	0.0	1
2757	Did Medicare Part D Reduce Mortality?. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
2758	High-Risk Atherosclerotic Cardiovascular Disease in a Real-World Employed Japanese Population: Prevalence, Cardiovascular Event Rates, and Costs. <i>Journal of Atherosclerosis and Thrombosis</i> , 2015, 22, 1287-1304.	0.9	38
2759	Protective and pathological roles of tissue factor in the heart. <i>Hamostaseologie</i> , 2015, 35, 37-46.	0.9	13
2760	Impact of treatment with rosuvastatin and atorvastatin on cardiovascular outcomes: evidence from the Archimedes-simulated clinical trials. <i>ClinicoEconomics and Outcomes Research</i> , 2015, 7, 555.	0.7	7
2761	State of the art paper Lipid-lowering therapy in older persons. <i>Archives of Medical Science</i> , 2015, 1, 43-56.	0.4	18
2762	Clinical Impact of Rapid Reduction of Low-Density Lipoprotein Cholesterol Level on Long-Term Outcome of Acute Myocardial Infarction in the Statin Era: Subanalysis of the ALPS-AMI Study. <i>PLoS ONE</i> , 2015, 10, e0127835.	1.1	11
2763	Risk Factors of Coronary Artery Disease in Secondary Prevention—Results from the AtheroGene—Study. <i>PLoS ONE</i> , 2015, 10, e0131434.	1.1	26
2764	Impact of Statins on Gene Expression in Human Lung Tissues. <i>PLoS ONE</i> , 2015, 10, e0142037.	1.1	4

#	ARTICLE	IF	CITATIONS
2765	MicroRNAs and High-Density Lipoprotein Cholesterol Metabolism. <i>International Heart Journal</i> , 2015, 56, 365-371.	0.5	18
2766	Differential Effects of Atorvastatin and Pitavastatin on Inflammation, Insulin Resistance, and the Carotid Intima-Media Thickness in Patients with Dyslipidemia. <i>Journal of Atherosclerosis and Thrombosis</i> , 2015, 22, 1158-1171.	0.9	29
2767	Polydatin Inhibits Formation of Macrophage-Derived Foam Cells. <i>Evidence-based Complementary and Alternative Medicine</i> , 2015, 2015, 1-8.	0.5	13
2768	PPAR- $\alpha$ Agonist Fenofibrate Decreased Serum Irisin Levels in Type 2 Diabetes Patients with Hypertriglyceridemia. <i>PPAR Research</i> , 2015, 2015, 1-8.	1.1	17
2769	Effects of Statin versus the Combination of Ezetimibe plus Statin on Serum Lipid Absorption Markers in Patients with Acute Coronary Syndrome. <i>Journal of Lipids</i> , 2015, 2015, 1-8.	1.9	7
2770	Association Between Virtual Histology Intravascular Ultrasound Findings and Subsequent Coronary Events in Patients With Acute Coronary Syndrome. <i>International Heart Journal</i> , 2015, 56, 157-162.	0.5	5
2771	Use of Atorvastatin in Lipid Disorders and Cardiovascular Disease in Chinese Patients. <i>Chinese Medical Journal</i> , 2015, 128, 259-266.	0.9	18
2772	All for Statins and Statins for All; An Update. <i>Current Pharmaceutical Design</i> , 2015, 22, 18-27.	0.9	19
2773	Health Care Resource Utilization and Costs Associated with Nonfatal Major Adverse Cardiovascular Events. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2015, 21, 443-450.	0.5	13
2774	Assessment of lipid profile when using lipid-lowering therapy (statins) in patients with coronary atherosclerosis. <i>Rational Pharmacotherapy in Cardiology</i> , 2015, 11, 459-463.	0.3	1
2775	Knowledge of PCSK9 and Continued Educational Gaps. <i>Critical Pathways in Cardiology</i> , 2015, 14, 48-51.	0.2	1
2776	Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2015, 372, 2387-2397.	13.9	3,337
2778	Triglyceride-Rich Lipoproteins and Coronary Artery Disease Risk. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, e3-9.	1.1	61
2779	Treatment of Acute ST-Elevation Myocardial Infarction. <i>Cardiovascular Medicine</i> , 2015, , 505-532.	0.0	0
2780	Niacin Therapy, HDL Cholesterol, and Cardiovascular Disease: Is the HDL Hypothesis Defunct?. <i>Current Atherosclerosis Reports</i> , 2015, 17, 43.	2.0	27
2781	Medical Treatment of Stable Angina. <i>Cardiovascular Medicine</i> , 2015, , 421-459.	0.0	0
2782	Women and Coronary Artery Disease. <i>Cardiovascular Medicine</i> , 2015, , 167-180.	0.0	1
2783	Biomarkers of Cardiometabolic Risk, Inflammation and Disease. , 2015, , .		4



#	ARTICLE	IF	CITATIONS
2784	A 2-Year Follow-Up of Oxidative Stress Levels in Patients With ST-Segment Elevation Myocardial Infarction. <i>Angiology</i> , 2015, 66, 271-277.	0.8	11
2785	Twenty-five years of statins: where do we go from here?. <i>Clinical Lipidology</i> , 2015, 10, 33-45.	0.4	2
2786	Fasting Triglycerides Predict Recurrent Ischemic Events in Patients With Acute Coronary Syndrome Treated With Statins. <i>Journal of the American College of Cardiology</i> , 2015, 65, 2267-2275.	1.2	210
2787	Residual Cardiovascular Risk in Chronic Kidney Disease: Role of High-density Lipoprotein. <i>Archives of Medical Research</i> , 2015, 46, 379-391.	1.5	42
2789	Clinical impacts of high-sensitivity C-reactive protein reduction for secondary prevention in Asian patients with one-year survivor after acute myocardial infarction. <i>International Journal of Cardiology</i> , 2015, 193, 20-22.	0.8	5
2790	Statins and Nonadherence. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2015, 20, 447-456.	1.0	14
2791	CYP-mediated drug-drug interactions with evacetrapib, an investigational CETP inhibitor: <i>in vitro</i> prediction and clinical outcome. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 1388-1398.	1.1	9
2792	Rho-GTPase and Atherosclerosis: Pleiotropic Effects of Statins. <i>Journal of the American Heart Association</i> , 2015, 4, .	1.6	50
2793	National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2. <i>Journal of Clinical Lipidology</i> , 2015, 9, S1-S122.e1.	0.6	430
2794	Lipids and Lipoproteins as Biomarkers of Vascular Complications in Diabetes and Their Modulation by Dietary Phytochemicals. , 2015, , 1-19.		0
2796	8. Cardiovascular Disease and Risk Management. <i>Diabetes Care</i> , 2015, 38, S49-S57.	4.3	224
2797	Angina. <i>Contemporary Cardiology</i> , 2015, , 283-309.	0.0	0
2798	Control de factores de riesgo cardiovascular en pacientes diabéticos revascularizados: un subanálisis del estudio ICP-Bypass. <i>Revista Espanola De Cardiologia</i> , 2015, 68, 115-120.	0.6	9
2799	Malondialdehyde-modified low-density lipoprotein is a predictor of cardiac events in patients with stable angina on lipid-lowering therapy after percutaneous coronary intervention using drug-eluting stent. <i>Atherosclerosis</i> , 2015, 239, 311-317.	0.4	24
2800	Control of Cardiovascular Risk Factors in Revascularized Patients With Diabetes: A Subanalysis of the ICP-Bypass Study. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2015, 68, 115-120.	0.4	2
2801	Early statin therapy in patients with acute intracerebral hemorrhage without prior statin use. <i>European Journal of Neurology</i> , 2015, 22, 773-780.	1.7	41
2803	Gaps in Guideline Implementation. <i>Journal of the American College of Cardiology</i> , 2015, 65, 278-280.	1.2	12
2804	Relationship Between Serum Low-Density Lipoprotein Cholesterol and In-hospital Mortality Following Acute Myocardial Infarction (The Lipid Paradox). <i>American Journal of Cardiology</i> , 2015, 115, 557-562.	0.7	96

#	ARTICLE	IF	CITATIONS
2805	Underutilization of High-Intensity Statin Therapy After Hospitalization for Coronary Heart Disease. <i>Journal of the American College of Cardiology</i> , 2015, 65, 270-277.	1.2	136
2806	PCSK9 Inhibition: Current Concepts and Lessons from Human Genetics. <i>Current Atherosclerosis Reports</i> , 2015, 17, 487.	2.0	9
2807	Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials. <i>Lancet</i> , The, 2015, 385, 1397-1405.	6.3	1,112
2808	How Do We Prevent the Vulnerable Atherosclerotic Plaque From Rupturing? Insights From In Vivo Assessments of Plaque, Vascular Remodeling, and Local Endothelial Shear Stress. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2015, 20, 261-275.	1.0	32
2809	The Myth of the "Vulnerable Plaque". <i>Journal of the American College of Cardiology</i> , 2015, 65, 846-855.	1.2	360
2810	Severe hepatic injury associated with different statins in patients with chronic liver disease: A nationwide population-based cohort study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 155-162.	1.4	31
2811	A novel therapeutic effect of statins on nephrogenic diabetes insipidus. <i>Journal of Cellular and Molecular Medicine</i> , 2015, 19, 265-282.	1.6	29
2812	Reverse epidemiology in different stages of heart failure. <i>International Journal of Cardiology</i> , 2015, 184, 216-224.	0.8	18
2813	Present status of statin therapy. <i>Trends in Cardiovascular Medicine</i> , 2015, 25, 216-225.	2.3	17
2814	Primary Prevention of Atherosclerotic Cardiovascular Disease. <i>Annals of Pharmacotherapy</i> , 2015, 49, 484-493.	0.9	9
2815	New-Onset Diabetes and Statins: Throw the Bath Water Out, But, Please, Keep the Baby!. <i>Metabolism: Clinical and Experimental</i> , 2015, 64, 471-475.	1.5	25
2816	Statin therapy in patients with acute coronary syndrome: low-density lipoprotein cholesterol goal attainment and effect of statin potency. <i>Therapeutics and Clinical Risk Management</i> , 2015, 11, 127.	0.9	19
2817	The Usefulness of a Cholesterol Absorption Inhibitor in Japanese Type 2 Diabetes Patients with Dyslipidemia. <i>Diabetes Technology and Therapeutics</i> , 2015, 17, 427-434.	2.4	1
2818	Statins: Risk-Benefits and Role in Treating Dyslipidemias. <i>Contemporary Endocrinology</i> , 2015, , 403-421.	0.3	0
2819	Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2015, 66, 495-507.	1.2	352
2820	Are PCSK9 Inhibitors the Next Breakthrough in the Cardiovascular Field?. <i>Journal of the American College of Cardiology</i> , 2015, 65, 2638-2651.	1.2	156
2822	Cardiovascular Biomarker Assessment Across Glycemic Status. , 2015, , 245-268.		1
2823	A phase 2 randomized, double-blind, placebo-controlled study of the effect of VIA-2291, a 5-lipoxygenase inhibitor, on vascular inflammation in patients after an acute coronary syndrome. <i>Atherosclerosis</i> , 2015, 240, 53-60.	0.4	47

#	ARTICLE	IF	CITATIONS
2824	Atherosclerotic plaque. , 2015, , 203-226.		1
2825	New Hope for Lipid-Lowering Beyond Statins: Effect of IMPROVE-IT on Understanding and Implementation of Atherosclerosis Prevention. Canadian Journal of Cardiology, 2015, 31, 585-587.	0.8	8
2826	Underutilization of High-Intensity Statin Therapy After Hospitalization for Coronary Heart Disease. Journal of the American College of Cardiology, 2015, 65, 2768-2769.	1.2	4
2827	Reply. Journal of the American College of Cardiology, 2015, 65, 2770.	1.2	0
2828	Utilization of and Adherence to Guideline-Recommended Lipid-Lowering Therapy After Acute Coronary Syndrome. Journal of the American College of Cardiology, 2015, 66, 184-192.	1.2	91
2829	Trial design, statins, atrial fibrillation, and prevention: Four horsemen of the apocalypse. Anatolian Journal of Cardiology, 2015, 15, 341-342.	0.5	0
2830	Patient adherence to generic versus brand statin therapy after acute myocardial infarction: Insights from the Can Rapid Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the American College of Cardiology/American Heart Association Guidelines Registry. American Heart Journal, 2015, 170, 55-61.	1.2	16
2831	On-Statins Resistin, Leptin, and Risk of Recurrent Coronary Events After Hospitalization for an Acute Coronary Syndrome (from the Pravastatin or Atorvastatin Evaluation and Infection) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 462 T	0.7	14
2833	Efficacy and safety of serial atorvastatin load in Chinese patients undergoing elective percutaneous coronary intervention: results of the ISCAP (Intensive Statin Therapy for Chinese Patients with) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 42	0.0	10
2834	trial. European Heart Journal Supplements, 2015, 17, B47-B56.		
2834	Current Treatment of Dyslipidemia: A New Paradigm for Statin Drug Use and the Need for Additional Therapies. Drugs, 2015, 75, 1187-1199.	4.9	24
2835	Effects of intensive lipid-lowering therapy on coronary plaques composition in patients with acute myocardial infarction: Assessment with serial coronary CT angiography. Atherosclerosis, 2015, 241, 579-587.	0.4	54
2836	Do statins reduce the risk of myocardial infarction in patients with heart failure? A pooled individual-level reanalysis of CORONA and GISSI-HF. European Journal of Heart Failure, 2015, 17, 434-441.	2.9	39
2837	Risk factor burden and control at the time of admission in patients with acute myocardial infarction: Results from the NCDR. American Heart Journal, 2015, 170, 173-179.e1.	1.2	3
2839	Newer treatment strategies: Mipomersen, Lomitapide and PCSK9. Journal of Indian College of Cardiology, 2015, 5, S58-S65.	0.1	0
2840	Del concepto de estatinas de alta potencia a los efectos extralipídicos de las estatinas. Revista Espanola De Cardiologia Suplementos, 2015, 15, 22-27.	0.2	2
2841	Optimal blood pressure targets in 2014 – Does the guideline recommendation match the evidence base?. Hipertension Y Riesgo Vascular, 2015, 32, 71-82.	0.3	0
2842	Physicians' adherence to acute coronary syndrome prescribing guidelines in vietnamese hospital practice: a cross-sectional study. Tropical Medicine and International Health, 2015, 20, 627-637.	1.0	6
2844	Estatinas en pacientes con síndrome coronario agudo. Más allá de las lipoproteínas de baja densidad. Revista Espanola De Cardiologia Suplementos, 2015, 15, 28-33.	0.2	0

#	ARTICLE	IF	CITATIONS
2846	Ezetimibe Plus Moderate-dose Simvastatin After Acute Coronary Syndrome: What Are We IMPROVEing On?. <i>American Journal of Medicine</i> , 2015, 128, 914.e1-914.e4.	0.6	11
2847	Visit-to-Visit Low-Density Lipoprotein Cholesterol Variability and Risk of Cardiovascular Outcomes. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1539-1548.	1.2	156
2848	Combination therapy analysis of ezetimibe and statins in Chinese patients with acute coronary syndrome and type 2 diabetes. <i>Lipids in Health and Disease</i> , 2015, 14, 10.	1.2	10
2849	Using inactivating mutations to provide insight into drug action. <i>Genome Medicine</i> , 2015, 7, 7.	3.6	2
2851	Clinical outcomes following percutaneous coronary intervention before and after introduction of drug-eluting stent. <i>Cardiovascular Intervention and Therapeutics</i> , 2015, 30, 338-346.	1.2	0
2852	Cellular and molecular mechanisms of statins: an update on pleiotropic effects. <i>Clinical Science</i> , 2015, 129, 93-105.	1.8	74
2853	Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. <i>Lancet, The</i> , 2015, 385, 2264-2271.	6.3	564
2854	Effect of Statins on Early and Late Clinical Outcomes of Carotid Endarterectomy and the Rate of Post-Carotid Endarterectomy Restenosis. <i>Journal of the American College of Surgeons</i> , 2015, 220, 481-487.	0.2	25
2855	Diagnosis and Management of Acute Coronary Syndrome: An Evidence-Based Update. <i>Journal of the American Board of Family Medicine</i> , 2015, 28, 283-293.	0.8	98
2856	Vorapaxar in Patients With Diabetes Mellitus and Previous Myocardial Infarction. <i>Circulation</i> , 2015, 131, 1047-1053.	1.6	73
2857	The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials. <i>European Heart Journal</i> , 2015, 36, 1536-1546.	1.0	126
2858	National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1â€”Full Report. <i>Journal of Clinical Lipidology</i> , 2015, 9, 129-169.	0.6	632
2859	Atherosclerosis: Recent trials, new targets and future directions. <i>International Journal of Cardiology</i> , 2015, 192, 72-81.	0.8	28
2860	Medical Management of Serum Lipids and Coronary Heart Disease. <i>Cardiovascular Medicine</i> , 2015, , 39-55.	0.0	0
2861	Managing Residual Risk After Myocardial Infarction Among Individuals with Low Cholesterol Levels. <i>Cardiology Clinics</i> , 2015, 33, 299-308.	0.9	3
2862	Statin Treatment by Low-Density Lipoprotein Cholesterol Levels in Patients With Nonâ€”ST-Segment Elevation Myocardial Infarction/Unstable Angina Pectoris (from the CRUSADE Registry). <i>American Journal of Cardiology</i> , 2015, 115, 1655-1660.	0.7	7
2864	Is Copeptin Level Associated With 1-Year Mortality After Out-of-Hospital Cardiac Arrest? Insights From the Paris Registry*. <i>Critical Care Medicine</i> , 2015, 43, 422-429.	0.4	8
2865	Phage-Display-Guided Nanocarrier Targeting to Atheroprone Vasculature. <i>ACS Nano</i> , 2015, 9, 4435-4446.	7.3	27

#	ARTICLE	IF	CITATIONS
2866	Pharmacotherapy in Chronic Kidney Disease Patients Presenting With Acute Coronary Syndrome. <i>Circulation</i> , 2015, 131, 1123-1149.	1.6	61
2867	DAPT Duration After DES. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1103-1106.	1.2	28
2868	Type 2 Diabetes. <i>Annals of Internal Medicine</i> , 2015, 162, ITC1-ITC16.	2.0	74
2869	Comparison of the effects of two low-density lipoprotein cholesterol goals for secondary prevention after acute myocardial infarction in real-world practice: a 50% reduction from baseline versus <70mg/dL. <i>International Journal of Cardiology</i> , 2015, 187, 478-485.	0.8	12
2871	Impact of Combined C-Reactive Protein and High-Density Lipoprotein Cholesterol Levels on Long-Term Outcomes in Patients With Coronary Artery Disease After a First Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2015, 116, 999-1002.	0.7	14
2872	Effect of Low Cholesterol on Steroid Hormones and Vitamin E Levels. <i>Circulation Research</i> , 2015, 117, 662-664.	2.0	11
2873	A Review of Current Diagnosis, Investigation, and Management of Acute Coronary Syndromes in Elderly Patients. <i>Cardiology and Therapy</i> , 2015, 4, 95-116.	1.1	13
2874	Sex-Stratified Trends in Enrollment, Patient Characteristics, Treatment, and Outcomes Among Non-ST-Segment Elevation Acute Coronary Syndrome Patients. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015, 8, 357-367.	0.9	30
2875	Effects of aliskiren in diabetic and non-diabetic patients with coronary artery disease: Insights from AQUARIUS. <i>Atherosclerosis</i> , 2015, 243, 553-559.	0.4	3
2876	Clinical indicators for recurrent cardiovascular events in acute coronary syndrome patients treated with statins under routine practice in Thailand: an observational study. <i>BMC Cardiovascular Disorders</i> , 2015, 15, 55.	0.7	4
2877	Plaque microstructures in patients with coronary artery disease who achieved very low low-density lipoprotein cholesterol levels. <i>Atherosclerosis</i> , 2015, 242, 490-495.	0.4	43
2878	The Challenges of Prevention, Diagnosis and Treatment of Ischemic Heart Disease in Women. <i>Cardiovascular Drugs and Therapy</i> , 2015, 29, 355-368.	1.3	37
2879	Ezetimibe plus a Statin after Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2015, 373, 1473-1477.	13.9	28
2880	Therapeutic Potential and Critical Analysis of the PCSK9 Monoclonal Antibodies Evolocumab and Alirocumab. <i>Annals of Pharmacotherapy</i> , 2015, 49, 1327-1335.	0.9	24
2881	Fundamentals of Clinical Trials. , 2015, , .		603
2882	Perspectives on Cholesterol Guidelines. <i>Contemporary Endocrinology</i> , 2015, , 313-327.	0.3	0
2883	Safety and efficacy of ezetimibe: A meta-analysis. <i>International Journal of Cardiology</i> , 2015, 201, 247-252.	0.8	70
2884	Long-Term Use of Cardiovascular Drugs. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1273-1285.	1.2	111

#	ARTICLE	IF	CITATIONS
2885	Effect of High-Dose Statin Therapy on Drug-Eluting Stent Strut Coverage. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 2460-2467.	1.1	13
2886	Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT. <i>Circulation</i> , 2015, 132, 1224-1233.	1.6	267
2887	Comparative effects of more versus less aggressive treatment with statins on the long-term outcome of patients with acute ischemic stroke. <i>Atherosclerosis</i> , 2015, 243, 65-70.	0.4	13
2888	An experimental study on amelioration of dyslipidemia-induced atherosclerosis by Clematichinenoside through regulating Peroxisome proliferator-activated receptor- $\alpha$ mediated apolipoprotein A-I, A-II and C-III. <i>European Journal of Pharmacology</i> , 2015, 761, 362-374.	1.7	19
2889	Effect of telmisartan on the therapeutic efficacy of pitavastatin in high-fat diet induced dyslipidemic guinea pigs. <i>European Journal of Pharmacology</i> , 2015, 762, 364-371.	1.7	8
2890	Alterations in the hepatic transcriptional landscape after RNAi mediated ApoB silencing in cynomolgus monkeys. <i>Atherosclerosis</i> , 2015, 242, 383-395.	0.4	5
2892	Statins in the Elderly: A Patient-Focused Approach. <i>Clinical Cardiology</i> , 2015, 38, 56-61.	0.7	38
2894	Ongoing challenges for pharmacotherapy for dyslipidemia. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 347-356.	0.9	6
2895	Gender Disparities in Evidence-Based Statin Therapy in Patients With Cardiovascular Disease. <i>American Journal of Cardiology</i> , 2015, 115, 21-26.	0.7	134
2896	Treating Coronary Disease and the Impact of Endothelial Dysfunction. <i>Progress in Cardiovascular Diseases</i> , 2015, 57, 431-442.	1.6	50
2897	Screening and Treatment by the Primary Care Provider of Common Diabetes Complications. <i>Medical Clinics of North America</i> , 2015, 99, 201-219.	1.1	16
2898	Acute Coronary Syndrome. <i>Journal of Intensive Care Medicine</i> , 2015, 30, 186-200.	1.3	94
2899	Comparison of the effects of pitavastatin versus pravastatin on coronary artery plaque phenotype assessed by tissue characterization using serial virtual histology intravascular ultrasound. <i>Heart and Vessels</i> , 2015, 30, 36-44.	0.5	8
2900	Remodeling pattern is related to the degree of coronary plaque regression induced by pitavastatin: a sub-analysis of the TOGETHAR trial with intravascular ultrasound and coronary angiography. <i>Heart and Vessels</i> , 2015, 30, 169-176.	0.5	8
2901	Effects of HDL-modifiers on cardiovascular outcomes: A meta-analysis of randomized trials. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2015, 25, 9-23.	1.1	29
2902	The effect of rosuvastatin on thromboinflammation in the setting of acute coronary syndrome. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 39, 186-195.	1.0	19
2903	Cardiac Drug Therapy. <i>Contemporary Cardiology</i> , 2015, , .	0.0	4
2904	Effect of high-intensity statin therapy on atherosclerosis in non-infarct-related coronary arteries (IBIS-4): a serial intravascular ultrasonography study. <i>European Heart Journal</i> , 2015, 36, 490-500.	1.0	168

#	ARTICLE	IF	CITATIONS
2905	What Is the Appropriate Duration of High-Dose Atorvastatin Therapy Post-Acute Coronary Syndrome?. <i>Journal of Pharmacy Practice</i> , 2015, 28, 555-560.	0.5	1
2906	Muscle- and skeletal-related side-effects of statins: tip of the iceberg?. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 88-110.	0.8	58
2908	Pleiotropic effects of statins: A boulevard to cardioprotection. <i>Arabian Journal of Chemistry</i> , 2016, 9, S21-S27.	2.3	22
2909	Cholesterol-Lowering Drugs and Therapies in Cardiovascular Disease. , 0, , .		1
2910	Bilateral upper extremity severe ecchymosis in a patient on alirocumab, rivaroxaban, and clopidogrel therapy. <i>Case Reports in Internal Medicine</i> , 2016, 3, .	0.0	0
2911	Reduction in total recurrent cardiovascular events in acute coronary syndrome patients with low-density lipoprotein cholesterol goal <70 mg/dL: a real-life cohort in a developing country. <i>Therapeutics and Clinical Risk Management</i> , 2016, 12, 353.	0.9	1
2912	Simultaneous administration of high-dose atorvastatin and clopidogrel does not interfere with platelet inhibition during percutaneous coronary intervention. <i>Clinical Pharmacology: Advances and Applications</i> , 2016, 8, 45.	0.8	3
2913	Omega-3 carboxylic acids monotherapy and combination with statins in the management of dyslipidemia. <i>Vascular Health and Risk Management</i> , 2016, Volume 12, 481-490.	1.0	9
2914	Does Pre-Treatment with High Dose Atorvastatin Prevent Microvascular Dysfunction after Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome?. <i>Korean Circulation Journal</i> , 2016, 46, 472.	0.7	16
2915	Differential Benefit of Statin in Secondary Prevention of Acute Myocardial Infarction according to the Level of Triglyceride and High Density Lipoprotein Cholesterol. <i>Korean Circulation Journal</i> , 2016, 46, 324.	0.7	10
2916	Patterns of Statin Use in a Real-World Population of Patients at High Cardiovascular Risk. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2016, 22, 685-698.	0.5	55
2917	The effects of vitamin D on severity of coronary artery atherosclerosis and lipid profile of cardiac patients. <i>Archives of Medical Science</i> , 2016, 6, 1199-1206.	0.4	33
2918	Stabilization of high-risk plaques. <i>Cardiovascular Diagnosis and Therapy</i> , 2016, 6, 304-321.	0.7	19
2919	Assessment of the management of acute myocardial infarction patients and their outcomes at the Nairobi Hospital from January 2007 to June 2009. <i>Cardiovascular Journal of Africa</i> , 2016, 27, 218-221.	0.2	11
2920	Impact of variants in CETP and apo AI genes on serum HDL cholesterol levels in men and women from the Polish population. <i>Archives of Medical Science</i> , 2016, 6, 1188-1198.	0.4	3
2921	Impact of the 2013 Cholesterol Guideline on Patterns of Lipid-Lowering Treatment in Patients with Atherosclerotic Cardiovascular Disease or Diabetes After 1 Year. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2016, 22, 901-908.	0.5	27
2922	Anti-Thrombotic Effects of Statins in Acute Coronary Syndromes: At the Intersection of Thrombosis, Inflammation, and Platelet-Leukocyte Interactions. <i>Current Cardiology Reviews</i> , 2016, 12, 324-329.	0.6	12
2923	Pathogenesis of Atherosclerosis A Review. <i>Medical &amp; Clinical Reviews</i> , 2016, 2, .	0.3	11

#	ARTICLE	IF	CITATIONS
2924	Disorders of Lipid Metabolism. , 2016, , 1660-1700.		7
2925	Early Effects of Intensive Lipid-Lowering Treatment on Plaque Characteristics Assessed by Virtual Histology Intravascular Ultrasound. Yonsei Medical Journal, 2016, 57, 1087.	0.9	8
2926	Impact of statins on risk of new onset diabetes mellitus: a population-based cohort study using the Korean National Health Insurance claims database. Therapeutics and Clinical Risk Management, 2016, Volume 12, 1533-1543.	0.9	23
2927	Antianginal drugs. , 2016, , 530-532.		0
2929	National Assessment of Statin Therapy in Patients Hospitalized with Acute Myocardial Infarction: Insight from China PEACE-Retrospective AMI Study, 2001, 2006, 2011. PLoS ONE, 2016, 11, e0150806.	1.1	10
2930	Trends in Statin Use in Seniors 1999 to 2013: Time Series Analysis. PLoS ONE, 2016, 11, e0158608.	1.1	18
2931	Appropriate Level of Low-Density Lipoprotein Cholesterol for Secondary Prevention of Coronary Artery Disease. Journal of Atherosclerosis and Thrombosis, 2016, 23, 413-421.	0.9	8
2932	Algorithms to Identify Statin Intolerance in Medicare Administrative Claim Data. Cardiovascular Drugs and Therapy, 2016, 30, 525-533.	1.3	23
2933	Changes in triglyceride, HDL-C, and non-HDL-C levels in patients with acute coronary syndrome. Wiener Klinische Wochenschrift, 2016, 128, 858-863.	1.0	6
2934	Preoperative statin therapy for patients undergoing cardiac surgery. The Cochrane Library, 2017, 2017, CD008493.	1.5	1
2935	Differences in Electrocardiographic Findings Between Acute Isolated Right Ventricular Myocardial Infarction and Acute Anterior Myocardial Infarction. JAMA Internal Medicine, 2016, 176, 1875.	2.6	1
2937	Statins in prevention and treatment of ischemic stroke. Human Physiology, 2016, 42, 858-864.	0.1	0
2938	Differences in Electrocardiographic Findings Between Acute Isolated Right Ventricular Myocardial Infarction and Acute Anterior Myocardial Infarction. JAMA Internal Medicine, 2016, 176, 1875.	2.6	2
2939	Low-Density Lipoprotein Levels and Risk of Major Cardiovascular Eventsâ€”Reply. JAMA Internal Medicine, 2016, 176, 1876.	2.6	0
2940	Coronary Plaque Morphology and the Anti-Inflammatory Impact of Atorvastatin. Circulation: Cardiovascular Imaging, 2016, 9, .	1.3	46
2941	Low-Density Lipoprotein Levels and Risk of Major Cardiovascular Events. JAMA Internal Medicine, 2016, 176, 1876.	2.6	1
2942	Perceived and actual risk of cardiovascular disease in patients with rheumatoid arthritis in Korea. Medicine (United States), 2016, 95, e5117.	0.4	14
2944	From Pilot to Practice: A Trainee-Integrated Pharmacy Practice Model in Cardiology. North Carolina Medical Journal, 2016, 77, 45-51.	0.1	5



#	ARTICLE	IF	CITATIONS
2945	Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV). <i>American Heart Journal</i> , 2016, 176, 83-92.	1.2	45
2946	Eicosapentaenoic acid to arachidonic acid (EPA/AA) ratio as an associated factor of high risk plaque on coronary computed tomography in patients without coronary artery disease. <i>Atherosclerosis</i> , 2016, 250, 30-37.	0.4	23
2947	A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality. <i>Journal of Clinical Lipidology</i> , 2016, 10, 472-489.	0.6	219
2948	Gender differences in the prognostic role of uric acid and confounding factors. <i>Journal of Cardiology</i> , 2016, 67, 483.	0.8	0
2949	Impact of Statin Therapy on Clinical Outcome in Patients With Coronary Spasm. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	51
2950	Preventive effects of simvastatin nanoliposome on isoproterenol-induced cardiac remodeling in mice. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2016, 12, 1899-1907.	1.7	12
2951	A VOYAGER Meta-Analysis of the Impact of Statin Therapy on Low-Density Lipoprotein Cholesterol and Triglyceride Levels in Patients With Hypertriglyceridemia. <i>American Journal of Cardiology</i> , 2016, 117, 1444-1448.	0.7	78
2952	Two Randomized Controlled Pilot Trials of Social Forces to Improve Statin Adherence among Patients with Diabetes. <i>Journal of General Internal Medicine</i> , 2016, 31, 402-410.	1.3	22
2953	Statin therapy in cardiac allograft vasculopathy progression in heart transplant patients: Does potency matter?. <i>Transplantation Reviews</i> , 2016, 30, 178-186.	1.2	15
2954	Secondary Prevention Beyond Hospital Discharge for Acute Coronary Syndrome: Evidence-Based Recommendations. <i>Canadian Journal of Cardiology</i> , 2016, 32, S15-S34.	0.8	9
2955	Trends in Enrollment, Clinical Characteristics, Treatment, and Outcomes According to Age in Non-ST-Segment Elevation Acute Coronary Syndromes Clinical Trials. <i>Circulation</i> , 2016, 133, 1560-1573.	1.6	17
2956	An update on management of the patient presenting with non-ST-elevation acute coronary syndromes. <i>Hospital Practice (1995)</i> , 2016, 44, 173-178.	0.5	1
2957	Recent Update to the US Cholesterol Treatment Guidelines. <i>Circulation</i> , 2016, 133, 1795-1806.	1.6	89
2958	Statin treatment is associated with insulin sensitivity decrease in type 1 diabetes mellitus: A prospective, observational 56-month follow-up study. <i>Journal of Clinical Lipidology</i> , 2016, 10, 1004-1010.	0.6	9
2959	Residual Ischemic Risk and Its Determinants in Patients With Previous Myocardial Infarction and Without Prior Stroke or TIA: Insights From the REACH Registry. <i>Clinical Cardiology</i> , 2016, 39, 670-677.	0.7	45
2960	Impact of the 2013 American College of Cardiology/American Heart Association cholesterol guidelines on the prescription of high-intensity statins in patients hospitalized for acute coronary syndrome or stroke. <i>American Heart Journal</i> , 2016, 181, 130-136.	1.2	16
2961	Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY Phase 3 clinical program trials. <i>International Journal of Cardiology</i> , 2016, 223, 750-757.	0.8	54
2962	Structural Plasticity of Cholesteryl Ester Transfer Protein Assists the Lipid Transfer Activity. <i>Journal of Biological Chemistry</i> , 2016, 291, 19462-19473.	1.6	20

#	ARTICLE	IF	CITATIONS
2963	Novel Therapies for Low-Density Lipoprotein Cholesterol Reduction. American Journal of Cardiology, 2016, 118, 19A-32A.	0.7	8
2964	Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions. JAMA - Journal of the American Medical Association, 2016, 316, 1289.	3.8	974
2965	Statins in Primary Prevention: Uncertainties and Gaps in Randomized Trial Data. American Journal of Cardiovascular Drugs, 2016, 16, 407-418.	1.0	6
2966	New directions for pharmacotherapy in the treatment of acute coronary syndrome. Expert Opinion on Pharmacotherapy, 2016, 17, 2291-2306.	0.9	15
2967	Clinical outcome of statin plus ezetimibe versus high-intensity statin therapy in patients with acute myocardial infarction propensity-score matching analysis. International Journal of Cardiology, 2016, 225, 50-59.	0.8	16
2968	Lipid effects of switching from prescription EPA+DHA (omega-3-acid ethyl esters) to prescription EPA only (icosapent ethyl) in dyslipidemic patients. Postgraduate Medicine, 2016, 128, 859-864.	0.9	7
2969	Management of Dyslipidemia in Patients with Hypertension, Diabetes, and Metabolic Syndrome. Current Hypertension Reports, 2016, 18, 76.	1.5	51
2970	Use of high-intensity statins for patients with atherosclerotic cardiovascular disease in the Veterans Affairs Health System: Practice impact of the new cholesterol guidelines. American Heart Journal, 2016, 182, 97-102.	1.2	44
2972	Consensus statement on the management of dyslipidaemias in adults. Diabetes and Metabolism, 2016, 42, 398-408.	1.4	18
2973	An evidence-based analysis of the National Lipid Association recommendations concerning non-HDL-C and apoB. Journal of Clinical Lipidology, 2016, 10, 1248-1258.	0.6	29
2974	The Risk of Hepatotoxicity, New Onset Diabetes and Rhabdomyolysis in the Era of High-Intensity Statin Therapy: Does Statin Type Matter?. Progress in Cardiovascular Diseases, 2016, 59, 145-152.	1.6	21
2975	Effect of fixed-dose combinations of ezetimibe plus rosuvastatin in patients with primary hypercholesterolemia: MRS-ROZE (Multicenter Randomized Study of ROsuvastatin and eZEtimibe). Cardiovascular Therapeutics, 2016, 34, 371-382.	1.1	45
2976	Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials. Lancet Diabetes and Endocrinology, 2016, 4, 829-839.	5.5	234
2977	Managing the lipid profile of coronary heart disease patients. Expert Review of Cardiovascular Therapy, 2016, 14, 1263-1271.	0.6	8
2978	Uterine Arcuate Artery Calcification on Transvaginal Sonography May Correlate With Known Risk Factors for Atherosclerosis. Journal of Ultrasound in Medicine, 2016, 35, 1209-1213.	0.8	4
2979	Safety of atorvastatin in Asian patients within clinical trials. Cardiovascular Therapeutics, 2016, 34, 431-440.	1.1	15
2980	Statin use in patients with peripheral arterial disease. Journal of Vascular Surgery, 2016, 64, 1881-1888.	0.6	42
2981	Effect of Statin Treatment and Low-Density Lipoprotein-Cholesterol on Short-Term Mortality in Acute Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention: A Multicenter Registry From Tokyo CCU Network Database. Circulation Journal, 2016, 80, 461-468.	0.7	17

#	ARTICLE	IF	CITATIONS
2982	Low-Density Lipoprotein Cholesterol Level and Statin Therapy in Patients With Acute Myocardial Infarction (Cholesterol Paradox). <i>Circulation Journal</i> , 2016, 80, 323-324.	0.7	8
2983	Effects of 4 Statins on Regression of Coronary Plaque in Acute Coronary Syndrome. <i>Circulation Journal</i> , 2016, 80, 1634-1643.	0.7	19
2984	Low-density lipoprotein cholesterol in a global cohort of 57,885 statin-treated patients. <i>Atherosclerosis</i> , 2016, 255, 200-209.	0.4	88
2985	Risk factors for lack of statin therapy in patients with diabetes and coronary artery disease. <i>Journal of Clinical Lipidology</i> , 2016, 10, 1406-1413.	0.6	7
2986	Clinical effect of ticagrelor administered in acute coronary syndrome patients following percutaneous coronary intervention. <i>Experimental and Therapeutic Medicine</i> , 2016, 11, 2177-2184.	0.8	9
2987	Amendment of the low-density lipoprotein cholesterol target in the "Chinese Guidelines for the Prevention and Treatment of Adult Dyslipidemia": Opinion. <i>Chronic Diseases and Translational Medicine</i> , 2016, 2, 7-9.	0.9	7
2988	Very low LDL-C levels may safely provide additional clinical cardiovascular benefit: the evidence to date. <i>International Journal of Clinical Practice</i> , 2016, 70, 886-897.	0.8	20
2989	Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies for Acute Coronary Syndrome. <i>Annals of Internal Medicine</i> , 2016, 164, 600.	2.0	55
2990	Reductions in Atherogenic Lipids and Major Cardiovascular Events. <i>Circulation</i> , 2016, 134, 1931-1943.	1.6	110
2991	Postoperative Care Following Major Vascular Surgery. , 2016, , 669-678.		0
2992	Efficacy and safety of long-term treatment with statins for coronary heart disease: A Bayesian network meta-analysis. <i>Atherosclerosis</i> , 2016, 254, 215-227.	0.4	23
2993	The relationship between Lp(a) and CVD outcomes: a systematic review. <i>Lipids in Health and Disease</i> , 2016, 15, 95.	1.2	47
2994	Rationale and Design of the Standard Versus Intensive Statin Therapy for Hypercholesterolemic Patients with Diabetic Retinopathy (EMPATHY) Study: a Randomized Controlled Trial. <i>Journal of Atherosclerosis and Thrombosis</i> , 2016, 23, 976-990.	0.9	22
2995	Randomized double blind clinical trial on the effect of oral Î±-cyclodextrin on serum lipids. <i>Lipids in Health and Disease</i> , 2016, 15, 115.	1.2	33
2996	Statin-induced myopathy in a usual care setting—a prospective observational study of gender differences. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 1171-1176.	0.8	15
2997	Austrian Lipid Consensus on the management of metabolic lipid disorders to prevent vascular complications. <i>Wiener Klinische Wochenschrift</i> , 2016, 128, 216-228.	1.0	8
2998	Association Between Achieved Low-Density Lipoprotein Levels and Major Adverse Cardiac Events in Patients With Stable Ischemic Heart Disease Taking Statin Treatment. <i>JAMA Internal Medicine</i> , 2016, 176, 1105.	2.6	66
2999	Efficacy of High-Intensity Atorvastatin for Asian Patients Undergoing Percutaneous Coronary Intervention. <i>Annals of Pharmacotherapy</i> , 2016, 50, 725-733.	0.9	18

#	ARTICLE	IF	CITATIONS
3000	Lipid profile associated with coronary plaque regression in patients with acute coronary syndrome: Subanalysis of PRECISE-IVUS trial. <i>Atherosclerosis</i> , 2016, 251, 367-372.	0.4	22
3001	Familial hypercholesterolemia in a large ambulatory population: Statin use, optimal treatment, and identification for advanced medical therapies. <i>Journal of Clinical Lipidology</i> , 2016, 10, 1182-1187.	0.6	18
3002	Coronary artery disease and diabetes mellitus. <i>Journal of Taibah University Medical Sciences</i> , 2016, 11, 330-338.	0.5	8
3003	PCSK9 inhibition as an emerging lipid lowering therapy: Unanswered questions. <i>Hellenic Journal of Cardiology</i> , 2016, 57, 86-91.	0.4	19
3005	A novel cost-effectiveness model of prescription eicosapentaenoic acid extrapolated to secondary prevention of cardiovascular diseases in the United States. <i>Journal of Medical Economics</i> , 2016, 19, 1003-1010.	1.0	6
3006	Treat-to-target versus dose-adapted statin treatment of cholesterol to reduce cardiovascular risk. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 275-281.	0.8	8
3007	Regression of coronary atherosclerosis: Current evidence and future perspectives. <i>Trends in Cardiovascular Medicine</i> , 2016, 26, 150-161.	2.3	22
3008	Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2016, 67, 353-361.	1.2	173
3009	Significance of Monoclonal PCSK9-Antibodies - New Approaches to the Therapy of Hypercholesterolemia. <i>Blood Purification</i> , 2016, 41, 270-276.	0.9	5
3010	Statins and myocardial infarction: Type, dose, and administration time: Does it matter?. <i>Trends in Cardiovascular Medicine</i> , 2016, 26, 433-441.	2.3	7
3011	The Role of Ezetimibe in the Treatment of Cardiovascular Disease. <i>Current Atherosclerosis Reports</i> , 2016, 18, 8.	2.0	3
3012	2013 Cholesterol Guidelines Revisited: Percent LDL Cholesterol Reduction or Attained LDL Cholesterol Level or Both for Prognosis?. <i>American Journal of Medicine</i> , 2016, 129, 384-391.	0.6	37
3013	No evidence to support high-intensity statin in Chinese patients with coronary heart disease. <i>International Journal of Cardiology</i> , 2016, 204, 57-58.	0.8	19
3014	Current Management of Hyperlipidemia in Patients Discharged With a Diagnosis of Acute Coronary Syndrome. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2016, 69, 83-84.	0.4	0
3015	Reduction of ischemic events in Improved Reduction of Outcomes: Vytorin Efficacy International Trial: Intensive cholesterol lowering or ezetimibe antithrombotic effects?. <i>American Heart Journal</i> , 2016, 172, 42-44.	1.2	1
3016	Defining the Role of PCSK9 Inhibitors in the Treatment of Hyperlipidemia. <i>American Journal of Cardiovascular Drugs</i> , 2016, 16, 83-92.	1.0	10
3017	Managing Residual Risk After Myocardial Infarction Among Individuals with Low Cholesterol Levels. <i>Endocrinology and Metabolism Clinics of North America</i> , 2016, 45, 171-184.	1.2	1
3018	Comparison of the Effect of Rosuvastatin 2.5mg vs 20mg on Coronary Plaque Determined by Angioscopy and Intravascular Ultrasound in Japanese With Stable Angina Pectoris (from the) <i>TJ ETQq1</i> 1 0.784314 0.77 / Overlock 10 17	0.7	17

#	ARTICLE	IF	CITATIONS
3019	The Success Story of LDL Cholesterol Lowering. <i>Circulation Research</i> , 2016, 118, 721-731.	2.0	48
3020	From Lipids to Inflammation. <i>Circulation Research</i> , 2016, 118, 732-749.	2.0	180
3021	A lipidologist perspective of global lipid guidelines and recommendations, part 2: Lipid treatment goals. <i>Journal of Clinical Lipidology</i> , 2016, 10, 240-264.	0.6	3
3022	Changes of coronary plaque composition correlate with C-reactive protein levels in patients with ST-elevation myocardial infarction following high-intensity statin therapy. <i>Atherosclerosis</i> , 2016, 247, 154-160.	0.4	22
3023	Meta-Analysis of Medium and Long-Term Efficacy of Loading Statins After Coronary Artery Bypass Grafting. <i>Annals of Thoracic Surgery</i> , 2016, 101, 990-995.	0.7	12
3024	Association between statin treatment and LDL-cholesterol levels on the rate of ST-elevation myocardial infarction among patients with acute coronary syndromes: ACS Israeli Survey (ACSIS) 2002-2010. <i>International Journal of Cardiology</i> , 2016, 210, 133-138.	0.8	6
3025	Accelerate and Decelerate in Primary Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 241-243.	1.1	0
3026	Regression of Some High-risk Features of Age-related Macular Degeneration (AMD) in Patients Receiving Intensive Statin Treatment. <i>EBioMedicine</i> , 2016, 5, 198-203.	2.7	106
3027	Guidelines for Management of Hyperlipidemia: Implications for Treatment of Patients with Stroke Secondary to Atherosclerotic Disease. <i>Current Neurology and Neuroscience Reports</i> , 2016, 16, 24.	2.0	12
3028	Inflammation, High-sensitivity C-reactive Protein, and Persistent Patent Ductus Arteriosus in Preterm Infants. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2016, 69, 84-85.	0.4	5
3029	Manejo actual de la hiperlipemia en pacientes dados de alta con el diagnóstico de síndrome coronario agudo. <i>Revista Espanola De Cardiologia</i> , 2016, 69, 83-84.	0.6	2
3030	Comparison of Intensive Versus Moderate Lipid-Lowering Therapy on Fibrous Cap and Atheroma Volume of Coronary Lipid-Rich Plaque Using Serial Optical Coherence Tomography and Intravascular Ultrasound Imaging. <i>American Journal of Cardiology</i> , 2016, 117, 800-806.	0.7	73
3031	Cochrane corner: early statin therapy in acute coronary syndromes—what is the clinical benefit?. <i>Heart</i> , 2016, 102, 653-654.	1.2	10
3032	Lipoprotein(a) levels predict adverse vascular events after acute myocardial infarction. <i>Heart and Vessels</i> , 2016, 31, 1923-1929.	0.5	24
3034	National Lipid Association Annual Summary of Clinical Lipidology 2016. <i>Journal of Clinical Lipidology</i> , 2016, 10, S1-S43.	0.6	99
3035	Current Controversies With Recent Cholesterol Treatment Guidelines. <i>Journal of Pharmacy Practice</i> , 2016, 29, 15-25.	0.5	6
3036	Statin use, intensity, and 3-year clinical outcomes among older patients with coronary artery disease. <i>American Heart Journal</i> , 2016, 173, 27-34.	1.2	17
3037	8. Cardiovascular Disease and Risk Management. <i>Diabetes Care</i> , 2016, 39, S60-S71.	4.3	237

#	ARTICLE	IF	CITATIONS
3038	Acute effects of statin on reduction of angiotensin-like 2 and glyceraldehyde-derived advanced glycation end-products levels in patients with acute myocardial infarction: a message from SAMIT (Statin for Acute Myocardial Infarction Trial). <i>Heart and Vessels</i> , 2016, 31, 1583-1589.	0.5	32
3039	Intensive LDL lowering therapy for prevention of recurrent cardiovascular events: a word of caution. <i>European Heart Journal</i> , 2016, 37, 520-523.	1.0	5
3040	Should all surgery patients get statins pre-operatively? Clear or blurry VISION?. <i>European Heart Journal</i> , 2016, 37, 186-188.	1.0	2
3041	Impact of Statins on Influenza Vaccine Effectiveness Against Medically Attended Acute Respiratory Illness. <i>Journal of Infectious Diseases</i> , 2016, 213, 1216-1223.	1.9	53
3042	Mortality benefit of statin use in traumatic spinal cord injury: a retrospective analysis. <i>Spinal Cord</i> , 2016, 54, 298-302.	0.9	9
3043	2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. <i>European Heart Journal</i> , 2016, 37, 267-315.	1.0	5,890
3044	Evaluation of Statin Prescribing for Secondary Prevention in Primary Care Following New Guideline Recommendations. <i>Annals of Pharmacotherapy</i> , 2016, 50, 17-21.	0.9	12
3045	Lipoprotein Metabolism and the Treatment of Lipid Disorders. , 2016, , 715-736.e7.		5
3046	Type 2 Diabetes. , 0, , .		4
3047	Effects of sitagliptin on coronary atherosclerosis evaluated using integrated backscatter intravascular ultrasound in patients with type 2 diabetes: rationale and design of the TRUST study. <i>Heart and Vessels</i> , 2016, 31, 649-654.	0.5	8
3048	Guideline Confusion for the Clinician. <i>Angiology</i> , 2016, 67, 5-9.	0.8	4
3049	Treatment of Hypercholesterolemia in 2015. <i>American Journal of Therapeutics</i> , 2017, 24, e121-e129.	0.5	2
3050	A Randomized Open-Label Trial to Assess the Effect of Plant Sterols Associated with Ezetimibe in Low-Density Lipoprotein Levels in Patients with Coronary Artery Disease on Statin Therapy. <i>Journal of Medicinal Food</i> , 2017, 20, 30-36.	0.8	12
3051	Lipid and other management to improve arterial disease and survival in end stage renal disease. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 343-349.	0.9	3
3052	In-hospital statin underutilization among high-risk patients: delayed uptake of the 2013 cholesterol guidelines in a U.S. cohort. <i>Hospital Practice (1995)</i> , 2017, 45, 16-20.	0.5	2
3053	Investigating the prevalence, predictors, and prognosis of suboptimal statin use early after a non-ST elevation acute coronary syndrome. <i>Journal of Clinical Lipidology</i> , 2017, 11, 204-214.	0.6	20
3054	Pleiotropic Effects of Statins on the Cardiovascular System. <i>Circulation Research</i> , 2017, 120, 229-243.	2.0	808
3055	Is non-HDL-cholesterol a better predictor of long-term outcome in patients after acute myocardial infarction compared to LDL-cholesterol? : a retrospective study. <i>BMC Cardiovascular Disorders</i> , 2017, 17, 10.	0.7	33

#	ARTICLE	IF	CITATIONS
3056	Consensus statement on the management of dyslipidaemias in adults. <i>Annales D'Endocrinologie</i> , 2017, 78, 43-53.	0.6	3
3057	Predictors of Nonuse of a High-Potency Statin After an Acute Coronary Syndrome: Insights From the Stabilization of Plaques Using Darapladib-Thrombolysis in Myocardial Infarction 52 (SOLID-TIMI 52) Trial. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	8
3058	Anticoagulants in ischemia-guided management of non-ST-elevation acute coronary syndromes. <i>American Journal of Emergency Medicine</i> , 2017, 35, 502-507.	0.7	3
3061	PCSK9 Monoclonal Antibodies in 2016: Current Status and Future Challenges. <i>Heart Lung and Circulation</i> , 2017, 26, 786-798.	0.2	2
3062	Elevated troponin in patients with acute stroke – Is it a true heart attack?. <i>Egyptian Heart Journal</i> , 2017, 69, 165-170.	0.4	10
3063	Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention. <i>Journal of the American College of Cardiology</i> , 2017, 69, 911-921.	1.2	157
3064	Ezetimibe: an update on its clinical usefulness in specific patient groups. <i>Therapeutic Advances in Chronic Disease</i> , 2017, 8, 4-11.	1.1	44
3065	Impact of Pharmacist Intervention to Increase Compliance With Guideline-Directed Statin Therapy During an Acute Coronary Syndrome Hospitalization. <i>Annals of Pharmacotherapy</i> , 2017, 51, 394-400.	0.9	5
3066	2017 Taiwan lipid guidelines for high risk patients. <i>Journal of the Formosan Medical Association</i> , 2017, 116, 217-248.	0.8	123
3067	Baseline adiponectin concentration and clinical outcomes among patients with diabetes and recent acute coronary syndrome in the <sc>EXAMINE</sc> trial. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 962-969.	2.2	26
3068	Pathophysiology and treatment of atherosclerosis. <i>Netherlands Heart Journal</i> , 2017, 25, 231-242.	0.3	186
3069	Effects of atorvastatin and diet interventions on atherosclerotic plaque inflammation and [18F]FDG uptake in Ldlr <sup>-/-</sup> /ApoB mice. <i>Atherosclerosis</i> , 2017, 263, 369-376.	0.4	18
3070	Fertility and Embryo-Fetal Development Assessment in Rats and Rabbits with Evacetrapib: A Cholesteryl Ester Transfer Protein Inhibitor. <i>Birth Defects Research</i> , 2017, 109, 513-527.	0.8	1
3071	Targeting LDL Cholesterol: Beyond Absolute Goals Toward Personalized Risk. <i>Current Cardiology Reports</i> , 2017, 19, 52.	1.3	13
3072	Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial. <i>European Heart Journal</i> , 2017, 38, 2264-2276.	1.0	94
3073	Intensity of Statin Treatment and Mortality – Reply. <i>JAMA Cardiology</i> , 2017, 2, 928.	3.0	2
3074	Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: The ACCENTUATE trial. <i>Atherosclerosis</i> , 2017, 261, 12-18.	0.4	32
3075	Alirocumab for the treatment of hypercholesterolaemia. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 571-582.	1.3	9

#	ARTICLE	IF	CITATIONS
3076	Association of cytochrome P4502E1 and NAD(P)H:quinone oxidoreductase 1 genetic polymorphisms with susceptibility to large artery atherosclerotic ischemic stroke: a case-control study in the Turkish population. <i>Neurological Sciences</i> , 2017, 38, 1077-1085.	0.9	6
3077	Clinical Significance of Lipid-Rich Plaque Detected by Optical Coherence Tomography. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2502-2513.	1.2	142
3078	Prenatal and Postnatal Assessment in Rabbits with Evacetrapib: A Cholesteryl Ester Transfer Protein Inhibitor. <i>Birth Defects Research</i> , 2017, 109, 486-496.	0.8	2
3079	Healthcare provider compliance with the 2013 ACC/AHA Adult Cholesterol Guideline recommendation for high-intensity dose statins for patients with coronary artery disease. <i>Heart and Lung: Journal of Acute and Critical Care</i> , 2017, 46, 328-333.	0.8	8
3080	Benefits of Statin Therapy in Patients With Acute Myocardial Infarction With Serum Low-Density Lipoprotein Cholesterol $\geq$ 50 mg/dl. <i>American Journal of Cardiology</i> , 2017, 120, 174-180.	0.7	6
3081	A study in high-risk, maximally pretreated patients to determine the potential use of PCSK9 inhibitors at various thresholds of total and LDL cholesterol levels. <i>Postgraduate Medical Journal</i> , 2017, 93, 205-208.	0.9	1
3082	Photodynamic therapy for the treatment of atherosclerotic plaque: Lost in translation?. <i>Cardiovascular Therapeutics</i> , 2017, 35, e12238.	1.1	26
3083	Influence of ezetimibe in addition to high-dose atorvastatin therapy on plaque composition in patients with ST-segment elevation myocardial infarction assessed by serial. <i>Cardiovascular Revascularization Medicine</i> , 2017, 18, 110-117.	0.3	30
3084	Discontinuation of Statins at the End of Life #322. <i>Journal of Palliative Medicine</i> , 2017, 20, 199-200.	0.6	4
3085	Intensive versus moderate atorvastatin therapy and one-year graft patency after CABG: Rationale and design of the ACTIVE (Aggressive Cholesterol Therapy to Inhibit Vein Graft Events) randomized controlled trial (NCT01528709). <i>Contemporary Clinical Trials</i> , 2017, 59, 98-104.	0.8	11
3086	Coronary artery disease: Risk stratification and patient selection for more aggressive secondary prevention. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 88-100.	0.8	45
3087	Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease. <i>New England Journal of Medicine</i> , 2017, 376, 1933-1942.	13.9	593
3088	Evidence for more intensive cholesterol lowering. <i>Current Opinion in Lipidology</i> , 2017, 28, 291-299.	1.2	13
3089	Adherence to lipid management guidelines is associated with lower mortality and major adverse limb events in patients undergoing revascularization for chronic limb-threatening ischemia. <i>Journal of Vascular Surgery</i> , 2017, 66, 572-578.	0.6	38
3090	Statin prescription strategies and atherogenic cholesterol goals attainment in Lebanese coronary artery disease patients. <i>International Journal of Clinical Pharmacy</i> , 2017, 39, 919-926.	1.0	4
3091	Pharmacologic Treatment of Dyslipidemia in Diabetes: A Case for Therapies in Addition to Statins. <i>Current Cardiology Reports</i> , 2017, 19, 62.	1.3	3
3092	Effectiveness of adherence to lipid lowering therapy on LDL-cholesterol in patients with very high cardiovascular risk: A real-world evidence study in primary care. <i>Atherosclerosis</i> , 2017, 263, 36-41.	0.4	59
3093	Renal Targeted Therapies of Antihypertensive and Cardiovascular Drugs for Patients With Stages 3 Through 5d Kidney Disease. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 450-458.	2.3	11



#	ARTICLE	IF	CITATIONS
3094	Pragmatic approach to chest pain patients discharged with undetectable high-sensitivity troponin T and normal <sc>electrocardiogram</sc>: the <sc>STABS</sc> + <sc>CT</sc> protocol. Internal Medicine Journal, 2017, 47, 698-701.	0.5	0
3095	Trends in Use of High-Intensity Statin Therapy After Myocardial Infarction, 2011 to 2014. Journal of the American College of Cardiology, 2017, 69, 2696-2706.	1.2	70
3096	Addition of omega-3 fatty acid and coenzyme Q10 to statin therapy in patients with combined dyslipidemia. Journal of Basic and Clinical Physiology and Pharmacology, 2017, 28, 327-336.	0.7	25
3097	Monocyte inflammatory profile is specific for individuals and associated with altered blood lipid levels. Atherosclerosis, 2017, 263, 15-23.	0.4	50
3098	A systematic literature review of methods of incorporating mortality in cost-effectiveness analyses of lipid-lowering therapies. Journal of Medical Economics, 2017, 20, 767-775.	1.0	2
3099	Mendelian randomisation in cardiovascular research: an introduction for clinicians. Heart, 2017, 103, 1400-1407.	1.2	126
3100	Has cost inhibited the uptake of more potent statins in England?. Pharmacoepidemiology and Drug Safety, 2017, 26, 984-991.	0.9	6
3101	Atheroprotective effects of statins in patients with unstable angina by regulating the blood-borne microRNA network. Molecular Medicine Reports, 2017, 16, 817-827.	1.1	8
3102	Teaching an Old Dog New Tricks: Colchicine in Cardiovascular Medicine. American Journal of Cardiovascular Drugs, 2017, 17, 347-360.	1.0	17
3103	Did Medicare Part D reduce mortality?. Journal of Health Economics, 2017, 53, 17-37.	1.3	39
3104	Hydrophilic vs lipophilic statins in coronary artery disease: A meta-analysis of randomized controlled trials. Journal of Clinical Lipidology, 2017, 11, 624-637.	0.6	30
3105	A randomized, controlled comparison of different intensive lipid-lowering therapies in Chinese patients with non-ST-elevation acute coronary syndrome (NSTEMI-ACS): Ezetimibe and rosuvastatin versus high-dose rosuvastatin. International Journal of Cardiology, 2017, 235, 49-55.	0.8	24
3106	Effects of dyslipidaemia on monocyte production and function in cardiovascular disease. Nature Reviews Cardiology, 2017, 14, 387-400.	6.1	66
3107	Relation of Intensity of Statin Therapy and Outcomes After Transcatheter Aortic Valve Replacement. American Journal of Cardiology, 2017, 119, 1832-1838.	0.7	24
3108	Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. New England Journal of Medicine, 2017, 376, 1713-1722.	13.9	4,179
3109	Impact of Paradoxical Decrease in High-density Lipoprotein Cholesterol Levels After Statin Therapy on Major Adverse Cardiovascular Events in Patients with Stable Angina Pectoris. Clinical Therapeutics, 2017, 39, 279-287.	1.1	4
3110	Impact of statin therapy on long-term clinical outcomes of vasospastic angina without significant stenosis: Improve or not?. International Journal of Cardiology, 2017, 229, 21-22.	0.8	0
3111	Early initiation of eicosapentaenoic acid and statin treatment is associated with better clinical outcomes than statin alone in patients with acute coronary syndromes: 1-year outcomes of a randomized controlled study. International Journal of Cardiology, 2017, 228, 173-179.	0.8	66

#	ARTICLE	IF	CITATIONS
3112	Inflammation and beyond: new directions and emerging drugs for treating atherosclerosis. Expert Opinion on Emerging Drugs, 2017, 22, 1-26.	1.0	45
3113	9. Cardiovascular Disease and Risk Management. Diabetes Care, 2017, 40, S75-S87.	4.3	203
3114	Lipid-lowering therapy stabilizes the complexity of non-culprit plaques in human coronary artery: a quantitative assessment using OCT bright spot algorithm. International Journal of Cardiovascular Imaging, 2017, 33, 453-461.	0.7	7
3115	Statin therapy in the prevention of atrial fibrillation in the early postoperative period after coronary artery bypass grafting: A meta-analysis. Cor Et Vasa, 2017, 59, e266-e271.	0.1	6
3116	Effects of Ethnicity on the Prevalence of Obstructive Sleep Apnoea in Patients with Acute Coronary Syndrome: A Pooled Analysis of the ISAACC Trial and Sleep and Stent Study. Heart Lung and Circulation, 2017, 26, 486-494.	0.2	14
3117	Variation in adherence to medications across the healthcare system in two comparative effectiveness research cohorts. Journal of Comparative Effectiveness Research, 2017, 6, 613-625.	0.6	2
3118	The CANTOS Trial. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, e174-e177.	1.1	66
3119	Statin Discontinuation, Reinitiation, and Persistence Patterns Among Medicare Beneficiaries After Myocardial Infarction. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	0.9	38
3120	Evaluation of the impact of statin therapy on the obesity paradox in patients with acute myocardial infarction. Medicine (United States), 2017, 96, e7180.	0.4	8
3121	Effects of Statin Intensity and Adherence on the Long-Term Prognosis After Acute Ischemic Stroke. Stroke, 2017, 48, 2723-2730.	1.0	62
3122	Many shades of grey: seeking the optimal medical therapy of acute coronary syndrome in older people. Journal of Pharmacy Practice and Research, 2017, 47, 403-410.	0.5	0
3123	Soluble interleukin-13 $\beta$ : a circulating regulator of glucose. American Journal of Physiology - Endocrinology and Metabolism, 2017, 313, E663-E671.	1.8	4
3124	The Effect of Cardiovascular Risk Factors on the Coronary Circulation. , 2017, , 81-98.		0
3125	Lipid management in contemporary community practice: Results from the Provider Assessment of Lipid Management (PALM) Registry. American Heart Journal, 2017, 193, 84-92.	1.2	55
3126	Time for new low density lipoprotein cholesterol (LDL-C) targets?. Expert Opinion on Pharmacotherapy, 2017, 18, 1539-1541.	0.9	2
3127	High-Intensity Statin Therapy Is Associated With Improved Survival in Patients With Peripheral Artery Disease. Journal of the American Heart Association, 2017, 6, .	1.6	44
3128	Current insights into the German lipoprotein apheresis standard: PCSK9-inhibitors, lipoprotein apheresis or both?. Atherosclerosis Supplements, 2017, 30, 44-49.	1.2	7
3129	Usefulness of Elevated Levels of Growth Differentiation Factor-15 to Classify Patients With Acute Coronary Syndrome Having Percutaneous Coronary Intervention Who Would Benefit from High-Dose Statin Therapy. American Journal of Cardiology, 2017, 120, 747-752.	0.7	6

#	ARTICLE	IF	CITATIONS
3130	High versus low dose statin therapy in Indian patients with acute ST-segment elevation myocardial infarction undergoing thrombolysis. <i>Indian Heart Journal</i> , 2017, 69, 453-457.	0.2	11
3131	Trans fatty acids and plaque vulnerability: Research continues. <i>Atherosclerosis</i> , 2017, 265, 244-245.	0.4	0
3132	Plaque burden, microstructures and compositions underachieving very low LDL-C levels. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2017, 24, 122-132.	1.2	7
3133	Goldilocks Dilemma of Dose Titration in Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2017, 10, .	1.6	2
3134	Prognostic impact of intensive statin therapy on N-terminal pro-BNP level in non-ST-segment elevation acute myocardial infarction patients. <i>Journal of Interventional Cardiology</i> , 2017, 30, 514-521.	0.5	6
3135	Where Does Inflammation Fit?. <i>Current Cardiology Reports</i> , 2017, 19, 84.	1.3	32
3136	Treatment Trends, Effectiveness, and Safety of Statins on Lipid Goal Attainment in Chinese Percutaneous Coronary Intervention Patients: a Multicenter, Retrospective Cohort Study. <i>Clinical Therapeutics</i> , 2017, 39, 1827-1839.e1.	1.1	7
3137	The differential effects of atorvastatin co-administered with ampicillin on the bacterial growth and biofilm formation of <i>Staphylococcus aureus</i> . <i>Current Medicine Research and Practice</i> , 2017, 7, 178-183.	0.1	4
3138	Cardiac Innervation and the Autonomic Nervous System in Sudden Cardiac Death. <i>Cardiac Electrophysiology Clinics</i> , 2017, 9, 665-679.	0.7	29
3140	2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2017, 70, 1082.	0.4	189
3141	Atherosclerotic Cardiovascular Risk in Japan. <i>Japanese Clinical Medicine</i> , 2017, 8, 117906601771271.	1.9	13
3142	Role of Cardiac PET in Clinical Practice. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2017, 19, 93.	0.4	11
3143	Closing the Remaining Evidence Gap. <i>Circulation</i> , 2017, 136, 1892-1894.	1.6	0
3144	Real-world study of low-density lipoprotein cholesterol levels and cardiovascular outcomes in Chinese: A retrospective cohort study in post-percutaneous coronary intervention acute coronary syndrome patients. <i>International Journal of Cardiology</i> , 2017, 249, 18-24.	0.8	20
3145	Lipid Management After First Diagnosis of Coronary Artery Disease: Contemporary Results From an Observational Cohort Study. <i>Clinical Therapeutics</i> , 2017, 39, 2311-2320.e2.	1.1	10
3146	Clinical Predictors for Lack of Favorable Vascular Response to Statin Therapy in Patients With Coronary Artery Disease: A Serial Optical Coherence Tomography Study. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	14
3147	Long-term Safety and Efficacy of New-Generation Drug-Eluting Stents in Women With Acute Myocardial Infarction. <i>JAMA Cardiology</i> , 2017, 2, 855.	3.0	25
3148	Considerations and treatment options for patients with comorbid atrial fibrillation and diabetes mellitus. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1101-1114.	0.9	12

#	ARTICLE	IF	CITATIONS
3149	Is age an important factor for vascular response to statin therapy? A serial optical coherence tomography and intravascular ultrasound study. <i>Coronary Artery Disease</i> , 2017, 28, 209-217.	0.3	8
3150	Are the PCSK9 inhibitors the panacea of atherosclerosis treatment?. <i>Expert Review of Cardiovascular Therapy</i> , 2017, 15, 491-494.	0.6	8
3151	Secondary prevention strategies after an acute ST-segment elevation myocardial infarction in the AMI code era: beyond myocardial mechanical reperfusion. <i>BMC Cardiovascular Disorders</i> , 2017, 17, 54.	0.7	18
3152	The Immunology of Cardiovascular Homeostasis and Pathology. <i>Advances in Experimental Medicine and Biology</i> , 2017, , .	0.8	14
3153	Risk factors associated with atherogenic dyslipidemia in the presence of optimal statin therapy. <i>International Journal of Cardiology</i> , 2017, 248, 355-360.	0.8	7
3154	Atherosclerosis. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1003, 121-144.	0.8	61
3155	The emerging role of proprotein convertase subtilisin/kexin type-9 inhibition in secondary prevention. <i>Current Opinion in Cardiology</i> , 2017, 32, 633-641.	0.8	2
3156	Role of Niacin in Current Clinical Practice: A Systematic Review. <i>American Journal of Medicine</i> , 2017, 130, 173-187.	0.6	66
3157	Association Between Intensity of Statin Therapy and Mortality in Patients With Atherosclerotic Cardiovascular Disease. <i>JAMA Cardiology</i> , 2017, 2, 47.	3.0	132
3158	Plaque imaging to refine indications for emerging lipid-lowering drugs. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2017, 3, 58-67.	1.4	26
3159	Impact of Intensive LDL Cholesterol Lowering on Coronary Artery Atherosclerosis Progression. <i>JACC: Cardiovascular Imaging</i> , 2017, 10, 437-446.	2.3	73
3160	Short-term changes in arterial inflammation predict long-term changes in atherosclerosis progression. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 141-150.	3.3	22
3161	Rationale, design features, and baseline characteristics: The Heart Institute of Japan-PROper level of lipid lowering with Pitavastatin and Ezetimibe in acute coronary syndrome (HIJ-PROPER). <i>Journal of Cardiology</i> , 2017, 69, 536-541.	0.8	9
3162	Cholesteryl Ester Transfer Protein Inhibitors. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2017, 22, 99-104.	1.0	11
3163	Acute myocardial infarction. <i>Lancet</i> , 2017, 389, 197-210.	6.3	869
3164	Treat-to-target lipid control is effective but highlighted poor prognosis without indication of statin following percutaneous coronary intervention. <i>Cardiovascular Intervention and Therapeutics</i> , 2017, 32, 358-364.	1.2	4
3165	Increased Benefit With Vorapaxar Use in Patients With a History of Myocardial Infarction and Diabetes Mellitus. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2017, 22, 133-141.	1.0	2
3166	Quality indicators for acute myocardial infarction: A position paper of the Acute Cardiovascular Care Association. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017, 6, 34-59.	0.4	109

#	ARTICLE	IF	CITATIONS
3168	Type 2 diabetes and cardiovascular disease: A metabolic overview of recent clinical trials. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 291-294.	1.2	3
3169	Targeting microsomal triglyceride transfer protein and lipoprotein assembly to treat homozygous familial hypercholesterolemia. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2017, 54, 26-48.	2.7	27
3170	A Systematic Review of Cardiovascular Outcomes-Based Cost-Effectiveness Analyses of Lipid-Lowering Therapies. <i>Pharmacoeconomics</i> , 2017, 35, 297-318.	1.7	15
3171	Statins and the cholesterol mortality paradox. <i>Scottish Medical Journal</i> , 2017, 62, 19-23.	0.7	10
3172	Sodium tanshinone IIA sulfate adjunct therapy reduces high-sensitivity C-reactive protein level in coronary artery disease patients: a randomized controlled trial. <i>Scientific Reports</i> , 2017, 7, 17451.	1.6	36
3173	ANMCO Scientific Statement: clinical management of hypercholesterolaemia in patients with acute coronary syndromes. <i>European Heart Journal Supplements</i> , 2017, 19, D64-D69.	0.0	2
3174	β-Blocker Therapy Prior to Admission for Acute Coronary Syndrome in Patients Without Heart Failure or Left Ventricular Dysfunction Improves In-Hospital and 12-Month Outcome: Results From the GULF-TRACE 2 (Gulf Registry of Acute Coronary Events). <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	9
3175	Life expectancy difference and life expectancy ratio: two measures of treatment effects in randomised trials with non-proportional hazards. <i>BMJ: British Medical Journal</i> , 2017, 357, j2250.	2.4	67
3176	Una historia resumida. Impacto de los avances en el control lipídico. <i>Revista Espanola De Cardiologia Suplementos</i> , 2017, 17, 7-9.	0.2	0
3177	Secondary prevention of major cerebrovascular events with seven different statins: a multi-treatment meta-analysis. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 2517-2526.	2.0	14
3178	High-density Lipoprotein and Low-density Lipoprotein Therapeutic Approaches in Acute Coronary Syndromes. <i>Current Cardiology Reviews</i> , 2017, 13, 168-182.	0.6	9
3179	Patterns of statin non-prescription in patients with established coronary artery disease: A report from a contemporary multicenter Japanese PCI registry. <i>PLoS ONE</i> , 2017, 12, e0182687.	1.1	11
3180	Lipid lowering therapy in patients with atherosclerotic cardiovascular diseases: Which matters in the real world? Statin intensity or low-density lipoprotein cholesterol level? Data from a multicenter registry cohort study in Taiwan. <i>PLoS ONE</i> , 2017, 12, e0186861.	1.1	20
3181	Impact of Lipoprotein (a) on Long-Term Outcomes in Patients with Coronary Artery Disease Treated with Statin After a First Percutaneous Coronary Intervention. <i>Journal of Atherosclerosis and Thrombosis</i> , 2017, 24, 1125-1131.	0.9	28
3183	Racial Differences in the Cholesterol-Lowering Effect of Statin. <i>Journal of Atherosclerosis and Thrombosis</i> , 2017, 24, 19-25.	0.9	78
3184	Lipid Lowering Therapy to Modify Plaque Microstructures. <i>Journal of Atherosclerosis and Thrombosis</i> , 2017, 24, 360-372.	0.9	7
3186	Acute Coronary Syndromes in the Elderly. <i>F1000Research</i> , 2017, 6, 1791.	0.8	35
3187	Differences in the Korea Acute Myocardial Infarction Registry Compared with Western Registries. <i>Korean Circulation Journal</i> , 2017, 47, 811.	0.7	26

#	ARTICLE	IF	CITATIONS
3188	Efficacy and safety of pitavastatins in patients with acute myocardial infarction: Livalo in Acute Myocardial Infarction Study (LAMIS) II. Korean Journal of Internal Medicine, 2017, 32, 656-667.	0.7	5
3189	Advances in Age-related Macular Degeneration Understanding and Therapy. US Ophthalmic Review, 2017, 10, 119.	0.2	53
3190	Statin-ezetimibe versus statin lipid-lowering therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention. Journal of Thoracic Disease, 2017, 9, 1345-1352.	0.6	6
3192	Functional Heterogeneity of NADPH Oxidases in Atherosclerotic and Aneurysmal Diseases. Journal of Atherosclerosis and Thrombosis, 2017, 24, 1-13.	0.9	19
3193	Treating Dyslipidemia in Type 2 Diabetes. Cardiology Clinics, 2018, 36, 233-239.	0.9	11
3194	Acute Myocardial Infarction Mortality During Dates of National Interventional Cardiology Meetings. Journal of the American Heart Association, 2018, 7, .	1.6	17
3195	Risk of new-onset diabetes mellitus during treatment with low-dose statins in Japan: A retrospective cohort study. Journal of Clinical Pharmacy and Therapeutics, 2018, 43, 536-542.	0.7	7
3196	Statin utilization and lipid goal attainment in high or very-high cardiovascular risk patients: Insights from Italian general practice. Atherosclerosis, 2018, 271, 120-127.	0.4	31
3197	Effects of Statin Intensity on Clinical Outcome in Acute Myocardial Infarction Patients. Circulation Journal, 2018, 82, 1112-1120.	0.7	18
3198	Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering. JAMA - Journal of the American Medical Association, 2018, 319, 1566.	3.8	339
3199	ST-Segment Elevation Myocardial Infarction. , 2018, , 311-327.		4
3200	Prevention and management of statin adverse effects: A practical approach for pharmacists. Canadian Pharmacists Journal, 2018, 151, 179-188.	0.4	19
3201	The prevalence and predictors of elevated C-reactive protein after a coronary heart disease event. European Journal of Preventive Cardiology, 2018, 25, 923-931.	0.8	31
3203	Peptide Amphiphile Nanostructures for Targeting of Atherosclerotic Plaque and Drug Delivery. Advanced Biology, 2018, 2, 1700123.	3.0	27
3204	Documented coronary atherothrombosis as the cause of death in post-discharge patients after coronary revascularization. Cardiovascular Revascularization Medicine, 2018, 19, 597-606.	0.3	0
3205	Clinical and pathophysiological evidence supporting the safety of extremely low LDL levels—the zero-LDL hypothesis. Journal of Clinical Lipidology, 2018, 12, 292-299.e3.	0.6	51
3206	The pharmacodynamic and clinical trial evidence for statin dose. British Journal of Clinical Pharmacology, 2018, 84, 1128-1135.	1.1	17
3207	Dose-Dependent Effects of Statins for Patients with Aneurysmal Subarachnoid Hemorrhage: Meta-Regression Analysis. World Neurosurgery, 2018, 113, 153-162.	0.7	5

#	ARTICLE	IF	CITATIONS
3208	Lipid Testing and Statin Dosing After Acute Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	22
3209	Therapeutic Advances in the Perioperative Period for Older Adults. <i>American Journal of Therapeutics</i> , 2018, 25, e81-e91.	0.5	0
3210	Human Immunodeficiency Virus Infection, Antiretroviral Therapy, and Statin: a Clinical Update. <i>Current Atherosclerosis Reports</i> , 2018, 20, 9.	2.0	8
3211	Impact of CD14 ++ CD16 + monocytes on coronary plaque vulnerability assessed by optical coherence tomography in coronary artery disease patients. <i>Atherosclerosis</i> , 2018, 269, 245-251.	0.4	32
3213	Dyslipidemia. , 2018, , 303-309.		0
3215	The effect of fasting status on lipids, lipoproteins, and inflammatory biomarkers assessed after hospitalization for an acute coronary syndrome: Insights from PROVE IT™/TIMI 22. <i>Clinical Cardiology</i> , 2018, 41, 68-73.	0.7	5
3216	Paradoxical impact of decreased low-density lipoprotein cholesterol level at baseline on the long-term prognosis in patients with acute coronary syndrome. <i>Heart and Vessels</i> , 2018, 33, 695-705.	0.5	16
3217	Present therapeutic role of cholesteryl ester transfer protein inhibitors. <i>Pharmacological Research</i> , 2018, 128, 29-41.	3.1	45
3218	Genetic variation in statin intolerance and a possible protective role for <i>UGT1A1</i> . <i>Pharmacogenomics</i> , 2018, 19, 83-94.	0.6	10
3220	¿Se deberÃa intensificar el tratamiento hipolipemiente tras la implantaciÃn de un stent farmacoactivo?. <i>Revista Espanola De Cardiologia</i> , 2018, 71, 416-417.	0.6	2
3222	Association of Statin Dose With Amputation and Survival in Patients With Peripheral Artery Disease. <i>Circulation</i> , 2018, 137, 1435-1446.	1.6	179
3223	Appropriateness of statin prescription in the elderly. <i>European Journal of Internal Medicine</i> , 2018, 50, 33-40.	1.0	43
3224	Dyslipidaemia in the elderly: to treat or not to treat?. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 259-278.	1.3	7
3225	LDL cholesterol: How low to go?. <i>Trends in Cardiovascular Medicine</i> , 2018, 28, 348-354.	2.3	12
3226	High-Sensitivity C-Reactive Protein Combined with Low-Density Lipoprotein Cholesterol as the Targets of Statin Therapy in Patients with Acute Coronary Syndrome. <i>International Heart Journal</i> , 2018, 59, 300-306.	0.5	7
3227	Variations in time to benefit among clinical trials of cholesterol-lowering drugs. <i>Journal of Clinical Lipidology</i> , 2018, 12, 857-862.	0.6	21
3228	First 24h in the management of non-ST segment elevation myocardial infarction. <i>European Heart Journal Supplements</i> , 2018, 20, B29-B38.	0.0	1
3229	A Phase III, Multicenter, Randomized, Double-blind, Active Comparator Clinical Trial to Compare the Efficacy and Safety of Combination Therapy With Ezetimibe and Rosuvastatin Versus Rosuvastatin Monotherapy in Patients With Hypercholesterolemia: I-ROSETTE (Ildong Rosuvastatin & Ezetimibe) Tj ETQq1 11-0.78431437rgBT /Ove	1.1	37

#	ARTICLE	IF	CITATIONS
3230	Temporal Trends of High-Intensity Statin Therapy Among Veterans Treated With Percutaneous Coronary Intervention. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	9
3231	Prognostic Impact of Statin Intensity in Heart Failure Patients With Ischemic Heart Disease: A Report From the CHART-2 (Chronic Heart Failure Registry and Analysis in the Tohoku District 2) Study. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	12
3232	Partners and Alerts in Medication Adherence: A Randomized Clinical Trial. <i>Journal of General Internal Medicine</i> , 2018, 33, 1536-1542.	1.3	19
3233	Lipid Lowering in Acute Coronary Syndrome. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 1325.	3.8	6
3234	6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial. <i>Lancet, The</i> , 2018, 391, 1274-1284.	6.3	261
3235	A consensus statement on lipid management after acute coronary syndrome. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2018, 7, 532-543.	0.4	27
3237	Which Came First, the Chicken or the Egg? Paradox in Peripheral Arterial Diseases. <i>Angiology</i> , 2018, 69, 83-84.	0.8	1
3238	High-intensity Statin Treatments in Clinically Stable Patients on Aspirin Monotherapy 12 Months After Drug-eluting Stent Implantation: A Randomized Study. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2018, 71, 423-431.	0.4	8
3239	The Immediate Effects of Statins on Coronary Atherosclerosis. <i>JACC: Cardiovascular Imaging</i> , 2018, 11, 839-841.	2.3	3
3240	2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. <i>European Heart Journal</i> , 2018, 39, 119-177.	1.0	7,100
3241	Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials. <i>European Heart Journal</i> , 2018, 39, 1172-1180.	1.0	150
3242	Regional evidence and international recommendations to guide lipid management in Asian patients with type 2 diabetes with special reference to renal dysfunction. <i>Journal of Diabetes</i> , 2018, 10, 200-212.	0.8	3
3243	Association between discordance of LDL-C and non-HDL-C and clinical outcomes in patients with stent implantation: from the FU-Registry. <i>Heart and Vessels</i> , 2018, 33, 102-112.	0.5	11
3244	Dysfunctional HDL in diabetes mellitus and its role in the pathogenesis of cardiovascular disease. <i>Molecular and Cellular Biochemistry</i> , 2018, 440, 167-187.	1.4	77
3245	Should an LDL-Cholesterol Target-Based Approach Be Readopted?. <i>Annals of Pharmacotherapy</i> , 2018, 52, 175-184.	0.9	6
3247	Atherogenic Lipoprotein Subfractions and Carotid Atherosclerosis in Menopausal Women. <i>Angiology</i> , 2018, 69, 666-671.	0.8	7
3248	Effect of Optimal Medical Therapy at Discharge in Patients With Reperused ST-Segment Elevation Myocardial Infarction on 1-Year Mortality (from the Regional RESCUE Registry). <i>American Journal of Cardiology</i> , 2018, 121, 403-409.	0.7	9
3249	9. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2018. <i>Diabetes Care</i> , 2018, 41, S86-S104.	4.3	461



#	ARTICLE	IF	CITATIONS
3250	Should We Up the Intensity of Statin Therapy After Placing a Drug-eluting Stent?. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2018, 71, 416-417.	0.4	0
3251	Comparative effectiveness of lipid-lowering treatments to reduce cardiovascular disease. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2018, 18, 51-69.	0.7	8
3252	Evaluation of the Pleiotropic Effects of Statins. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 262-265.	1.1	32
3253	Apo A-I (Apolipoprotein A-I) Vascular Gene Therapy Provides Durable Protection Against Atherosclerosis in Hyperlipidemic Rabbits. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 206-217.	1.1	30
3254	Low triglyceride as a marker for increased risk of cardiovascular diseases in patients with long-term type 2 diabetes: A cross-sectional survey in China. <i>Diabetes/Metabolism Research and Reviews</i> , 2018, 34, e2960.	1.7	11
3255	Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. <i>Lancet, The</i> , 2018, 391, 319-328.	6.3	628
3257	Morphine, Oxygen, Nitrates, and Mortality Reducing Pharmacological Treatment for Acute Coronary Syndrome: An Evidence-based Review. <i>Cureus</i> , 2018, 10, e2114.	0.2	15
3258	Therapeutic effects of different Atorvastatin doses on vulnerable plaques in coronary arteries assessed by intracoronary optical coherence tomography. <i>Medicine (United States)</i> , 2018, 97, e11718.	0.4	5
3259	Timing of high intensity statin for acute coronary syndrome: how earlier initiation makes better?. <i>Journal of Thoracic Disease</i> , 2018, 10, S2149-S2152.	0.6	2
3260	Quality Indicators for the Management of Acute Myocardial Infarction. , 2018, , 230-239.		0
3261	Primary Prevention of Atherosclerotic Cardiovascular Disease. , 2018, , 433-458.		0
3262	Reduction of Vascular Inflammation, LDL-C, or Both for the Protection from Cardiovascular Events?. <i>Open Cardiovascular Medicine Journal</i> , 2018, 12, 29-40.	0.6	19
3263	Cardiovascular Disease and Risk Management: Review of the American Diabetes Association Standards of Medical Care in Diabetes 2018. <i>Annals of Internal Medicine</i> , 2018, 168, 640-650.	2.0	66
3264	Prevalence of lipid abnormalities and cholesterol target value attainment in patients with stable coronary heart disease or an acute coronary syndrome in Saudi Arabia. <i>Journal of King Abdulaziz University, Islamic Economics</i> , 2018, 39, 697-704.	0.5	3
3265	OBSOLETE: STEMI: Management. , 2018, , .		0
3266	OBSOLETE: Quality Indicators for the Management of Acute Myocardial Infarction. , 2018, , .		0
3269	Intensive Versus Moderate Statin Therapy Discontinuation in Patients With Acute Ischemic Stroke or Transient Ischemic Attack. <i>Clinical Therapeutics</i> , 2018, 40, 2041-2049.	1.1	1
3270	Short Term Comparison Between Safety and Efficacy of Rosuvastatin 40 mg and Atorvastatin 80 mg in Patients with Acute Coronary Syndrome. <i>Rational Pharmacotherapy in Cardiology</i> , 2018, 14, 636-645.	0.3	3

#	ARTICLE	IF	CITATIONS
3271	Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2018, 379, 2097-2107.	13.9	2,211
3272	Moderate-intensity versus high-intensity statin therapy in Korean patients with angina undergoing percutaneous coronary intervention with drug-eluting stents: A propensity-score matching analysis. <i>PLoS ONE</i> , 2018, 13, e0207889.	1.1	9
3273	Statin intensity and postoperative mortality following open repair of intact abdominal aortic aneurysm. <i>BJS Open</i> , 2018, 2, 411-418.	0.7	16
3274	Anti-inflammatory Effects of a Vegan Diet Versus the American Heart Association Recommended Diet in Coronary Artery Disease Trial. <i>Journal of the American Heart Association</i> , 2018, 7, e011367.	1.6	110
3275	Current concepts in atherosclerosis. <i>Indian Journal of Thoracic and Cardiovascular Surgery</i> , 2018, 34, 198-205.	0.2	4
3276	Medical Therapy for Long-Term Prevention of Atherothrombosis Following an Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2018, 72, 2886-2903.	1.2	68
3277	Palliative chemotherapy outcomes in patients with ECOG-PS higher than 1. <i>Ecancermedicalsecience</i> , 2018, 12, 831.	0.6	23
3278	Lack of Correlation of Plasma HDL With Fecal Cholesterol and Plasma Cholesterol Efflux Capacity Suggests Importance of HDL Functionality in Attenuation of Atherosclerosis. <i>Frontiers in Physiology</i> , 2018, 9, 1222.	1.3	10
3279	Current Therapies Focused on High-Density Lipoproteins Associated with Cardiovascular Disease. <i>Molecules</i> , 2018, 23, 2730.	1.7	33
3280	High-Intensity Versus Non-High-Intensity Statins in Patients Achieving Low-Density Lipoprotein Cholesterol Goal After Percutaneous Coronary Intervention. <i>Journal of the American Heart Association</i> , 2018, 7, e009517.	1.6	13
3281	Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 934-943.	5.5	96
3282	Managing Clinical Heterogeneity: An Argument for Benefit-Based Action Limits. <i>Journal of Engineering and Science in Medical Diagnostics and Therapy</i> , 2018, 1, .	0.3	4
3283	Effect of visit-to-visit LDL-, HDL-, and non-HDL-cholesterol variability on mortality and cardiovascular outcomes after percutaneous coronary intervention. <i>Atherosclerosis</i> , 2018, 279, 1-9.	0.4	47
3284	Safety and efficacy of statin therapy. <i>Nature Reviews Cardiology</i> , 2018, 15, 757-769.	6.1	239
3285	Guideline-Recommended Therapies and Clinical Outcomes According to the Risk for Recurrent Cardiovascular Events After an Acute Coronary Syndrome. <i>Journal of the American Heart Association</i> , 2018, 7, e009885.	1.6	21
3286	Measurement of Low-Density Lipoprotein Cholesterol Levels in Primary and Secondary Prevention Patients: Insights From the PALM Registry. <i>Journal of the American Heart Association</i> , 2018, 7, e009251.	1.6	9
3287	Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017. <i>Journal of Atherosclerosis and Thrombosis</i> , 2018, 25, 846-984.	0.9	541
3288	Different perspectives on outcomes in patients with non-ST-elevation myocardial infarction when observed in clinical trials and in real life. <i>European Heart Journal</i> , 2018, 39, 3821-3824.	1.0	8

#	ARTICLE	IF	CITATIONS
3289	A comment to: Predictors of low-density lipoprotein cholesterol target value attainment in the DYSIS II Europe Study. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 1964-1965.	0.8	0
3290	Lipids: a personal view of the past decade. <i>Hormones</i> , 2018, 17, 461-478.	0.9	5
3291	Diagnostic expansion in clinical trials: myocardial infarction, stroke, cancer recurrence, and metastases may not be the hard endpoints you thought they were. <i>BMJ: British Medical Journal</i> , 2018, 362, k3783.	2.4	7
3292	LDL-C does not cause cardiovascular disease: a comprehensive review of the current literature. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 959-970.	1.3	88
3293	Biologic bases of residual risk of cardiovascular events: A flawed concept. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 1831-1835.	0.8	8
3294	Optimising treatment of hyperlipidaemia: Quantitative evaluation of UK, USA and European guidelines taking account of both LDL cholesterol levels and cardiovascular disease risk. <i>Atherosclerosis</i> , 2018, 278, 135-142.	0.4	20
3295	Prevalence of lipid abnormalities and cholesterol target value attainment in Egyptian patients presenting with an acute coronary syndrome. <i>Egyptian Heart Journal</i> , 2018, 70, 129-134.	0.4	4
3296	Relationship between Atherogenic Indices and Carotid Intima-Media Thickness in Prediabetes: A Cross-Sectional Study from Central India. <i>Medical Sciences (Basel, Switzerland)</i> , 2018, 6, 55.	1.3	8
3297	Statin Use and Adverse Effects Among Adults >75 Years of Age: Insights From the Patient and Provider Assessment of Lipid Management (PALM) Registry. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	49
3298	Low-Density Lipoprotein Cholesterol Goal Attainment Rates by Initial Statin Monotherapy Among Patients With Dyslipidemia and High Cardiovascular Risk in Japan – A Retrospective Database Analysis. <i>Circulation Journal</i> , 2018, 82, 1605-1613.	0.7	10
3299	Factors Associated with Intima-Media Complex Thickness of the Common Carotid Artery in Japanese Noncardioembolic Stroke Patients with Hyperlipidemia: The J-STARS Echo Study. <i>Journal of Atherosclerosis and Thrombosis</i> , 2018, 25, 359-373.	0.9	20
3300	The Association of Statin Therapy with Incident Diabetes: Evidence, Mechanisms, and Recommendations. <i>Current Cardiology Reports</i> , 2018, 20, 50.	1.3	22
3301	Risk factor profile and anatomic features of previously asymptomatic patients presenting with carotid-related stroke. <i>Journal of Vascular Surgery</i> , 2018, 68, 1390-1395.	0.6	26
3302	Statin Utilization Patterns and Outcomes for Patients with Acute Coronary Syndrome During and Following Inpatient Admissions. <i>Cardiovascular Drugs and Therapy</i> , 2018, 32, 273-280.	1.3	10
3303	Lipids, Apolipoproteins, and Inflammatory Biomarkers of Cardiovascular Risk: What Have We Learned?. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 244-256.	2.3	14
3304	Have we reached the bottom of the bottomless pit- lessons from the recent lipid-lowering trials?. <i>Indian Heart Journal</i> , 2018, 70, 331-334.	0.2	0
3305	Effects of Ezetimibe-Statin Combination Therapy on Coronary Atherosclerosis in Acute Coronary Syndrome. <i>Circulation Journal</i> , 2018, 82, 757-766.	0.7	31
3306	Gemcabene downregulates inflammatory, lipid-altering and cell-signaling genes in the STAM <sub>2</sub> model of NASH. <i>PLoS ONE</i> , 2018, 13, e0194568.	1.1	20

#	ARTICLE	IF	CITATIONS
3307	Anti-Inflammatory Treatment. , 2018, , 237-271.		0
3308	Lipid management in ACS: Should we go lower faster?. <i>Atherosclerosis</i> , 2018, 275, 368-375.	0.4	27
3309	Extreme-risk category: High prevalence among stable coronary patients and an emerging widening treatment gap in achieving LDL-cholesterol less than 55 mg/dL. <i>Atherosclerosis</i> , 2018, 275, 262-264.	0.4	13
3310	Treating Lipid Disorders in Athletes. , 2018, , 25-48.		0
3311	STEMI: Management. , 2018, , 474-488.		0
3312	Atorvastatin Inhibits the HIF1 $\alpha$ -PPAR Axis, Which Is Essential for Maintaining the Function of Human Induced Pluripotent Stem Cells. <i>Molecular Therapy</i> , 2018, 26, 1715-1734.	3.7	14
3313	A Component Formula of Chinese Medicine for Hypercholesterolemia Based on Virtual Screening and Biology Network. <i>Evidence-based Complementary and Alternative Medicine</i> , 2018, 2018, 1-11.	0.5	8
3314	Demographic, clinical and lifestyle factors associated with high-intensity statin therapy in Australia: the AusDiab study. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 1493-1501.	0.8	5
3315	Antiinflammatory Therapy in Clinical Care: The CANTOS Trial and Beyond. <i>Frontiers in Cardiovascular Medicine</i> , 2018, 5, 62.	1.1	72
3316	Lipid lowering drugs and inflammatory changes: an impact on cardiovascular outcomes?. <i>Annals of Medicine</i> , 2018, 50, 461-484.	1.5	28
3317	The Evolving Future of PCSK9 Inhibitors. <i>Journal of the American College of Cardiology</i> , 2018, 72, 314-329.	1.2	162
3318	2018 Guidelines of the Taiwan Society of Cardiology, Taiwan Society of Emergency Medicine and Taiwan Society of Cardiovascular Interventions for the management of non ST-segment elevation acute coronary syndrome. <i>Journal of the Formosan Medical Association</i> , 2018, 117, 766-790.	0.8	44
3319	Cardiovascular Risk Assessment in Patients with Hypertriglyceridemia. <i>Current Cardiology Reports</i> , 2018, 20, 71.	1.3	0
3320	Precipitants of Myocardial Ischemia. , 2018, , 69-77.		5
3321	Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. <i>Cardiovascular Diabetology</i> , 2018, 17, 83.	2.7	1,198
3322	High-Dose Versus Low-Dose Pitavastatin in Japanese Patients With Stable Coronary Artery Disease (REAL-CAD). <i>Circulation</i> , 2018, 137, 1997-2009.	1.6	174
3323	High- Versus Low-Dose Statin. <i>Circulation</i> , 2018, 137, 2013-2015.	1.6	6
3324	Improvement in LDL is associated with decrease in non-calcified plaque volume on coronary CTA as measured by automated quantitative software. <i>Journal of Cardiovascular Computed Tomography</i> , 2018, 12, 385-390.	0.7	21

#	ARTICLE	IF	CITATIONS
3325	Baseline serum sitosterol level as predictor of adverse clinical events in acute coronary syndrome patients with dyslipidaemia: A sub-analysis of HJ-PROPER. <i>Atherosclerosis</i> , 2018, 274, 139-145.	0.4	28
3326	Healthcare Utilization and Statin Re-initiation Among Medicare Beneficiaries With a History of Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	4
3327	Rationale and Design of Randomized Evaluation of Aggressive or Moderate Lipid Lowering Therapy with Pitavastatin in Coronary Artery Disease (REAL-CAD) Trial. <i>International Heart Journal</i> , 2018, 59, 315-320.	0.5	11
3328	Dose-dependent Inhibitory effect of rosuvastatin In Japanese patients with Acute myocardial infarction on serum concentration of matrix metalloproteinases – INVITATION trial. <i>Journal of Cardiology</i> , 2018, 72, 350-355.	0.8	3
3329	Reasons for disparity in statin adherence rates between clinical trials and real-world observations: a review. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 230-236.	1.4	39
3330	Consensus Document ANMCO/ANCE/ARCA/GICR-IACPR/GISE/SICOA: Long-term Antiplatelet Therapy in Patients with Coronary Artery Disease. <i>European Heart Journal Supplements</i> , 2018, 20, F1-F74.	0.0	25
3331	Diabetes and the Cardiovascular System. <i>Endocrinology</i> , 2018, , 1-29.	0.1	0
3332	The ODYSSEY Outcomes trial: Clinical implications and exploration of the limits of what can be achieved through lipid lowering. <i>Journal of Clinical Lipidology</i> , 2018, 12, 1102-1105.	0.6	8
3333	Lipid-lowering therapy with PCSK9 inhibitors in the real-world setting: Two-year experience of a regional lipid clinic. <i>Cardiovascular Therapeutics</i> , 2018, 36, e12439.	1.1	27
3334	Cardiovascular outcomes of patients with rheumatoid arthritis prescribed disease modifying anti-rheumatic drugs: a review. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 697-708.	1.0	14
3335	Lowering LDL Cholesterol and CV Benefits: Is There a Limit to How Low LDL Needs to be for Optimal Health Benefits?. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 290-296.	2.3	6
3336	Underutilization of Statin Therapy for Secondary Prevention of Cardiovascular Disease Among Older Adults. <i>Population Health Management</i> , 2019, 22, 74-82.	0.8	12
3337	Platelet-activating factor acetylhydrolases: An overview and update. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2019, 1864, 922-931.	1.2	38
3338	Short- and long-term clinical impact of tissue protrusion after newer-generation drug-eluting stent implantation for acute coronary syndrome. <i>Cardiovascular Intervention and Therapeutics</i> , 2019, 34, 155-163.	1.2	1
3339	Intensive versus moderate statin therapy and early graft occlusion after coronary bypass surgery: The Aggressive Cholesterol Therapy to Inhibit Vein Graft Events randomized clinical trial. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2019, 157, 151-161.e1.	0.4	24
3340	Biomarkers and Clinical Cardiovascular Outcomes With Ezetimibe in the IMPROVE-IT Trial. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1057-1068.	1.2	32
3341	Association Between Baseline, Achieved, and Reduction of CRP and Cardiovascular Outcomes After LDL Cholesterol Lowering with Statins or Ezetimibe: A Systematic Review and Meta-Analysis. <i>Journal of the American Heart Association</i> , 2019, 8, e012428.	1.6	10
3342	More- Versus Less-Intensive Lipid-Lowering Therapy. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e005460.	0.9	8

#	ARTICLE	IF	CITATIONS
3343	Add-on ezetimibe treatment to low-dose statins vs medium-intensity statin monotherapy in coronary artery disease patients with poorly controlled dyslipidemia. <i>Hypertension Research</i> , 2019, 42, 1923-1931.	1.5	7
3344	Pharmacological lipid-modification therapies for prevention of ischaemic heart disease: current and future options. <i>Lancet, The</i> , 2019, 394, 697-708.	6.3	67
3345	Myocardial Infarctionâ€”From Atherosclerosis to Thrombosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, e176-e185.	1.1	90
3346	Influence of Secondary Prevention and Risk Factors to Recurrent Miocard Infark on Acute Coronary Syndrome Patients in General Hospital Surakarta Indonesia. <i>International Journal of Online and Biomedical Engineering</i> , 2019, 15, 136.	0.9	0
3347	Anti-inflammatory effect of statin is continuously working throughout use: a prospective three time point 18F-FDG PET/CT imaging study. <i>International Journal of Cardiovascular Imaging</i> , 2019, 35, 1745-1753.	0.7	8
3348	Diabetes and the Cardiovascular System. <i>Endocrinology</i> , 2019, , 1-29.	0.1	0
3349	The cost-effectiveness of omega-3 polyunsaturated fatty acids â€” The Australian healthcare perspective. <i>European Journal of Internal Medicine</i> , 2019, 67, 70-76.	1.0	14
3350	Effect of Simvastatin-Ezetimibe Compared With Simvastatin Monotherapy After Acute Coronary Syndrome Among Patients 75 Years or Older. <i>JAMA Cardiology</i> , 2019, 4, 846.	3.0	81
3351	Impact of Lipid-Lowering Therapy on Mortality According to the Baseline Non-HDL Cholesterol Level: A Meta-Analysis. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2019, 26, 263-272.	1.0	7
3352	Extreme Atherosclerotic Cardiovascular Disease (ASCVD) Risk Recognition. <i>Current Diabetes Reports</i> , 2019, 19, 61.	1.7	44
3353	Inflammation as a Therapeutic Target in Atherosclerosis. <i>Journal of Clinical Medicine</i> , 2019, 8, 1109.	1.0	118
3354	Low-Density Lipoprotein Cholesterol After an Acute Coronary Syndrome: How Low to Go?. <i>Current Cardiology Reports</i> , 2019, 21, 77.	1.3	6
3355	Optimal Non-invasive Strategies to Reduce Recurrent Atherosclerotic Cardiovascular Disease Risk. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2019, 21, 38.	0.4	1
3356	Association of baseline LDL-C with total and cardiovascular mortality in patients using proprotein convertase subtilisin-kexin type 9 inhibitors: A systematic review and meta-analysis. <i>Journal of Clinical Lipidology</i> , 2019, 13, 538-549.	0.6	16
3357	Current trends in nonâ€”HDL cholesterol and LDL cholesterol levels in adults with atherosclerotic cardiovascular disease. <i>Journal of Clinical Lipidology</i> , 2019, 13, 563-567.	0.6	17
3358	DRESS secundario a uso de estatinas, a propÃ³sito de un caso en la ciudad de MedellÃn, Colombia. <i>Atencion Primaria Practica</i> , 2019, 1, 95-96.	0.0	0
3359	Design and rationale for the â€œMe & My Heartâ€•(eMocial) study: A randomized evaluation of a new smartphoneâ€”based support tool to increase therapy adherence of patients with acute coronary syndrome. <i>Clinical Cardiology</i> , 2019, 42, 1054-1062.	0.7	4
3360	Comparison of alternative approaches to trim subjects in the tails of the propensity score distribution. <i>Pharmacoepidemiology and Drug Safety</i> , 2019, 28, 1290-1298.	0.9	19

#	ARTICLE	IF	CITATIONS
3362	Meta-analysis of Randomized Controlled Trials Assessing the Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies on Mortality and Cardiovascular Outcomes. <i>American Journal of Cardiology</i> , 2019, 124, 1869-1875.	0.7	15
3363	IL-1 $\beta$ and Statin Treatment in Patients with Myocardial Infarction and Diabetic Cardiomyopathy. <i>Journal of Clinical Medicine</i> , 2019, 8, 1764.	1.0	21
3364	Highlighting Residual Atherosclerotic Cardiovascular Disease Risk. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, e1-e9.	1.1	45
3365	2018 Guidelines for the Management of Dyslipidemia in Korea. <i>Journal of Lipid and Atherosclerosis</i> , 2019, 8, 78.	1.1	100
3366	Intensive lipid-lowering therapy in the 12 months after an acute coronary syndrome in Australia: an observational analysis. <i>Medical Journal of Australia</i> , 2019, 211, 284.	0.8	2
3367	Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes. <i>Circulation</i> , 2019, 140, 1578-1589.	1.6	34
3368	Statins in Females. <i>Indian Journal of Cardiovascular Disease in Women WINCARS</i> , 2019, 04, 099-106.	0.1	0
3370	Cholesterol-Lowering Agents. <i>Circulation Research</i> , 2019, 124, 354-363.	2.0	33
3371	Association of statin therapy with clinical outcomes in patients with vasospastic angina: Data from Korean health insurance review and assessment service. <i>PLoS ONE</i> , 2019, 14, e0210498.	1.1	7
3372	PCSK9 inhibition 2018: riding a new wave of coronary prevention. <i>Clinical Science</i> , 2019, 133, 205-224.	1.8	8
3373	Risk Factors Associated with Failure to Achieve the Low Density Lipoprotein Cholesterol Therapeutic Target in Patients with Acute Coronary Syndrome: A Longitudinal, Single Centre Investigation. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2019, 26, 37-43.	1.0	2
3374	Analysis of secondary prevention measures implemented in patients with a history of acute coronary syndrome. <i>Revista Colombiana De Cardiologia</i> , 2019, 26, 63-69.	0.1	0
3375	Advances in cardiovascular imaging. <i>Current Opinion in Biomedical Engineering</i> , 2019, 9, A3.	1.8	0
3376	Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 2414.	3.8	602
3377	The Habit Formation trial of behavioral economic interventions to improve statin use and reduce the risk of cardiovascular disease: Rationale, design and methodologies. <i>Clinical Trials</i> , 2019, 16, 399-409.	0.7	8
3378	MRTF-A regulates proliferation and survival properties of pro-atherogenic macrophages. <i>Journal of Molecular and Cellular Cardiology</i> , 2019, 133, 26-35.	0.9	16
3379	Lipid Profile of Patients with Acute Myocardial Infarction (AMI). <i>Cureus</i> , 2019, 11, e4265.	0.2	8
3381	Effects of Icosapent Ethyl on Total Ischemic Events. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2791-2802.	1.2	208

#	ARTICLE	IF	CITATIONS
3382	Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease. <i>JAMA Cardiology</i> , 2019, 4, 613.	3.0	66
3383	Peptide Amphiphile Supramolecular Nanostructures as a Targeted Therapy for Atherosclerosis. <i>Macromolecular Bioscience</i> , 2019, 19, e1900066.	2.1	29
3384	Clinical characteristics and lipid lowering treatment of patients initiated on proprotein convertase subtilisin-kexin type 9 inhibitors: a nationwide cohort study. <i>BMJ Open</i> , 2019, 9, e022702.	0.8	4
3386	Pharmaceutical strategies for reducing LDL-C and risk of cardiovascular disease. <i>Atherosclerosis: X</i> , 2019, 39, 100002.	0.0	9
3387	Relative Effect of Current Intensive Lipid-Lowering Drugs on Cardiovascular Outcomes in Secondary Prevention—A Meta-Analysis of 12 Randomized Trials. <i>Circulation Journal</i> , 2019, 83, 1356-1367.	0.7	6
3388	The extent to which statins have improved cardiovascular outcomes: Lessons from randomized trials and observational studies of "real world" practice in people with diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 17-27.	2.2	8
3389	Evaluation of discharge prescriptions for secondary prevention in patients with acute coronary syndromes in Iraq. <i>Pharmacy Practice</i> , 2019, 17, 1372.	0.8	4
3390	Serum triglycerides as a risk factor for cardiovascular diseases in type 2 diabetes mellitus: a systematic review and meta-analysis of prospective studies. <i>Cardiovascular Diabetology</i> , 2019, 18, 48.	2.7	76
3391	Association of Lowering Low-Density Lipoprotein Cholesterol With Contemporary Lipid-Lowering Therapies and Risk of Diabetes Mellitus: A Systematic Review and Meta-Analysis. <i>Journal of the American Heart Association</i> , 2019, 8, e011581.	1.6	46
3392	Apolipoprotein profiling as a personalized approach to the diagnosis and treatment of dyslipidaemia. <i>Annals of Clinical Biochemistry</i> , 2019, 56, 338-356.	0.8	27
3393	Statins: Rationale, Mode of Action, and Side Effects. , 2019, , 171-200.		6
3394	Colchicine for Stroke Prevention: A Systematic Review and Meta-analysis. <i>Clinical Therapeutics</i> , 2019, 41, 582-590.e3.	1.1	29
3395	Association of Initial and Serial C-Reactive Protein Levels With Adverse Cardiovascular Events and Death After Acute Coronary Syndrome. <i>JAMA Cardiology</i> , 2019, 4, 314.	3.0	79
3396	Remnant cholesterol and coronary atherosclerotic plaque burden assessed by computed tomography coronary angiography. <i>Atherosclerosis</i> , 2019, 284, 24-30.	0.4	37
3397	Assessment of the LDL-C/HDL-C ratio as a predictor of one year clinical outcomes in patients with acute coronary syndromes after percutaneous coronary intervention and drug-eluting stent implantation. <i>Lipids in Health and Disease</i> , 2019, 18, 40.	1.2	39
3398	The Role of Statins in the Management of Heart Failure with Preserved Ejection Fraction. <i>Current Pharmacology Reports</i> , 2019, 5, 210-213.	1.5	0
3399	Effect of Statin Therapy and Long-Term Mortality Following Transcatheter Aortic Valve Implantation. <i>American Journal of Cardiology</i> , 2019, 123, 1978-1982.	0.7	8
3400	Evaluating the efficacy and safety of atorvastatin + ezetimibe in a fixed-dose combination for the treatment of hypercholesterolemia. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 917-928.	0.9	17



#	ARTICLE	IF	CITATIONS
3401	Emerging Fixed-Dose Combination Treatments for Hyperlipidemia. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2019, 24, 315-322.	1.0	14
3402	Most Promising Therapies in Interventional Cardiology. <i>Current Cardiology Reports</i> , 2019, 21, 26.	1.3	6
3403	Rationale and design of the Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE): Effects of pitavastatin on coronary artery disease and inflammatory biomarkers. <i>American Heart Journal</i> , 2019, 212, 1-12.	1.2	43
3404	Lipid Lowering Therapy, Low-Density Lipoprotein Level and Risk of Intracerebral Hemorrhage â€” A Meta-Analysis. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2019, 28, 1703-1709.	0.7	31
3405	Targeting Residual Inflammatory Risk: A Shifting Paradigm for Atherosclerotic Disease. <i>Frontiers in Cardiovascular Medicine</i> , 2019, 6, 16.	1.1	109
3406	Revascularization Strategies for Non-ST-Elevation Myocardial Infarction. <i>Current Cardiology Reports</i> , 2019, 21, 39.	1.3	4
3407	ACC/AHA lipids & ASCVD guidelines: 2018 update. <i>Metabolism: Clinical and Experimental</i> , 2019, 99, 116-118.	1.5	4
3408	Association Between Secondary Prevention Medication Use and Outcomes in Frail Older Adults After Acute Myocardial Infarction. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e004942.	0.9	13
3409	The Role of PCSK9 Inhibitors in the Improvement of Outcomes in Patients after Acute Coronary Syndrome: Results of ODYSSEY OUTCOMES Trial. <i>Rational Pharmacotherapy in Cardiology</i> , 2019, 14, 922-934.	0.3	5
3410	An analysis of randomized controlled trials underpinning ST-elevation myocardial infarction management guidelines. <i>American Journal of Emergency Medicine</i> , 2019, 37, 2229-2238.	0.7	2
3411	Current pharmacotherapies for atherosclerotic cardiovascular diseases. <i>Archives of Pharmacal Research</i> , 2019, 42, 206-223.	2.7	10
3412	Statin use improves limb salvage after intervention for peripheral arterial disease. <i>Journal of Vascular Surgery</i> , 2019, 70, 539-546.	0.6	20
3413	Time-dependent prognostic effect of high sensitivity C-reactive protein with statin therapy in acute myocardial infarction. <i>Journal of Cardiology</i> , 2019, 74, 74-83.	0.8	12
3414	Association of Statin Adherence With Mortality in Patients With Atherosclerotic Cardiovascular Disease. <i>JAMA Cardiology</i> , 2019, 4, 206.	3.0	216
3415	Type 2 Diabetes. <i>Annals of Internal Medicine</i> , 2019, 171, ITC65-ITC80.	2.0	46
3416	10. Cardiovascular Disease and Risk Management: <i>Standards of Medical Care in Diabetesâ€”2019</i>. <i>Diabetes Care</i> , 2019, 42, S103-S123.	4.3	676
3417	Clinical consequences of poor adherence to lipid-lowering therapy in patients with cardiovascular disease: can we do better?. <i>Heart Asia</i> , 2019, 11, e011200.	1.1	4
3418	2018 Guidelines for the management of dyslipidemia. <i>Korean Journal of Internal Medicine</i> , 2019, 34, 723-771.	0.7	144

#	ARTICLE	IF	CITATIONS
3419	Statin adherence and persistence on secondary prevention of cardiovascular disease in Taiwan. <i>Heart Asia</i> , 2019, 11, e011176.	1.1	5
3421	Evidence, Guidelines and Treatment Algorithms for Patients with Arterial Hypertension and Dyslipidemia: the Need for Compromise and Optimization of Tactics in Practical Healthcare. <i>Rational Pharmacotherapy in Cardiology</i> , 2019, 15, 578-585.	0.3	0
3422	Nationwide trends in acute coronary syndrome by subtype in New Zealand 2006â€“2016. <i>Heart</i> , 2019, 106, heartjnl-2019-315655.	1.2	11
3423	Epidemiology, treatment patterns and outcomes in patients with coronary or lower extremity artery disease in France. <i>Archives of Cardiovascular Diseases</i> , 2019, 112, 670-679.	0.7	8
3424	Initiating PCSK9 Inhibition in Hospital for ACS. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2463-2465.	1.2	2
3425	Effect of <i>Lactobacillus paracasei</i> H101 on lipid profile and blood parameters in hypercholesterolemic patients: A preliminary study. <i>Asian Journal of Medical Sciences</i> , 2019, 11, 7-11.	0.0	0
3426	Statins and myocardial infarction. <i>Journal of Cardiovascular Medicine</i> , 2019, 20, 220-222.	0.6	4
3427	Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at â€œExtremeâ€•ASCVD Risk. <i>Current Diabetes Reports</i> , 2019, 19, 146.	1.7	5
3428	Effect of intensive and standard lipid-lowering therapy on the progression of stroke in patients with coronary artery syndromes. <i>Journal of Cardiovascular Pharmacology</i> , 2019, 75, 1.	0.8	4
3429	Is hypertriglyceridemia atherogenic?. <i>Current Opinion in Lipidology</i> , 2019, 30, 291-299.	1.2	11
3430	Diabetes and Cardiovascular Disease: an Update. <i>Current Diabetes Reports</i> , 2019, 19, 161.	1.7	53
3431	Management of Hyperlipidemia After Stroke. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2019, 21, 93.	0.4	11
3432	The role of statins in chronic obstructive pulmonary disease. <i>Current Opinion in Pulmonary Medicine</i> , 2019, 25, 173-178.	1.2	1
3433	Comparative efficacy between atorvastatin and rosuvastatin in the prevention of cardiovascular disease recurrence. <i>Lipids in Health and Disease</i> , 2019, 18, 216.	1.2	16
3434	A Low Early High-density Lipoprotein Cholesterol Level Is an Independent Predictor of In-hospital Death in Patients with Acute Coronary Syndrome. <i>Internal Medicine</i> , 2019, 58, 337-343.	0.3	3
3435	The Hypercholesterolemia Paradox in Percutaneous Coronary Intervention: An Analysis of a Multicenter PCI Registry. <i>Internal Medicine</i> , 2019, 58, 345-353.	0.3	6
3436	Pharmacological Options in Atherosclerosis: A Review of the Existing Evidence. <i>Cardiology and Therapy</i> , 2019, 8, 5-20.	1.1	17
3437	Is very low LDL-C harmful?. <i>Current Pharmaceutical Design</i> , 2019, 24, 3658-3664.	0.9	16

#	ARTICLE	IF	CITATIONS
3438	Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Circulation</i> , 2019, 139, e1144-e1161.	1.6	87
3439	2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. <i>Journal of the American College of Cardiology</i> , 2019, 73, e285-e350.	1.2	1,550
3440	Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. <i>New England Journal of Medicine</i> , 2019, 380, 11-22.	13.9	2,153
3441	2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Circulation</i> , 2019, 139, e1046-e1081.	1.6	361
3442	2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Circulation</i> , 2019, 139, e1082-e1143.	1.6	2,380
3443	Optimal Medical Therapy Prescribing Patterns and Disparities Identified in Patients with Acute Coronary Syndromes at an Academic Medical Center in an Area with High Coronary Heart Disease-Related Mortality. <i>American Journal of Cardiovascular Drugs</i> , 2019, 19, 185-193.	1.0	2
3444	2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary. <i>Journal of the American College of Cardiology</i> , 2019, 73, 3168-3209.	1.2	1,128
3445	Trends in low-density lipoprotein cholesterol blood values between 2012 and 2017 suggest sluggish adoption of the recent 2013 treatment guidelines. <i>Clinical Cardiology</i> , 2019, 42, 101-110.	0.7	12
3446	Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. <i>Journal of the American College of Cardiology</i> , 2019, 73, 3210-3227.	1.2	124
3447	Two-year outcomes of statin therapy in patients with acute myocardial infarction with or without dyslipidemia after percutaneous coronary intervention in the era of new-generation drug-eluting stents within Korean population: Data from the Korea Acute Myocardial Infarction Registry. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 1264-1275.	0.7	12
3448	Clinical utility of non-contrast T1-weighted magnetic resonance imaging in percutaneous coronary intervention: A case report. <i>Journal of Cardiology Cases</i> , 2019, 19, 9-11.	0.2	1
3449	Intensity-Dependent Benefit of Statins in Survival Among Prospective Kidney Transplant Patients. <i>American Journal of Cardiology</i> , 2019, 123, 254-259.	0.7	7
3450	Cardiovascular event rates in a high atherosclerotic cardiovascular disease risk population: estimates from Swedish population-based register data. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2019, 5, 225-232.	1.8	30
3451	FURIN Inhibition Reduces Vascular Remodeling and Atherosclerotic Lesion Progression in Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 387-401.	1.1	51
3452	Adjunctive Pharmacologic Therapies in Acute Myocardial Infarction. , 2019, , 117-138.e7.		2
3453	Hypercholesterolaemia and coronary artery disease: A silent killer with several faces. <i>Archives of Cardiovascular Diseases</i> , 2019, 112, 75-78.	0.7	5
3454	Drug Therapy of Dyslipidemia in the Elderly. <i>Drugs and Aging</i> , 2019, 36, 321-340.	1.3	22
3455	Association of Clinician Knowledge and Statin Beliefs With Statin Therapy Use and Lipid Levels (A) <i>TJ ETQq1</i> 1 0.784314 rgBT/Overlook	0.7	16

#	ARTICLE	IF	CITATIONS
3456	Post-myocardial Infarction (MI) Care: Medication Adherence for Secondary Prevention After MI in a Large Real-world Population. <i>Clinical Therapeutics</i> , 2019, 41, 107-117.	1.1	43
3457	Medication Discontinuation in the IMPROVE-IT Trial. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e005041.	0.9	23
3458	Pre-existing treatment with aspirin or statins influences clinical presentation, infarct size and inflammation in patients with de novo acute coronary syndromes. <i>International Journal of Cardiology</i> , 2019, 275, 171-178.	0.8	16
3459	Motivational interviewing to support LDL-C therapeutic goals and lipid-lowering therapy compliance in patients with acute coronary syndromes (IDEAL-LDL) study: rationale and design. <i>Hellenic Journal of Cardiology</i> , 2019, 60, 249-253.	0.4	9
3460	Temporal trends, determinants, and impact of high-intensity statin prescriptions after percutaneous coronary intervention. <i>American Heart Journal</i> , 2019, 207, 10-18.	1.2	7
3461	Imaging as a surrogate marker of drug efficacy in cardiovascular disease. <i>Heart</i> , 2019, 105, 567-578.	1.2	13
3462	Unstable Angina and Non-ST Elevation Myocardial Infarction. <i>Contemporary Cardiology</i> , 2019, , 233-259.	0.0	0
3463	Management of Dyslipidemia. <i>Contemporary Cardiology</i> , 2019, , 39-69.	0.0	0
3465	Association of pre-admission statin therapy and the inflammatory response in ST elevation myocardial infarction patients. <i>Biomarkers</i> , 2019, 24, 17-22.	0.9	1
3466	Modern Management of ST-Segment Elevation Myocardial Infarction. <i>Current Problems in Cardiology</i> , 2020, 45, 100393.	1.1	26
3467	Statin therapy increases lipoprotein(a) levels. <i>European Heart Journal</i> , 2020, 41, 2275-2284.	1.0	265
3468	A performance guide for major risk factors control in patients with atherosclerotic cardiovascular disease in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 674-684.	0.8	10
3469	Clinical Practice Guideline of Integrative Chinese and Western Medicine for Acute Myocardial Infarction. <i>Chinese Journal of Integrative Medicine</i> , 2020, 26, 539-551.	0.7	12
3470	High-intensity lipid-lowering regimens in patients with stable coronary artery disease: the intriguing question of all-cause mortality. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 328-330.	1.4	3
3471	Simvastatin nanoliposome induces myocardial and hepatic toxicities due to its absorption enhancement in mice. <i>Asian Journal of Pharmaceutical Sciences</i> , 2020, 15, 112-120.	4.3	7
3472	Statin Intolerance Clinical Guide 2018. <i>Journal of Atherosclerosis and Thrombosis</i> , 2020, 27, 375-396.	0.9	17
3473	Safety Outcomes of Atorvastatin 80 mg Versus Atorvastatin 40 mg in a Veteran Population. <i>Annals of Pharmacotherapy</i> , 2020, 54, 151-156.	0.9	2
3474	Trends and predictors of high-intensity statin therapy and LDL-C goal achievement among Thai patients with acute coronary syndrome. <i>Journal of Cardiology</i> , 2020, 75, 275-281.	0.8	4

#	ARTICLE	IF	CITATIONS
3475	Residual inflammatory risk after contemporary lipid lowering therapy. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2020, 6, 105-111.	1.8	6
3476	PCSK9 inhibitors and cardiovascular outcomes. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 35-47.	1.4	26
3477	Statin-Associated Bilateral Foot Myopathy. <i>Journal of Pharmacy Practice</i> , 2020, 33, 899-902.	0.5	4
3478	Association of lowering apolipoprotein B with cardiovascular outcomes across various lipid-lowering therapies: Systematic review and meta-analysis of trials. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 1255-1268.	0.8	33
3479	Safety of High-Intensity Statins in the Veteran Population: Atorvastatin 40 to 80 mg Compared With Rosuvastatin 20 to 40 mg. <i>Annals of Pharmacotherapy</i> , 2020, 54, 405-413.	0.9	8
3480	Therapeutic strategy for atherosclerosis based on bone-vascular axis hypothesis. , 2020, 206, 107436.		17
3481	Efficacy and Safety of High-intensity Statins in Patients With Acute Myocardial Infarction: An Asian Perspective. <i>Canadian Journal of Cardiology</i> , 2020, 36, 886-892.	0.8	6
3482	Getting to an ImprOved Understanding of Low-Density Lipoprotein-Cholesterol and Dyslipidemia Management (GOULD): Methods and baseline data of a registry of high cardiovascular risk patients in the United States. <i>American Heart Journal</i> , 2020, 219, 70-77.	1.2	18
3483	New candidate genes for ST â€levation myocardial infarction. <i>Journal of Internal Medicine</i> , 2020, 287, 66-77.	2.7	7
3484	Overall Mortality and LDL Cholesterol Reduction in Secondary Prevention Trials of Cardiovascular Disease. <i>American Journal of Cardiovascular Drugs</i> , 2020, 20, 325-332.	1.0	0
3485	SP-8356, a Novel Inhibitor of CD147-Cyclophilin A Interactions, Reduces Plaque Progression and Stabilizes Vulnerable Plaques in apoE-Deficient Mice. <i>International Journal of Molecular Sciences</i> , 2020, 21, 95.	1.8	12
3486	Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics. <i>European Heart Journal</i> , 2020, 41, 2304-2312.	1.0	54
3487	Efficacy of combination therapy with ezetimibe and statins versus a double dose of statin monotherapy in participants with hypercholesterolemia: a meta-analysis of literature. <i>Lipids in Health and Disease</i> , 2020, 19, 1.	1.2	86
3488	Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: a systematic review and meta-analysis of randomised trials including 327â€037 participants. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 36-49.	5.5	115
3489	Left Ventricular Post-Infarct Remodeling. <i>JACC: Heart Failure</i> , 2020, 8, 131-140.	1.9	80
3490	Evolving concepts on the management of dyslipidaemia. <i>Acta Clinica Belgica</i> , 2020, 75, 80-90.	0.5	3
3491	Molecular pathways involved in the cardioprotective effects of intravenous statin administration during ischemia. <i>Basic Research in Cardiology</i> , 2020, 115, 2.	2.5	26
3492	Statin-Related Myotoxicity: A Comprehensive Review of Pharmacokinetic, Pharmacogenomic and Muscle Components. <i>Journal of Clinical Medicine</i> , 2020, 9, 22.	1.0	122

#	ARTICLE	IF	CITATIONS
3493	Current Concepts in Management of Lipid Abnormalities in Patients With Coronary Artery Disease. Indian Journal of Clinical Cardiology, 2020, 1, 164-173.	0.3	0
3494	Diminished response to statins predicts the occurrence of heart failure after acute myocardial infarction. Cardiovascular Diagnosis and Therapy, 2020, 10, 705-716.	0.7	3
3495	Lipoprotein(a) and long-term recurrent infarction after an episode of ST-segment elevation acute myocardial infarction. Coronary Artery Disease, 2020, 31, 378-384.	0.3	3
3496	Role of Bempedoic Acid in Dyslipidemia Management. Journal of Cardiovascular Pharmacology, 2020, 76, 376-388.	0.8	6
3497	Statins in primary prevention: is the enthusiasm justified?. Indian Heart Journal, 2020, 72, 221-224.	0.2	0
3498	Comparing a novel machine learning method to the Friedewald formula and Martin-Hopkins equation for low-density lipoprotein estimation. PLoS ONE, 2020, 15, e0239934.	1.1	26
3499	Calcium deposition within coronary atherosclerotic lesion: Implications for plaque stability. Atherosclerosis, 2020, 306, 85-95.	0.4	94
3500	Management of multivessel coronary artery disease in patients with non-ST-elevation myocardial infarction: a complex path to precision medicine. Therapeutic Advances in Chronic Disease, 2020, 11, 204062232093852.	1.1	19
3501	Lipid-lowering therapy and low-density lipoprotein cholesterol goal attainment after acute coronary syndrome: a Danish population-based cohort study. BMC Cardiovascular Disorders, 2020, 20, 336.	0.7	13
3502	Statin use in patients with <scp>nonâ€œHMGCRC</scp> idiopathic inflammatory myopathies: A retrospective study. Clinical Cardiology, 2020, 43, 732-742.	0.7	12
3503	Nicotinamide Prevents Apolipoprotein B-Containing Lipoprotein Oxidation, Inflammation and Atherosclerosis in Apolipoprotein E-Deficient Mice. Antioxidants, 2020, 9, 1162.	2.2	11
3504	The Impact of Information Technology on the Diffusion of New Pharmaceuticals. American Economic Journal: Applied Economics, 2020, 12, 1-39.	1.5	5
3505	Role of Lipid-Lowering Therapy in Low-Density Lipoprotein Cholesterol Goal Attainment: Focus on Patients With Acute Coronary Syndrome. Journal of Cardiovascular Pharmacology, 2020, 76, 658-670.	0.8	9
3506	Hitos histÃ³ricos en el tratamiento hipolipemiente antes de la era de los inhibidores de la proproteína convertasa subtilisina/kexina tipo 9. Revista Espanola De Cardiologia Suplementos, 2020, 20, 8-14.	0.2	0
3507	Anticuerpos monoclonales inhibidores de la proproteína convertasa subtilisina/kexina tipo 9: nuevas evidencias. Revista Espanola De Cardiologia Suplementos, 2020, 20, 15-20.	0.2	1
3508	The Role of Statins in Current Guidelines. Current Atherosclerosis Reports, 2020, 22, 50.	2.0	17
3509	Risk Differences in Secondary Prevention Patients Who Present With Acute Coronary Syndrome and Implications of Guideline-Directed Cholesterol Management. American Journal of Cardiology, 2020, 133, 1-6.	0.7	0
3510	Timeâ€œDependent Cardiovascular Treatment Benefit Model for Lipidâ€œLowering Therapies. Journal of the American Heart Association, 2020, 9, e016506.	1.6	8

#	ARTICLE	IF	CITATIONS
3511	Comparative Effect of Statins and Omega-3 Supplementation on Cardiovascular Events: Meta-Analysis and Network Meta-Analysis of 63 Randomized Controlled Trials Including 264,516 Participants. <i>Nutrients</i> , 2020, 12, 2218.	1.7	8
3512	Lipoproteins and lipids in cardiovascular disease: from mechanistic insights to therapeutic targeting. <i>Advanced Drug Delivery Reviews</i> , 2020, 159, 4-33.	6.6	113
3513	10. Cardiovascular Disease and Risk Management: <i>Standards of Medical Care in Diabetesâ€”2020</i>. <i>Diabetes Care</i> , 2020, 43, S111-S134.	4.3	421
3514	<sup>18</sup> F-Fluorodeoxyglucose-Positron Emission Tomography Imaging Detects Response to Therapeutic Intervention and Plaque Vulnerability in a Murine Model of Advanced Atherosclerotic Diseaseâ€”Brief Report. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 2821-2828.	1.1	10
3515	Simvastatin Posttreatment Controls Inflammation and Improves Bacterial Clearance in Experimental Sepsis. <i>Mediators of Inflammation</i> , 2020, 2020, 1-11.	1.4	6
3516	<p>Cardiovascular Outcomes and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: Current Data and Future Prospects</p>. <i>Vascular Health and Risk Management</i> , 2020, Volume 16, 403-418.	1.0	4
3517	Association of Hypertriglyceridemia with Allâ€”Cause Mortality and Atherosclerotic Cardiovascular Events in a Lowâ€”Risk Italian Population: The TGâ€”REAL Retrospective Cohort Analysis. <i>Journal of the American Heart Association</i> , 2020, 9, e015801.	1.6	38
3518	Health Insurance and Mortality: Experimental Evidence from Taxpayer Outreach. <i>Quarterly Journal of Economics</i> , 2020, 136, 1-49.	3.8	53
3519	High-intensity statin therapy yields better outcomes in acute coronary syndrome patients: a meta-analysis involving 26,497 patients. <i>Lipids in Health and Disease</i> , 2020, 19, 194.	1.2	13
3520	An Evaluation of Statin Use Among Patients with Type 2 Diabetes at High Risk of Cardiovascular Events Across Multiple Health Care Systems. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2020, 26, 1090-1098.	0.5	1
3521	Lysosomal Storage Disease-Associated Neuropathy: Targeting Stable Nucleic Acid Lipid Particle (SNALP)-Formulated siRNAs to the Brain as a Therapeutic Approach. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5732.	1.8	5
3522	Plaque Regression and Endothelial Progenitor Cell Mobilization With Intensive Lipid Elimination Regimen (PREMIER). <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e008933.	1.4	10
3523	Shared Decisions: A Qualitative Study on Clinician and Patient Perspectives on Statin Therapy and Statinâ€”Associated Side Effects. <i>Journal of the American Heart Association</i> , 2020, 9, e017915.	1.6	14
3524	The role of intracoronary imaging in translational research. <i>Cardiovascular Diagnosis and Therapy</i> , 2020, 10, 1480-1507.	0.7	3
3525	Real-world effectiveness of treatments for type 2 diabetes, hypercholesterolemia, and hypertension in Canadian routine care â€” Results from the CardioVascular and metabolic treatment in Canada: Assessment of REal-life therapeutic value (CV-CARE) registry, 12-months results. <i>Diabetes Research and Clinical Practice</i> , 2020, 170, 108416.	1.1	0
3526	Lipid Management in Patients Presenting With Acute Coronary Syndromes: A Review. <i>Journal of the American Heart Association</i> , 2020, 9, e018897.	1.6	23
3527	Inflammation in Coronary Atherosclerosis and Its Therapeutic Implications. <i>Cardiovascular Drugs and Therapy</i> , 2022, 36, 347-362.	1.3	23
3528	Higher baseline lipid levels amplify the benefit of secondary prevention therapy with statins in Chinese patients with acute coronary syndrome. <i>Journal of International Medical Research</i> , 2020, 48, 030006052096584.	0.4	0

#	ARTICLE	IF	CITATIONS
3529	An innovative lipid-lowering approach to enhance attainment of low-density lipoprotein cholesterol goals. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020, 9, 879-887.	0.4	17
3530	Comparing effectiveness of high-dose Atorvastatin and Rosuvastatin among patients undergone Percutaneous Coronary Interventions: A non-concurrent cohort study in India. <i>PLoS ONE</i> , 2020, 15, e0233230.	1.1	9
3531	The Evolving Understanding and Approach to Residual Cardiovascular Risk Management. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 88.	1.1	82
3532	Hyperlipidemias in elderly patients: results from the Berlin Aging Study II (BASEII), a cross-sectional study. <i>Lipids in Health and Disease</i> , 2020, 19, 92.	1.2	22
3533	Influence of lipoproteins and antiplatelet agents on vein graft patency 1Âyear after coronary artery bypass grafting. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2022, 163, 1030-1039.e4.	0.4	4
3534	Translating evidence into practice: eligibility criteria fail to eliminate clinically significant differences between real-world and study populations. <i>Npj Digital Medicine</i> , 2020, 3, 67.	5.7	75
3535	A tale of two technologies: Can nuclear cardiology survive the emergence of cardiac CT the seventeenth annual Mario S. Verani lectureship. <i>Journal of Nuclear Cardiology</i> , 2020, 27, 865-890.	1.4	0
3536	Preliminary Pilot Study of Combined Effects of Physical Activity and Achievement of LDL-Cholesterol Target on Coronary Plaque Volume Changes in Patients with Acute Coronary Syndrome. <i>Journal of Clinical Medicine</i> , 2020, 9, 1578.	1.0	0
3537	Established and Emerging Pharmacological Therapies for Post-Myocardial Infarction Patients with Heart Failure: a Review of the Evidence. <i>Cardiovascular Drugs and Therapy</i> , 2020, 34, 723-735.	1.3	11
3538	Current Status of Dyslipidemia Treatment for Stroke Prevention. <i>Current Neurology and Neuroscience Reports</i> , 2020, 20, 31.	2.0	11
3539	PCSK9 Inhibitors in Secondary Preventionâ€”An Opportunity for Personalized Therapy. <i>Journal of Cardiovascular Pharmacology</i> , 2020, 75, 410-420.	0.8	11
3540	Statins Alone or in Combination with Ezetimibe or PCSK9 Inhibitors in Atherosclerotic Cardiovascular Disease Protection. , 2020, , .		1
3541	Coronary and Peripheral Artery Plaques: Do Differences in Plaque Characteristics Translate to Differences in Lipid Management?. <i>Journal of Investigative Medicine</i> , 2020, 68, 1141-1151.	0.7	9
3542	What is the Sweet Spot for Platelet Reactivity in Japanese Patients?. <i>Journal of Atherosclerosis and Thrombosis</i> , 2020, 27, 1-3.	0.9	1
3543	Treating Dyslipidemias in the Primary Prevention of Atherosclerotic Cardiovascular Disease in Older Adults with Diabetes Mellitus. <i>Clinics in Geriatric Medicine</i> , 2020, 36, 457-476.	1.0	2
3544	Reasons Why Combination Therapy Should Be the New Standard of Care to Achieve the LDL-Cholesterol Targets. <i>Current Cardiology Reports</i> , 2020, 22, 66.	1.3	26
3545	Galectin-3 Is a Potential Mediator for Atherosclerosis. <i>Journal of Immunology Research</i> , 2020, 2020, 1-11.	0.9	62
3546	Intravenous Statin Administration During Myocardial Infarction Compared With Oral Post-Infarct Administration. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1386-1402.	1.2	30



#	ARTICLE	IF	CITATIONS
3547	Efficacy and Safety of High-Dose Atorvastatin in Moderate-to-High Cardiovascular Risk Postmenopausal Korean Women with Dyslipidemia. <i>Journal of Lipid and Atherosclerosis</i> , 2020, 9, 162.	1.1	6
3548	Statins reduce vascular inflammation in atherogenesis: A review of underlying molecular mechanisms. <i>International Journal of Biochemistry and Cell Biology</i> , 2020, 122, 105735.	1.2	47
3549	Management of <sc>LDL</sc> cholesterol after an acute coronary syndrome: Key comparisons of the American and European clinical guidelines to the attention of the healthcare providers. <i>Clinical Cardiology</i> , 2020, 43, 684-690.	0.7	7
3550	Immediate versus deferred percutaneous coronary intervention for patients with acute coronary syndrome: A meta-analysis of randomized controlled trials. <i>PLoS ONE</i> , 2020, 15, e0234655.	1.1	2
3551	Cardiovascular mortality after intensive LDL-Cholesterol lowering: Does baseline LDL-Cholesterol really matter?. <i>American Journal of Preventive Cardiology</i> , 2020, 1, 100013.	1.3	10
3552	A novel method for interpreting survival analysis data: description and test on three major clinical trials on cardiovascular prevention. <i>Trials</i> , 2020, 21, 578.	0.7	3
3553	Prevalence and Correlates of Statin Underuse for Secondary Prevention of Cardiovascular Disease in Older Adults 65â€“79 Years of Age: The Italian Health Examination Survey 2008â€“2012. <i>Rejuvenation Research</i> , 2020, 23, 394-400.	0.9	5
3554	Patient and Diseaseâ€“Specific Induced Pluripotent Stem Cells for Discovery of Personalized Cardiovascular Drugs and Therapeutics. <i>Pharmacological Reviews</i> , 2020, 72, 320-342.	7.1	121
3555	Older Patient and Caregiver Perspectives on Medication Value and Deprescribing: A Qualitative Study. <i>Journal of the American Geriatrics Society</i> , 2020, 68, 746-753.	1.3	25
3556	High-sensitivity cardiac troponin assays for cardiovascular risk stratification in the general population. <i>European Heart Journal</i> , 2020, 41, 4050-4056.	1.0	83
3557	What Lessons Have We Learned and What Remains to be Clarified for PCSK9 Inhibitors? A Review of FOURIER and ODYSSEY Outcomes Trials. <i>Cardiology and Therapy</i> , 2020, 9, 59-73.	1.1	16
3558	In stroke patients, lower LDL-cholesterol is actually better. <i>European Journal of Internal Medicine</i> , 2020, 75, 117-118.	1.0	0
3559	Usefulness of a Structured Adult Education Program in Modifying Markers of Cardiovascular Risk After Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 2020, 125, 845-850.	0.7	5
3560	The relationship between protein convertase subtilisin kexin type-9 levels and extent of coronary artery disease in patients with non-ST-elevation myocardial infarction. <i>Coronary Artery Disease</i> , 2020, 31, 81-86.	0.3	6
3561	Meta-Analysis of Usefulness of Treatment of Hypercholesterolemia With Statins for Primary Prevention in Patients Older Than 75 Years. <i>American Journal of Cardiology</i> , 2020, 125, 1154-1157.	0.7	11
3562	Outcome of pitavastatin versus atorvastatin therapy in patients with hypercholesterolemia at high risk for atherosclerotic cardiovascular disease. <i>International Journal of Cardiology</i> , 2020, 305, 139-146.	0.8	20
3563	Different Statin Effects of ST-elevation Versus Non-ST-Elevation Acute Myocardial Infarction After Stent Implantation. <i>American Journal of the Medical Sciences</i> , 2020, 359, 156-167.	0.4	3
3564	Lipid-Lowering Therapy and Low-Density Lipoprotein Cholesterol (LDL-C) Goal Achievement in High-Cardiovascular-Risk Patients in Fuzhou, China. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2020, 25, 307-315.	1.0	4

#	ARTICLE	IF	CITATIONS
3565	Predicting Cardiovascular Outcomes by Baseline Lipoprotein(a) Concentrations: A Large Cohort and Long-Term Follow-Up Study on Real-World Patients Receiving Percutaneous Coronary Intervention. <i>Journal of the American Heart Association</i> , 2020, 9, e014581.	1.6	37
3566	Update to Evidence-Based Secondary Prevention Strategies After Acute Coronary Syndrome. <i>CJC Open</i> , 2020, 2, 402-415.	0.7	6
3567	Impact of LR11 as Residual Risk on Long-Term Clinical Outcomes in Patients with Coronary Artery Disease Treated with Statins after First Percutaneous Coronary Intervention. <i>International Heart Journal</i> , 2020, 61, 470-475.	0.5	2
3568	Atorvastatin-loaded solid lipid nanoparticles as eye drops: proposed treatment option for age-related macular degeneration (AMD). <i>Drug Delivery and Translational Research</i> , 2020, 10, 919-944.	3.0	59
3569	Low-Density Lipoprotein Cholesterol. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2119-2121.	1.2	20
3570	An overview of statin-induced myopathy and perspectives for the future. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 601-615.	1.0	38
3571	Not even a peripheral role for statins in end-stage renal disease?. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1645-1647.	0.4	2
3572	Design and rationale of a randomized control trial testing the effectiveness of combined therapy with STAtin plus FENOibrate and statin alone in non-diabetic, combined dyslipidemia patients with non-intervened intermediate coronary artery disease - STAFENO study. <i>Trials</i> , 2020, 21, 353.	0.7	2
3573	Atorvastatin Reduces In Vivo Fibrin Deposition and Macrophage Accumulation, and Improves Primary Patency Duration and Maturation of Murine Arteriovenous Fistula. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 931-945.	3.0	8
3574	Room for improvement: initiation of lipid-lowering treatment and achievement of lipid target levels—a Danish registry-based study. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2021, 7, 181-188.	1.8	3
3575	Imaging-guided PCI for event suppression in Japanese acute coronary syndrome patients: community-based observational cohort registry. <i>Cardiovascular Intervention and Therapeutics</i> , 2021, 36, 81-90.	1.2	24
3576	Achieved low-density lipoprotein cholesterol level and stroke risk: A meta-analysis of 23 randomised trials. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 905-916.	0.8	13
3577	Association of lipoprotein (a) and in-hospital outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention. <i>Postgraduate Medicine</i> , 2021, 133, 195-201.	0.9	7
3578	Bempedoic Acid: A New Drug for an Old Problem. <i>Annals of Pharmacotherapy</i> , 2021, 55, 246-251.	0.9	8
3579	Low-density lipoprotein cholesterol reduction and target achievement after switching from statin monotherapy to statin/ezetimibe combination therapy: Real-world evidence. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021, 46, 134-142.	0.7	6
3580	Time to Deprescribe: A Time-Centric Model for Deprescribing at End of Life. <i>Journal of Palliative Medicine</i> , 2021, 24, 273-284.	0.6	5
3581	New Approaches for the Prevention and Treatment of Cardiovascular Disease: Focus on Lipoproteins and Inflammation. <i>Annual Review of Medicine</i> , 2021, 72, 431-446.	5.0	9
3582	The relationship between residual cholesterol risk and plaque characteristics in patients with acute coronary syndrome: Insights from an optical coherence tomography study. <i>Atherosclerosis</i> , 2021, 317, 10-15.	0.4	6

#	ARTICLE	IF	CITATIONS
3583	Residual Cardiovascular Risk at Low LDL: Remnants, Lipoprotein(a), and Inflammation. <i>Clinical Chemistry</i> , 2021, 67, 143-153.	1.5	120
3584	10. Cardiovascular Disease and Risk Management: <i>Standards of Medical Care in Diabetesâ€™2021</i>. <i>Diabetes Care</i> , 2021, 44, S125-S150.	4.3	359
3585	Simvastatinâ€™Ezetimibe enhances growth factor expression and attenuates neuron loss in the hippocampus in a model of intracerebral hemorrhage. <i>Fundamental and Clinical Pharmacology</i> , 2021, 35, 634-644.	1.0	6
3586	Impact of daily glucose fluctuations on cardiovascular outcomes after percutaneous coronary intervention for patients with stable coronary artery disease undergoing lipidâ€™lowering therapy. <i>Journal of Diabetes Investigation</i> , 2021, 12, 1015-1024.	1.1	5
3587	Causal Inference Methods to Integrate Omics and Complex Traits. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2021, 11, a040493.	2.9	9
3588	Impact of high-dose statin on cardiovascular outcomes in real-world patients with ST-elevation acute myocardial infarction. <i>Heart and Vessels</i> , 2021, 36, 297-307.	0.5	3
3589	Most important advances in preventive cardiology during this past decade: Viewpoint from the American Society for Preventive Cardiology. <i>Trends in Cardiovascular Medicine</i> , 2021, 31, 49-56.	2.3	12
3590	How low is safe? The frontier of very low (&lt;30 mg/dL) LDL cholesterol. <i>European Heart Journal</i> , 2021, 42, 2154-2169.	1.0	28
3591	A randomized, open-label, parallel, multi-center Phase IV study to compare the efficacy and safety of atorvastatin 10 and 20 mg in high-risk Asian patients with hypercholesterolemia. <i>PLoS ONE</i> , 2021, 16, e0245481.	1.1	5
3592	ST-elevation versus non-ST-elevation myocardial infarction after combined use of statin with reninâ€™angiotensin system inhibitor: Data from the Korea Acute Myocardial Infarction Registry. <i>Cardiology Journal</i> , 2021, , .	0.5	0
3593	Dose-Dependent Inhibitory Effect of Rosuvastatin in Japanese Patients with Acute Myocardial Infarction on Serum Concentration of Matrix Metalloproteinasesâ€™INVITATION Trialâ€™. <i>Journal of Atherosclerosis and Thrombosis</i> , 2022, 29, 229-241.	0.9	1
3594	Research Progress of Blood Pressure Variation in Elderly Patients with Hypertension. <i>Advances in Clinical Medicine</i> , 2021, 11, 2436-2441.	0.0	0
3596	The importance of omega fatty acids for the prevention of cardiovascular disease. <i>Profilakticheskaya Meditsina</i> , 2021, 24, 90.	0.2	0
3597	The Novelty of Icosapent Ethyl in the Management of Hypertriglyceridemia and Alleviating Cardiovascular Risk. <i>Journal of Lipids</i> , 2021, 2021, 1-5.	1.9	1
3598	Drugs in Myocardial Infarction. , 2021, , 115-124.		0
3599	Recent Updates of Lipoprotein(a) and Cardiovascular Disease. <i>Chonnam Medical Journal</i> , 2021, 57, 36.	0.5	14
3600	Ulcerative Colitis Diagnosis and Management: Past, Present, and Future Directions. <i>Clinical Gastroenterology</i> , 2021, , 61-88.	0.0	1
3601	High Sensitivity C-reactive Protein (hsCRP) and its Implications in Cardiovascular Outcomes. <i>Current Pharmaceutical Design</i> , 2021, 27, 263-275.	0.9	27

#	ARTICLE	IF	CITATIONS
3602	AssociaÃ§Ã£o entre Terapia com Estatinas e Menor IncidÃªncia de Hiperglicemia em Pacientes Internados com SÃndromes Coronarianas Agudas. Arquivos Brasileiros De Cardiologia, 2021, 116, 285-294.	0.3	1
3603	Clinical impact of PCSK9 inhibitor on stabilization and regression of lipid-rich coronary plaques: a near-infrared spectroscopy study. European Heart Journal Cardiovascular Imaging, 2022, 23, 217-228.	0.5	23
3604	2020 Update of the quality indicators for acute myocardial infarction: a position paper of the Association for Acute Cardiovascular Care: the study group for quality indicators from the ACVC and the NSTEMI-ACS guideline group. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 224-233.	0.4	54
3605	Neuraminidases 1 and 3 Trigger Atherosclerosis by Desialylating Low-Density Lipoproteins and Increasing Their Uptake by Macrophages. Journal of the American Heart Association, 2021, 10, e018756.	1.6	29
3606	Antibiotics for secondary prevention of coronary heart disease. The Cochrane Library, 2021, 2021, CD003610.	1.5	11
3607	Liver Fibrosis Scoring Systems as Novel Tools for Predicting Cardiovascular Outcomes in Patients Following Elective Percutaneous Coronary Intervention. Journal of the American Heart Association, 2021, 10, e018869.	1.6	20
3608	Effects and Issues of Diet Fat on Cardiovascular Metabolism. , 0, , .		0
3609	Effect of statin treatment in patients with acute myocardial infarction with prediabetes and type 2 diabetes mellitus. Medicine (United States), 2021, 100, e24733.	0.4	4
3610	A randomized, placebo-controlled, double-blinded clinical trial of colchicine to improve vascular health in people living with HIV. Aids, 2021, 35, 1041-1050.	1.0	10
3611	Emerging views of statin pleiotropy and cholesterol lowering. Cardiovascular Research, 2022, 118, 413-423.	1.8	54
3612	Awareness and Knowledge Among Internal Medicine House-Staff for Dose Adjustment of Cardiovascular Drugs in Chronic Kidney Disease. High Blood Pressure and Cardiovascular Prevention, 2021, 28, 177-184.	1.0	2
3613	Lipid goal achievements after acute myocardial infarction: the gap between real-life and ESC 2019 guidelines. European Journal of Preventive Cardiology, 2022, 29, e65-e67.	0.8	2
3614	Cardiovascular Disease among Patients with Diabetes: The Current Scenario in Saudi Arabia. Current Diabetes Reviews, 2021, 17, 180-185.	0.6	10
3615	Management of LDL-Cholesterol levels in patients with Diabetes Mellitus in Cardiology Practice: Real-life evidence of Under-treatment from the EPHEUS registry. European Journal of Clinical Investigation, 2021, 51, e13528.	1.7	12
3616	Multi-modality intravascular imaging for guiding coronary intervention and assessing coronary atheroma: the Novasight Hybrid IVUS-OCT system. Minerva Cardiology and Angiology, 2021, 69, 655-670.	0.4	5
3617	Metabolic Dyslipidemia and Cardiovascular Outcomes in Type 2 Diabetes Mellitus: Findings From the Look AHEAD Study. Journal of the American Heart Association, 2021, 10, e016947.	1.6	49
3618	Baseline low-density lipoprotein cholesterol predicts the benefit of adding ezetimibe on statin in statin-naïve acute coronary syndrome. Scientific Reports, 2021, 11, 7480.	1.6	5
3619	Lipid Testing, Lipid-Modifying Therapy, and PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Eligibility in 27,979 Patients With Incident Acute Coronary Syndrome. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e006646.	0.9	13

#	ARTICLE	IF	CITATIONS
3620	Effects of hydrogen as adjuvant treatment for unstable angina. <i>Experimental Biology and Medicine</i> , 2021, 246, 1981-1989.	1.1	3
3621	Is the effect of atorvastatin 60 mg on stabilization of lipid-rich plaque equivalent to that of rosuvastatin 10 mg? A serial optical coherence tomography combined with intravascular ultrasound imaging. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 1097-1107.	0.7	0
3622	Lipid-lowering therapy and percutaneous coronary interventions. <i>EuroIntervention</i> , 2021, 16, 1389-1403.	1.4	12
3623	Who is susceptible to online health misinformation? A test of four psychosocial hypotheses. <i>Health Psychology</i> , 2021, 40, 274-284.	1.3	59
3624	The Emerging Role of CT-Based Imaging in Adipose Tissue and Coronary Inflammation. <i>Cells</i> , 2021, 10, 1196.	1.8	12
3625	2020 Clinical practice guidelines for Acute coronary syndrome without ST segment elevation. <i>Russian Journal of Cardiology</i> , 2021, 26, 4449.	0.4	63
3626	Statin (mis)use in older people: A cross-sectional study using French health insurance databases. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 1084-1090.	0.9	0
3627	Association between antecedent statin use and severe disease outcomes in COVID-19: A retrospective study with propensity score matching. <i>Journal of Clinical Lipidology</i> , 2021, 15, 451-459.	0.6	22
3628	Zebrafish as a Model for the Study of Lipid-Lowering Drug-Induced Myopathies. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5654.	1.8	7
3629	Hydrophilic or Lipophilic Statins?. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 687585.	1.1	89
3630	Proatherogenic Sialidases and Desialylated Lipoproteins: 35 Years of Research and Current State from Bench to Bedside. <i>Biomedicines</i> , 2021, 9, 600.	1.4	26
3631	Intensity of statin therapy and muscle symptoms: a network meta-analysis of 153 000 patients. <i>BMJ Open</i> , 2021, 11, e043714.	0.8	14
3633	Utilizing coronary artery calcium to guide statin use. <i>Atherosclerosis</i> , 2021, 326, 17-24.	0.4	7
3634	Special Considerations for Lipid-Lowering Therapy in Women Reflecting Recent Randomized Trials. <i>Current Atherosclerosis Reports</i> , 2021, 23, 42.	2.0	2
3635	Thrombolysis In Myocardial Infarction (TIMI) Study Group. <i>Journal of the American College of Cardiology</i> , 2021, 77, 2822-2845.	1.2	23
3636	How to fill the GAPS-I in secondary prevention: application of a strategy based on GLP1 analogues, antithrombotic agents, PCSK9 inhibitors, SGLT2 inhibitors and immunomodulators. <i>Panminerva Medica</i> , 2022, 64, .	0.2	4
3637	Pharmacological Management of Hyperlipidemia in Older Individuals. , 2021, 36, 284-303.		1
3638	Effect of More Intensive LDL-Cholesterol Lowering Therapy on Long-term Cardiovascular Outcomes in Early-Phase Acute Coronary Syndrome: A Systematic Review and Meta-analysis. <i>Clinical Therapeutics</i> , 2021, 43, e217-e229.	1.1	1

#	ARTICLE	IF	CITATIONS
3639	Secondary prevention after acute coronary syndrome: are dyslipidaemia guideline targets achieved?. <i>European Journal of Preventive Cardiology</i> , 2022, 29, e122-e124.	0.8	2
3640	Trends in optimal medical therapy at discharge and clinical outcomes in patients with acute coronary syndrome in Thailand. <i>Journal of Cardiology</i> , 2021, 77, 669-676.	0.8	2
3641	Clinical impact and room for improvement of intensity and adherence to lipid lowering therapy: Five years of clinical follow-up from 164,565 post-myocardial infarction patients. <i>International Journal of Cardiology</i> , 2021, 332, 22-28.	0.8	16
3642	The TIMI Study Group's Contributions to the Advancement of Cardiology -With Focus on Atherosclerotic Cardiovascular Disease-. <i>Journal of Atherosclerosis and Thrombosis</i> , 2021, 28, 563-572.	0.9	1
3643	Design and rationale of the randomized trial of comprehensive lifestyle modification, optimal pharmacological treatment and utilizing PET imaging for quantifying and managing stable coronary artery disease (the CENTURY study). <i>American Heart Journal</i> , 2021, 237, 135-146.	1.2	2
3644	Atorvastatin Pretreatment Ameliorates Mesenchymal Stem Cell Migration through miR-146a/CXCR4 Signaling. <i>Tissue Engineering and Regenerative Medicine</i> , 2021, 18, 863-873.	1.6	8
3645	LDL-C, NON-HDL-C and APO-B for cardiovascular risk assessment: Looking for the ideal marker. <i>Indian Heart Journal</i> , 2021, 73, 544-548.	0.2	22
3646	Application of Information Technology to Clinical Trial Evaluation and Enrollment. <i>JAMA Oncology</i> , 2021, 7, 1559.	3.4	17
3647	Diretrizes da Sociedade Brasileira de Cardiologia sobre Angina Instável e Infarto Agudo do Miocárdio sem Supradesnível do Segmento ST – 2021. <i>Arquivos Brasileiros De Cardiologia</i> , 2021, 117, 181-264.	0.3	45
3648	Discovery of analogues of non- $\hat{2}$ oxidizable long-chain dicarboxylic fatty acids as dual inhibitors of fatty acids and cholesterol synthesis: Efficacy of lead compound in hyperlipidemic hamsters reveals novel mechanism. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 2490-2506.	1.1	3
3649	Statin Therapy and Intensity: Prognosis in Patients with Myocardial Injury. <i>American Journal of Medicine</i> , 2021, , .	0.6	1
3650	How much should LDL cholesterol be lowered in secondary prevention? Clinical efficacy and safety in the era of PCSK9 inhibitors. <i>Progress in Cardiovascular Diseases</i> , 2021, 67, 65-74.	1.6	23
3651	Association and Implications of Blood and Plaque n-3 Polyunsaturated Fatty Acid Composition in Patients Treated with Oral Eicosapentaenoic Acid before Carotid Endarterectomy. <i>International Journal of Angiology</i> , 0, , .	0.2	0
3652	Combined lipid-lowering therapy from standpoint of modern guidelines for management of dyslipidaemias. <i>Medical Alphabet</i> , 2021, , 13-19.	0.0	1
3653	Cholesterol: the race to the bottom. <i>European Heart Journal</i> , 2021, 42, 4612-4613.	1.0	10
3654	Human Angiotensin-like Protein 3/ANGPTL3 Antibodies. <i>Journal of Cardiovascular Pharmacology</i> , 2021, Publish Ahead of Print, e631-e640.	0.8	0
3655	Assessing the Impact of Colchicine on Coronary Plaque Phenotype After Myocardial Infarction with Optical Coherence Tomography: Rationale and Design of the COCOMO-ACS Study. <i>Cardiovascular Drugs and Therapy</i> , 2022, 36, 1175-1186.	1.3	7
3656	Ischemic/bleeding event after short dual-antiplatelet therapy in patients with high bleeding risk: Sub-analysis of the MODEL U-SES study. <i>Journal of Cardiology</i> , 2021, 78, 107-113.	0.8	1

#	ARTICLE	IF	CITATIONS
3657	Irreversible post-translational modifications â€œ Emerging cardiovascular risk factors. <i>Molecular Aspects of Medicine</i> , 2022, 86, 101010.	2.7	6
3658	The prognostic significance of the lipid profile after an ischemic stroke. <i>Neurological Research</i> , 2022, 44, 139-145.	0.6	5
3659	How to Use Statins in Secondary Prevention of Atherosclerotic Diseases: from the Beneficial Early Initiation to the Potentially Unfavorable Discontinuation. <i>Cardiovascular Drugs and Therapy</i> , 2021, , 1.	1.3	1
3660	A Comparative Study of High-intensity Rosuvastatin Versus Atorvastatin Therapy Post-acute Coronary Syndrome Using Real-world Data. <i>Current Problems in Cardiology</i> , 2022, 47, 100956.	1.1	7
3661	Characteristics and Outcomes of Early Recurrent Myocardial Infarction After Acute Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2021, 10, e019270.	1.6	16
3662	Clinical determinants of coronary artery disease burden and vulnerability using optical coherence tomography co-registered with intravascular ultrasound. <i>Coronary Artery Disease</i> , 2021, Publish Ahead of Print, .	0.3	3
3663	Use of Lipid-Lowering Therapies Over 2 Years in GOULD, a Registry of Patients With Atherosclerotic Cardiovascular Disease in the US. <i>JAMA Cardiology</i> , 2021, 6, 1060.	3.0	86
3664	Have We Learnt all from IMPROVE-IT? Part I. Core Results and Subanalyses on the Effects of Ezetimibe Added to Statin Therapy Related to Age, Gender and Selected Chronic Diseases (Kidney Disease, Diabetes) Tj ETQq b.30.7843i14 rgBT		
3665	Analysis of PRX Gene Family and Its Function on Cell Lignification in Pears ( <i>Pyrus bretschneideri</i> ). <i>Plants</i> , 2021, 10, 1874.	1.6	4
3666	Moderate-Intensity Statins Plus Ezetimibe vs. High-Intensity Statins After Coronary Revascularization: A Cohort Study. <i>Cardiovascular Drugs and Therapy</i> , 2023, 37, 141-150.	1.3	4
3667	Real-world Evidence for Adherence and Persistence with Atorvastatin Therapy. <i>Cardiology and Therapy</i> , 2021, 10, 445-464.	1.1	7
3668	Nrf2 for cardiac protection: pharmacological options against oxidative stress. <i>Trends in Pharmacological Sciences</i> , 2021, 42, 729-744.	4.0	64
3669	Effects of Statin Therapy and Dose on Cardiovascular and Limb Outcomes in Peripheral Arterial Disease: A Systematic Review and Meta-analysis. <i>European Journal of Vascular and Endovascular Surgery</i> , 2021, 62, 450-461.	0.8	5
3671	Assessment of Albumin ECM Accumulation and Inflammation as Novel In Vivo Diagnostic Targets for Multi-Target MR Imaging. <i>Biology</i> , 2021, 10, 964.	1.3	2
3672	Lipid-lowering therapy use in primary and secondary care in Central and Eastern Europe: DA VINCI observational study. <i>Atherosclerosis</i> , 2021, 334, 66-75.	0.4	29
3673	High-Intensity Statins Benefit High-Risk Patients: Why and How to Do Better. <i>Mayo Clinic Proceedings</i> , 2021, 96, 2660-2670.	1.4	7
3674	Dyslipidemia. , 2022, , 387-393.		0
3675	ST-Segment Elevation Myocardial Infarction. , 2022, , 395-411.		1

#	ARTICLE	IF	CITATIONS
3676	It's never too early to beat your low-density lipoprotein cholesterol. Archives of Cardiovascular Diseases, 2021, 114, 1-3.	0.7	1
3677	The Returns to Nursing: Evidence from a Parental-Leave Program. Review of Economic Studies, 2021, 88, 2308-2343.	2.9	11
3678	Study of Lipid Profile, Atherogenic Indices and Carotid Intima-Media Thickness as Predictors of Cardiovascular Disease in Individuals with Prediabetes. International Journal of Current Research and Review (discontinued), 2021, 13, 146-152.	0.1	1
3679	Association Between the Level of Low-Density Lipoprotein Cholesterol and Coronary Atherosclerosis in Patients Who Have Undergone Coronary Computed Tomography Angiography. Cardiology Research, 2021, 12, 10-15.	0.5	1
3680	Differential RNA expression profiles and competing endogenous RNA-associated regulatory networks during the progression of atherosclerosis. Epigenomics, 2021, 13, 99-112.	1.0	5
3681	Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction. JAMA Cardiology, 2020, 5, 952.	3.0	56
3682	Dyslipidemia and Endothelial Dysfunction: Pathophysiology and Therapy. , 0, , 245-257.		3
3684	Statins in Critical Illness. , 2005, , 477-487.		2
3685	Pharmacotherapy of Diabetes: New Developments. , 2007, , .		3
3687	Approach to Clinical and Genetic Characterization of Statin-Induced Myopathy. Methods in Molecular Biology, 2014, 1175, 67-90.	0.4	6
3688	Fatty Acids in the Causation and Therapy of Metabolic Syndrome. , 2008, , 263-284.		18
3689	High-Density Lipoproteins. , 2007, , 159-199.		1
3690	Secondary Prevention of Coronary Heart Disease: Impact of Nutrition on the Risk of Fatal Complications and Importance of the Concept of Omega-3 Deficiency. , 2007, , 181-193.		2
3691	Treatment of Acute ST-Elevation Myocardial Infarction. , 2007, , 963-977.		1
3692	Issues in Data Analysis. , 2015, , 403-462.		2
3693	Use of Combination Statin and Bile Acid Sequestrant Therapy to Treat Dyslipidemia. , 2015, , 1-10.		2
3694	Lipidsenkende Mittel. , 2010, , 665-680.		1
3695	Prevention of Cardiovascular Disease in Older Adults. , 2015, , 1763-1786.		1



#	ARTICLE	IF	CITATIONS
3696	Stable Ischemic Heart Disease Stable Ischemic Heart Disease. , 2015, , 2109-2172.		1
3697	Stable Ischemic Heart Disease. , 2014, , 1-70.		1
3699	DYSLIPIDEMIAS. , 2009, , 303-320.		1
3700	ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-“ST-Segment Elevation Myocardial Infarction” A Summary Article. , 2011, , 385-404.		2
3702	Lipid-Lowering Strategies and Reduction of Coronary Heart Disease Risk. , 2010, , 81-86.e2.		3
3703	Unstable Angina and Non-“ST Elevation Myocardial Infarction. , 2012, , 1178-1209.		5
3704	Special Patient Populations: Diabetes and Metabolic Syndrome. , 2009, , 443-462.		1
3705	Special Patient Populations: Women and Elderly. , 2009, , 463-472.		1
3706	Lipid-lowering therapy and low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: The ACS patient pathway project. Atherosclerosis Supplements, 2020, 42, e49-e58.	1.2	23
3707	Clinical approach to the inflammatory etiology of cardiovascular diseases. Pharmacological Research, 2020, 159, 104916.	3.1	56
3708	Acute coronary syndromes: diagnosis and management, part I. Mayo Clinic Proceedings, 2009, 84, 917-38.	1.4	147
3709	Carotid intima-media thickness and coronary artery calcium score as indications of subclinical atherosclerosis. Mayo Clinic Proceedings, 2009, 84, 229-33.	1.4	37
3710	Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk. Lancet, The, 2005, 365, 434-41.	6.3	283
3713	An Overview of Sociological Perspectives on the Definitions, Causes, and Responses to Mental Health and Illness. , 2017, , 6-19.		2
3714	The Measurement of Mental Disorder. , 2017, , 20-44.		3
3715	Defining Mental Disorders: Sociological Investigations into the Classification of Mental Disorders. , 2017, , 45-65.		5
3716	The Dual Continua Model: The Foundation of the Sociology of Mental Health and Mental Illness. , 2017, , 66-81.		7
3718	Studying Stress in the Twenty-First-Century: An Update of Stress Concepts and Research. , 2017, , 180-206.		13

#	ARTICLE	IF	CITATIONS
3719	Understanding the Connection between Social Support and Mental Health. , 2017, , 207-223.		7
3720	Work and Unemployment as Stressors. , 2017, , 224-238.		1
3721	Socioeconomic Stratification and Mental Disorder. , 2017, , 239-265.		3
3722	Gender and Mental Health. , 2017, , 266-280.		4
3723	Race and Mental Health. , 2017, , 281-303.		4
3724	African American Women and Mental Well-Being: The Intersection of Race, Gender, and Socioeconomic Status. , 2017, , 304-321.		6
3725	Marital Status and Mental Health. , 2017, , 322-337.		2
3726	Well-Being across the Life Course. , 2017, , 338-356.		3
3727	Labeling and Stigma. , 2017, , 393-408.		5
3728	The Context and Dynamic Social Processes Underlying Mental Health Treatment: Classic and Contemporary Approaches to Understanding Individuals' Responses to Illness in Light of the Affordable Care Act. , 2017, , 409-430.		1
3729	PCSK9 inhibition for LDL lowering and beyond " implications for patients with peripheral artery disease. Vasa - European Journal of Vascular Medicine, 2018, 47, 165-176.	0.6	7
3731	Lipids and cholesterol. , 2005, , 174-186.		1
3732	Low-density lipoprotein cholesterol reduction and statin intensity in myocardial infarction patients and major adverse outcomes: a Swedish nationwide cohort study. European Heart Journal, 2021, 42, 243-252.	1.0	84
3733	Efficacy and safety for the achievement of guideline-recommended lower low-density lipoprotein cholesterol levels: a systematic review and meta-analysis. European Journal of Preventive Cardiology, 2022, 28, 2001-2009.	0.8	10
3734	Diabetes Mellitus and Metabolic Syndrome. , 2009, , 465-496.		5
3735	Statin Therapy in Rheumatoid Arthritis. Southern Medical Journal, 2005, 98, 534-540.	0.3	9
3736	Addressing Lipid Treatment Targets Beyond Cholesterol: A Role for Prescription Omega-3 Fatty Acid Therapy. Southern Medical Journal, 2009, 102, 390-396.	0.3	4
3738	Smooth muscle glucose metabolism promotes monocyte recruitment and atherosclerosis in a mouse model of metabolic syndrome. JCI Insight, 2018, 3, .	2.3	21

#	ARTICLE	IF	CITATIONS
3739	Calpain-6 confers atherogenicity to macrophages by dysregulating pre-mRNA splicing. <i>Journal of Clinical Investigation</i> , 2016, 126, 3417-3432.	3.9	29
3740	2016 Chinese guidelines for the management of dyslipidemia in adults. <i>Journal of Geriatric Cardiology</i> , 2018, 15, 1-29.	0.2	226
3741	Resveratrol as Cardioprotective Agent. <i>Oxidative Stress and Disease</i> , 2005, , 539-555.	0.3	2
3742	Serum lipid and lipoprotein concentrations in health and in disease. , 2007, , 66-91.		1
3743	JCS 2018 Guideline on Diagnosis and Treatment of Acute Coronary Syndrome. <i>Circulation Journal</i> , 2019, 83, 1085-1196.	0.7	324
3744	PPAR- $\alpha$ Agonist Fenofibrate Decreased RANTES Levels in Type 2 Diabetes Patients with Hypertriglyceridemia. <i>Medical Science Monitor</i> , 2016, 22, 743-751.	0.5	21
3745	Apolipoprotein B-containing lipoproteins and atherosclerotic cardiovascular disease. <i>F1000Research</i> , 2017, 6, 134.	0.8	63
3746	Standards of Medical Care in Diabetes 2014. <i>Majmaah Journal of Health Sciences</i> , 2014, 2, 64-64.	0.1	1
3747	Comparing High-Intensity Versus Low-to Moderate-Intensity Statin Therapy in Korean Patients with Acute Myocardial Infarction. <i>Journal of Lipid and Atherosclerosis</i> , 2014, 3, 97.	1.1	6
3748	Lack of Effect of Lowering LDL Cholesterol on Cancer: Meta-Analysis of Individual Data from 175,000 People in 27 Randomised Trials of Statin Therapy. <i>PLoS ONE</i> , 2012, 7, e29849.	1.1	270
3749	Niacin Reduces Atherosclerosis Development in APOE*3Leiden.CETP Mice Mainly by Reducing NonHDL-Cholesterol. <i>PLoS ONE</i> , 2013, 8, e66467.	1.1	36
3750	Electronegative Low-Density Lipoprotein Increases C-Reactive Protein Expression in Vascular Endothelial Cells through the LOX-1 Receptor. <i>PLoS ONE</i> , 2013, 8, e70533.	1.1	39
3751	Strategies for Primary Prevention of Coronary Heart Disease Based on Risk Stratification by the ACC/AHA Lipid Guidelines, ATP III Guidelines, Coronary Calcium Scoring, and C-Reactive Protein, and a Global Treat-All Strategy: A Comparative-Effectiveness Modeling Study. <i>PLoS ONE</i> , 2015, 10, e0138092.	1.1	32
3752	Effects of Statin Therapy on Clinical Outcomes of Survivors of Acute Myocardial Infarction with Severe Systolic Heart Failure. <i>PLoS ONE</i> , 2015, 10, e0144602.	1.1	3
3753	High Dose Atorvastatin Associated with Increased Risk of Significant Hepatotoxicity in Comparison to Simvastatin in UK GPRD Cohort. <i>PLoS ONE</i> , 2016, 11, e0151587.	1.1	48
3754	Statin Intensity or Achieved LDL? Practice-based Evidence for the Evaluation of New Cholesterol Treatment Guidelines. <i>PLoS ONE</i> , 2016, 11, e0154952.	1.1	11
3755	Comparison of the Risk of Gastrointestinal Bleeding among Different Statin Exposures with Concomitant Administration of Warfarin: Electronic Health Record-Based Retrospective Cohort Study. <i>PLoS ONE</i> , 2016, 11, e0158130.	1.1	12
3756	Statin Intensity and Clinical Outcome in Patients with Stable Coronary Artery Disease and Very Low LDL-Cholesterol. <i>PLoS ONE</i> , 2016, 11, e0166246.	1.1	9

#	ARTICLE	IF	CITATIONS
3757	Intensive Statin Therapy in NSTEMI-ACS Patients Undergoing PCI: Clinical and Biochemical Effects. <i>Texas Heart Institute Journal</i> , 2015, 42, 528-536.	0.1	10
3758	Statins: Then and Now. <i>Methodist DeBakey Cardiovascular Journal</i> , 2021, 15, 23.	0.5	54
3759	Cardiovascular outcomes trials with statins in diabetes. <i>British Journal of Diabetes</i> , 2018, 18, 7-13.	0.1	12
3761	Atorvastatin: evidence base 15 years later. <i>Cardiovascular Therapy and Prevention (Russian)</i> Tj ETQq1 1 0.784314 rgBT /Overlock 10 T 9,4 4	0.4	132
3762	2020 Clinical practice guidelines for Acute ST-segment elevation myocardial infarction. <i>Russian Journal of Cardiology</i> , 2020, 25, 4103.	0.4	132
3763	Manejo da HDL: avanços recentes e perspectivas à luz da redução de LDL. <i>Arquivos Brasileiros De Cardiologia</i> , 2006, 87, 788-794.	0.3	8
3764	Métodos por imagem da aterosclerose em estudos de progressão/regressão: marcador substituto ou janela direta para o processo patológico da aterosclerose?. <i>Arquivos Brasileiros De Cardiologia</i> , 2008, 91, 418-431.	0.3	5
3765	Drugs and lifestyle for the treatment and prevention of coronary artery disease: comparative analysis of the scientific basis. <i>Brazilian Journal of Medical and Biological Research</i> , 2011, 44, 973-991.	0.7	15
3767	Saroglitazar: A New Drug to Treat Diabetic Hypertriglyceridemia. <i>Heart Research - Open Journal</i> , 2017, 4, 12-17.	0.2	1
3768	Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease. , 2010, , .		28
3769	Meta-analysis of clinical studies on the use of statins for prevention of atrial fibrillation soon after coronary bypass surgery. <i>Klinicheskaia Meditsina</i> , 2016, 94, 85-92.	0.2	3
3770	Choosing statins: a review to guide clinical practice. <i>Archives of Endocrinology and Metabolism</i> , 2020, 64, 639-653.	0.3	7
3771	Management of hyperlipidemia with statins in the older patient. <i>Clinical Interventions in Aging</i> , 2006, 1, 433-438.	1.3	10
3772	Optimal lipid modification: the rationale for combination therapy. <i>Vascular Health and Risk Management</i> , 2005, 1, 317-331.	1.0	21
3773	Complementary therapy to target LDL cholesterol: the role of the ezetimibe/ simvastatin combination. <i>Vascular Health and Risk Management</i> , 2006, 2, 31-38.	1.0	10
3774	Evaluation of efficacy and safety of fixed dose lovastatin and niacinER combination in Asian Indian dyslipidemic patients: a multicentric study. <i>Vascular Health and Risk Management</i> , 2006, 2, 87-93.	1.0	17
3775	Who should receive a statin drug to lower cardiovascular risk? Does the drug and the dose of the drug matter?. <i>Vascular Health and Risk Management</i> , 2006, 2, 441-446.	1.0	2
3776	Is global cardiovascular risk considered in current practice? Treatment and control of hypertension, hyperlipidemia, and diabetes according to patients' risk level. <i>Vascular Health and Risk Management</i> , 2006, 2, 507-514.	1.0	18

#	ARTICLE	IF	CITATIONS
3777	High density lipoprotein cholesterol: an evolving target of therapy in the management of cardiovascular disease. <i>Vascular Health and Risk Management</i> , 2008, 4, 39-57.	1.0	44
3778	Endothelial Dysfunction in Dyslipidaemia: Molecular Mechanisms and Clinical Implications. <i>Current Medicinal Chemistry</i> , 2020, 27, 1021-1040.	1.2	21
3779	Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors, Reality or Dream in Managing Patients with Cardiovascular Disease. <i>Current Drug Metabolism</i> , 2019, 20, 72-82.	0.7	12
3780	PCSK9 Inhibitors: Novel Therapeutic Strategies for Lowering LDLCholesterol. <i>Mini-Reviews in Medicinal Chemistry</i> , 2018, 19, 165-176.	1.1	26
3781	The Pleiotropic Effects of Statins “ From Coronary Artery Disease and Stroke to Atrial Fibrillation and Ventricular Tachyarrhythmia. <i>Current Vascular Pharmacology</i> , 2019, 17, 222-232.	0.8	54
3782	The Anti-Inflammatory Effects of Statins on Coronary Artery Disease: An Updated Review of the Literature. <i>Current Cardiology Reviews</i> , 2017, 13, 209-216.	0.6	132
3783	Effects of Evolocumab on Cardiovascular Events. <i>Current Cardiology Reviews</i> , 2017, 13, 319-324.	0.6	3
3784	Toward Preparing a Knowledge Base to Explore Potential Drugs and Biomedical Entities Related to COVID-19: Automated Computational Approach. <i>JMIR Medical Informatics</i> , 2020, 8, e21648.	1.3	9
3785	Raising high-density lipoprotein cholesterol for better prevention of cardiovascular disease. <i>Future Lipidology</i> , 2006, 1, 47-54.	0.5	1
3787	The risks of a new hypothesis: why did JUPITER patients have almost twice the predicted event rate of reduction?. <i>Journal of Cardiovascular Medicine</i> , 2011, 12, 66-70.	0.6	1
3788	Patient after myocardial infarction: how to reduce the risk of recurrent ischemic events?. <i>Cardiosomatics</i> , 2015, 6, 12-19.	0.2	8
3789	High-Density Lipoprotein Cholesterol. , 2016, , 321-366.		2
3790	High-Density Lipoprotein Cholesterol. <i>Fundamental and Clinical Cardiology</i> , 2006, , 295-340.	0.0	2
3791	Cardiovascular Drug Therapy in the Elderly. <i>Fundamental and Clinical Cardiology</i> , 2008, , 99-136.	0.0	4
3792	Therapy of Acute Myocardial Infarction. <i>Fundamental and Clinical Cardiology</i> , 2008, , 293-326.	0.0	2
3793	Management of the Older Patient After Myocardial Infarction. <i>Fundamental and Clinical Cardiology</i> , 2008, , 327-350.	0.0	2
3794	Lipoprotein-associated phospholipase A2 (Lp-PLA(2)): a novel and promising biomarker for cardiovascular risks assessment. <i>Disease Markers</i> , 2013, 34, 323-31.	0.6	34
3795	The Treatment of Disorders of Lipid Metabolism. <i>Deutsches A&amp;#x0308;rzteblatt International</i> , 2016, 113, 261-8.	0.6	55

#	ARTICLE	IF	CITATIONS
3796	Better guidelines for better care: accounting for multimorbidity in clinical guidelines – structured examination of exemplar guidelines and health economic modelling. <i>Health Services and Delivery Research</i> , 2017, 5, 1-150.	1.4	18
3797	A systematic review and economic evaluation of statins for the prevention of coronary events. <i>Health Technology Assessment</i> , 2007, 11, 1-160, iii-iv.	1.3	311
3798	Optimal strategies for monitoring lipid levels in patients at risk or with cardiovascular disease: a systematic review with statistical and cost-effectiveness modelling. <i>Health Technology Assessment</i> , 2015, 19, 1-402.	1.3	30
3799	The usual dosage regimen of statins and adherence to target LDL-cholesterol levels by Czech patients in the secondary prevention of coronary heart disease. <i>Cor Et Vasa</i> , 2009, 51, 92-96.	0.1	1
3800	A Randomized Controlled Study to Compare the Effects of Rosuvastatin 5 mg and Atorvastatin 10 mg on the Plasma Lipid Profile in Japanese Patients with Hypercholesterolemia (ASTRO-2). <i>Annals of Vascular Diseases</i> , 2009, 2, 159-73.	0.2	5
3801	A Prospective, Multicentre, Single Arm Clinical Study to Evaluate the Effect of Saroglitazar on Non High-Density Lipoprotein Cholesterol in Patients with Diabetic Dyslipidemia Inadequately Controlled with Diet, Exercise, and Statin-The GLIDDER Study. , 2019, 10, .		1
3802	EURASIAN CLINICAL GUIDELINES ON DIAGNOSIS AND TREATMENT OF ACUTE CORONARY SYNDROME WITH ST SEGMENT ELEVATION (STEMI). <i>Eurasian Heart Journal</i> , 2020, , 4-77.	0.2	17
3803	Clinical Significance of On-Treatment Triglyceride Level in Patients Treated by Percutaneous Coronary Intervention for Non-ST-Segment Elevation Acute Coronary Syndrome. <i>Korean Journal of Internal Medicine</i> , 2009, 24, 330.	0.7	1
3804	Usual Dose of Simvastatin Does Not Inhibit Plaque Progression and Lumen Loss at the Peri-Stent Reference Segments after Bare-Metal Stent Implantation: A Serial Intravascular Ultrasound Analysis. <i>Korean Journal of Internal Medicine</i> , 2010, 25, 356.	0.7	3
3805	Characteristics of Subjects with Very Low Serum Low-Density Lipoprotein Cholesterol and the Risk for Intracerebral Hemorrhage. <i>Korean Journal of Internal Medicine</i> , 2012, 27, 317.	0.7	12
3806	Contemporary use of lipid-lowering therapy for secondary prevention in Korean patients with atherosclerotic cardiovascular diseases. <i>Korean Journal of Internal Medicine</i> , 2020, 35, 593-604.	0.7	8
3807	9. Statins in the treatment and prevention of cardiovascular diseases. <i>Human Health Handbooks</i> , 2016, , 155-178.	0.1	3
3808	Lessons from the PROVE-IT trial. Higher dose of potent statin better for high-risk patients.. <i>Cleveland Clinic Journal of Medicine</i> , 2004, 71, 609-616.	0.6	14
3809	Dose-related statin myopathy: is it an issue?. <i>Cleveland Clinic Journal of Medicine</i> , 2005, 72, 751-753.	0.6	9
3810	Perioperative statins: More than lipid-lowering?. <i>Cleveland Clinic Journal of Medicine</i> , 2008, 75, 654-662.	0.6	5
3811	JUPITER to Earth: A statin helps people with normal LDL-C and high hs-CRP, but what does it mean?. <i>Cleveland Clinic Journal of Medicine</i> , 2009, 76, 37-44.	0.6	17
3812	Advances in the treatment of dyslipidemia. <i>Cleveland Clinic Journal of Medicine</i> , 2016, 83, 181-186.	0.6	12
3813	Statin treatment before percutaneous coronary intervention. <i>Journal of Thoracic Disease</i> , 2013, 5, 335-42.	0.6	22

#	ARTICLE	IF	CITATIONS
3814	Evaluation of the physical-mechanical properties of cement-lime based masonry mortars produced with mixed recycled aggregates. <i>Materiales De Construccion</i> , 2020, 70, 210.	0.2	15
3815	The Short-term Effect of Atorvastatin on Flow-Mediated Vasodilation, Pulse Wave Velocity and Carotid Intima-Media Thickness in Patients With Moderate Cholesterolemia. <i>Korean Circulation Journal</i> , 2008, 38, 144.	0.7	4
3816	Benefit of Early Statin Therapy in Acute Myocardial Infarction in Korea. <i>Korean Circulation Journal</i> , 2019, 49, 434.	0.7	4
3817	2020 Korean Society of Myocardial Infarction Expert Consensus Document on Pharmacotherapy for Acute Myocardial Infarction. <i>Korean Circulation Journal</i> , 2020, 50, 845.	0.7	16
3818	Depression and Failure of Cholesterol Lowering After Acute Myocardial Infarction. <i>Primary Care Companion To the Journal of Clinical Psychiatry</i> , 2010, 12, PCC.08m00766.	0.6	6
3819	Comparative effectiveness research and its utility in In-clinic practice. <i>Perspectives in Clinical Research</i> , 2016, 7, 9.	0.5	10
3820	Statins: Cholesterol guidelines and Indian perspective. <i>Indian Journal of Endocrinology and Metabolism</i> , 2015, 19, 546.	0.2	13
3821	Pleiotropic effects of statins. <i>Indian Journal of Endocrinology and Metabolism</i> , 2015, 19, 554.	0.2	125
3822	Prevalence of lipid abnormalities and cholesterol target value attainment in patients with stable and acute coronary heart disease in the United Arab Emirates. <i>Heart Views</i> , 2019, 20, 37.	0.1	5
3823	Outcomes of a Multidisciplinary Partnership to Improve Cardiac Wellness: An Opportunity for Pharmacists. <i>The Consultant Pharmacist</i> , 2010, 25, 105-116.	0.4	6
3824	Head-to-Head Comparison of Auto-Antibodies for Cardiovascular Outcome Prediction after Myocardial Infarction: a Prospective Study. <i>Journal of Clinical &amp; Experimental Cardiology</i> , 2011, 02, .	0.0	9
3825	Evolving Concepts in LDL-Lowering Strategies: Are We There?. <i>Journal of Clinical &amp; Experimental Cardiology</i> , 2016, 7, .	0.0	2
3826	Review of Medical Treatment of Stable Ischemic Heart Disease. <i>International Journal of Clinical Medicine</i> , 2014, 05, 249-259.	0.1	2
3827	Doctor-reported hospital management of acute coronary syndrome in China: A nationwide survey of 1029 hospitals in 30 provinces. <i>World Journal of Cardiovascular Diseases</i> , 2012, 02, 168-176.	0.0	5
3828	Acute ST-segment myocardial infarctionâ€™ Evolution of treatment strategies. <i>World Journal of Cardiovascular Diseases</i> , 2013, 03, 551-560.	0.0	2
3829	Preclinical investigation of neoatherosclerosis in magnesium-based bioresorbable scaffolds versus thick-strut drug-eluting stents. <i>EuroIntervention</i> , 2020, 16, e922-e929.	1.4	7
3830	Long-term outcome after statin treatment in routine clinical practice: results from a prospective PCI cohort study. <i>EuroIntervention</i> , 2012, 7, 1420-1427.	1.4	5
3831	2014 ESC/EACTS Guidelines on myocardial revascularization. <i>EuroIntervention</i> , 2015, 10, 1024-1094.	1.4	251

#	ARTICLE	IF	CITATIONS
3832	FOURIER to ODYSSEY: the end of the journey for lipid-lowering therapy trials? Lessons from recent clinical trials with anti-PCSK9 antibodies. <i>EuroIntervention</i> , 2018, 14, 144-146.	1.4	1
3833	Working together: Farnesyl transferase inhibitors and statins block protein prenylation. <i>Molecular and Cellular Pharmacology</i> , 2009, 1, 1-6.	1.7	19
3834	Statins in clinical medicine. <i>Swiss Medical Weekly</i> , 2011, 141, w13310.	0.8	16
3835	Diabetes care among older adults in primary care in Austria - a cross-sectional study. <i>Swiss Medical Weekly</i> , 2012, 142, w13646.	0.8	5
3836	Alternate-day versus daily atorvastatin in coronary artery disease: a randomized study. <i>Anatolian Journal of Cardiology</i> , 2012, 12, 90-6.	0.4	6
3837	Clinical Effects of Portulaca Oleracea Seeds on Dyslipidemia in Obese Adolescents: a Triple-blinded Randomized Controlled Trial. <i>Medicinski Arhiv = Medical Archives = Archives De Médecine</i> , 2014, 68, 195.	0.4	17
3838	Clinical Effects of Rhus coriaria Fruits on Dyslipidemia in Adolescents: a Triple-blinded Randomized Placebo-controlled Trial. <i>Medicinski Arhiv = Medical Archives = Archives De Médecine</i> , 2014, 68, 308.	0.4	21
3839	HDL-C as a new therapeutic target in the treatment of dyslipidemia. <i>Medicine Science</i> , 2012, 1, 141.	0.0	2
3840	Gender Disparities In Optimal Lipid Control Among Patients with Coronary Artery Disease. <i>Journal of Atherosclerosis and Thrombosis</i> , 2014, 21 Suppl 1, S20-S28.	0.9	17
3841	Effect of moderate-intensity statin therapy on plaque inflammation in patients with acute coronary syndrome: A prospective interventional study evaluated by 18F-FDG PET/CT of the carotid artery. <i>Cardiology Journal</i> , 2020, 27, 762-771.	0.5	6
3843	The Impact of Statin on Influenza Vaccine Efficacy in the Elderly and Patients With Acute Respiratory Illness. <i>Archives of Clinical Infectious Diseases</i> , 2016, 11, .	0.1	1
3844	Clinical Lipid Control Success Rate Before and After Percutaneous Coronary Intervention in Iran; a Single Center Study. <i>Iranian Red Crescent Medical Journal</i> , 2013, 15, 467-72.	0.5	4
3845	Repeated In-Stent Restenosis Despite Aggressive Lipid Lowering by PCSK-9 Inhibitor Treatment: A Case Report. <i>Tohoku Journal of Experimental Medicine</i> , 2021, 255, 123-126.	0.5	4
3846	Apolipoprotein B and Cardiovascular Disease: Biomarker and Potential Therapeutic Target. <i>Metabolites</i> , 2021, 11, 690.	1.3	95
3847	New opportunities for biomarkers in cardiovascular risk stratification. Resolution of Advisory board. <i>Russian Journal of Cardiology</i> , 2021, 26, 4700.	0.4	1
3848	Effect of Financial Incentives for Process, Outcomes, or Both on Cholesterol Level Change. <i>JAMA Network Open</i> , 2021, 4, e2121908.	2.8	1
3849	Residual Cardiovascular Risk Factors in Dyslipidemia. , 0, , .		0
3850	Assessment of Nonfatal Myocardial Infarction as a Surrogate for All-Cause and Cardiovascular Mortality in Treatment or Prevention of Coronary Artery Disease. <i>JAMA Internal Medicine</i> , 2021, 181, 1575.	2.6	28





#	ARTICLE	IF	CITATIONS
3870	Measurement of Atherogenic Lipoproteins in Cardiovascular Risk Assessment. , 2006, , 497-517.		0
3871	Dyslipidemias. , 2006, , 389-409.		0
3873	Effects of Acute Treatment With Pravastatin on Cerebral Vasospasm, Autoregulation, and Delayed Ischemic Deficits After Aneurysmal Subarachnoid Hemorrhage: A Phase II Randomized Placebo-Controlled Trial. Yearbook of Neurology and Neurosurgery, 2006, 2006, 30-32.	0.0	0
3875	Antianginal drugs. , 2006, , 260-263.		0
3876	The Evaluation of Short and Long Term Administration of Drugs Improving Life Expectancy in Patients with Myocardial Infarction in a Hungarian County Hospital. Central European Journal of Public Health, 2006, 14, 6-9.	0.4	0
3877	Update in General Internal Medicine. Annals of Internal Medicine, 2006, 145, 52.	2.0	2
3879	Women and Coronary Heart Disease. Fundamental and Clinical Cardiology, 2006, , 689-720.	0.0	0
3880	Inflammatory Mediators and C-Reactive Protein. Fundamental and Clinical Cardiology, 2006, , 441-462.	0.0	0
3881	Non-ST Segment Elevation Acute Coronary Syndromes. Southern Medical Journal, 2006, 99, 1053-1054.	0.3	0
3883	Prescribing options for chronic stable angina. Independent Nurse, 2006, 2006, .	0.0	0
3884	Safety of Dyslipidemic Agents. Fundamental and Clinical Cardiology, 2006, , 389-408.	0.0	0
3885	Vascular Biology of the Metabolic Syndrome. , 2006, , 79-108.		1
3886	Sudden cardiac death: the size of the problem. , 2006, , 25-36.		0
3887	Cardiac Rehabilitation: Statins and the Rationale for Implementation of Lipid-Lowering Therapy. , 2007, , 141-156.		0
3888	Special Considerations in Research. , 2007, , 275-350.		0
3889	Percutaneous Coronary Intervention for Unstable Coronary Artery Disease. , 2007, , 1005-1020.		0
3890	Chronic Stable Angina. , 2007, , 290-313.		0
3892	Dietary Prescriptions to Control Dyslipidemias and Coronary Disease Risk. , 2007, , 113-120.		0

#	ARTICLE	IF	CITATIONS
3893	Study on Drugs Prescribed for Treatment of Hyperlipidemia. Iryo Yakugaku (Japanese Journal of) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 74	0.0	0
3894	High-Dose Atorvastatin vs Usual-Dose Simvastatin for Secondary Prevention After Myocardial Infarction: The IDEAL Study: A Randomized Controlled Trial. Yearbook of Endocrinology, 2007, 2007, 106-108.	0.0	0
3895	Title is missing!. Japanese Journal of Clinical Pharmacology and Therapeutics, 2007, 38, 317-321.	0.1	0
3897	Management of Cholesterol Disorders. , 2007, , 2667-2691.		0
3898	Atherosclerosis: Pathogenesis, Morphology, and Risk Factors. , 2007, , 1593-1613.		2
3899	Management of Lipids in the Elderly. , 2007, , 369-387.		0
3900	Management of Diabetic Dyslipidaemia. , 2007, , 173-186.		1
3901	Familial Hypercholesterolemia and Lipid Apheresis. , 2007, , 267-289.		1
3902	Drugs for Elevated LDL-Cholesterol. , 2007, , 528-539.		0
3903	ST-Elevation Myocardial Infarction. , 2007, , 246-289.		0
3904	Overview of diabetes mellitus. , 2007, , 1-16.		0
3905	Averting a pandemic health crisis in Europe by 2020: what physicians need to know regarding cholesterol management. European Journal of Cardiovascular Prevention and Rehabilitation, 2007, 14, 340-345.	3.1	2
3906	Cardiovascular interventional pharmacology in the diabetic patient. , 2007, , 473-482.		0
3907	Lipid-lowering agents. , 2007, , 155-170.		0
3908	The acute coronary syndrome patient. , 2007, , 465-472.		0
3910	Lechenie dislipidemii kak vazhnyy faktor profilaktiki ateroskleroza i ego oslozhneniy. Systemic Hypertension, 2007, 4, 35-43.	0.1	0
3911	Nutrition in Diabetes Mellitus. , 2007, , 785-813.		0
3912	Dyslipidemia and Diabetes. , 2007, , 405-416.		1

#	ARTICLE	IF	CITATIONS
3913	The Evaluation of Cardiac and Peripheral Arterial Disease in Patients with Diabetes Mellitus. , 2007, , 437-461.		0
3914	Statin therapy for secondary prevention of coronary heart disease: an update. Primary Care Cardiovascular Journal, 2008, 1, 41.	0.1	0
3915	Lipidsenkende Mittel. , 2008, , 645-659.		0
3916	Overview of Evidence Supporting the Treatment of Hyperlipidemia. , 2008, , 1-13.		0
3917	Miscellaneous therapies. , 2008, , 55-60.		0
3918	Dietary Prevention of Coronary Heart Disease. , 2008, , 227-242.		1
3919	Diagnosis and Treatment of Unstable Angina. , 2008, , 73-85.		0
3921	Diabetes mellitusAntiguas asunciones y nuevas realidades. , 2008, , 23-32.		0
3922	Biochemical Aspects, Laboratory Diagnosis and Follow-Up of High Blood Cholesterol: NCEP ATP III Guidelines. Journal of Medical Biochemistry, 2008, 27, 64-85.	0.7	0
3924	Miscellaneous therapies. , 2009, , 61-67.		0
3925	Therapeutic Targeting of High-Density Lipoprotein Metabolism. , 2009, , 544-552.		0
3926	Evolving Targets of Therapy. , 2009, , 387-395.		0
3927	Lifestyle and Pharmacology Approaches for the Treatment of Hypertension and Hyperlipidemia. , 2009, , 279-288.		0
3928	Modulation of Biomarkers of Inflammation. , 2009, , 396-409.		1
3929	Lipidsenkende Mittel. , 2009, , 637-652.		0
3931	Type 2 Diabetes. , 2009, , 33-53.		1
3933	Invasive Imaging Modalities and Atherosclerosis: The Role of Intravascular Ultrasound. , 2009, , 410-419.		1
3935	Nutrition and Lifestyle Change in Older Adults with Diabetes Mellitus and Metabolic Syndrome. , 2009, , 279-317.		1

#	ARTICLE	IF	CITATIONS
3936	Lipid Disorders. , 2009, , 65-75.		0
3937	NHG-Standaard Cardiovasculair risicomangement. , 2009, , 106-152.		4
3938	Intravascular Ultrasound. , 2009, , 83-93.		0
3939	CMS and Type 2 Diabetes Mellitus: Bound Together by the Renin Angiotensin Aldosterone System. , 2009, , 187-206.		0
3940	Treatment Guidelines Overview. , 2009, , 202-216.		0
3941	Noninvasive Imaging Modalities and Atherosclerosis: The Role of Ultrasound. , 2009, , 420-431.		1
3942	Special Patient Populations: Acute Coronary Syndromes. , 2009, , 473-485.		0
3943	NHG-Standaard Beleid na een doorgemaakt myocardinfarct. , 2009, , 87-105.		1
3944	Management of Disease in Women with Diabetes. , 2009, , 435-452.		0
3945	Are the upper limits for serum cholesterol levels necessary?. Journal of Lipid Nutrition, 2009, 18, 33-50.	0.1	0
3946	Synthetic Factor Xa Inhibition in Acute Coronary Syndromes. , 2010, , 203-215.		0
3947	The Link Between Inflammation and Thrombosis. , 2010, , 39-61.		0
3948	Nutrition, Metabolic Syndrome, and Diabetes in the Senior Years. , 2010, , 389-417.		1
3949	Should we target HDL cholesterol level in lowering cardiovascular risk?. Polish Archives of Internal Medicine, 2009, 119, 667-672.	0.3	9
3951	Pharmacological intervention trials. , 2009, , 103-110.		0
3952	Ä«Conflict of InterestÄ» oder Interesse am Konflikt? Vom Umgang mit Erkenntnis und Interesse in der Medizin. , 2010, , 123-135.		0
3953	Kidney Disease and Medications. , 2010, , 208-217.		0
3955	Recent Cholesterol-Lowering Drug Trials: New Data, New Questions. , 2010, , 185-191.		0

#	ARTICLE	IF	CITATIONS
3956	Effects of Statins on HDL Metabolism. , 2010, , 151-155.		0
3957	Teorie degenerativa e infiammatoria e ruolo della risposta immunitaria. , 2010, , 45-51.		0
3958	Atherosclerotic Plaque Imaging. , 2010, , 341-350.		0
3959	Chronic Heart Failure in Children with Congenital Heart Disease. , 2010, , 43-58.		0
3960	Lipoprotein Metabolism and the Treatment of Lipid Disorders. , 2010, , 788-807.		0
3961	Should We Aggressively Treat the Patient with High Levels of Cholesterol Even in Japanese?. Health Evaluation and Promotion, 2010, 37, 673-678.	0.0	0
3962	Monitoring of Subclinical Atherosclerotic Disease. , 2011, , 549-567.		0
3964	Assessment of Plaque Burden and Plaque Composition Using Intravascular Ultrasound. , 2011, , 483-493.		0
3966	Residual Risk Reduction Initiative: vÃ½zva ke snÃ¼enÃ½-reziduÃ½;nÃ½ho vaskulÃ½;nÃ½ho rizika u pacientÃ½ s dyslipidemiÃ½: Cor Et Vasa, 2010, 52, 212-228.	0.1	0
3967	Comentario: Problemas y mercadeo de las estatinas. Revista Medica De Chile, 2010, 138, .	0.1	0
3968	Management of Dyslipidemia. , 2011, , 59-89.		0
3969	Unstable Angina and Non-ST Elevation Myocardial Infarction. , 2011, , 195-225.		0
3970	3ST-POL trial: standards of statin use in Poland in the context of the European Society of Cardiology guidelines. Polish Archives of Internal Medicine, 2010, 120, 328-333.	0.3	5
3971	Strategies for Treating Abnormal Lipid Profiles with Drugs. , 2011, , 163-193.		1
3972	Rust and Rupture: Atherosclerosis. , 2011, , 89-97.		0
3974	Drug Therapy and Follow-Up. , 2011, , 563-631.		0
3975	Cardiovascular Complications of Cancer Therapeutics. , 2011, , 87-115.		0
3976	Statins and Acute Lung Injury. , 2011, , 889-898.		0

#	ARTICLE	IF	CITATIONS
3978	Biomarkers in Acute Ischemic Heart Disease. , 2011, , 101-112.		1
3979	Management of ST-elevation myocardial infarction. , 2011, , 474-484.		0
3980	Secondary prevention of coronary heart disease. , 2011, , 659-666.		0
3981	The impact of statin therapy on long-term cardiovascular outcomes in an outpatient cardiology practice. Medical Science Monitor, 2011, 17, CR683-CR686.	0.5	6
3984	Lipid Regulation with Niacin Extended-Release (Niaspan-R&trade;). Clinical Medicine Reviews in Vascular Health, 0, 3, 53-70.	3.0	1
3985	NHG-Standaard Beleid na een doorgemaakt myocardinfarct. , 2011, , 341-359.		0
3986	Fenofibric Acid: Safety and Efficacy in the Treatment of Dyslipidemia, Hypertriglyceridemia and Hyperlipidemia. Clinical Medicine Reviews in Vascular Health, 0, 3, 99-105.	3.0	0
3987	Risk Factors for Atherosclerosis in the Elderly. , 2011, , 635-648.		0
3988	Management of the postcoronary patient. , 2011, , 650-659.		0
3989	Stabilizing unstable plaque in acute coronary syndromes. , 2011, , 338-345.		0
3990	Plaque Passivation and Endothelial Therapy. , 2011, , 289-298.		0
3991	Coronary artery disease and myocardial infarction. , 2011, , 301-306.		0
3992	Lipid management after a coronary event. , 2011, , 328-337.		0
3993	Efficacy and Safety of Single-Pill Amlodipine Besylate/Atorvastatin Calcium in the Management of Hypertension and Angina. Clinical Medicine Reviews in Vascular Health, 0, 3, 21-30.	3.0	0
3995	Disorders of Lipid Metabolism. , 2011, , 1633-1674.		5
3996	Relationship of low- and high-density lipoprotein cholesterol with atherosclerosis. Academic Journal of Second Military Medical University, 2011, 31, 224-226.	0.0	0
3997	Stable Angina. , 2012, , 1-18.		0
3998	Atherosclerosis: Basic Principles and Medical Management. , 2011, , 1-24.		0

#	ARTICLE	IF	CITATIONS
3999	Hyperlipidemia. , 2012, , 141-151.		1
4000	Dynamics of clinical, functional, and immune parameters in patients with myocardial infarction and early fluvastatin administration. Cardiovascular Therapy and Prevention (Russian Federation), 2011, 10, 52-58.	0.4	0
4001	A closer look at lipid management following an acute coronary syndrome. , 2011, , 45-54.		0
4002	Biomarkers and Coronary Atherosclerotic Burden and Activity as Assessed by Coronary Angiography and Intra-Coronary Imaging Modalities. , 0, , .		0
4003	Therapeutic Goals in Patients with Refractory Angina. , 2012, , 29-37.		0
4004	Secondary Prevention Strategies. , 2012, , 169-182.		0
4007	Nutzenbewertung von Arzneimitteln. , 2012, , 127-165.		1
4008	Role of Aggressive LDL Reduction in Patients With Coronary Heart Disease. Southern Medical Journal, 2012, 105, 48-55.	0.3	3
4011	The effects of early statin therapy on endothelial function in patients with acute myocardial infarction: A randomized study. Srce I Krvni Sudovi, 2012, 31, 77-81.	0.1	0
4012	Novel Treatment Strategies. , 2012, , 261-291.		0
4016	Dietary oats and modulation of atherogenic pathways. Molecular Nutrition and Food Research, 2012, , n/a-n/a.	1.5	0
4017	Inflammation and Atherosclerosis: Current Pathogenesis. Indonesian Biomedical Journal, 2012, 4, 73.	0.2	32
4021	Preventive Cardiology. , 2013, , 767-780.		0
4022	Treatment of Hypercholesterolemia. Journal of Clinical & Experimental Cardiology, 2013, 01, .	0.0	0
4024	Dyslipidemia. , 2014, , 489-502.		1
4025	Drugs in the Primary and Secondary Prevention of Coronary Artery Disease. , 2014, , 1-32.		0
4026	Residual Risk and Biology of the Disease: Implications for Plaque Imaging. Contemporary Cardiology, 2014, , 1-21.	0.0	1
4027	Prevention of Cardiovascular Disease in Older Adults. , 2014, , 1-28.		0



#	ARTICLE	IF	CITATIONS
4028	Non-statin Therapies for CKD with Dyslipidemia. , 2014, , 153-178.		0
4029	Acute cardiac syndromes, investigations and interventions. , 2014, , 167-190.e4.		0
4030	The ideal management of blood cholesterol: a review of the updated 2013 ACC/AHA cholesterol guideline for reducing cardiovascular risk. Journal of the Korean Medical Association, 2014, 57, 857.	0.1	0
4032	Medical Management of Coronary Artery Disease. , 2014, , 1-17.		0
4034	Hallmark Clinical Trials. Contemporary Cardiology, 2015, , 675-727.	0.0	0
4035	A Review of the 2005 Clinical Practice Guidelines for the Management of Dyslipidaemia in the Philippines. Journal of the ASEAN Federation of Endocrine Societies, 2014, 29, 116-121.	0.1	1
4036	Is Vitamin D a New Therapeutic Option in Coronary Artery Disease? Overview Data. Cardiovascular Pharmacology: Open Access, 0, s1, .	0.1	0
4037	Medical Management of Coronary Artery Disease. , 2015, , 2369-2382.		0
4038	The Statin Trilogy (III): Welcome to the United "Statins"™ of America. , 2015, , 627-630.		0
4040	Principles of Primary and Secondary Prevention of Cardiovascular Disease. , 2015, , 1627-1664.		0
4042	Drugs in the Primary and Secondary Prevention of Coronary Artery Disease. , 2015, , 1665-1693.		0
4043	Biomarkers of Coronary Plaque Composition and Vulnerability. , 2015, , 1-17.		0
4046	Lipids and Lipoproteins as Biomarkers of Vascular Complications in Diabetes and Their Modulation by Dietary Phytochemicals. , 2016, , 653-672.		0
4047	Previous Statin Therapy Improves Clinical Outcome of Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Cardiovascular Pharmacology: Open Access, 2016, 5, .	0.1	0
4048	Stable Ischemic Heart Disease. , 2016, , 1-70.		5
4049	Biomarkers of Coronary Plaque Composition and Vulnerability. , 2016, , 897-913.		0
4050	Additional Lipid Targets to Modulate Atherosclerotic Plaques beyond LDL-C Lowering. Journal of the Japanese Coronary Association, 2016, 22, 217-227.	0.0	0
4051	Ezetimibe: Clinical and Scientific Meaning of the IMPROVE-IT Study. Arquivos Brasileiros De Cardiologia, 2016, 106, 247-9.	0.3	1

#	ARTICLE	IF	CITATIONS
4052	Coronary Artery Disease, Hyperlipidemia, Microorganisms and Statins. British Journal of Medicine and Medical Research, 2016, 14, 1-7.	0.2	0
4053	Use of Cholesterol-Lowering Medications of Patients with Myocardial Infarction from 2007-2015 in Cardiology Clinic to "Mother Teresa" University Hospital in Albania. Pharmacology & Pharmacy, 2016, 07, 236-245.	0.2	0
4055	12. Some chronobiological investigations relevant to cholesterol. Human Health Handbooks, 2016, , 203-234.	0.1	1
4057	Correction of the factors of cardiovascular risk in patients with type 2 diabetes. Family Medicine, 2016, .	0.1	1
4058	Are Sex Differences in Outcomes of Patients with ACS from Observational Registries Similar to the Findings from Randomized Clinical Trials?. Current Pharmaceutical Design, 2016, 22, 3779-3789.	0.9	0
4059	COMPLICATIONS OF STATIN THERAPY AND THEIR MANAGEMENT. Journal of Evolution of Medical and Dental Sciences, 2016, 5, 4745-4750.	0.1	0
4060	Balanced Contribution. Deutsches A&#x0308;rztblatt International, 2016, 113, 643.	0.6	0
4061	Cardiovascular medicine. , 2016, , .		0
4063	Acute Coronary Syndrome. , 2017, , 194-225.		0
4064	Efficacy of Lipid Lowering Therapy for the Patients with Ischemic Heart Disease. Journal of the Nihon University Medical Association, 2017, 76, 245-248.	0.0	0
4065	Designing Phase 4 Trials. Springer Series in Pharmaceutical Statistics, 2017, , 139-151.	0.0	0
4066	Management of Acute Coronary Syndrome. , 2017, , 111-120.		0
4067	Impact of statins therapy on morphological changes in lipid-rich plaques stratified by 10-Year framingham risk score: A serial optical coherence tomography study. Oncotarget, 2017, 8, 27401-27411.	0.8	2
4070	Mental Illness and the Criminal Justice System. , 2017, , 467-492.		1
4073	Community Mental Health Care Organizations. , 2017, , 431-446.		1
4075	Cultural Diversity and Mental Health Treatment. , 2017, , 493-511.		2
4077	The Mental Health Consumers/Survivors Movement in the US. , 2017, , 529-549.		1
4082	Clinical study FOURIER. Vnitřni Lekarství, 2017, 63, 411-414.	0.1	2

#	ARTICLE	IF	CITATIONS
4088	Mental Health and Terrorism. , 2017, , 357-386.		2
4089	Simvastatin dose and acute kidney injury without concurrent serious muscle injury: A nationwide nested case-control study. PLoS ONE, 2017, 12, e0182066.	1.1	1
4090	High-intensity therapy: rationale, indications and safety issues. Prospects of rosuvastatin in clinical practice. Cardiosomatics, 2017, 8, 15-24.	0.2	0
4091	ACUTE CORONARY SYNDROME; FREQUENCY OF RAISED LDL CHOLESTEROL IN PATIENTS. The Professional Medical Journal, 2017, 24, 1818-1822.	0.0	0
4092	Percutaneous Coronary Intervention: Special Considerations in Women. , 2018, , 275-289.		0
4093	Diabetes and the Cardiovascular System. Endocrinology, 2018, , 131-159.	0.1	0
4095	HIGH INTENSITY HYPOLIPIDEMIC THERAPY AND DECREASED LEVEL OF LOW DENSITY LIPOPROTEIDES CHOLESTEROL: IS THE APPROACH JUSTIFIED? POINT OF VIEW. Russian Journal of Cardiology, 2018, , 191-201.	0.4	0
4096	New clinical and pharmacological aspects of the use of atorvastatin for primary and secondary prevention of complications of cardiovascular diseases. Meditsinskiy Sovet, 2018, , 110-117.	0.1	0
4098	Consejos prÁcticos de rehabilitaci3n cardiaca para los pacientes con cardiopatAa isquA©mica. FMC Formacion Medica Continuada En Atencion Primaria, 2018, 25, 539-546.	0.0	0
4099	An overview of pleiotropic effect of statins in cardiovascular disease. Pharmacy & Pharmacology International Journal, 2018, 6, .	0.1	0
4100	TEN-YEAR STATIN ADHERENCE IN SURVIVORS OF ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION: INSIGHTS FROM THE AMI-QUEBEC STUDY. Canadian Journal of Clinical Pharmacology, 2018, 25, e63-e77.	1.1	2
4101	Comparison of Adverse Events between High-intensity and Moderate- to Low-intensity Statin Group. Korean Journal of Clinical Pharmacy, 2018, 28, 293-299.	0.0	2
4102	Atherosclerotic Plaque Imaging. , 2019, , 335-342.e3.		0
4103	Atherosclerosis Risk Factors. , 2019, , 9-45.		0
4104	Management of Coronary Artery Disease & Dyslipidemia and Pharmacist's Role. , 2019, , 169-187.		0
4105	Intensity of Statin Treatment in Korean Patients with Acute Myocardial Infarction and Very Low LDL Cholesterol. Journal of Lipid and Atherosclerosis, 2019, 8, 208.	1.1	2
4106	Diabetes and the Cardiovascular System. Endocrinology, 2019, , 1-29.	0.1	0
4107	COMPARING HIGH INTENSITY WITH LOW INTENSITY STATINS IN ACHIEVING OPTIMAL LDL GOALS AMONG CORONARY ARTERY DISEASE PATIENTS IN SUBURBAN POPULATION IN SOUTH INDIA. Journal of Evolution of Medical and Dental Sciences, 2019, 8, 364-368.	0.1	0

#	ARTICLE	IF	CITATIONS
4108	Cardiovascular Protection in Chronic Kidney Disease. , 2019, , 295-308.		0
4109	The changes in achievement of target LDL-cholesterol levels between 2006 and 2017 in Czech patients with chronic coronary heart disease. <i>Cor Et Vasa</i> , 2019, 61, 20-27.	0.1	1
4110	Liver Enzymes as Biomarkers for Hepatotoxicity of Statins in Patients with Dyslipidemia. <i>IFMBE Proceedings</i> , 2020, , 611-615.	0.2	0
4111	Comparative evaluation of changes in lipid profile in patients with Q-myocardial infarction complicated by acute heart failure with carbohydrate metabolism disorders. <i>ScienceRise: Medical Science</i> , 2019, .	0.0	0
4112	Short-term and long-term prognosis in patients with Q-myocardial infarction complicated by acute heart failure with hyperglycemia. <i>ZaporoÅ¼skij Medicinskij Å½urnal</i> , 2019, .	0.0	0
4113	LDL como objetivo terapÃ©utico. <i>ClÃnica E InvestigaciÃ³n En Arteriosclerosis</i> , 2019, 31, 1-15.	0.4	2
4116	EURASIAN ASSOCIATION OF CARDIOLOGY (EAC)/ RUSSIAN NATIONAL ATHEROSCLEROSIS SOCIETY (RNAS,) Tj ETQq0 0 0 rgBT /Overlo TREATMENT OF ATHEROSCLEROSIS (2020). <i>Eurasian Heart Journal</i> , 2020, , 6-29.	0.2	28
4118	Proprotein convertase subtilisin/kexin type 9 inhibition in cardiovascular disease: current status and future perspectives. <i>Korean Journal of Internal Medicine</i> , 2020, 35, 1045-1058.	0.7	7
4119	Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL. <i>Circulation</i> , 2021, 144, 1750-1759.	1.6	36
4120	Impact of Baseline LDL-C and Lp(a) Elevation on Coronary Revascularization in Patients with Acute Coronary Syndrome One-Year after First Percutaneous Coronary Intervention. <i>World Journal of Cardiovascular Diseases</i> , 2020, 10, 102-115.	0.0	0
4121	Management of Hypertriglyceridemia (Including Fibrates and n-3 FattyÃcids). <i>Contemporary Cardiology</i> , 2021, , 295-306.	0.0	1
4122	Implementation of clinical practices and pathways optimizing ACS patients lipid management: Focus on eight European initiatives. <i>Atherosclerosis Supplements</i> , 2020, 42, e59-e64.	1.2	8
4123	The Low-Density Lipoprotein Cholesterol Hypothesis: An Update. <i>Contemporary Cardiology</i> , 2021, , 121-138.	0.0	0
4124	Focus on Cardiovascular Health Promotion and Disease Prevention: Opportunities for Improvement. <i>Contemporary Cardiology</i> , 2021, , 1-16.	0.0	0
4125	Diabetes and the Cardiovascular System. <i>Endocrinology</i> , 2020, , 131-159.	0.1	0
4127	Acute Coronary Syndrome. , 2020, , 3-17.		0
4128	Statins, diabetic oxidative stress, and vascular tissue. , 2020, , 333-341.		0
4130	Factors associated with time to initiation of a PCSK9 inhibitor after hospital discharge for acute myocardial infarction. <i>Journal of Clinical Lipidology</i> , 2022, 16, 75-82.	0.6	2

#	ARTICLE	IF	CITATIONS
4131	Acute Coronary Syndrome. Advances in Medical Technologies and Clinical Practice Book Series, 0, , 136-167.	0.3	0
4132	Research Utility of Intravascular Ultrasound. Advances in Bioinformatics and Biomedical Engineering Book Series, 0, , 109-136.	0.2	0
4134	Natural History and Impact of Interventions on Coronary Calcium. , 2006, , 97-106.		0
4135	Implications of changing national cholesterol education program goals for the treatment and control of hypercholesterolemia. Journal of General Internal Medicine, 2006, 21, 171-6.	1.3	14
4136	Koronarinsuffizienz und Herzinfarkt. , 2005, , 3-33.		0
4137	Störungen des Lipidstoffwechsels. , 2005, , 418-423.		0
4138	Lipidsenkende Mittel. , 0, , 698-715.		0
4139	Lipide. , 2005, , 362-377.		0
4140	Diabetische Neuropathie. , 2005, , 120-124.		0
4141	Stable Angina. , 2005, , 451-470.		0
4142	Unstable Angina and Non-ST Segment Elevation Myocardial Infarction (Acute Coronary Syndromes). , 2005, , 471-487.		0
4143	Preventive Cardiology. , 2005, , 789-806.		0
4144	Introduction to Diabetes. , 2006, , 1-37.		2
4145	Innovative Models for the Delivery Preventive Cardiovascular Care. , 2006, , 325-338.		0
4146	Low-Density Lipoprotein Cholesterol and Coronary Artery Disease. , 2006, , 49-80.		0
4147	Epidemiology and Prevention of Cardiovascular Disease in Diabetes. , 2009, , 19-33.		0
4148	Management of Acute Myocardial Infarction. , 2007, , 183-210.		0
4149	Management of Dyslipidemias. , 2007, , 307-322.		0

#	ARTICLE	IF	CITATIONS
4150	Hallmark Clinical Trials. , 2007, , 381-394.		0
4151	Controversies in Evaluation and Management of Lipid Disorders in Diabetes. , 2008, , 291-315.		0
4152	Pharmacotherapy in Prevention and Rehabilitation. , 2007, , 439-453.		1
4155	Gene Therapy for Apolipoprotein A-I and HDLâ€™The Ultimate Treatment for Atherosclerosis. , 2008, , 197-212.		0
4156	Effectiveness of using rosuvastatin in difficult-to-control dyslipidemia patients: an audit in secondary care. Therapy: Open Access in Clinical Medicine, 2005, 2, 895-900.	0.2	0
4157	Lipids and Peripheral Arterial Disease. , 2007, , 35-40.		0
4161	StÃ¶rungen des Lipidstoffwechsels. , 2007, , 466-472.		0
4163	Early, aggressive lipid management in the treatment of acute coronary syndromes. Therapy: Open Access in Clinical Medicine, 2004, 1, 213-216.	0.2	0
4164	Acute Coronary Syndrome. , 2021, , 59-80.		0
4166	Management of hyperlipidaemia among statin-intolerant patients after acute coronary syndrome: where do we stand in 2020?. European Journal of Preventive Cardiology, 2021, 28, 30-32.	0.8	1
4167	2004: that was the year that was. Texas Heart Institute Journal, 2005, 32, 2-6.	0.1	49
4168	The Jeremiah Metzger Lecture: Evolution of management of acute coronary syndromes (unstable) Tj ETQq1 1 0.784314 rgBT /Overload Climatological Association, 2005, 116, 41-53.	0.9	0
4169	Management strategies of dyslipidemia in the elderly: 2005. MedGenMed: Medscape General Medicine, 2005, 7, 8.	0.2	0
4170	Update for primary healthcare providers: recent statin trials and revised National Cholesterol Education Program III guidelines. MedGenMed: Medscape General Medicine, 2006, 8, 54.	0.2	1
4171	Rationale for recommendations for lipid testing and reporting by Australian pathology laboratories. Clinical Biochemist Reviews, 2007, 28, 46-9.	3.3	0
4172	Relationship between glycemic status and progression of carotid intima-media thickness during treatment with combined statin and extended-release niacin in ARBITER 2. Vascular Health and Risk Management, 2007, 3, 159-64.	1.0	11
4173	Comprehensive cardiovascular risk management--what does it mean in practice?. Vascular Health and Risk Management, 2007, 3, 587-603.	1.0	13
4174	Are pleiotropic effects of statins real?. Vascular Health and Risk Management, 2007, 3, 611-3.	1.0	21

#	ARTICLE	IF	CITATIONS
4175	Cholesterol lowering for secondary prevention: what statin dose should we use?. <i>Vascular Health and Risk Management</i> , 2007, 3, 615-27.	1.0	8
4176	Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? The single pill of amlodipine/atorvastatin. <i>Vascular Health and Risk Management</i> , 2007, 3, 711-9.	1.0	3
4177	Multivariate risk assessment and risk score cards in hypertension. <i>Vascular Health and Risk Management</i> , 2007, 3, 313-20.	1.0	4
4178	Rationale of the REPARATOR study: A randomised trial with serial cardiac MRI follow-up testing the ability of atorvastatin to reduce reperfusion damage after primary PCI for acute MI. <i>Netherlands Heart Journal</i> , 2006, 14, 95-99.	0.3	5
4179	Recommendations for management of dyslipidemia in high cardiovascular risk patients. <i>Experimental and Clinical Cardiology</i> , 2008, 13, 71-4.	1.3	2
4180	Targeting C-reactive protein levels using high-dose atorvastatin before coronary artery bypass graft surgery. <i>Experimental and Clinical Cardiology</i> , 2008, 13, 171-4.	1.3	10
4182	Statins in the first-line therapy of acute coronary syndrome - similar to aspirin?. <i>Experimental and Clinical Cardiology</i> , 2005, 10, 9-16.	1.3	2
4186	Non-HDL cholesterol as a metric of good quality of care: opportunities and challenges. <i>Texas Heart Institute Journal</i> , 2011, 38, 160-2.	0.1	49
4187	Practical use of the Framingham risk score in primary prevention: Canadian perspective. <i>Canadian Family Physician</i> , 2011, 57, 417-23.	0.1	38
4188	Rosuvastatin therapy does not affect serum MMP-13 or TIMP-1 levels in hypercholesterolemic patients. <i>Texas Heart Institute Journal</i> , 2011, 38, 229-33.	0.1	3
4189	Implications for reproductive medicine: Sex differences in cardiovascular disease. <i>Sexuality, Reproduction &amp; Menopause</i> , 2011, 9, 21-28.	1.0	12
4190	Rapid changes in plaque composition and morphology after intensive lipid lowering therapy: study with serial coronary CT angiography. <i>American Journal of Cardiovascular Disease</i> , 2012, 2, 84-8.	0.5	14
4191	Challenges in initiating antiretroviral therapy in 2010. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2010, 21 Suppl C, 1C-15C.	0.7	0
4192	Low density Lipoprotein cholesterol target: Changing goal posts. <i>Indian Journal of Endocrinology and Metabolism</i> , 2012, 16, S233-5.	0.2	0
4193	Statins as first-line therapy for acute coronary syndrome?. <i>Experimental and Clinical Cardiology</i> , 2012, 17, 227-36.	1.3	9
4194	A predictor of atheroma progression in patients achieving very low levels of low-density lipoprotein cholesterol. <i>American Journal of Cardiovascular Disease</i> , 2013, 3, 255-63.	0.5	3
4196	The evaluation of low-density lipoprotein cholesterol goals achieved in patients with established cardiovascular disease and/or hyperlipidaemia receiving lipid-lowering therapy: the South African Not at Goal study (SA-NAG). <i>Cardiovascular Journal of Africa</i> , 2008, 19, 88-94.	0.2	4
4197	Method of LDL cholesterol measurement influences classification of LDL cholesterol treatment goals: clinical research study. <i>Journal of Investigative Medicine</i> , 2010, 58, 945-9.	0.7	10

#	ARTICLE	IF	CITATIONS
4199	Estimates of commercial population at high risk for cardiovascular events: impact of aggressive cholesterol reduction. <i>American Health and Drug Benefits</i> , 2009, 2, 224-32.	0.5	0
4200	Lipid-lowering activity of Cow urine ark in guinea pigs fed with a high cholesterol diet. <i>Avicenna Journal of Phytomedicine</i> , 2014, 4, 354-63.	0.1	1
4201	The Effect of Intensified Low Density Lipoprotein Cholesterol Reduction on Recurrent Myocardial Infarction and Cardiovascular Mortality. <i>Acta Cardiologica Sinica</i> , 2013, 29, 404-12.	0.1	11
4202	Lack of Association between High-Density Lipoprotein Cholesterol and Angiographic Coronary Lesion Severity in Chinese Patients with Low Background Low-Density Lipoprotein Cholesterol. <i>Acta Cardiologica Sinica</i> , 2015, 31, 528-35.	0.1	4
4203	Comparison of efficacy and adverse effect profile of high dose versus standard dose atorvastatin in acute ST elevation myocardial infarction patients. <i>Heart Asia</i> , 2011, 3, 82-6.	1.1	1
4204	Impact of Statins Therapy for Ischemic Heart Disease Patients with Low-Density Lipoprotein Cholesterol Levels Less Than 100 mg/dL. <i>Acta Cardiologica Sinica</i> , 2016, 32, 565-569.	0.1	5
4205	Effects of sitagliptin on coronary atherosclerosis in patients with type 2 diabetes-A serial integrated backscatter-intravascular ultrasound study. <i>American Journal of Cardiovascular Disease</i> , 2016, 6, 153-162.	0.5	3
4206	Statin Therapy Prescribing for Patients with Type 2 Diabetes Mellitus: A Review of Current Evidence and Challenges. <i>Journal of Pharmacy and Bioallied Sciences</i> , 2017, 9, 80-87.	0.2	18
4207	Predictors of Mortality in Elderly Patients with Non-ST Elevation Acute Coronary Syndrome - Data from Taiwan Acute Coronary Syndrome Full Spectrum Registry. <i>Acta Cardiologica Sinica</i> , 2017, 33, 377-383.	0.1	11
4208	Lipid Lowering Therapy for Acute Coronary Syndrome and Coronary Artery Disease: Highlights of the 2017 Taiwan Lipid Guidelines for High Risk Patients. <i>Acta Cardiologica Sinica</i> , 2018, 34, 371-378.	0.1	12
4209	Red yeast rice for dyslipidemia. <i>Missouri Medicine</i> , 2013, 110, 349-54.	0.3	4
4210	Simultaneous Analysis of Clopidogrel Bisulfate, Acetylsalicylic Acid and Atorvastatin calcium in Tablets by HPLC Method. <i>Current Health Sciences Journal</i> , 2015, 41, 172-178.	0.2	1
4211	Group-Based Trajectory Models to Identify Sociodemographic and Clinical Predictors of Adherence Patterns to Statin Therapy Among Older Adults. <i>American Health and Drug Benefits</i> , 2019, 12, 202-211.	0.5	11
4212	Significant reduction in the LDL cholesterol increases the risk of intracerebral hemorrhage: a systematic review and meta-analysis of 33 randomized controlled trials. <i>American Journal of Translational Research (discontinued)</i> , 2020, 12, 463-477.	0.0	6
4213	The Effectiveness of Target Low-Density Lipoprotein Cholesterol Achieved with Strict Management in Secondary Prevention of Long-Term Coronary Events in Japanese Patients. <i>Acta Cardiologica Sinica</i> , 2021, 37, 65-73.	0.1	0
4214	Daily Consumption of Caper Fruit Along With Atorvastatin Has Synergistic Effects in Hyperlipidemic Patients: Randomized Clinical Trial. <i>Galen</i> , 2019, 8, e1345.	0.6	0
4215	Impact of statin intensity on adverse cardiac and cerebrovascular events in older adult patients with myocardial infarction. <i>Journal of Geriatric Cardiology</i> , 2021, 18, 609-622.	0.2	0
4216	Addressing disparities of care in non-ST-segment elevation myocardial infarction patients without standard modifiable risk factors: insights from a nationwide cohort study. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 1084-1092.	0.8	19





#	ARTICLE	IF	CITATIONS
4240	Impact of Lipoprotein(a) as a Residual Risk Factor in Long-Term Cardiovascular Outcomes in Patients With Acute Coronary Syndrome Treated With Statins. <i>American Journal of Cardiology</i> , 2022, 168, 11-16.	0.7	10
4241	Statin treatment effectiveness and the <i>SLCO1B1</i> *5 reduced function genotype: Long-term outcomes in women and men. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 3230-3240.	1.1	7
4242	The Role of Inflammation as a Preponderant Risk Factor in Cardiovascular Diseases. <i>Current Vascular Pharmacology</i> , 2022, 20, 244-259.	0.8	5
4243	Serum Albumin and Bleeding Events After Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction (from the HAGAKURE-ACS Registry). <i>American Journal of Cardiology</i> , 2022, 165, 19-26.	0.7	4
4244	Moderate-intensity statin use for primary prevention for more than 5 years is associated with decreased all-cause mortality in 75 years and older. <i>Archives of Gerontology and Geriatrics</i> , 2022, 100, 104644.	1.4	3
4245	TREATMENT EFFECTIVENESS ANALYSIS OF OUTPATIENTS WITH ARTERIAL HYPERTENSION PLUS CORONARY HEART DISEASE IN UKRAINE. <i>Eurasian Heart Journal</i> , 2012, , 17-29.	0.2	0
4246	Ideal cardiovascular health duration and risk of chronic kidney disease and cardiovascular disease. <i>Heart</i> , 2022, 108, 523-528.	1.2	6
4247	10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetesâ€”2022. <i>Diabetes Care</i> , 2022, 45, S144-S174.	4.3	282
4248	Statin therapy prescribing for patients with type 2 diabetes mellitus: A review of current evidence and challenges. <i>Journal of Pharmacy and Bioallied Sciences</i> , 2017, 9, 80.	0.2	28
4250	Coronary atherosclerosis progression by intravascular ultrasound with intensive versus moderate lipid lowering. <i>Current Cardiology Reports</i> , 2004, 6, 437-8; discussion 437-8.	1.3	0
4251	Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes. <i>Current Atherosclerosis Reports</i> , 2005, 7, 7-8.	2.0	0
4252	Intensive versus moderate lipid lowering with statins in acute coronary syndromes. <i>Current Atherosclerosis Reports</i> , 2005, 7, 85-6.	2.0	1
4253	Aggressive low-density lipoprotein cholesterol lowering in secondary prevention of coronary heart disease. <i>Current Atherosclerosis Reports</i> , 2006, 8, 7-8.	2.0	0
4254	High-dose atorvastatin versus usual-dose simvastatin for secondary prevention after myocardial infarction. <i>Current Atherosclerosis Reports</i> , 2007, 9, 5-6.	2.0	1
4255	Effects of lipid-lowering therapy on coronary heart disease in older patients: the SAGE study. <i>Current Atherosclerosis Reports</i> , 2008, 10, 5-6.	2.0	2
4257	The Pattern of Dyslipidaemia and Factors Associated With Elevated Non-HDL-Cholesterol Levels Among Patients With Type 2 Diabetes Mellitus in the Ho Municipality: A Cross Sectional Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
4258	Estimated Cardiovascular Benefits of Bempedoic Acid in Patients with Established Cardiovascular Disease. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
4259	Diagnosis and Treatment of Acute Coronary Syndromes. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 662.	3.8	219

#	ARTICLE	IF	CITATIONS
4260	â€œCirculating Cytokines in Myocardial Infarction Are Associated With Coronary Blood Flow. <i>Frontiers in Immunology</i> , 2022, 13, 837642.	2.2	11
4261	Relative contributions of statin intensity, achieved low-density lipoprotein cholesterol level, and statin therapy duration to cardiovascular risk reduction in patients with type 2 diabetes: population based cohort study. <i>Cardiovascular Diabetology</i> , 2022, 21, 28.	2.7	5
4263	JCS 2022 Guideline Focused Update on Diagnosis and Treatment in Patients With Stable Coronary Artery Disease. <i>Circulation Journal</i> , 2022, 86, 882-915.	0.7	37
4264	Contemporary Management of Dyslipidemia. <i>Drugs</i> , 2022, 82, 559-576.	4.9	14
4265	Differences in outcomes of patients with in-hospital versus out-of-hospital ST-elevation myocardial infarction: a registry analysis. <i>BMJ Open</i> , 2022, 12, e052000.	0.8	2
4266	Aggressive lipid-lowering therapy after percutaneous coronary intervention &ndash; for whom and how?. <i>AsiaIntervention</i> , 2022, 8, 24-31.	0.1	0
4267	Lipid-Targeted Atherosclerotic Risk Reduction in Older Adults: A Review. <i>Geriatrics (Switzerland)</i> , 2022, 7, 38.	0.6	0
4268	Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction. <i>JACC: Cardiovascular Imaging</i> , 2022, 15, 1308-1321.	2.3	137
4270	Molecular Biological and Clinical Understanding of the Statin Residual Cardiovascular Disease Risk and Peroxisome Proliferator-Activated Receptor Alpha Agonists and Ezetimibe for Its Treatment. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3418.	1.8	8
4271	The pleiotropic benefits of statins include the ability to reduce CD47 and amplify the effect of pro-erfferocytic therapies in atherosclerosis. , 2022, 1, 253-262.		22
4272	Optimal low-density lipoprotein cholesterol target level in Korean acute myocardial infarction patients (<70Âmg/dL vs. <55Âmg/dL): Based on Korea acute myocardial infarction registry-National Institute of Health. <i>International Journal of Cardiology</i> , 2022, 351, 15-22.	0.8	3
4273	Effects of the Current Japanese Guideline for Dedicated, Intensive Lipid-lowering Therapy on Lipid Profile and Coronary Events in Patients After Acute Coronary Syndrome. , 0, 1, .		0
4274	Current Status of Low-Density Lipoprotein Cholesterol Target Achievement in Patients with Type 2 Diabetes Mellitus in Korea Compared with Recent Guidelines. <i>Diabetes and Metabolism Journal</i> , 2022, 46, 464-475.	1.8	8
4275	Common genetic variants do not predict recurrent events in coronary heart disease patients. <i>BMC Cardiovascular Disorders</i> , 2022, 22, 96.	0.7	0
4276	LDL como objetivo terapÃ©utico. <i>ClÃnica E InvestigaciÃ³n En Arteriosclerosis</i> , 2022, , .	0.4	0
4277	Impact of a cardiology pharmacistâ€™ed intervention on highâ€™intensity statin prescribing upon discharge after acute myocardial infarction. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 0, , .	0.5	0
4278	Statinâ€™associated muscle symptomsâ€™A review: Individualizing the approach to optimize care. <i>Pharmacotherapy</i> , 2022, 42, 428-438.	1.2	10
4279	Intravascular imaging assessment of pharmacotherapies targeting atherosclerosis: advantages and limitations in predicting their prognostic implications. <i>Cardiovascular Research</i> , 2023, 119, 121-135.	1.8	7

#	ARTICLE	IF	CITATIONS
4280	New insights to atherosclerosis management: Role of nanomaterials. Applied Materials Today, 2022, 27, 101466.	2.3	3
4281	Primary and Secondary Prevention of CAD: A Review. International Journal of Angiology, 2022, 31, 016-026.	0.2	2
4282	Comparison of High-Statin Therapy vs Moderate-Statin Therapy in Achieving Positive Low-Density Lipoprotein Change in Patients After Acute Coronary Syndrome: A Randomized-Control Trial. Cureus, 2021, 13, e20710.	0.2	0
4283	Alirocumab after acute coronary syndrome in patients with a history of heart failure. European Heart Journal, 2022, 43, 1554-1565.	1.0	23
4284	Modifiable Risk Factors and Residual Risk Following Coronary Revascularization. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2021, 5, 1138-1152.	1.2	5
4286	Preventing Recurrent Stroke and Other Serious Vascular Events. , 0, , 789-901.		4
4287	An Interventionalist's Perspective. , 0, , 343-349.		0
4288	Treatment of Endothelial Dysfunction and Atherosclerosis by Cholesterol Lowering. , 0, , 300-314.		0
4290	Low density Lipoprotein cholesterol target: Changing goal posts. Indian Journal of Endocrinology and Metabolism, 2012, 16, 233.	0.2	1
4291	High-Dose Statins in Acute Coronary Syndromes. JAMA - Journal of the American Medical Association, 2005, 293, 36.	3.8	1
4292	High-Dose Statins in Acute Coronary Syndromes. JAMA - Journal of the American Medical Association, 2005, 293, 36.	3.8	0
4303	OUP accepted manuscript. European Heart Journal Quality of Care & Clinical Outcomes, 2022, , .	1.8	0
4304	Undertreatment or Overtreatment With Statins: Where Are We?. Frontiers in Cardiovascular Medicine, 2022, 9, 808712.	1.1	9
4306	High-Intensity Statin Use Among Patients With Atherosclerosis in the U.S.. Journal of the American College of Cardiology, 2022, 79, 1802-1813.	1.2	52
4307	Unstable Angina as a Component of Primary Composite Endpoints in Clinical Cardiovascular Trials: Pros and Cons. Cardiology, 2022, , .	0.6	5
4308	New insight into dyslipidemia-induced cellular senescence in atherosclerosis. Biological Reviews, 2022, 97, 1844-1867.	4.7	27
4309	Part 5: Acute Coronary Syndromes. Circulation, 2005, 112, .	1.6	4
4310	Lipid-modifying and antiatherosclerotic drugs. , 2013, , 398-435.		3

#	ARTICLE	IF	CITATIONS
4311	STATINS IN ACUTE CORONARY SYNDROMES. Eurasian Heart Journal, 2019, , 54-64.	0.2	0
4314	Clinical opportunities and healthcare impact of optimal treatment in the post-ACS patient. Global & Regional Health Technology Assessment, 2022, 9, 17-26.	0.2	0
4315	Alirocumab and Cardiovascular Outcomes in Patients With Previous Myocardial Infarction: Prespecified Subanalysis From ODYSSEY OUTCOMES. Canadian Journal of Cardiology, 2022, 38, 1542-1549.	0.8	4
4316	Estimated cardiovascular benefits of bempedoic acid in patients with established cardiovascular disease. Atherosclerosis Plus, 2022, 49, 20-27.	0.3	4
4321	Clinical impact of statin intensity according to age in patients with acute myocardial infarction. PLoS ONE, 2022, 17, e0269301.	1.1	1
4322	Early statin use and cardiovascular outcomes after myocardial infarction: A population-based case-control study. Atherosclerosis, 2022, 354, 8-14.	0.4	3
4323	Proprotein convertase subtilisin/kexin type 9 inhibition after acute coronary syndrome or prior myocardial infarction. Current Opinion in Lipidology, 2022, 33, 147-159.	1.2	7
4324	Vasculome. , 2022, , 441-451.		0
4325	Best Practices in Pharmacotherapy for Acute Coronary Syndromes. US Cardiology Review, 0, 16, .	0.5	0
4326	Alcohol-Induced Oxidative Stress and the Role of Antioxidants in Alcohol Use Disorder: A Systematic Review. Antioxidants, 2022, 11, 1374.	2.2	28
4327	Harmonisation of large-scale, heterogeneous individual participant adverse event data from randomised trials of statin therapy. Clinical Trials, 2022, 19, 593-604.	0.7	2
4328	Relationship between PCSK9 and endothelial function in patients with acute myocardial infarction. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 2105-2111.	1.1	3
4329	Intensity of and Adherence to Lipid-Lowering Therapy as Predictors of Major Adverse Cardiovascular Outcomes in Patients With Coronary Heart Disease. Journal of the American Heart Association, 2022, 11, .	1.6	13
4330	Omega-3 and cardiovascular prevention “ Is this still a choice?. Pharmacological Research, 2022, 182, 106342.	3.1	13
4331	Intensive lipid lowering agents and coronary atherosclerosis: Insights from intravascular imaging. American Journal of Preventive Cardiology, 2022, 11, 100366.	1.3	12
4332	Angiographic severity in acute coronary syndrome patients with and without standard modifiable risk factors. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	6
4333	Inter-Individual Variability in Lipid Response: A Narrative Review. American Journal of Medicine, 2022, 135, 1427-1433.e7.	0.6	2
4334	Photorenewable Azobenzene Polymer Brush-Modified Nanoadsorbent for Selective Adsorption of LDL in Serum. ACS Applied Materials & Interfaces, 2022, 14, 34388-34399.	4.0	4

#	ARTICLE	IF	CITATIONS
4335	Combination therapy in the guidelines: from high-intensity statins to high-intensity lipid-lowering therapies: Combination therapy in the guideline. , 2022, 1, 25-29.		2
4336	An intensive, structured, mobile devices-based healthcare intervention to optimize the lipid-lowering therapy improves lipid control after an acute coronary syndrome. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	0
4337	Retrospective Evaluation of In-Hospital and Thirty-Month Mortality Parameters in Cases of Acute Coronary Syndrome. , 0, , .		0
4338	Icosapent ethyl for reduction of persistent cardiovascular risk: a critical review of major medical society guidelines and statements. <i>Expert Review of Cardiovascular Therapy</i> , 2022, 20, 609-625.	0.6	7
4339	The prevalence of hyperlipidemia and features of lipid-lowering therapy in patients with myocardial infarction according to the Russian register of acute myocardial infarction REGION-MI. <i>Kardiologiya</i> , 2022, 62, 12-22.	0.3	2
4340	Management of Dyslipidemia after Stroke. <i>Journal of the Korean Neurological Association</i> , 2022, 40, 217-227.	0.0	1
4341	Pleiotropic properties of statins via angiogenesis modulation in cardiovascular disease. <i>Drug Discovery Today</i> , 2022, 27, 103325.	3.2	5
4342	Bempedoic Acid: for Whom and When. <i>Current Atherosclerosis Reports</i> , 2022, 24, 791-801.	2.0	23
4343	The pattern of dyslipidaemia and factors associated with elevated levels of non-HDL-cholesterol among patients with type 2 diabetes mellitus in the Ho municipality: A cross sectional study. <i>Heliyon</i> , 2022, 8, e10279.	1.4	4
4344	Associations between statins and adverse events in secondary prevention of cardiovascular disease: Pairwise, network, and dose-response meta-analyses of 47 randomized controlled trials. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	1
4345	Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab. <i>Circulation</i> , 2022, 146, 657-672.	1.6	32
4346	Pharmacological rationale for the very early treatment of acute coronary syndrome with monoclonal antibodies anti-PCSK9. <i>Pharmacological Research</i> , 2022, 184, 106439.	3.1	10
4347	Cancer therapy's impact on lipid metabolism: Mechanisms and future avenues. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	5
4348	Impact of Prior Statin Therapy on In-Hospital Outcome of STEMI Patients Treated with Primary Percutaneous Coronary Intervention. <i>Journal of Clinical Medicine</i> , 2022, 11, 5298.	1.0	0
4349	LDL as a therapeutic target. <i>Clínica E Investigaci3n En Arteriosclerosis (English Edition)</i> , 2022, 34, 271-284.	0.1	0
4350	Probiotics Bring New Hope for Atherosclerosis Prevention and Treatment. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-13.	1.9	4
4351	Could Plasma CXCL12 Predict Ventricular Dysfunction in Patients with Severe Myocardial Infarction?. <i>International Journal of Angiology</i> , 0, , .	0.2	0
4352	Biochemistry and Nanomechanical Properties of Human Colon Cells upon Simvastatin, Lovastatin, and Mevastatin Supplementations: Raman Imaging and AFM Studies. <i>Journal of Physical Chemistry B</i> , 2022, 126, 7088-7103.	1.2	1

#	ARTICLE	IF	CITATIONS
4353	Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials. <i>Lancet, The</i> , 2022, 400, 832-845.	6.3	87
4354	Statin-Induced Autoimmune Necrotizing Myositis: A Case Report. <i>Cureus</i> , 2022, , .	0.2	0
4355	Is non-high-density lipoprotein associated with metabolic syndrome? A systematic review and meta-analysis. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	5
4356	Cardiovascular Pharmacology. <i>Emergency Medicine Clinics of North America</i> , 2022, , .	0.5	0
4357	Evolocumab for prevention of microvascular dysfunction in patients undergoing percutaneous coronary intervention: the randomised, open-label EVOCATION trial. <i>EuroIntervention</i> , 2022, 18, e647-e655.	1.4	7
4358	âœVascular inflammation and cardiovascular disease: review about the role of PET imagingâœ. <i>International Journal of Cardiovascular Imaging</i> , 2023, 39, 433-440.	0.7	6
4359	Obesity is associated with coronary artery stenosis independently of metabolic risk factors: The population-based SCAPIS study. <i>Atherosclerosis</i> , 2022, 362, 1-10.	0.4	2
4360	Antihyperlipidemic Treatment Options in Statin Resistance and Intolerance. <i>Cardiology in Review</i> , 0, Publish Ahead of Print, .	0.6	1
4361	Non-fasting changes of Hs-CRP level in Chinese patients with coronary heart disease after a daily meal. <i>Scientific Reports</i> , 2022, 12, .	1.6	0
4362	Lipoprotein(a) and the risk of recurrent events in patient with acute myocardial infarction treated by percutaneous coronary intervention. <i>Minerva Cardiology and Angiology</i> , 0, , .	0.4	1
4363	Long-term Management of Patients with Myocardial Infarction: An Updated Review. , 0, Publish Ahead of Print, .		1
4364	Dyslipidemia treatment strategies in primary and secondary prevention. <i>Dyslipemia Registry of the Spanish Arteriosclerosis Society. ClÃnica E InvestigaciÃn En Arteriosclerosis (English Edition)</i> , 2022, , .	0.1	0
4367	Initial statin dose after myocardial infarction and long-term cardiovascular outcomes. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2023, 9, 156-164.	1.4	2
4368	Optimal target of LDL cholesterol level for statin treatment: challenges to monotonic relationship with cardiovascular events. <i>BMC Medicine</i> , 2022, 20, .	2.3	6
4369	Atherogenic Lipoproteins for the Statin Residual Cardiovascular Disease Risk. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13499.	1.8	10
4370	Statin associated muscle symptoms: An update and review. <i>Progress in Cardiovascular Diseases</i> , 2022, 75, 40-48.	1.6	10
4371	Generating Practice-Based Evidence in the Use of Guideline-Recommended Combination Therapy for Secondary Prevention of Acute Myocardial Infarction. <i>Pharmacy (Basel, Switzerland)</i> , 2022, 10, 147.	0.6	1
4374	Current issues of lipid-lowering therapy in patients with high-risk hypertension. <i>Profilakticheskaya Meditsina</i> , 2022, 25, 42.	0.2	0

#	ARTICLE	IF	CITATIONS
4375	Sex disparities and dyslipidemic control in a coronary rehabilitation program. <i>International Journal of Cardiology</i> , 2023, 370, 72-74.	0.8	0
4376	Prevalence and Control of Hypercholesterolaemia as Defined by NCEP-ATPIII Guidelines and Predictors of LDL-C Goal Attainment in a Multi-Ethnic Asian Population. <i>Annals of the Academy of Medicine, Singapore</i> , 2013, 42, 379-387.	0.2	10
4377	Le patient atteint de maladies cardiovasculaires. , 2022, , 99-122.		0
4378	European, Russian and American Clinical Guidelines on dyslipidemias management “ where do we stand? European, Russian, and US guidelines on dyslipidemias. , 2022, 1, 48-53.		0
4379	Altered cardiovascular risk pattern of LDL cholesterol in older adults. <i>Current Opinion in Lipidology</i> , 0, Publish Ahead of Print, .	1.2	0
4380	Lipid-Lowering Trials Are Not Representative of Patients Managed in Clinical Practice: A Systematic Review and Meta-Analysis of Exclusion Criteria. <i>Journal of the American Heart Association</i> , 2023, 12, .	1.6	11
4381	10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes”2023. <i>Diabetes Care</i> , 2023, 46, S158-S190.	4.3	156
4382	Prevalence and Effects of High-Intensity Statins for Japanese Patients Presenting With Acute Coronary Syndrome—A Post Hoc Secondary Analysis of STOPDAPT-2 ACS. <i>Circulation Journal</i> , 2022, , .	0.7	0
4383	Heart failure as a complication of myocardial infarction: rational therapy. Case report. <i>Consilium Medicum</i> , 2022, 24, 732-740.	0.1	0
4384	Pharmaco-invasive therapy: Early implementation of statins and proprotein convertase subtilisin/kexin type 9 inhibitors after acute coronary syndrome. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	2
4385	Lipoprotein(a) and Atherosclerotic Cardiovascular Disease, the Impact of Available Lipid-Lowering Medications on Lipoprotein(a): An Update on New Therapies. <i>Endocrine Practice</i> , 2023, 29, 491-497.	1.1	2
4386	Therapy for hypertension and dyslipidemia: potential of Lipertans (on the example of a clinical) Tj ETQq1 1 0.784314 rgBT /Overlock 10	0.4	2
4387	Potential for residual cardiovascular risk reduction: Eligibility for icosapent ethyl in the VERTIS CV population with type 2 diabetes and atherosclerotic cardiovascular disease. <i>Diabetes, Obesity and Metabolism</i> , 2023, 25, 1398-1402.	2.2	1
4388	Alert-LDL-2: adherence to guidelines and goals attainment in the treatment of diabetic patients with dyslipidemia. <i>Minerva Cardiology and Angiology</i> , 0, , .	0.4	1
4389	Value of expert opinion in recommending early intensive lipid lowering in patients with ACS. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2022, 11, 936-938.	0.4	1
4390	Acute LDL-C reduction post ACS: strike early and strike strong: from evidence to clinical practice. A clinical consensus statement of the Association for Acute Cardiovascular Care (ACVC), in collaboration with the European Association of Preventive Cardiology (EAPC) and the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2022, 11, 939-949.	0.4	21
4391	A Hidden Organism, Chlamydia in the Age of Atherosclerosis. <i>Infectious Diseases</i> , 0, , .	4.0	0
4392	Optimal Low-Density Lipoprotein Cholesterol Level for Primary Prevention in Koreans with Type 2 Diabetes Mellitus. <i>Diabetes and Metabolism Journal</i> , 2023, 47, 42-44.	1.8	0



#	ARTICLE	IF	CITATIONS
4393	Residual risks and evolving atherosclerotic plaques. <i>Molecular and Cellular Biochemistry</i> , 2023, 478, 2629-2643.	1.4	6
4394	Combination Moderate-Intensity Statin and Ezetimibe Therapy for Elderly Patients With Atherosclerosis. <i>Journal of the American College of Cardiology</i> , 2023, 81, 1339-1349.	1.2	8
4395	Association of remnant cholesterol with risk of cardiovascular disease events, stroke, and mortality: A systemic review and meta-analysis. <i>Atherosclerosis</i> , 2023, 371, 21-31.	0.4	12
4397	How Low Can You Go? New Evidence Supports No Lower Bound to Low-Density Lipoprotein Cholesterol Level in Secondary Prevention. <i>Circulation</i> , 2023, 147, 1204-1207.	1.6	0
4398	Statin treatment intensity, discontinuation and long-term outcome in patients with acute myocardial infarction and impaired kidney function. <i>Journal of Cardiovascular Pharmacology</i> , 2023, Publish Ahead of Print, .	0.8	1
4399	Effect of Solvent Extracts of <i>Tephrosia vogelii</i> Leaves and Stem on Lipid Profile of Poloxamer 407-Induced Hyperlipidemic Rats. <i>Ibnosina Journal of Medicine and Biomedical Sciences</i> , 2022, 14, 135-144.	0.2	1
4400	Association Between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLE. <i>Circulation</i> , 2023, 147, 1192-1203.	1.6	41
4401	Cholesterol Remnants, Triglyceride-Rich Lipoproteins and Cardiovascular Risk. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4268.	1.8	7
4402	Comparative efficacy and safety among high-intensity statins. Systematic Review and Meta-Analysis. <i>Journal of Comparative Effectiveness Research</i> , 2023, 12, .	0.6	3
4403	THE ACUTE CORONARY SYNDROME: THE POSSIBILITY OF THE MODERN THERAPY (REFERENCES REVIEW. PART) <a href="#">Tj ETQq1 1 0,784314</a> <a href="#">0,0</a>		
4404	Incidence and predictors of cardiovascular outcomes after acute coronary syndrome in a population-based cohort study. <i>Scientific Reports</i> , 2023, 13, .	1.6	1
4405	Inclisiran: new era of lipid-lowering therapy?. <i>Cor Et Vasa</i> , 2023, 65, 69-75.	0.1	0
4407	Treat-to-Target or High-Intensity Statin in Patients With Coronary Artery Disease. <i>JAMA - Journal of the American Medical Association</i> , 2023, 329, 1078.	3.8	16
4408	Transient very low LDL-C levels: a legacy effect for cardiovascular prevention?. <i>European Heart Journal</i> , 2023, 44, 1418-1420.	1.0	3
4409	Lipid-lowering Efficacy and Safety of High Doses of Atorvastatin and Rosuvastatin. <i>Kardiologiya</i> , 2023, 63, 59-67.	0.3	1
4410	Transiently achieved very low LDL-cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial. <i>European Heart Journal</i> , 0, , .	1.0	3
4411	Intracoronary Imaging of Coronary Atherosclerotic Plaque: From Assessment of Pathophysiological Mechanisms to Therapeutic Implication. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5155.	1.8	5
4412	Statin Treatment Is Associated with Alterations in the Platelet Lipidome. <i>Thrombosis and Haemostasis</i> , 2023, 123, 585-596.	1.8	5

#	ARTICLE	IF	CITATIONS
4414	Lipid lowering combination therapy: From prevention to atherosclerosis plaque treatment. <i>Pharmacological Research</i> , 2023, 190, 106738.	3.1	1
4415	Recent Trials on the Cardioprotective Effects of New Generation Anti-diabetic and Lipid-Lowering Agents. <i>Frontiers in Clinical Drug Research Diabetes and Obesity</i> , 2023, , 117-167.	0.1	0
4416	Gene transfer and genome editing for familial hypercholesterolemia. <i>Frontiers in Molecular Medicine</i> , 0, 3, .	0.6	0
4418	French expert group proposal for lipid-lowering therapy in the first 3 months after acute myocardial infarction. <i>Panminerva Medica</i> , 0, , .	0.2	0
4419	Lipid-lowering therapy in patients with coronary artery disease undergoing percutaneous coronary interventions in Italy: an expert opinion paper of Interventional Cardiology Working Group of Italian Society of Cardiology. <i>Journal of Cardiovascular Medicine</i> , 2023, 24, e86-e94.	0.6	1
4420	High-Intensity Statin Reduces the Risk of Mortality Among Chronic Liver Disease Patients With Atherosclerotic Cardiovascular Disease: A Population-Based Cohort Study. <i>Journal of the American Heart Association</i> , 2023, 12, .	1.6	0
4421	Medical Management of Dyslipidemia for Secondary Stroke Prevention: Narrative Review. <i>Medicina (Lithuania)</i> , 2023, 59, 776.	0.8	3
4422	Understanding the molecular mechanisms of statin pleiotropic effects. <i>Archives of Toxicology</i> , 2023, 97, 1529-1545.	1.9	9
4424	Hypocholesterolaemic treatment in coronary unit: from statins to anti PCSK9 therapies and bempedoic acid. <i>European Heart Journal Supplements</i> , 2023, 25, B55-B59.	0.0	1
4431	Diabetes and Dyslipidemia. <i>Contemporary Cardiology</i> , 2023, , 425-472.	0.0	3
4438	Special Patient Populations. , 2024, , 375-382.e2.		0
4439	Special Patient Populations. , 2024, , 345-357.e3.		0
4441	Atherosklerose-Risikofaktoren. , 2023, , 9-47.		0
4450	Phospholipase A2: An emerging biomarker in vascular diseases. , 2023, , 85-103.		0
4465	Oxidized phospholipids in cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2024, 21, 170-191.	6.1	4
4472	Inflammation and Vascular Pathologies. <i>Contemporary Endocrinology</i> , 2023, , 147-163.	0.3	0
4485	Lipid Lowering Drugs in Acute Coronary Syndromes (ACS). <i>Current Atherosclerosis Reports</i> , 0, , .	2.0	0
4514	A Practical Approach to the Management of Residual Cardiovascular Risk: United Arab Emirates Expert Consensus Panel on the Evidence for Icosapent Ethyl and Omega-3 Fatty Acids. <i>Cardiovascular Drugs and Therapy</i> , 0, , .	1.3	0

#	ARTICLE	IF	CITATIONS
---	---------	----	-----------